No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, 3kfaB, 1.0000, 0.00, 1.000, 284, 283, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
2, 3kfaA, 0.9999, 0.05, 1.000, 284, 283, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3, 3oy3B, 0.9942, 0.51, 0.996, 284, 283, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
4, 3oy3A, 0.9940, 0.50, 0.996, 284, 283, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
5, 3ik3B, 0.9917, 0.59, 0.993, 286, 283, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
6, 3ik3A, 0.9728, 0.51, 0.996, 280, 277, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
7, 3k5vA, 0.9443, 1.36, 0.993, 286, 275, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
8, 1opjB, 0.9430, 1.53, 0.982, 288, 276, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
9, 3oxzA, 0.9386, 0.46, 0.996, 268, 267, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN BOUND WITH A DFG-OUT INHIBITOR AP24534
10, 1opjA, 0.9381, 1.64, 0.993, 287, 276, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
11, 1iepA, 0.9370, 0.91, 0.993, 274, 270, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
12, 3k5vB, 0.9361, 1.46, 0.993, 283, 273, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
13, 1iepB, 0.9353, 0.99, 0.996, 274, 270, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
14, 1fpuA, 0.9348, 1.12, 0.989, 275, 271, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
15, 2f4jA, 0.9342, 1.45, 0.993, 287, 272, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
16, 2hiwA, 0.9334, 1.17, 0.978, 274, 271, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
17, 2hznA, 0.9304, 0.90, 0.989, 272, 268, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AFG210
18, 2hiwB, 0.9300, 1.22, 0.985, 274, 271, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
19, 3ms9B, 0.9298, 0.80, 0.989, 272, 267, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
20, 2e2bA, 0.9293, 0.70, 0.989, 270, 266, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
21, 3qriA, 0.9278, 1.24, 0.989, 275, 270, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
22, 2qohB, 0.9263, 1.30, 0.996, 281, 269, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
23, 2hyyB, 0.9258, 0.69, 0.996, 265, 265, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
24, 2z60A, 0.9256, 1.38, 0.996, 281, 269, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
25, 3cs9A, 0.9244, 0.61, 0.996, 264, 264, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
26, 2hyyD, 0.9219, 0.70, 0.992, 264, 264, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
27, 3pyyA, 0.9210, 0.85, 0.996, 265, 265, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
28, 3gvuA, 0.9190, 0.96, 0.913, 271, 265, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH GLEEVEC
29, 3kf4A, 0.9188, 1.37, 0.996, 281, 267, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
30, 1fpuB, 0.9186, 1.12, 0.996, 270, 266, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
31, 3qrkA, 0.9182, 1.20, 0.996, 270, 268, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DP- 987
32, 2hyyC, 0.9178, 0.59, 0.996, 262, 262, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
33, 2hyyA, 0.9177, 0.73, 0.989, 263, 263, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
34, 3u6jA, 0.9157, 1.97, 0.368, 308, 277, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
35, 3mssB, 0.9150, 0.88, 0.992, 264, 263, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
36, 3mssD, 0.9145, 0.91, 0.992, 264, 263, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
37, 3mssC, 0.9143, 0.93, 0.992, 264, 263, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
38, 3mssA, 0.9142, 0.93, 0.992, 264, 263, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
39, 3ms9A, 0.9131, 0.79, 0.996, 265, 262, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
40, 3qrjB, 0.9103, 1.16, 0.989, 265, 265, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
41, 1t45A, 0.9103, 1.88, 0.377, 331, 273, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
42, 4u0iA, 0.9097, 1.84, 0.384, 297, 271, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
43, 1t46A, 0.9084, 1.87, 0.384, 297, 271, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
44, 2xirA, 0.9079, 1.86, 0.380, 296, 271, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH PF-00337210 (N2-DIMETHYL-6-(7-(2-MORPHOLINOETHOXY) QUINOLIN-4-YLOXY)BENZOFURAN-3-CARBOXAMIDE)
45, 4ag8A, 0.9072, 1.88, 0.380, 296, 271, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
46, 4asdA, 0.9065, 1.89, 0.380, 305, 271, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
47, 3vntA, 0.9060, 1.89, 0.380, 301, 271, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
48, 3vo3A, 0.9055, 1.90, 0.380, 303, 271, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
49, 4aseA, 0.9054, 1.88, 0.380, 305, 271, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
50, 3beaA, 0.9046, 2.15, 0.387, 310, 274, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
51, 4wa9B, 0.9041, 1.40, 0.992, 276, 264, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
52, 4agcA, 0.9039, 1.91, 0.380, 304, 271, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
53, 2i1mA, 0.9032, 2.05, 0.388, 311, 273, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
54, 2e2bB, 0.9031, 0.63, 0.992, 262, 258, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
55, 5grnA, 0.9025, 1.83, 0.383, 285, 269, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
56, 3vheA, 0.9023, 1.87, 0.381, 303, 270, CRYSTAL STRUCTURE OF HUMAN VEGFR2 KINASE DOMAIN WITH A NOVEL PYRROLOPYRIMIDINE INHIBITOR.
57, 3cs9D, 0.9020, 1.17, 0.996, 263, 263, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
58, 3qriB, 0.9018, 1.25, 0.989, 262, 262, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
59, 3wzeA, 0.9014, 1.86, 0.383, 298, 269, KDR IN COMPLEX WITH LIGAND SORAFENIB
60, 4hvsA, 0.9013, 1.86, 0.387, 326, 269, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
61, 1m52B, 0.9012, 1.13, 1.000, 272, 260, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
62, 4agdA, 0.9006, 1.94, 0.380, 303, 271, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5-FLUORO-2-OXO-1H-INDOL-3- YLIDENE)METHYL)-24-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE)
63, 3vhkA, 0.9005, 1.87, 0.383, 297, 269, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BACK POCKET BINDER
64, 5k5xA, 0.8964, 2.12, 0.376, 345, 271, CRYSTAL STRUCTURE OF HUMAN PDGFRA
65, 4rt7A, 0.8962, 1.96, 0.399, 274, 268, CRYSTAL STRUCTURE OF FLT3 WITH A SMALL MOLECULE INHIBITOR
66, 2qohA, 0.8947, 1.28, 0.996, 271, 259, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
67, 1m52A, 0.8945, 1.24, 1.000, 271, 259, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
68, 3g0eA, 0.8934, 1.98, 0.383, 332, 269, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
69, 2g2hB, 0.8927, 1.43, 0.981, 272, 260, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
70, 3ewhA, 0.8926, 2.10, 0.389, 300, 270, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDYL-PYRIMIDINE BENZIMIDAZOLE INHIBITOR
71, 2g2hA, 0.8924, 1.46, 0.988, 272, 260, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
72, 3pyyB, 0.8922, 0.91, 0.992, 257, 257, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
73, 2g2fA, 0.8913, 1.74, 0.992, 275, 263, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
74, 4twpB, 0.8911, 1.45, 0.992, 271, 260, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
75, 4r7hA, 0.8911, 1.90, 0.393, 308, 267, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
76, 4at5A, 0.8901, 2.10, 0.375, 294, 272, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
77, 4zogB, 0.8894, 1.13, 0.988, 268, 257, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
78, 4at3A, 0.8886, 2.08, 0.370, 289, 270, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
79, 4hw7A, 0.8879, 1.90, 0.391, 289, 266, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX647-OME
80, 4r7iA, 0.8878, 1.91, 0.391, 290, 266, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR GLEEVEC
81, 5kmnA, 0.8876, 2.39, 0.367, 296, 275, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
82, 3g0fA, 0.8872, 2.21, 0.379, 291, 269, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
83, 4f0iB, 0.8871, 2.09, 0.370, 294, 270, CRYSTAL STRUCTURE OF APO TRKA
84, 5kmlA, 0.8869, 2.41, 0.367, 296, 275, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
85, 3qrjA, 0.8868, 1.13, 0.992, 258, 258, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
86, 5x02A, 0.8867, 2.02, 0.397, 305, 267, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
87, 4pmmA, 0.8866, 2.01, 0.375, 285, 269, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
88, 3zosB, 0.8857, 2.23, 0.404, 303, 270, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
89, 4xeyA, 0.8856, 1.29, 0.996, 269, 257, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
90, 3kf4B, 0.8856, 1.50, 1.000, 270, 259, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
91, 3zosA, 0.8853, 2.08, 0.407, 301, 268, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
92, 3g0fB, 0.8852, 2.24, 0.379, 293, 269, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
93, 2ogvA, 0.8848, 2.17, 0.381, 317, 270, CRYSTAL STRUCTURE OF THE AUTOINHIBITED HUMAN C-FMS KINASE DOMAIN
94, 4aszA, 0.8843, 2.22, 0.376, 289, 271, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
95, 1lufA, 0.8842, 1.85, 0.417, 275, 264, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
96, 4ymjB, 0.8841, 1.96, 0.386, 275, 267, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
97, 2i0vA, 0.8834, 1.93, 0.404, 303, 265, C-FMS TYROSINE KINASE IN COMPLEX WITH A QUINOLONE INHIBITOR
98, 4at4A, 0.8828, 2.15, 0.370, 292, 270, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
99, 5kmjA, 0.8827, 2.43, 0.366, 300, 273, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
100, 5kvtA, 0.8820, 2.09, 0.365, 287, 271, THE STRUCTURE OF TRKA KINASE DOMAIN BOUND TO THE INHIBITOR ENTRECTINIB
101, 3dk3B, 0.8818, 1.32, 0.984, 269, 256, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
102, 6d20A, 0.8817, 2.22, 0.374, 296, 270, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE AND 5-{[2;4- DICHLORO-5-(PYRIDIN-2-YL)BENZENE-1-CARBONYL]AMINO}-N-(2-HYDROXY-2- METHYLPROPYL)-1-PHENYL-1H-PYRAZOLE-3-CARBOXAMIDE INHIBITORS 
103, 3dk7B, 0.8817, 1.33, 0.980, 268, 256, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
104, 2gqgB, 0.8815, 1.56, 0.973, 276, 259, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
105, 4pmpA, 0.8809, 1.94, 0.376, 280, 266, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
106, 4zogA, 0.8808, 1.44, 0.996, 269, 257, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
107, 3ue4A, 0.8808, 1.51, 0.996, 270, 258, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
108, 3hngA, 0.8807, 2.08, 0.389, 288, 265, CRYSTAL STRUCTURE OF VEGFR1 IN COMPLEX WITH N-(4-CHLOROPHENYL)-2- ((PYRIDIN-4-YLMETHYL)AMINO)BENZAMIDE
109, 3krjA, 0.8805, 2.08, 0.392, 304, 265, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
110, 6d22A, 0.8802, 2.26, 0.373, 299, 271, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR 
111, 5kmiA, 0.8801, 2.33, 0.365, 300, 271, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
112, 4twpA, 0.8801, 1.33, 0.992, 266, 255, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
113, 5hu9A, 0.8799, 1.75, 0.985, 266, 261, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
114, 5kmkA, 0.8795, 2.37, 0.368, 304, 272, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
115, 4xufB, 0.8794, 1.97, 0.413, 274, 264, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR QUIZARTINIB (AC220)
116, 2i0yA, 0.8794, 1.93, 0.402, 289, 264, CFMS TYROSINE KINASE (FGF KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
117, 2gqgA, 0.8794, 1.66, 0.992, 277, 260, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
118, 6d1yA, 0.8793, 2.16, 0.373, 300, 268, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 2;4-DICHLORO-N-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)BENZAMIDE INHIBITOR 
119, 4mxcA, 0.8793, 2.14, 0.369, 290, 268, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
120, 4pmsA, 0.8792, 2.08, 0.373, 283, 268, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
121, 5kmmA, 0.8789, 2.37, 0.368, 301, 272, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
122, 2hziA, 0.8789, 1.47, 0.996, 268, 256, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
123, 6bl8B, 0.8785, 1.55, 0.977, 268, 257, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
124, 3ue4B, 0.8785, 1.40, 0.992, 268, 256, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
125, 5nkgA, 0.8781, 2.24, 0.384, 292, 268, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
126, 6d1zA, 0.8780, 2.18, 0.373, 290, 268, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE INHIBITOR 
127, 3dk3A, 0.8777, 1.15, 0.996, 266, 254, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
128, 2rl5A, 0.8777, 1.70, 0.378, 294, 262, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A 23-DIHYDRO-14-BENZOXAZINE INHIBITOR
129, 3dk7A, 0.8776, 1.17, 0.992, 265, 254, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
130, 5htiA, 0.8775, 2.14, 0.369, 290, 268, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
131, 5nkfA, 0.8771, 2.27, 0.384, 291, 268, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
132, 5ia2A, 0.8762, 2.42, 0.381, 287, 270, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
133, 1oplA, 0.8762, 2.03, 0.973, 451, 261, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
134, 1opkA, 0.8760, 2.04, 0.977, 449, 261, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
135, 6bl8A, 0.8758, 1.76, 0.996, 270, 258, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
136, 4xufA, 0.8756, 1.91, 0.408, 270, 262, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR QUIZARTINIB (AC220)
137, 3dtwA, 0.8756, 1.69, 0.379, 288, 261, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
138, 1oplB, 0.8754, 1.41, 0.992, 365, 255, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
139, 3b8qA, 0.8753, 1.94, 0.380, 292, 263, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
140, 3zzeA, 0.8750, 2.13, 0.366, 286, 268, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
141, 2v7aA, 0.8749, 1.62, 0.992, 269, 258, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
142, 6dkiA, 0.8743, 2.15, 0.368, 279, 266, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 19. 
143, 5wr7A, 0.8742, 2.17, 0.369, 301, 268, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
144, 2hziB, 0.8739, 1.10, 0.996, 264, 252, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
145, 4f0iA, 0.8737, 2.16, 0.371, 284, 267, CRYSTAL STRUCTURE OF APO TRKA
146, 2wd1A, 0.8736, 2.14, 0.366, 289, 268, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
147, 3lcoA, 0.8735, 1.98, 0.388, 293, 263, INHIBITOR BOUND TO A DFG-OUT STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
148, 4ymjA, 0.8732, 1.84, 0.385, 270, 262, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
149, 5kmoA, 0.8731, 2.38, 0.363, 291, 270, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
150, 4gt5A, 0.8731, 2.22, 0.375, 290, 269, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
151, 3rhkA, 0.8729, 2.35, 0.358, 298, 271, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
152, 2wkmA, 0.8728, 2.43, 0.367, 286, 270, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
153, 3c4fB, 0.8727, 2.12, 0.391, 290, 266, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
154, 2wgjA, 0.8727, 2.09, 0.372, 289, 266, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
155, 3c4fA, 0.8726, 2.27, 0.397, 290, 267, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
156, 2oh4A, 0.8722, 2.09, 0.374, 297, 265, CRYSTAL STRUCTURE OF VEGFR2 WITH A BENZIMIDAZOLE-UREA INHIBITOR
157, 2fo0A, 0.8722, 1.94, 0.992, 465, 261, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
158, 3zclA, 0.8718, 2.13, 0.367, 289, 267, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
159, 5h3qA, 0.8717, 2.38, 0.370, 302, 270, CRYSTAL STRUCTURE OF TRKA KINASE WITH LIGAND
160, 4ap7A, 0.8715, 2.14, 0.367, 289, 267, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
161, 3dk6A, 0.8714, 1.08, 0.992, 262, 251, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
162, 5nk9A, 0.8713, 2.28, 0.383, 285, 266, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
163, 5nk4A, 0.8713, 2.38, 0.384, 290, 268, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
164, 5nkbA, 0.8712, 2.27, 0.383, 285, 266, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
165, 4xeyB, 0.8709, 1.21, 0.996, 359, 252, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
166, 4r1vA, 0.8709, 2.20, 0.366, 289, 268, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
167, 2v7aB, 0.8709, 1.76, 0.988, 268, 258, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
168, 3zxzA, 0.8706, 2.16, 0.367, 289, 267, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
169, 1rjbA, 0.8704, 2.13, 0.403, 298, 263, CRYSTAL STRUCTURE OF FLT3
170, 2p2iA, 0.8702, 2.05, 0.376, 289, 263, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
171, 4aoiA, 0.8701, 2.16, 0.367, 289, 267, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
172, 3zbxA, 0.8700, 2.16, 0.367, 282, 267, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
173, 4rwjA, 0.8697, 2.15, 0.390, 307, 264, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
174, 5zv2B, 0.8694, 2.34, 0.400, 282, 265, FGFR-1 IN COMPLEX WITH LIGAND LENVATINIB 
175, 5nk6A, 0.8694, 2.25, 0.381, 284, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
176, 5nk1A, 0.8694, 2.25, 0.381, 284, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
177, 3b8rA, 0.8692, 1.83, 0.385, 289, 260, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
178, 5eg3A, 0.8691, 2.40, 0.386, 301, 267, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
179, 4zsaA, 0.8690, 2.33, 0.393, 289, 267, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
180, 3zc5A, 0.8687, 2.18, 0.367, 289, 267, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
181, 3rhkB, 0.8687, 2.27, 0.368, 299, 269, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
182, 5nk7A, 0.8685, 2.27, 0.381, 284, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
183, 5nk2A, 0.8685, 2.33, 0.380, 290, 266, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
184, 4ckrA, 0.8685, 2.28, 0.395, 295, 266, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
185, 3krlA, 0.8684, 1.95, 0.410, 281, 261, CFMS TYROSINE KINASE IN COMPLEX WITH 5-CYANO-FURAN-2-CARBOXYLIC ACID [4-(4-METHYL-PIPERAZIN-1-YL)-2-PIPERIDIN-1-YL-PHENYL]-AMIDE
186, 4rwiA, 0.8683, 2.30, 0.389, 305, 265, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
187, 5eobA, 0.8680, 2.29, 0.366, 288, 268, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
188, 3js2A, 0.8679, 2.34, 0.390, 295, 267, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
189, 5i9xA, 0.8678, 2.26, 0.381, 284, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
190, 4v05A, 0.8678, 2.37, 0.393, 287, 267, FGFR1 IN COMPLEX WITH AZD4547.
191, 3cpbA, 0.8675, 1.57, 0.385, 285, 257, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
192, 4uwcA, 0.8674, 2.38, 0.393, 300, 267, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
193, 3eflA, 0.8674, 1.84, 0.383, 286, 261, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
194, 5dg5B, 0.8673, 2.45, 0.375, 297, 267, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
195, 3cp9A, 0.8669, 1.64, 0.388, 288, 258, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
196, 4deiA, 0.8668, 2.33, 0.369, 287, 268, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
197, 4rwkA, 0.8667, 2.08, 0.392, 308, 263, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
198, 3ky2A, 0.8665, 2.18, 0.388, 307, 263, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
199, 2g2fB, 0.8664, 1.34, 0.988, 264, 252, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
200, 6dkgA, 0.8661, 2.11, 0.373, 276, 263, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 13B. 
201, 4v05B, 0.8661, 2.21, 0.396, 286, 265, FGFR1 IN COMPLEX WITH AZD4547.
202, 3f66A, 0.8656, 2.46, 0.364, 288, 269, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
203, 6gwrA, 0.8655, 2.28, 0.403, 300, 268, STRUCTURE OF THE KINASE DOMAIN OF HUMAN DDR1 IN COMPLEX WITH A POTENT AND SELECTIVE INHIBITOR OF DDR1 AND DDR2 
204, 4yc8B, 0.8654, 1.31, 0.996, 264, 252, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
205, 4xyfA, 0.8654, 2.35, 0.362, 290, 268, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
206, 2hz4A, 0.8654, 1.31, 0.996, 262, 251, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
207, 4qrcA, 0.8653, 2.24, 0.426, 297, 263, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
208, 5am6A, 0.8652, 2.21, 0.394, 295, 264, NATIVE FGFR1 WITH AN INHIBITOR
209, 5nkdA, 0.8651, 2.33, 0.381, 287, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
210, 4tyjA, 0.8651, 1.78, 0.432, 278, 257, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
211, 2xynA, 0.8651, 1.52, 0.921, 264, 253, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
212, 4ypsA, 0.8650, 1.92, 0.356, 280, 261, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
213, 5zv2A, 0.8647, 2.16, 0.392, 284, 263, FGFR-1 IN COMPLEX WITH LIGAND LENVATINIB 
214, 5eydA, 0.8647, 2.38, 0.362, 289, 268, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
215, 5dg5A, 0.8646, 2.49, 0.375, 297, 267, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
216, 4bkjB, 0.8645, 2.30, 0.395, 297, 266, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
217, 5bvkA, 0.8644, 1.98, 0.399, 278, 263, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
218, 2j0jA, 0.8644, 2.09, 0.396, 611, 260, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
219, 4uxqA, 0.8643, 2.05, 0.427, 286, 262, FGFR4 IN COMPLEX WITH PONATINIB
220, 3tt0A, 0.8643, 2.22, 0.386, 305, 264, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
221, 5nkcA, 0.8642, 2.35, 0.381, 286, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
222, 4v04B, 0.8641, 2.37, 0.396, 287, 265, FGFR1 IN COMPLEX WITH PONATINIB.
223, 4uwbB, 0.8641, 2.52, 0.393, 299, 267, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
224, 3v5qB, 0.8640, 1.62, 0.381, 265, 257, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
225, 4bkjA, 0.8639, 2.30, 0.395, 295, 266, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
226, 5a46A, 0.8636, 2.49, 0.393, 289, 267, FGFR1 IN COMPLEX WITH DOVITINIB
227, 3cs9B, 0.8636, 0.65, 0.996, 247, 247, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
228, 1fgiA, 0.8636, 2.24, 0.398, 283, 264, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
229, 4uwbA, 0.8635, 2.48, 0.393, 299, 267, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
230, 5ew8A, 0.8634, 2.49, 0.393, 291, 267, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
231, 5o49B, 0.8632, 2.42, 0.395, 286, 266, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
232, 4gg7A, 0.8632, 2.31, 0.360, 278, 267, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
233, 4gu6A, 0.8630, 1.80, 0.378, 271, 259, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
234, 4rwjB, 0.8629, 2.33, 0.402, 282, 264, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
235, 5eycA, 0.8628, 2.37, 0.371, 288, 267, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
236, 3clyA, 0.8628, 2.29, 0.402, 289, 266, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
237, 4xliA, 0.8627, 1.61, 0.921, 264, 253, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
238, 4nkaB, 0.8626, 2.51, 0.395, 287, 266, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
239, 4gg5A, 0.8626, 2.08, 0.354, 274, 263, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
240, 4qqjA, 0.8624, 2.17, 0.420, 282, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
241, 5o49A, 0.8622, 2.43, 0.395, 289, 266, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
242, 4rwlB, 0.8621, 2.35, 0.396, 285, 265, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
243, 5a46B, 0.8620, 2.43, 0.391, 297, 266, FGFR1 IN COMPLEX WITH DOVITINIB
244, 4nk9A, 0.8620, 2.48, 0.395, 281, 266, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
245, 3cpcA, 0.8618, 1.68, 0.385, 284, 257, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
246, 5ew8B, 0.8617, 2.43, 0.391, 290, 266, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
247, 4uwcB, 0.8616, 2.35, 0.392, 301, 265, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
248, 3rhxA, 0.8616, 2.41, 0.395, 289, 266, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
249, 3be2A, 0.8616, 2.09, 0.392, 290, 260, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZAMIDE INHIBITOR
250, 5vndB, 0.8615, 2.42, 0.391, 295, 266, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
251, 4xliB, 0.8615, 1.61, 0.921, 264, 253, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
252, 2qu6A, 0.8615, 1.70, 0.385, 283, 257, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
253, 4dehA, 0.8614, 2.30, 0.368, 286, 266, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
254, 4degA, 0.8613, 2.24, 0.362, 286, 265, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDAZINE INHIBITOR 2
255, 5am7A, 0.8612, 2.24, 0.395, 294, 263, FGFR1 MUTANT WITH AN INHIBITOR
256, 4rwkB, 0.8612, 2.09, 0.395, 282, 261, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
257, 5i9yA, 0.8611, 2.35, 0.383, 287, 264, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
258, 5a4cB, 0.8611, 2.46, 0.391, 286, 266, FGFR1 LIGAND COMPLEX
259, 2xynC, 0.8611, 1.41, 0.920, 262, 251, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
260, 5bvnA, 0.8610, 2.01, 0.399, 278, 263, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
261, 4nk9B, 0.8610, 2.31, 0.390, 282, 264, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
262, 3v5qA, 0.8610, 1.60, 0.371, 263, 256, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
263, 2qu5A, 0.8608, 2.04, 0.387, 292, 261, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
264, 2xynB, 0.8605, 1.57, 0.921, 264, 253, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
265, 6dkbA, 0.8604, 2.06, 0.372, 272, 261, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 10B. 
266, 1u59A, 0.8604, 2.04, 0.356, 282, 261, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
267, 4f65A, 0.8603, 2.26, 0.388, 279, 263, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
268, 5vndA, 0.8602, 2.52, 0.393, 302, 267, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
269, 5o4aA, 0.8602, 2.43, 0.391, 290, 266, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
270, 3hmiA, 0.8600, 1.73, 0.926, 268, 256, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
271, 2g15A, 0.8599, 2.37, 0.368, 301, 266, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
272, 5bvoA, 0.8598, 1.86, 0.395, 276, 261, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
273, 5a4cA, 0.8597, 2.42, 0.389, 294, 265, FGFR1 LIGAND COMPLEX
274, 4v04A, 0.8597, 2.18, 0.397, 290, 262, FGFR1 IN COMPLEX WITH PONATINIB.
275, 4zsaB, 0.8594, 2.14, 0.397, 282, 262, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
276, 4v01B, 0.8593, 1.91, 0.398, 275, 259, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
277, 4rwlA, 0.8591, 2.29, 0.392, 282, 263, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
278, 2g1tC, 0.8591, 2.31, 0.970, 276, 265, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
279, 4xcuA, 0.8590, 2.13, 0.416, 288, 262, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
280, 4xmoA, 0.8588, 2.36, 0.365, 289, 266, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
281, 3cblA, 0.8588, 2.01, 0.421, 356, 259, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
282, 2oiqA, 0.8587, 2.39, 0.479, 265, 261, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
283, 4nkaA, 0.8585, 2.25, 0.397, 279, 262, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
284, 4knbA, 0.8580, 2.27, 0.377, 273, 265, C-MET IN COMPLEX WITH OSI LIGAND
285, 3vw8A, 0.8580, 2.37, 0.390, 303, 264, CRYSTAL STRUCTURE OF HUMAN C-MET KINASE DOMAIN WITH ITS INHIBITOR
286, 3lw0B, 0.8580, 2.49, 0.434, 292, 267, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
287, 3lw0A, 0.8580, 2.49, 0.434, 292, 267, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
288, 3dpkA, 0.8580, 1.98, 0.401, 279, 257, CFMS TYROSINE KINASE IN COMPLEX WITH A PYRIDOPYRIMIDINONE INHIBITOR
289, 2etmB, 0.8580, 1.72, 0.397, 263, 257, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
290, 4uxlA, 0.8579, 2.08, 0.418, 288, 261, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
291, 3lw0D, 0.8579, 2.50, 0.434, 292, 267, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
292, 3lq8A, 0.8579, 2.11, 0.379, 278, 261, STRUCTURE OF THE KINASE DOMAIN OF C-MET BOUND TO XL880 (GSK1363089)
293, 3ky2B, 0.8579, 2.20, 0.402, 280, 261, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
294, 3lw0C, 0.8578, 2.50, 0.434, 292, 267, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
295, 2p2hA, 0.8577, 2.07, 0.385, 292, 260, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDINYL-TRIAZINE INHIBITOR
296, 4v01A, 0.8576, 2.32, 0.397, 273, 262, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
297, 2j0lA, 0.8576, 2.15, 0.404, 274, 260, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
298, 6gwrB, 0.8575, 2.05, 0.412, 285, 262, STRUCTURE OF THE KINASE DOMAIN OF HUMAN DDR1 IN COMPLEX WITH A POTENT AND SELECTIVE INHIBITOR OF DDR1 AND DDR2 
299, 3gqlA, 0.8575, 2.61, 0.400, 287, 265, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
300, 2g2iA, 0.8575, 1.76, 0.992, 271, 253, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
301, 5b7vB, 0.8573, 2.21, 0.398, 277, 261, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
302, 1p4oA, 0.8573, 2.53, 0.428, 308, 269, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
303, 3kxxA, 0.8572, 2.30, 0.399, 305, 263, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
304, 5hhwA, 0.8569, 2.28, 0.401, 306, 267, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
305, 3l8vA, 0.8569, 2.15, 0.383, 293, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
306, 4qqtA, 0.8568, 2.15, 0.419, 283, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
307, 3gqiA, 0.8568, 2.23, 0.397, 304, 262, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
308, 1p4oB, 0.8568, 2.54, 0.428, 314, 269, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
309, 3js2B, 0.8567, 2.41, 0.398, 291, 264, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
310, 3cd3A, 0.8567, 1.88, 0.420, 352, 257, CRYSTAL STRUCTURE OF PHOSPHORYLATED HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V-FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
311, 5mo4A, 0.8565, 1.68, 0.980, 429, 253, ABL1 KINASE (T334I_D382N) IN COMPLEX WITH ASCIMINIB AND NILOTINIB
312, 2j0kA, 0.8565, 1.77, 0.400, 598, 255, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
313, 5o4aB, 0.8564, 2.39, 0.398, 291, 264, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
314, 3kxxB, 0.8563, 2.23, 0.401, 305, 262, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
315, 5nk3A, 0.8560, 2.49, 0.392, 281, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
316, 5i8aA, 0.8558, 1.70, 0.375, 269, 256, TRKA WITH (6~{R})-3-METHYLSULFANYL-6-PHENYL-1-(1~{H}-PYRAZOL-3-YL)-6 7-DIHYDRO-5~{H}-THIENO[34-C]PYRIDIN-4-ONE
317, 4rwiB, 0.8558, 2.26, 0.406, 280, 261, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
318, 5b7vA, 0.8557, 2.24, 0.391, 282, 261, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
319, 4j96B, 0.8557, 2.20, 0.414, 305, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
320, 3f66B, 0.8556, 2.05, 0.368, 269, 261, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
321, 5bvwA, 0.8552, 1.90, 0.394, 274, 259, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
322, 5flfB, 0.8550, 2.29, 0.405, 292, 262, DISEASE LINKED MUTATION IN FGFR
323, 3h3cA, 0.8549, 1.91, 0.401, 263, 257, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
324, 3etaB, 0.8547, 1.95, 0.404, 292, 260, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
325, 2hz4B, 0.8547, 1.46, 0.996, 261, 250, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
326, 1m7nB, 0.8546, 2.58, 0.428, 299, 269, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
327, 4uwyA, 0.8545, 2.09, 0.391, 296, 258, FGFR1 APO STRUCTURE
328, 3ri1A, 0.8544, 2.13, 0.412, 285, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
329, 3dk6B, 0.8543, 1.28, 0.984, 259, 247, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
330, 1m7nA, 0.8542, 2.58, 0.428, 299, 269, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
331, 2j0kB, 0.8541, 1.94, 0.395, 612, 256, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
332, 5ew3A, 0.8540, 1.62, 0.395, 274, 253, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
333, 5am7B, 0.8540, 2.17, 0.396, 287, 260, FGFR1 MUTANT WITH AN INHIBITOR
334, 4wunA, 0.8540, 2.12, 0.411, 282, 258, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
335, 3b2tA, 0.8540, 2.28, 0.405, 288, 262, STRUCTURE OF PHOSPHOTRANSFERASE
336, 3a4pA, 0.8540, 2.43, 0.362, 285, 265, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
337, 3g6gA, 0.8538, 2.38, 0.477, 264, 260, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
338, 4tygA, 0.8532, 2.36, 0.417, 293, 264, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
339, 5hlwA, 0.8531, 2.41, 0.367, 284, 264, CRYSTAL STRUCTURE OF C-MET MUTANT Y1230H IN COMPLEX WITH COMPOUND 14
340, 2hz4C, 0.8530, 1.34, 0.992, 259, 248, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
341, 5ui0B, 0.8525, 2.20, 0.408, 304, 260, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
342, 5ui0A, 0.8525, 2.23, 0.406, 301, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
343, 3cd8A, 0.8525, 2.25, 0.374, 278, 262, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
344, 2hz0A, 0.8525, 1.94, 0.992, 265, 254, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
345, 2pl0A, 0.8523, 2.35, 0.471, 268, 263, LCK BOUND TO IMATINIB
346, 2psqA, 0.8522, 2.19, 0.412, 287, 260, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
347, 3etaA, 0.8521, 2.11, 0.405, 293, 262, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
348, 5ya5A, 0.8520, 2.00, 0.359, 273, 259, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NOVEL INHIBITOR 
349, 5flfD, 0.8520, 2.28, 0.406, 290, 261, DISEASE LINKED MUTATION IN FGFR
350, 1fgiB, 0.8519, 2.11, 0.399, 272, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
351, 4j96A, 0.8518, 2.24, 0.414, 302, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
352, 3ri1B, 0.8516, 2.24, 0.406, 283, 261, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
353, 2g2iB, 0.8515, 1.79, 0.996, 265, 252, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
354, 3o23A, 0.8511, 2.22, 0.431, 293, 262, HUMAN UNPHOSPHORYLATED IGF1-R KINASE DOMAIN IN COMPLEX WITH AN HYDANTOIN INHIBITOR
355, 1qpdA, 0.8510, 2.14, 0.477, 270, 258, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
356, 3bymA, 0.8509, 2.15, 0.473, 271, 258, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
357, 3ad6A, 0.8509, 2.19, 0.475, 272, 259, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
358, 4cnhB, 0.8506, 2.69, 0.408, 293, 265, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
359, 2ofuA, 0.8505, 2.15, 0.477, 272, 258, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
360, 1irkA, 0.8505, 2.42, 0.401, 303, 267, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
361, 2rfsA, 0.8504, 1.93, 0.378, 264, 259, X-RAY STRUCTURE OF SU11274 BOUND TO C-MET
362, 2psqB, 0.8501, 2.28, 0.410, 286, 261, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
363, 4f65B, 0.8500, 2.30, 0.398, 279, 261, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
364, 3dtwB, 0.8500, 1.44, 0.392, 269, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
365, 3c7qA, 0.8500, 2.32, 0.370, 286, 262, STRUCTURE OF VEGFR2 KINASE DOMAIN IN COMPLEX WITH BIBF1120
366, 4yneA, 0.8498, 2.15, 0.378, 281, 259, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
367, 4knbC, 0.8497, 2.24, 0.370, 271, 262, C-MET IN COMPLEX WITH OSI LIGAND
368, 4j98B, 0.8497, 2.20, 0.417, 304, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
369, 5am6B, 0.8496, 2.26, 0.413, 280, 259, NATIVE FGFR1 WITH AN INHIBITOR
370, 3rhxB, 0.8496, 2.27, 0.400, 275, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
371, 3b8qB, 0.8496, 1.46, 0.392, 271, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
372, 2of4A, 0.8496, 2.15, 0.477, 271, 258, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
373, 5hibA, 0.8495, 2.47, 0.374, 314, 262, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
374, 3kmmA, 0.8493, 2.20, 0.473, 270, 258, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
375, 2g1tB, 0.8492, 2.28, 0.969, 273, 261, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
376, 2r2pA, 0.8491, 2.55, 0.386, 283, 264, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
377, 2j0mB, 0.8490, 1.55, 0.402, 257, 251, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
378, 5fdpA, 0.8489, 2.26, 0.407, 285, 263, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2099 INHIBITOR AT 2.25 ANGSTROMS RESOLUTION.
379, 4d58B, 0.8489, 1.76, 0.388, 261, 255, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
380, 5iuhA, 0.8488, 2.03, 0.406, 285, 256, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
381, 4yc8A, 0.8488, 1.31, 0.988, 259, 247, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
382, 3tz8B, 0.8488, 2.38, 0.471, 263, 259, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
383, 3ac2A, 0.8488, 2.17, 0.477, 270, 258, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
384, 1qpcA, 0.8488, 2.18, 0.473, 270, 258, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
385, 3lckA, 0.8487, 2.18, 0.477, 270, 258, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
386, 3ac5A, 0.8487, 2.18, 0.473, 270, 258, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
387, 4f63A, 0.8486, 2.23, 0.394, 278, 259, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
388, 3vidA, 0.8486, 2.22, 0.371, 299, 259, CRYSTAL STRUCTURE OF HUMAN VEGFR2 KINASE DOMAIN WITH COMPOUND A.
389, 3ac1A, 0.8486, 2.18, 0.477, 270, 258, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
390, 1fgkA, 0.8486, 2.23, 0.394, 278, 259, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
391, 5fdxA, 0.8485, 2.15, 0.410, 280, 261, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
392, 4f64A, 0.8485, 2.25, 0.398, 278, 259, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
393, 3gqlC, 0.8484, 2.34, 0.404, 275, 260, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
394, 2zm1A, 0.8484, 2.17, 0.477, 270, 258, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
395, 3fzpA, 0.8483, 1.62, 0.403, 259, 253, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
396, 2of2A, 0.8483, 2.17, 0.477, 271, 258, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
397, 5nwzA, 0.8481, 2.04, 0.437, 271, 256, FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
398, 3ac3A, 0.8481, 2.19, 0.477, 270, 258, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
399, 2ijmB, 0.8481, 1.91, 0.418, 261, 256, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
400, 2etmA, 0.8481, 1.86, 0.398, 262, 256, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
401, 1agwA, 0.8481, 2.25, 0.398, 278, 259, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
402, 5flfA, 0.8480, 2.29, 0.408, 296, 260, DISEASE LINKED MUTATION IN FGFR
403, 5iugA, 0.8478, 2.13, 0.409, 285, 257, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5A
404, 4d4sB, 0.8478, 1.73, 0.390, 260, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN
405, 3acjA, 0.8478, 2.19, 0.477, 270, 258, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
406, 2zybA, 0.8478, 2.19, 0.473, 270, 258, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
407, 2zm4A, 0.8478, 2.21, 0.473, 270, 258, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
408, 3ackA, 0.8477, 2.19, 0.477, 270, 258, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
409, 5i9zA, 0.8476, 2.14, 0.398, 273, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
410, 3ad5A, 0.8476, 2.20, 0.477, 270, 258, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
411, 2jkmA, 0.8475, 1.78, 0.406, 260, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
412, 3ccnA, 0.8473, 2.23, 0.373, 275, 260, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
413, 3byoA, 0.8473, 2.21, 0.477, 270, 258, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
414, 3ad4A, 0.8473, 2.20, 0.477, 270, 258, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
415, 2pvfA, 0.8473, 2.23, 0.405, 285, 259, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
416, 3byuA, 0.8472, 1.90, 0.475, 256, 255, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE REVERSE AMIDE 23
417, 4gmyA, 0.8471, 2.41, 0.370, 298, 262, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
418, 1ywnA, 0.8471, 2.31, 0.365, 279, 260, VEGFR2 IN COMPLEX WITH A NOVEL 4-AMINO-FURO[23-D]PYRIMIDINE
419, 3bkbA, 0.8470, 2.24, 0.419, 373, 260, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)
420, 3ac8A, 0.8470, 2.18, 0.477, 270, 258, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
421, 3ac4A, 0.8469, 2.21, 0.477, 270, 258, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
422, 4pmtA, 0.8468, 2.06, 0.367, 273, 259, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N~4~-(4-MORPHOLIN- 4-YLPHENYL)-N~6~-(PYRIDIN-3-YLMETHYL)PYRIDO[32-D]PYRIMIDINE-46- DIAMINE
423, 4tyiA, 0.8467, 2.41, 0.434, 277, 258, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4
424, 5tt7A, 0.8466, 2.04, 0.389, 274, 257, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
425, 2pwlB, 0.8466, 2.31, 0.412, 286, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
426, 4jiaA, 0.8465, 2.46, 0.370, 298, 262, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
427, 2g1tA, 0.8465, 2.26, 0.969, 271, 260, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
428, 5uafA, 0.8464, 2.30, 0.375, 291, 261, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
429, 5uadA, 0.8464, 2.30, 0.375, 291, 261, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
430, 5nwzB, 0.8464, 2.11, 0.432, 268, 257, FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
431, 4fnyA, 0.8464, 2.06, 0.404, 273, 255, CRYSTAL STRUCTURE OF THE R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
432, 3i5nA, 0.8464, 2.20, 0.365, 280, 260, CRYSTAL STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR 13
433, 2pwlA, 0.8463, 2.26, 0.413, 284, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
434, 1qpeA, 0.8463, 2.22, 0.473, 270, 258, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
435, 3gqlB, 0.8462, 2.36, 0.402, 276, 259, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
436, 2fgiA, 0.8461, 2.38, 0.394, 274, 259, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
437, 4j98A, 0.8459, 2.22, 0.405, 304, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
438, 3lctA, 0.8459, 2.58, 0.402, 308, 264, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
439, 5uq0A, 0.8458, 2.01, 0.404, 266, 255, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
440, 5flfC, 0.8457, 2.40, 0.406, 283, 261, DISEASE LINKED MUTATION IN FGFR
441, 5ia5A, 0.8456, 2.39, 0.402, 273, 261, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH GOLVATINIB (E7050)
442, 4f63B, 0.8456, 2.28, 0.399, 271, 258, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
443, 5u9dA, 0.8454, 2.80, 0.451, 271, 268, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
444, 3ikaA, 0.8454, 2.71, 0.383, 310, 264, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
445, 3g6gB, 0.8452, 2.38, 0.477, 263, 258, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
446, 3dqwA, 0.8452, 2.80, 0.471, 278, 263, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
447, 2ijmA, 0.8452, 1.79, 0.408, 260, 255, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
448, 5ur1A, 0.8451, 2.25, 0.405, 278, 257, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
449, 5cxhA, 0.8451, 2.00, 0.389, 277, 257, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
450, 3cp9B, 0.8451, 1.47, 0.394, 269, 249, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
451, 6fnfA, 0.8450, 1.91, 0.401, 267, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH NVP-BHG712 
452, 5nudA, 0.8450, 2.04, 0.435, 267, 255, FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
453, 5ia3A, 0.8450, 2.47, 0.407, 275, 258, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
454, 5vfiA, 0.8449, 2.67, 0.449, 271, 267, BRUTON S TYROSINE KINASE (BTK) WITH GDC-0853
455, 4ibmA, 0.8449, 2.50, 0.407, 301, 268, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
456, 3oezA, 0.8448, 2.40, 0.479, 261, 257, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
457, 2yjrA, 0.8448, 2.19, 0.412, 278, 257, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
458, 6fnhA, 0.8447, 2.77, 0.392, 277, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
459, 4d5hB, 0.8447, 1.77, 0.390, 260, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN
460, 1fgkB, 0.8447, 2.28, 0.403, 272, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
461, 1agwB, 0.8447, 2.29, 0.403, 272, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
462, 3et7A, 0.8446, 1.78, 0.407, 261, 253, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
463, 3dqwD, 0.8446, 2.66, 0.473, 276, 262, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
464, 2py3B, 0.8446, 2.18, 0.409, 284, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
465, 5mjbA, 0.8445, 2.46, 0.392, 276, 260, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
466, 4d4yB, 0.8445, 1.77, 0.390, 260, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN
467, 4nksB, 0.8443, 2.18, 0.405, 271, 257, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
468, 4f64B, 0.8443, 2.30, 0.407, 272, 258, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
469, 4nksA, 0.8441, 2.25, 0.395, 265, 258, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
470, 4cd0A, 0.8441, 2.46, 0.406, 295, 261, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
471, 4j97A, 0.8440, 2.10, 0.414, 282, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
472, 4j97C, 0.8439, 2.12, 0.414, 283, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
473, 5u6bB, 0.8438, 2.29, 0.448, 291, 259, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
474, 5ia4A, 0.8438, 2.36, 0.404, 269, 260, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
475, 3dqwB, 0.8438, 2.65, 0.475, 278, 261, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
476, 2g1tD, 0.8437, 2.36, 0.966, 277, 261, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
477, 4j97B, 0.8436, 2.09, 0.406, 283, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
478, 3zbfA, 0.8436, 2.17, 0.424, 281, 257, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
479, 2py3A, 0.8436, 2.23, 0.409, 282, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
480, 3lcsA, 0.8435, 2.80, 0.402, 304, 266, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
481, 5njzA, 0.8434, 2.31, 0.395, 273, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
482, 4r1yA, 0.8434, 1.94, 0.363, 265, 256, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITOR
483, 3fzrA, 0.8434, 1.80, 0.407, 261, 253, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
484, 2fgiB, 0.8434, 2.29, 0.403, 272, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
485, 5hznE, 0.8433, 2.40, 0.435, 296, 260, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
486, 5hznA, 0.8433, 2.39, 0.435, 296, 260, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
487, 5ftoA, 0.8433, 2.53, 0.403, 298, 263, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
488, 3l9pA, 0.8433, 2.58, 0.402, 303, 264, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
489, 5u6bD, 0.8432, 2.29, 0.448, 291, 259, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
490, 3bysA, 0.8432, 1.86, 0.466, 255, 253, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE AMIDE 10B
491, 5ugxA, 0.8431, 2.26, 0.402, 297, 259, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
492, 3qquB, 0.8431, 2.50, 0.432, 288, 266, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
493, 3f3vB, 0.8431, 2.43, 0.473, 262, 258, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
494, 3ce3A, 0.8431, 2.43, 0.378, 293, 262, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOPYRIDINEPYRIDONE BASED INHIBITOR
495, 5p9kA, 0.8430, 2.82, 0.451, 271, 268, CRYSTAL STRUCTURE OF BTK WITH CNX 774
496, 5l6pA, 0.8430, 2.39, 0.375, 274, 261, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 6)
497, 5l6oA, 0.8430, 2.33, 0.388, 267, 258, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 3)
498, 1y57A, 0.8429, 2.91, 0.462, 452, 264, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
499, 4o2pA, 0.8428, 2.52, 0.452, 265, 259, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
500, 5ugbA, 0.8427, 2.58, 0.382, 307, 262, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
501, 3f3wA, 0.8427, 2.37, 0.471, 261, 257, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
502, 5uhnA, 0.8426, 2.31, 0.405, 282, 259, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
503, 5hg8A, 0.8426, 2.89, 0.385, 300, 265, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
504, 4wd5A, 0.8426, 2.66, 0.388, 307, 263, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH QL-X138
505, 3f3vA, 0.8426, 2.34, 0.475, 261, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
506, 3cs9C, 0.8426, 0.89, 0.992, 243, 243, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
507, 5xgnA, 0.8425, 2.65, 0.376, 302, 263, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
508, 4ckjA, 0.8425, 2.37, 0.415, 292, 260, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
509, 3lcdA, 0.8425, 2.13, 0.398, 290, 254, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
510, 4aojA, 0.8424, 1.90, 0.376, 260, 255, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
511, 5mjbB, 0.8423, 2.47, 0.396, 278, 260, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
512, 2ivsA, 0.8423, 2.38, 0.417, 284, 259, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
513, 5p9mA, 0.8422, 2.58, 0.440, 271, 266, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
514, 4y93A, 0.8422, 2.83, 0.446, 429, 267, CRYSTAL STRUCTURE OF THE PH-TH-KINASE CONSTRUCT OF BRUTON S TYROSINE KINASE (BTK)
515, 5hg5A, 0.8421, 2.90, 0.385, 302, 265, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
516, 4y95A, 0.8421, 2.63, 0.456, 266, 263, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
517, 2itxA, 0.8421, 2.57, 0.382, 307, 262, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
518, 5iuiA, 0.8420, 2.52, 0.403, 303, 263, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
519, 5em8A, 0.8420, 2.55, 0.379, 303, 261, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
520, 4wunB, 0.8420, 2.02, 0.408, 268, 255, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
521, 4d55A, 0.8420, 1.66, 0.398, 260, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
522, 5p9iA, 0.8419, 2.83, 0.451, 271, 268, BTK1 SOAKED WITH IBRUTINIB-REV
523, 3dqwC, 0.8419, 2.63, 0.475, 275, 261, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
524, 1r0pA, 0.8419, 2.58, 0.360, 301, 264, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH THE MICROBIAL ALKALOID K-252A
525, 3cthA, 0.8418, 2.31, 0.369, 295, 260, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
526, 4u5jB, 0.8417, 2.49, 0.481, 267, 258, C-SRC IN COMPLEX WITH RUXOLITINIB
527, 4c7tA, 0.8417, 1.70, 0.381, 259, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
528, 5hznB, 0.8416, 2.43, 0.435, 296, 260, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
529, 3cc6A, 0.8416, 2.24, 0.400, 269, 260, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PROTEIN TYROSINE KINASE 2 BETA (PTK2B)
530, 2itqA, 0.8416, 2.50, 0.377, 300, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
531, 5hznG, 0.8415, 2.43, 0.435, 296, 260, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
532, 5hznC, 0.8415, 2.43, 0.435, 296, 260, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
533, 4j95B, 0.8415, 2.24, 0.411, 282, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
534, 3b8rB, 0.8415, 1.66, 0.398, 267, 249, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
535, 5hznF, 0.8414, 2.43, 0.435, 296, 260, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
536, 5ek7B, 0.8414, 2.41, 0.398, 286, 259, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
537, 3tz8A, 0.8414, 2.38, 0.475, 261, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
538, 3eflB, 0.8414, 1.46, 0.387, 263, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
539, 1vr2A, 0.8414, 2.10, 0.379, 275, 256, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN
540, 5jfsA, 0.8413, 2.16, 0.376, 277, 255, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
541, 4tksA, 0.8413, 2.54, 0.379, 307, 261, NATIVE-SAD PHASING FOR HUMAN EGFR KINASE DOMAIN.
542, 4gfgA, 0.8413, 2.07, 0.393, 277, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
543, 4z3vA, 0.8412, 2.87, 0.451, 271, 268, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
544, 6fngA, 0.8411, 2.29, 0.392, 277, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AN ISOMER OF NVP-BHG712 
545, 3kulB, 0.8411, 1.95, 0.387, 271, 253, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
546, 5uglA, 0.8410, 2.30, 0.405, 285, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
547, 5tr6A, 0.8410, 1.93, 0.388, 272, 255, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
548, 4fobA, 0.8410, 2.44, 0.406, 295, 261, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
549, 4brxA, 0.8410, 1.71, 0.381, 259, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
550, 3f3tA, 0.8410, 2.37, 0.475, 261, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
551, 5j9yA, 0.8408, 2.48, 0.375, 300, 261, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
552, 4eevA, 0.8407, 2.06, 0.384, 283, 255, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH LY2801653
553, 1qpjA, 0.8407, 2.12, 0.478, 265, 255, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
554, 5y9tA, 0.8406, 2.53, 0.375, 300, 261, CRYSTAL STRUCTURE OF EGFR T790M MUTANT IN COMPLEX WITH NAQUOTINIB 
555, 5ew3B, 0.8406, 1.39, 0.393, 266, 247, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
556, 3nw6A, 0.8406, 2.70, 0.431, 301, 269, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11A)
557, 5uabA, 0.8405, 2.24, 0.380, 288, 258, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
558, 4tyeA, 0.8405, 2.49, 0.425, 292, 261, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
559, 4gt4B, 0.8404, 2.29, 0.347, 273, 262, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
560, 4ckiA, 0.8404, 2.53, 0.414, 293, 261, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
561, 3f3uA, 0.8404, 2.38, 0.475, 261, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
562, 5u8lA, 0.8403, 2.87, 0.381, 289, 265, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH A SULFONYL FLUORIDE PROBE XO44
563, 4ebwA, 0.8402, 2.33, 0.402, 259, 256, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
564, 3wzdA, 0.8402, 1.78, 0.390, 278, 251, KDR IN COMPLEX WITH LIGAND LENVATINIB
565, 4mkcA, 0.8401, 2.56, 0.405, 303, 262, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
566, 5j7hA, 0.8400, 2.44, 0.404, 291, 260, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
567, 4cljA, 0.8400, 2.49, 0.406, 295, 261, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
568, 3bz3A, 0.8400, 1.97, 0.410, 259, 256, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
569, 1m17A, 0.8400, 2.54, 0.379, 312, 261, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
570, 1gjoA, 0.8400, 2.23, 0.420, 280, 257, THE FGFR2 TYROSINE KINASE DOMAIN
571, 5ugxB, 0.8399, 2.27, 0.403, 282, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
572, 4kaoB, 0.8399, 1.67, 0.414, 254, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
573, 5xdkA, 0.8398, 2.66, 0.378, 307, 262, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
574, 4ebvA, 0.8398, 2.32, 0.402, 262, 256, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
575, 3r7oA, 0.8398, 2.54, 0.383, 299, 261, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
576, 3qquA, 0.8398, 2.46, 0.432, 285, 264, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
577, 2pz5A, 0.8398, 2.16, 0.412, 280, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
578, 2jkqA, 0.8398, 1.72, 0.409, 258, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
579, 1oecA, 0.8398, 2.23, 0.424, 280, 257, FGFR2 KINASE DOMAIN
580, 5mjaB, 0.8397, 2.49, 0.400, 274, 260, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
581, 5hznD, 0.8397, 2.45, 0.435, 304, 260, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
582, 1m14A, 0.8397, 2.59, 0.379, 307, 261, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
583, 4j95C, 0.8396, 2.22, 0.409, 281, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
584, 2q0bB, 0.8396, 2.20, 0.406, 282, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
585, 2j6mA, 0.8396, 2.41, 0.386, 306, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
586, 5jfvA, 0.8395, 1.95, 0.375, 277, 253, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
587, 5hznH, 0.8395, 2.45, 0.435, 303, 260, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
588, 6fnkA, 0.8394, 2.65, 0.389, 274, 262, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
589, 5i9vA, 0.8394, 2.16, 0.404, 279, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
590, 4jq8A, 0.8394, 2.60, 0.379, 303, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
591, 4j99C, 0.8394, 2.30, 0.415, 291, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
592, 4e4mA, 0.8394, 2.58, 0.370, 296, 262, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
593, 5jfwA, 0.8393, 2.18, 0.376, 277, 255, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
594, 4y95D, 0.8393, 2.63, 0.458, 265, 262, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
595, 4uwyB, 0.8393, 1.98, 0.407, 273, 253, FGFR1 APO STRUCTURE
596, 4j99B, 0.8393, 2.30, 0.411, 291, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
597, 3tz9A, 0.8393, 2.37, 0.475, 261, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
598, 4j95A, 0.8392, 2.25, 0.415, 279, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
599, 3u6iA, 0.8392, 2.13, 0.379, 281, 256, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
600, 2pzpA, 0.8392, 2.17, 0.416, 280, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
601, 2pz5B, 0.8392, 2.17, 0.412, 280, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
602, 2itpA, 0.8392, 2.53, 0.377, 305, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
603, 5x2kA, 0.8391, 2.56, 0.381, 314, 260, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH WZ4003
604, 5ek7A, 0.8391, 2.56, 0.396, 286, 260, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
605, 4j95D, 0.8391, 2.01, 0.425, 271, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
606, 4e4mE, 0.8391, 2.57, 0.366, 296, 262, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
607, 2p2iB, 0.8391, 1.41, 0.389, 263, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
608, 4r3pA, 0.8390, 2.66, 0.378, 310, 262, CRYSTAL STRUCTURES OF EGFR IN COMPLEX WITH MIG6
609, 3dkfA, 0.8390, 2.33, 0.367, 294, 259, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
610, 2q0bA, 0.8390, 2.15, 0.404, 280, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
611, 4j97D, 0.8389, 2.08, 0.413, 285, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
612, 3w2qA, 0.8389, 2.65, 0.374, 307, 262, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
613, 5nkhA, 0.8388, 2.56, 0.398, 295, 259, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
614, 3f6xB, 0.8388, 2.51, 0.473, 267, 258, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
615, 2pzpB, 0.8388, 2.18, 0.416, 282, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
616, 4j99D, 0.8387, 2.14, 0.420, 281, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
617, 3q6wA, 0.8387, 2.68, 0.378, 297, 262, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
618, 3pixA, 0.8386, 2.34, 0.444, 268, 261, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-ISOPROPYL-7- (4-METHYL-PIPERAZIN-1-YL)-4-(5-METHYL-2H-PYRAZOL-3-YLAMINO)-2H- PHTHALAZIN-1-ONE
619, 3f3wB, 0.8386, 2.35, 0.473, 260, 256, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
620, 2itwA, 0.8385, 2.44, 0.382, 300, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
621, 4y95C, 0.8384, 2.56, 0.454, 266, 262, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
622, 4e4mB, 0.8384, 2.53, 0.366, 296, 262, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
623, 6dkwA, 0.8383, 1.94, 0.383, 284, 253, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 3. 
624, 4aojC, 0.8383, 1.96, 0.376, 261, 255, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
625, 2qu6B, 0.8382, 1.38, 0.398, 260, 246, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
626, 6fnhB, 0.8381, 2.47, 0.400, 271, 260, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
627, 4y95B, 0.8381, 2.57, 0.454, 266, 262, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
628, 4jr3A, 0.8381, 2.62, 0.379, 303, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
629, 4e4mD, 0.8381, 2.53, 0.366, 296, 262, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
630, 4cmoA, 0.8381, 2.48, 0.408, 295, 260, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
631, 5jfxA, 0.8380, 2.00, 0.379, 277, 253, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
632, 5cavA, 0.8380, 2.54, 0.381, 306, 260, EGFR KINASE DOMAIN WITH COMPOUND 41A
633, 4zlzA, 0.8380, 2.86, 0.449, 270, 267, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
634, 4jq7A, 0.8380, 2.62, 0.379, 303, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
635, 3qtiA, 0.8380, 2.52, 0.360, 292, 261, C-MET KINASE IN COMPLEX WITH NVP-BVU972
636, 5nkeA, 0.8379, 2.52, 0.399, 292, 258, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
637, 3pxkB, 0.8379, 1.86, 0.415, 258, 253, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
638, 2jiuA, 0.8377, 2.74, 0.390, 303, 264, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
639, 5wevA, 0.8376, 2.28, 0.374, 293, 257, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
640, 5ugaA, 0.8376, 2.77, 0.385, 283, 262, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH 4-(4-{[2-{[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9- (PROPAN-2-YL)-9H-PURIN-6-YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
641, 4i23A, 0.8376, 2.53, 0.382, 304, 259, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
642, 3oezB, 0.8376, 2.50, 0.475, 261, 257, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
643, 4k8aB, 0.8375, 1.85, 0.415, 258, 253, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
644, 3tt0B, 0.8375, 2.06, 0.407, 272, 253, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
645, 5fdxB, 0.8374, 2.25, 0.399, 274, 258, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
646, 5aaaA, 0.8374, 2.50, 0.412, 294, 260, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
647, 4gu6B, 0.8374, 1.79, 0.413, 258, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
648, 3g6hB, 0.8374, 2.36, 0.471, 259, 255, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
649, 4qq5A, 0.8373, 2.20, 0.434, 275, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
650, 4k33A, 0.8373, 2.29, 0.403, 293, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
651, 4cmuA, 0.8372, 2.49, 0.408, 294, 260, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
652, 2dq7X, 0.8372, 2.05, 0.476, 262, 252, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
653, 4j99A, 0.8371, 2.23, 0.416, 280, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
654, 3w2oA, 0.8371, 2.66, 0.378, 305, 262, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
655, 5ia0B, 0.8370, 2.51, 0.394, 266, 259, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
656, 3nw5A, 0.8370, 2.73, 0.428, 302, 269, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11B)
657, 2x2kA, 0.8370, 2.37, 0.415, 289, 258, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
658, 2gs2A, 0.8370, 2.50, 0.381, 305, 260, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
659, 5czhA, 0.8369, 2.68, 0.378, 311, 262, EGFR L858R MUTANT IN COMPLEX WITH AN OPTIMAL PEPTIDE SUBSTRATE
660, 4qqcA, 0.8369, 2.09, 0.435, 273, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
661, 3f6xD, 0.8369, 2.57, 0.477, 267, 258, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
662, 2xvdA, 0.8369, 2.59, 0.382, 270, 259, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
663, 5tehA, 0.8368, 2.44, 0.467, 261, 257, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
664, 5ia0C, 0.8368, 2.29, 0.396, 269, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
665, 3geqB, 0.8368, 2.67, 0.471, 273, 259, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
666, 3u6hA, 0.8367, 2.11, 0.380, 280, 255, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
667, 5nkaA, 0.8366, 2.21, 0.402, 271, 254, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
668, 4zlyA, 0.8366, 2.87, 0.449, 270, 267, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
669, 4kabB, 0.8366, 1.92, 0.417, 258, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
670, 4gt4A, 0.8366, 2.26, 0.331, 274, 260, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
671, 4d5kB, 0.8366, 1.74, 0.406, 256, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
672, 5cziA, 0.8365, 2.69, 0.378, 310, 262, EGFR L858R MUTANT IN COMPLEX WITH A SHC PEPTIDE SUBSTRATE
673, 5aa9A, 0.8365, 2.51, 0.412, 295, 260, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
674, 4li5A, 0.8364, 2.53, 0.381, 306, 260, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
675, 4kabA, 0.8364, 1.87, 0.401, 255, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
676, 5uwdA, 0.8363, 2.77, 0.375, 271, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH THE COVALENT INHIBITOR CO-1686
677, 3tz7A, 0.8363, 2.32, 0.475, 260, 255, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL103
678, 2jkkA, 0.8363, 1.84, 0.405, 258, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
679, 5p9fA, 0.8362, 2.57, 0.454, 266, 262, BTK IN COMPLEX WITH GDC-0834
680, 4jrvA, 0.8361, 2.60, 0.381, 300, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
681, 4bb4A, 0.8361, 2.55, 0.384, 265, 258, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
682, 4fodA, 0.8360, 2.48, 0.404, 308, 260, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
683, 4cliA, 0.8360, 2.50, 0.408, 294, 260, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
684, 3cjgA, 0.8360, 1.75, 0.392, 280, 250, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
685, 4focA, 0.8359, 2.45, 0.377, 296, 260, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
686, 4ot6A, 0.8358, 2.53, 0.444, 265, 261, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
687, 2eb2A, 0.8357, 2.55, 0.375, 305, 259, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
688, 5jebA, 0.8356, 2.70, 0.385, 299, 262, CRYSTAL STRUCTURE OF EGFR TYROSINE KINASE DOMAIN WITH NOVEL INHIBITOR OF ACTIVE STATE OF HER2
689, 4rx7A, 0.8356, 2.11, 0.396, 272, 255, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
690, 3cpbB, 0.8356, 1.37, 0.392, 263, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
691, 6fekA, 0.8355, 2.39, 0.412, 294, 257, ONCOGENIC POINT MUTATION OF RET RECEPTOR TYROSINE KINASE
692, 5kz0A, 0.8355, 2.52, 0.408, 293, 260, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
693, 4u5jA, 0.8355, 2.49, 0.482, 267, 257, C-SRC IN COMPLEX WITH RUXOLITINIB
694, 3sxsA, 0.8355, 2.07, 0.431, 264, 253, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
695, 3kulA, 0.8355, 2.19, 0.383, 267, 253, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
696, 3cpcB, 0.8355, 1.36, 0.388, 262, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
697, 5i9wA, 0.8354, 1.94, 0.400, 267, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
698, 2x2mA, 0.8354, 2.29, 0.418, 286, 256, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
699, 3kxxC, 0.8353, 2.19, 0.408, 286, 255, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
700, 2pzrB, 0.8353, 2.22, 0.404, 282, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
701, 5xp5B, 0.8352, 2.58, 0.481, 267, 258, C-SRC IN COMPLEX WITH ATP-CHF
702, 4fnzA, 0.8352, 2.18, 0.402, 287, 256, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PIPERIDINE-CARBOXAMIDE INHIBITOR 2
703, 4e93A, 0.8352, 2.18, 0.426, 361, 256, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)IN COMPLEX WITH TAE684
704, 3piyA, 0.8352, 2.42, 0.438, 262, 258, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH R406
705, 5ia1A, 0.8351, 2.10, 0.397, 261, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
706, 3fqsA, 0.8351, 2.04, 0.403, 268, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
707, 3b2wA, 0.8350, 2.40, 0.486, 261, 255, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
708, 1xbcA, 0.8350, 1.97, 0.393, 268, 252, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
709, 5i9uA, 0.8349, 2.30, 0.400, 281, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
710, 5gtzA, 0.8349, 2.49, 0.384, 317, 258, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
711, 5p9gA, 0.8348, 2.54, 0.452, 265, 261, STRUCTURE OF BTK WITH RN486
712, 5cxzA, 0.8348, 1.98, 0.395, 269, 253, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
713, 4riyD, 0.8348, 2.60, 0.396, 297, 260, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
714, 3kxxD, 0.8348, 2.20, 0.416, 288, 255, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
715, 3bceB, 0.8348, 2.75, 0.396, 286, 260, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
716, 2pzrA, 0.8348, 2.16, 0.406, 280, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
717, 3en4B, 0.8347, 2.61, 0.479, 266, 259, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
718, 4dceB, 0.8346, 2.09, 0.406, 284, 254, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
719, 3b2tB, 0.8346, 2.29, 0.412, 287, 255, STRUCTURE OF PHOSPHOTRANSFERASE
720, 1xbbA, 0.8346, 2.01, 0.403, 268, 253, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
721, 4i0tA, 0.8345, 1.86, 0.398, 266, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
722, 4d4vB, 0.8345, 1.73, 0.404, 255, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN
723, 3bceC, 0.8345, 2.62, 0.398, 286, 259, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
724, 5xfjA, 0.8344, 2.22, 0.439, 266, 253, CRYSTAL STRUCTURE OF LY2874455 IN COMPLEX OF FGFR4 GATEKEEPER MUTATION (V550M) 
725, 4r3rA, 0.8344, 2.62, 0.379, 309, 261, CRYSTAL STRUCTURES OF EGFR IN COMPLEX WITH MIG6
726, 1yomA, 0.8344, 2.40, 0.463, 260, 255, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
727, 4riwD, 0.8343, 2.68, 0.395, 297, 261, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
728, 4iwdA, 0.8343, 2.52, 0.381, 299, 260, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
729, 3g6hA, 0.8343, 2.53, 0.475, 266, 257, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
730, 2ivtA, 0.8343, 2.35, 0.416, 288, 257, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
731, 2gs6A, 0.8343, 2.44, 0.386, 311, 259, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
732, 1k9aE, 0.8343, 2.40, 0.449, 440, 256, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
733, 1k9aB, 0.8343, 2.51, 0.450, 441, 258, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
734, 5ftqA, 0.8342, 2.49, 0.405, 293, 259, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
735, 4yhfA, 0.8342, 2.75, 0.445, 268, 263, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
736, 4rixD, 0.8342, 2.51, 0.386, 297, 259, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
737, 4e6qA, 0.8342, 2.64, 0.370, 296, 262, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
738, 4dggA, 0.8341, 2.48, 0.471, 261, 257, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
739, 3geqA, 0.8341, 2.62, 0.473, 272, 258, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
740, 2pvyA, 0.8341, 2.08, 0.407, 288, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
741, 3zfxH, 0.8339, 2.21, 0.406, 266, 254, CRYSTAL STRUCTURE OF EPHB1
742, 3f3uB, 0.8339, 2.41, 0.471, 259, 255, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
743, 2ivsB, 0.8339, 2.16, 0.421, 277, 254, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
744, 5gmpA, 0.8338, 2.46, 0.381, 305, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
745, 5c26A, 0.8338, 2.04, 0.398, 272, 254, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
746, 4tt7A, 0.8338, 2.42, 0.409, 291, 257, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
747, 4aojB, 0.8338, 2.09, 0.370, 258, 254, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
748, 4z55A, 0.8337, 2.67, 0.406, 294, 261, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
749, 4mxzB, 0.8337, 2.51, 0.469, 264, 256, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
750, 4mxyB, 0.8337, 2.51, 0.469, 264, 256, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
751, 4h1jA, 0.8337, 2.01, 0.408, 263, 255, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
752, 3of0A, 0.8337, 2.46, 0.477, 260, 256, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
753, 3f82A, 0.8337, 2.01, 0.385, 278, 252, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH N- (4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4- ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
754, 2itoA, 0.8337, 2.41, 0.381, 303, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH IRESSA
755, 5nkiA, 0.8335, 2.17, 0.401, 268, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4B
756, 4fynA, 0.8335, 1.98, 0.401, 267, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
757, 3qlgA, 0.8335, 2.43, 0.478, 259, 255, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
758, 3el8A, 0.8335, 2.49, 0.477, 263, 256, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
759, 2j5eA, 0.8335, 2.68, 0.383, 309, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
760, 4fl2A, 0.8334, 2.37, 0.377, 555, 260, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
761, 2vx0A, 0.8334, 2.62, 0.385, 273, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
762, 1k9aA, 0.8334, 2.46, 0.451, 439, 257, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
763, 5aabA, 0.8333, 2.48, 0.411, 293, 258, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
764, 3vjnA, 0.8333, 2.48, 0.374, 297, 257, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
765, 3bceA, 0.8333, 2.64, 0.394, 285, 259, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
766, 2ivuA, 0.8333, 2.44, 0.419, 288, 258, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
767, 1y6bA, 0.8333, 1.71, 0.384, 266, 250, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 2-ANILINO-5-ARYL-OXAZOLE INHIBITOR
768, 3nw7A, 0.8332, 2.69, 0.431, 297, 267, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (34)
769, 2xb7A, 0.8332, 2.46, 0.411, 286, 258, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- TAE684
770, 3w2pA, 0.8331, 2.72, 0.378, 308, 262, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
771, 3vjoA, 0.8331, 2.51, 0.376, 298, 258, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
772, 2x9fA, 0.8331, 2.57, 0.389, 265, 257, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
773, 6fnjB, 0.8330, 2.21, 0.395, 262, 253, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH AN ISOMER OF NVP-BHG712 
774, 4mxxB, 0.8330, 2.44, 0.471, 260, 255, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
775, 4i0sA, 0.8330, 1.98, 0.397, 267, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
776, 4zimB, 0.8329, 2.59, 0.372, 294, 261, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
777, 4gu9B, 0.8329, 1.87, 0.417, 255, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
778, 2vwzA, 0.8329, 2.63, 0.385, 274, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
779, 5xp5A, 0.8328, 2.61, 0.481, 267, 258, C-SRC IN COMPLEX WITH ATP-CHF
780, 4ccuA, 0.8328, 2.43, 0.409, 292, 257, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
781, 3tz7B, 0.8328, 2.47, 0.473, 260, 256, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL103
782, 6fnjA, 0.8327, 2.20, 0.395, 262, 253, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH AN ISOMER OF NVP-BHG712 
783, 5calA, 0.8327, 2.42, 0.374, 300, 257, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
784, 4rx9A, 0.8327, 2.00, 0.395, 268, 253, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
785, 5nk5A, 0.8326, 2.40, 0.400, 287, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
786, 5jkgA, 0.8326, 2.25, 0.439, 266, 253, THE CRYSTAL STRUCTURE OF FGFR4 KINASE DOMAIN IN COMPLEX WITH LY2874455
787, 2vwyA, 0.8326, 2.64, 0.385, 274, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
788, 4fyoA, 0.8325, 2.00, 0.401, 267, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
789, 5j87B, 0.8324, 2.96, 0.451, 274, 266, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
790, 3dzqA, 0.8324, 2.24, 0.390, 268, 254, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH INHIBITOR AWL-II- 38.3
791, 5feqA, 0.8323, 2.49, 0.374, 290, 257, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE
792, 4e6qB, 0.8323, 2.66, 0.370, 296, 262, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
793, 2vx1A, 0.8323, 2.64, 0.385, 274, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
794, 2vwxA, 0.8323, 2.63, 0.385, 274, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
795, 4ibmB, 0.8322, 2.39, 0.414, 294, 263, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
796, 4dceA, 0.8322, 2.29, 0.409, 288, 257, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
797, 3eqpB, 0.8322, 2.05, 0.399, 270, 253, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
798, 5y25A, 0.8321, 2.40, 0.371, 292, 256, EGFR KINASE DOMAIN MUTANT (T790M/L858R) WITH COVALENT LIGAND NS-062 
799, 5uhnB, 0.8321, 2.14, 0.413, 269, 254, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
800, 4d4vA, 0.8321, 1.77, 0.402, 256, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
801, 3zfxD, 0.8321, 2.18, 0.403, 265, 253, CRYSTAL STRUCTURE OF EPHB1
802, 3c1xA, 0.8321, 2.14, 0.374, 290, 254, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOTRIAZINE BASED INHIBITOR
803, 5fxsA, 0.8320, 2.77, 0.414, 308, 268, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
804, 4wnmA, 0.8320, 1.99, 0.395, 273, 253, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
805, 3tz9B, 0.8320, 2.32, 0.472, 259, 254, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
806, 5edpA, 0.8319, 2.48, 0.372, 295, 258, EGFR KINASE (T790M/L858R) APO
807, 4rfyA, 0.8319, 2.50, 0.444, 263, 259, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
808, 4r6vA, 0.8319, 2.23, 0.435, 273, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-3 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
809, 4dfnA, 0.8319, 1.93, 0.401, 269, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
810, 3zfxA, 0.8319, 2.18, 0.403, 267, 253, CRYSTAL STRUCTURE OF EPHB1
811, 4ueuA, 0.8318, 2.06, 0.675, 256, 252, TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL
812, 3uqgA, 0.8318, 2.49, 0.475, 263, 255, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
813, 2x2lA, 0.8318, 2.48, 0.416, 287, 257, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
814, 4ot5A, 0.8317, 2.65, 0.446, 263, 260, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
815, 2pvyD, 0.8317, 2.13, 0.411, 283, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
816, 5xp7A, 0.8316, 2.57, 0.475, 265, 257, C-SRC IN COMPLEX WITH ATP-CHCL
817, 5nk0A, 0.8316, 2.30, 0.398, 273, 254, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
818, 5cf5B, 0.8316, 2.54, 0.372, 294, 261, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
819, 5amnA, 0.8316, 2.45, 0.420, 287, 257, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
820, 4rfzA, 0.8316, 2.65, 0.446, 263, 260, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
821, 4gu9A, 0.8316, 1.68, 0.406, 252, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
822, 4d2rA, 0.8315, 2.78, 0.429, 300, 268, HUMAN IGF IN COMPLEX WITH A DYRK1B INHIBITOR
823, 3tudA, 0.8315, 1.80, 0.392, 256, 250, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH N-(4-METHYL-3-(8-METHYL-7- OXO-2-(PHENYLAMINO)-78-DIHYDROPYRIDO[23-D]PYRIMIDIN-6-YL)PHENYL)-3- (TRIFLUOROMETHYL)BENZAMIDE
824, 2pvyC, 0.8315, 1.99, 0.414, 285, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
825, 6d8eA, 0.8313, 2.60, 0.380, 304, 258, DISCOVERY OF A HIGHLY POTENT AND BROADLY EFFECTIVE EGFR AND HER2 EXON 20 INSERTION MUTANT INHIBITOR 
826, 5ia0A, 0.8313, 2.34, 0.396, 263, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
827, 5canA, 0.8313, 2.45, 0.374, 301, 257, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
828, 5c8mA, 0.8313, 2.45, 0.374, 302, 257, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
829, 4otqA, 0.8313, 2.52, 0.444, 263, 259, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
830, 3pxkA, 0.8313, 1.77, 0.406, 256, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
831, 2oj9A, 0.8313, 2.64, 0.410, 295, 266, STRUCTURE OF IGF-1R KINASE DOMAIN COMPLEXED WITH A BENZIMIDAZOLE INHIBITOR
832, 1yi6B, 0.8313, 2.72, 0.481, 274, 260, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
833, 5mjaA, 0.8312, 2.55, 0.393, 271, 257, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
834, 5capA, 0.8312, 2.34, 0.375, 303, 256, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
835, 4anqA, 0.8312, 2.49, 0.411, 293, 258, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
836, 3eqrA, 0.8312, 2.12, 0.403, 270, 253, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
837, 6fnmA, 0.8311, 2.58, 0.394, 270, 259, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH DASATINIB 
838, 4rixB, 0.8311, 2.64, 0.388, 293, 258, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
839, 5c8kA, 0.8310, 2.45, 0.374, 300, 257, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
840, 5bq0A, 0.8310, 2.73, 0.426, 265, 263, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
841, 4rx5A, 0.8310, 2.73, 0.454, 265, 262, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
842, 3ugcA, 0.8310, 1.97, 0.381, 274, 252, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
843, 5x28A, 0.8309, 2.47, 0.381, 310, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(6)
844, 4d4sA, 0.8309, 1.74, 0.400, 255, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN
845, 2ityA, 0.8309, 2.44, 0.385, 300, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
846, 5sysB, 0.8308, 2.46, 0.469, 258, 254, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
847, 3qquC, 0.8308, 2.75, 0.429, 293, 268, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
848, 3en4A, 0.8308, 2.32, 0.474, 257, 253, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
849, 2ituA, 0.8308, 2.45, 0.377, 304, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
850, 5vgoA, 0.8307, 2.73, 0.454, 265, 262, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
851, 4mxxA, 0.8307, 2.49, 0.473, 266, 256, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
852, 4mxoA, 0.8307, 2.61, 0.475, 266, 257, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
853, 5kupA, 0.8306, 2.59, 0.452, 265, 261, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
854, 5c27A, 0.8306, 2.08, 0.398, 272, 254, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
855, 4ansA, 0.8306, 2.50, 0.411, 293, 258, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
856, 3d7uB, 0.8306, 2.40, 0.469, 258, 254, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
857, 2ittA, 0.8306, 2.45, 0.377, 302, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
858, 5ghvB, 0.8305, 1.91, 0.404, 265, 250, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
859, 6gl9A, 0.8304, 2.42, 0.364, 292, 258, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
860, 3zfxI, 0.8304, 2.25, 0.407, 263, 253, CRYSTAL STRUCTURE OF EPHB1
861, 2hz0B, 0.8304, 1.28, 0.992, 243, 242, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
862, 5cy3A, 0.8303, 2.30, 0.393, 276, 257, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
863, 5caqA, 0.8303, 2.47, 0.374, 301, 257, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
864, 4rx8A, 0.8302, 2.04, 0.395, 269, 253, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
865, 2pvyB, 0.8302, 1.93, 0.416, 286, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
866, 5em7A, 0.8301, 2.42, 0.371, 300, 256, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
867, 2bdfB, 0.8301, 2.66, 0.479, 265, 259, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
868, 5ghvA, 0.8300, 1.95, 0.408, 265, 250, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
869, 5x26A, 0.8299, 2.49, 0.381, 302, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(3)
870, 5edqA, 0.8299, 2.47, 0.370, 298, 257, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
871, 4o2pB, 0.8299, 2.50, 0.473, 265, 256, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
872, 4i4fA, 0.8299, 2.19, 0.409, 255, 252, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH AN ALLOSTERIC BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
873, 3zfxE, 0.8299, 2.14, 0.409, 262, 252, CRYSTAL STRUCTURE OF EPHB1
874, 2yfxA, 0.8299, 2.50, 0.407, 292, 258, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
875, 5j9zA, 0.8298, 2.59, 0.376, 291, 258, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
876, 4rg0A, 0.8298, 2.52, 0.444, 263, 259, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
877, 5t0pB, 0.8297, 2.52, 0.471, 263, 255, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
878, 4otrA, 0.8297, 2.53, 0.444, 263, 259, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
879, 3svvA, 0.8297, 2.43, 0.465, 261, 254, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
880, 2itvA, 0.8297, 2.46, 0.381, 303, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
881, 5k9iB, 0.8296, 2.50, 0.475, 262, 255, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
882, 5hicA, 0.8296, 2.47, 0.374, 302, 257, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
883, 5caoA, 0.8296, 2.42, 0.371, 300, 256, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
884, 3uqfA, 0.8296, 2.50, 0.475, 260, 255, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
885, 3efkA, 0.8296, 2.19, 0.382, 276, 254, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
886, 3dqxA, 0.8296, 2.56, 0.482, 267, 257, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
887, 1yomB, 0.8296, 2.42, 0.467, 261, 255, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
888, 5ur1B, 0.8295, 2.22, 0.413, 265, 254, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
889, 5cf4B, 0.8295, 2.45, 0.375, 291, 259, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
890, 5l3aA, 0.8294, 2.25, 0.373, 290, 255, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
891, 5a9uA, 0.8294, 2.48, 0.409, 292, 257, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
892, 3i81A, 0.8294, 2.71, 0.434, 296, 265, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH BMS-754807 [1-(4-((5-CYCLOPROPYL- 1H-PYRAZOL-3-YL)AMINO)PYRROLO[21-F][124]TRIAZIN-2-YL)-N- (6-FLUORO-3-PYRIDINYL)-2-METHYL-L-PROLINAMIDE]
893, 5ugcA, 0.8293, 2.93, 0.378, 280, 262, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(3- METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO]-9-METHYL-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
894, 5t3qA, 0.8293, 2.05, 0.373, 278, 252, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
895, 4anlA, 0.8293, 2.50, 0.411, 292, 258, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE
896, 3qquD, 0.8293, 2.80, 0.429, 292, 268, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
897, 2og8B, 0.8293, 1.98, 0.474, 249, 249, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
898, 5x27A, 0.8292, 2.49, 0.381, 302, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(5)
899, 5hcyA, 0.8292, 2.47, 0.374, 302, 257, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
900, 3q6uA, 0.8292, 2.22, 0.384, 287, 255, STRUCTURE OF THE APO MET RECEPTOR KINASE IN THE DUALLY-PHOSPHORYLATED ACTIVATED STATE
901, 3fqeA, 0.8291, 2.19, 0.398, 269, 254, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
902, 5xp7B, 0.8290, 2.66, 0.475, 267, 257, C-SRC IN COMPLEX WITH ATP-CHCL
903, 5cf6B, 0.8290, 2.50, 0.375, 290, 259, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
904, 5ug8A, 0.8289, 2.94, 0.378, 280, 262, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(1- METHYL-1H-PYRAZOL-4-YL)AMINO]-9-(PROPAN-2-YL)-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
905, 3q32B, 0.8289, 2.59, 0.372, 294, 261, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
906, 3kxzA, 0.8289, 2.17, 0.478, 263, 253, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
907, 3d94A, 0.8289, 2.65, 0.438, 288, 258, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
908, 2itnA, 0.8288, 2.48, 0.377, 304, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
909, 2hk5A, 0.8288, 2.27, 0.478, 269, 253, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
910, 5ug9A, 0.8287, 2.94, 0.378, 280, 262, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(3- METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO]-9-(PROPAN-2-YL)-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
911, 5hcxA, 0.8287, 2.44, 0.375, 298, 256, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
912, 4twnA, 0.8287, 2.66, 0.394, 276, 259, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH BIRB796
913, 2oiqB, 0.8287, 2.45, 0.478, 265, 255, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
914, 5swhA, 0.8286, 2.49, 0.469, 258, 254, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
915, 4mxoB, 0.8286, 2.46, 0.478, 264, 255, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
916, 4ctbA, 0.8286, 2.47, 0.409, 292, 257, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (5R)-8-AMINO-3-FLUORO-519-DIMETHYL-20-OXO-5181920- TETRAHYDRO-711-(AZENO)PYRIDO(2 1 :23)IMIDAZO(45-H)(2511) BENZOXADIAZACYCLOTETRADECINE-14-CARBONITRILE
917, 4i4eA, 0.8285, 1.78, 0.400, 254, 250, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH HINGE BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
918, 3qtiB, 0.8285, 2.41, 0.363, 280, 256, C-MET KINASE IN COMPLEX WITH NVP-BVU972
919, 3q32A, 0.8285, 2.36, 0.376, 291, 258, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
920, 6fnhC, 0.8284, 2.37, 0.396, 270, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
921, 4riyB, 0.8284, 2.57, 0.393, 293, 257, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
922, 4pv0A, 0.8284, 1.98, 0.397, 268, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
923, 5edrA, 0.8283, 2.50, 0.374, 299, 257, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
924, 5aacA, 0.8283, 2.49, 0.409, 292, 257, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
925, 4yhfB, 0.8283, 2.79, 0.454, 269, 262, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
926, 4mxzA, 0.8283, 2.63, 0.467, 266, 257, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
927, 4mxyA, 0.8283, 2.63, 0.467, 266, 257, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
928, 4ivaA, 0.8283, 2.23, 0.371, 290, 256, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
929, 3genA, 0.8283, 2.72, 0.452, 264, 261, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
930, 5hg9A, 0.8282, 2.80, 0.381, 280, 260, EGFR (L858R T790M V948R) IN COMPLEX WITH 1-[(3R4R)-3-[({2-[(1- METHYL-1H-PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY) METHYL]-4-(TRIFLUOROMETHYL)PYRROLIDIN-1-YL]PROP-2-EN-1-ONE
931, 5em6A, 0.8282, 2.45, 0.375, 301, 256, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
932, 4z16B, 0.8282, 2.18, 0.368, 276, 253, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
933, 4d5kA, 0.8282, 1.78, 0.400, 255, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN
934, 4d58A, 0.8282, 1.78, 0.400, 255, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
935, 2eb3A, 0.8282, 2.46, 0.371, 294, 256, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
936, 6gl9B, 0.8280, 2.40, 0.366, 291, 257, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
937, 5uglB, 0.8280, 2.21, 0.413, 271, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
938, 5c8nA, 0.8280, 2.45, 0.375, 300, 256, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
939, 4rj4A, 0.8279, 2.45, 0.371, 299, 256, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
940, 4d5hA, 0.8279, 1.78, 0.400, 255, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN
941, 6fniA, 0.8278, 2.30, 0.395, 261, 253, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH NVP-BHG712 
942, 5zj6A, 0.8278, 2.59, 0.452, 271, 259, CRYSTAL STRUCTURE OF HCK KINASE COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4- PHENOXYPHENYL)-7H-PYRROLO[2;3-D]PYRIMIDIN-4-AMINE 
943, 4xg6A, 0.8278, 2.01, 0.397, 271, 252, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
944, 4lqmA, 0.8278, 2.44, 0.381, 305, 257, EGFR L858R IN COMPLEX WITH PD168393
945, 4d4yA, 0.8278, 1.79, 0.400, 255, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN
946, 5p9jA, 0.8277, 2.73, 0.444, 263, 261, BTK1 COCRYSTALLIZED WITH IBRUTINIB
947, 5aa8A, 0.8277, 2.51, 0.412, 292, 257, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
948, 4k9yA, 0.8277, 2.56, 0.408, 271, 260, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-[4-(6-AMINO- PURIN-9-YL)-PHENYL]-3-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-UREA
949, 4aqcB, 0.8277, 2.65, 0.370, 295, 262, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
950, 3ocsA, 0.8277, 2.58, 0.454, 264, 260, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
951, 3dqxB, 0.8277, 2.66, 0.481, 268, 258, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
952, 2xyuA, 0.8277, 2.29, 0.387, 260, 253, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH VUF 12058
953, 4i0rA, 0.8276, 1.94, 0.404, 264, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
954, 4ewhA, 0.8275, 2.20, 0.398, 274, 254, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
955, 4knbB, 0.8274, 1.89, 0.371, 256, 251, C-MET IN COMPLEX WITH OSI LIGAND
956, 4fz6A, 0.8274, 2.00, 0.402, 266, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
957, 5tiuA, 0.8272, 1.85, 0.392, 266, 250, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
958, 2z8cA, 0.8272, 2.54, 0.415, 297, 258, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
959, 5p9hA, 0.8271, 2.59, 0.454, 264, 260, BTK1 COCRYSTALLIZED WITH RN983
960, 3a4oX, 0.8271, 2.40, 0.480, 259, 256, LYN KINASE DOMAIN
961, 5fedA, 0.8270, 2.50, 0.380, 288, 255, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
962, 4fnwA, 0.8270, 2.40, 0.406, 304, 256, CRYSTAL STRUCTURE OF THE APO F1174L ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
963, 4agwA, 0.8270, 2.42, 0.469, 258, 254, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
964, 5zj6B, 0.8269, 2.61, 0.452, 270, 259, CRYSTAL STRUCTURE OF HCK KINASE COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4- PHENOXYPHENYL)-7H-PYRROLO[2;3-D]PYRIMIDIN-4-AMINE 
965, 5hg7A, 0.8269, 2.81, 0.381, 280, 260, EGFR (L858R T790M V948R) IN COMPLEX WITH 1-{(3R4R)-3-[5-CHLORO-2- (1-METHYL-1H-PYRAZOL-4-YLAMINO)-7H-PYRROLO[23-D]PYRIMIDIN-4- YLOXYMETHYL]-4-METHOXY-PYRROLIDIN-1-YL}PROPENONE (PF-06459988)
966, 4rj5A, 0.8269, 2.42, 0.373, 296, 255, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
967, 3zewA, 0.8269, 2.33, 0.389, 269, 252, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
968, 1xbaA, 0.8269, 1.95, 0.394, 266, 251, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
969, 3ctjA, 0.8268, 2.34, 0.380, 289, 255, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
970, 4g5pA, 0.8267, 2.75, 0.382, 299, 262, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
971, 4d0xA, 0.8267, 2.44, 0.372, 291, 258, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
972, 1mqbB, 0.8267, 2.46, 0.395, 265, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
973, 5xdlA, 0.8266, 2.44, 0.380, 292, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
974, 5lwnA, 0.8266, 2.38, 0.363, 290, 256, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
975, 4xg4A, 0.8266, 1.96, 0.410, 264, 249, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
976, 4riwB, 0.8266, 2.59, 0.397, 293, 257, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
977, 4r5sA, 0.8266, 2.57, 0.377, 299, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
978, 4ctcA, 0.8266, 2.47, 0.410, 288, 256, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
979, 4ccbA, 0.8266, 2.45, 0.410, 287, 256, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 3-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(5-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE
980, 4agwB, 0.8266, 2.40, 0.470, 257, 253, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
981, 4k8aA, 0.8265, 1.72, 0.415, 251, 248, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
982, 3ug1A, 0.8265, 2.44, 0.374, 296, 254, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
983, 3e64A, 0.8265, 2.45, 0.376, 291, 258, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
984, 2y6oA, 0.8265, 2.31, 0.383, 263, 253, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH DASATINIB.
985, 2j5fA, 0.8265, 2.45, 0.385, 308, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
986, 5lwmA, 0.8264, 2.39, 0.363, 290, 256, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
987, 4csvA, 0.8264, 1.47, 0.675, 244, 243, TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL BOUND TO GLEEVEC
988, 3eqrB, 0.8264, 2.21, 0.401, 271, 252, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
989, 2yhvA, 0.8264, 2.50, 0.405, 291, 257, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE
990, 2itzA, 0.8264, 2.52, 0.381, 302, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
991, 4dflA, 0.8263, 1.83, 0.398, 263, 249, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
992, 3fy2A, 0.8263, 2.55, 0.391, 285, 258, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BOUND TO SUBSTRATE KQWDNYEFIW
993, 2reiA, 0.8263, 2.44, 0.382, 277, 254, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7)
994, 5hczA, 0.8262, 2.47, 0.375, 300, 256, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
995, 4fl1A, 0.8262, 2.01, 0.402, 268, 251, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
996, 5fboA, 0.8261, 2.25, 0.451, 255, 255, BTK-INHIBITOR CO-STRUCTURE
997, 5aepA, 0.8261, 2.46, 0.370, 287, 257, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
998, 2jitA, 0.8261, 2.76, 0.363, 299, 262, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
999, 4rj8A, 0.8260, 2.42, 0.376, 298, 255, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
1000, 3qlfB, 0.8260, 2.40, 0.470, 258, 253, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
1001, 2helA, 0.8258, 2.22, 0.403, 256, 253, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
1002, 6drwA, 0.8257, 2.39, 0.369, 289, 255, JAK2 JH1 IN COMPLEX WITH JNJ-7706621 (CRYSTAL FORM 2) 
1003, 5t68A, 0.8257, 2.06, 0.406, 266, 251, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
1004, 5sysA, 0.8257, 2.33, 0.472, 258, 252, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
1005, 5fxqA, 0.8257, 2.78, 0.414, 302, 266, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
1006, 4rj7A, 0.8257, 2.39, 0.374, 295, 254, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
1007, 4k2rA, 0.8257, 2.72, 0.365, 551, 263, STRUCTURAL BASIS FOR ACTIVATION OF ZAP-70 BY PHOSPHORYLATION OF THE SH2-KINASE LINKER
1008, 3pjcA, 0.8257, 2.25, 0.364, 286, 253, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
1009, 1fvrB, 0.8257, 2.79, 0.390, 300, 259, TIE2 KINASE DOMAIN
1010, 4ybjA, 0.8256, 2.19, 0.472, 255, 250, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
1011, 3ug2A, 0.8256, 2.54, 0.375, 299, 256, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
1012, 3e62A, 0.8256, 2.49, 0.376, 291, 258, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
1013, 3bu6A, 0.8256, 2.40, 0.418, 294, 256, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
1014, 3aoxA, 0.8255, 2.36, 0.408, 298, 255, X-RAY CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CH5424802
1015, 5j87A, 0.8254, 2.73, 0.454, 263, 260, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1016, 4ybjB, 0.8254, 2.20, 0.470, 253, 249, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
1017, 4lrmB, 0.8254, 2.64, 0.385, 293, 260, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
1018, 2jkoA, 0.8254, 1.91, 0.402, 256, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1019, 1mqbA, 0.8254, 2.39, 0.396, 263, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
1020, 3krrA, 0.8253, 2.39, 0.374, 291, 257, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
1021, 5bpyA, 0.8252, 2.72, 0.454, 263, 260, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
1022, 3efjA, 0.8251, 2.24, 0.378, 276, 254, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
1023, 3e63A, 0.8251, 2.45, 0.377, 290, 257, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
1024, 5swhB, 0.8250, 2.56, 0.467, 261, 255, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
1025, 4xlvA, 0.8250, 2.48, 0.413, 307, 259, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
1026, 4gk4A, 0.8250, 2.58, 0.393, 275, 257, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
1027, 4fz7A, 0.8250, 2.03, 0.398, 265, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
1028, 4bbeC, 0.8250, 2.20, 0.372, 288, 253, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1029, 3vf8A, 0.8250, 1.92, 0.396, 265, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
1030, 3qlgB, 0.8250, 2.51, 0.470, 260, 253, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
1031, 3g5dB, 0.8250, 2.27, 0.480, 257, 250, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
1032, 3cjfA, 0.8250, 2.33, 0.381, 276, 252, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
1033, 5casA, 0.8249, 2.45, 0.376, 299, 255, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
1034, 4nwmB, 0.8249, 2.67, 0.461, 261, 258, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
1035, 4bbeD, 0.8249, 2.18, 0.372, 288, 253, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1036, 4aw5A, 0.8249, 2.27, 0.387, 261, 253, COMPLEX OF THE EPHB4 KINASE DOMAIN WITH AN OXINDOLE INHIBITOR
1037, 3efkB, 0.8248, 2.17, 0.385, 272, 252, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
1038, 5cf5A, 0.8247, 2.35, 0.375, 287, 256, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1039, 2ozoA, 0.8247, 2.96, 0.347, 545, 265, AUTOINHIBITED INTACT HUMAN ZAP-70
1040, 5t0pA, 0.8245, 2.57, 0.471, 264, 255, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
1041, 3fxxA, 0.8245, 2.56, 0.391, 288, 258, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BOUND TO SUBSTRATE KQWDNYE[PTYR]IW
1042, 4bbeB, 0.8244, 2.21, 0.372, 288, 253, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1043, 6fnlA, 0.8243, 2.31, 0.398, 262, 254, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE 
1044, 5fm2A, 0.8243, 2.28, 0.421, 273, 252, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
1045, 4gk3A, 0.8242, 2.55, 0.391, 275, 256, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
1046, 4d0wA, 0.8242, 2.37, 0.371, 289, 256, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
1047, 4bbfB, 0.8242, 2.23, 0.375, 288, 253, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1048, 3eqpA, 0.8241, 2.07, 0.398, 268, 251, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
1049, 3eknA, 0.8241, 2.57, 0.409, 297, 259, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
1050, 2vwvA, 0.8241, 2.24, 0.385, 255, 252, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1051, 5xgmA, 0.8240, 2.45, 0.384, 288, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH GO6976
1052, 4rj6A, 0.8240, 2.46, 0.373, 297, 255, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
1053, 5fxrA, 0.8239, 2.80, 0.414, 300, 266, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
1054, 4bbfC, 0.8239, 2.26, 0.375, 288, 253, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1055, 2zvaA, 0.8239, 2.19, 0.480, 261, 252, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
1056, 5cauA, 0.8238, 2.46, 0.376, 297, 255, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
1057, 4bbeA, 0.8238, 2.21, 0.372, 288, 253, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1058, 5uq0B, 0.8237, 1.88, 0.415, 256, 248, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
1059, 4fnxA, 0.8237, 2.61, 0.399, 292, 258, CRYSTAL STRUCTURE OF THE APO R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
1060, 4ewhB, 0.8237, 2.22, 0.399, 273, 253, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
1061, 6glbB, 0.8236, 2.49, 0.367, 288, 256, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
1062, 6glbA, 0.8236, 2.50, 0.367, 288, 256, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
1063, 5y5tA, 0.8236, 1.89, 0.399, 263, 248, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
1064, 1jpaA, 0.8236, 2.54, 0.390, 273, 254, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
1065, 5fm3A, 0.8234, 2.27, 0.421, 276, 252, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
1066, 3f6xA, 0.8233, 2.44, 0.474, 264, 253, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1067, 5em5A, 0.8232, 2.47, 0.369, 298, 255, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
1068, 5cf8B, 0.8232, 2.48, 0.377, 288, 257, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1069, 4xi2A, 0.8232, 2.93, 0.452, 421, 263, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
1070, 2x2mB, 0.8232, 2.09, 0.422, 279, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
1071, 5lmaA, 0.8231, 2.06, 0.400, 267, 250, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
1072, 1yolB, 0.8231, 2.21, 0.462, 253, 249, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
1073, 4p5qA, 0.8230, 2.55, 0.391, 275, 256, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
1074, 3efjB, 0.8230, 2.22, 0.375, 275, 253, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
1075, 1yvjA, 0.8230, 2.28, 0.369, 288, 255, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
1076, 5tehB, 0.8229, 2.73, 0.465, 262, 258, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
1077, 4rssA, 0.8228, 2.13, 0.397, 269, 252, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
1078, 4nwmA, 0.8228, 2.70, 0.461, 261, 258, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
1079, 3pj2A, 0.8228, 1.80, 0.460, 248, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[4-(2- DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-6-(4-FLUORO-PHENOXY)-8-METHYL-8H- PYRIDO[23-D]PYRIMIDIN-7-ONE
1080, 3kckA, 0.8228, 2.12, 0.377, 285, 252, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
1081, 1yolA, 0.8228, 2.34, 0.462, 256, 251, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
1082, 5cf6A, 0.8227, 2.24, 0.378, 285, 254, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1083, 4px6A, 0.8227, 1.97, 0.406, 262, 249, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
1084, 4ji9B, 0.8227, 2.46, 0.377, 288, 257, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
1085, 4c3fA, 0.8227, 2.12, 0.450, 257, 251, STRUCTURE OF LCK IN COMPLEX WITH A COMPOUND DISCOVERED BY VIRTUAL FRAGMENT LINKING
1086, 2y6mA, 0.8227, 2.31, 0.393, 262, 252, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN
1087, 6glaA, 0.8226, 2.51, 0.367, 288, 256, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
1088, 4f09A, 0.8226, 2.32, 0.376, 288, 255, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
1089, 1y6aA, 0.8226, 1.59, 0.384, 261, 245, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 2-ANILINO-5-ARYL-OXAZOLE INHIBITOR
1090, 5nk8A, 0.8225, 1.98, 0.403, 266, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2F
1091, 4hctA, 0.8225, 2.87, 0.416, 265, 262, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
1092, 1fvrA, 0.8225, 2.78, 0.391, 299, 258, TIE2 KINASE DOMAIN
1093, 6glaB, 0.8224, 2.52, 0.367, 286, 256, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
1094, 3f6xC, 0.8224, 2.56, 0.465, 265, 254, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1095, 5j5sA, 0.8223, 2.47, 0.472, 258, 254, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
1096, 4ythA, 0.8223, 2.19, 0.375, 287, 253, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
1097, 2bdfA, 0.8223, 2.61, 0.477, 261, 256, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
1098, 5feeA, 0.8222, 2.51, 0.374, 287, 254, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
1099, 2bdjA, 0.8222, 2.08, 0.490, 254, 249, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
1100, 5usyB, 0.8221, 2.33, 0.378, 287, 254, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
1101, 5nudB, 0.8221, 2.27, 0.431, 271, 253, FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
1102, 4hvgA, 0.8221, 2.22, 0.364, 281, 253, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
1103, 4d1sA, 0.8221, 2.13, 0.380, 280, 250, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
1104, 3sxrA, 0.8221, 2.06, 0.426, 260, 249, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
1105, 5d12A, 0.8220, 2.42, 0.464, 260, 252, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
1106, 4gfmA, 0.8220, 2.44, 0.379, 289, 256, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
1107, 3zzwA, 0.8220, 2.56, 0.328, 269, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
1108, 2og8A, 0.8220, 1.89, 0.472, 246, 246, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
1109, 5usyA, 0.8219, 2.35, 0.378, 287, 254, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
1110, 4xg3B, 0.8218, 2.02, 0.414, 267, 249, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1111, 4g2fA, 0.8218, 2.64, 0.391, 275, 256, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
1112, 3mpmA, 0.8218, 2.22, 0.450, 257, 251, LCK COMPLEXED WITH A PYRAZOLOPYRIMIDINE
1113, 1mp8A, 0.8218, 1.82, 0.406, 252, 249, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE (FAK)
1114, 4mcvB, 0.8217, 2.56, 0.457, 265, 256, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
1115, 4gvjA, 0.8217, 2.32, 0.341, 290, 255, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
1116, 3zfyA, 0.8217, 2.53, 0.378, 260, 254, CRYSTAL STRUCTURE OF EPHB3
1117, 3tjcB, 0.8217, 2.40, 0.379, 287, 256, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
1118, 3fztA, 0.8216, 1.99, 0.414, 259, 251, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-4618433
1119, 2xp2A, 0.8216, 2.43, 0.409, 285, 254, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB (PF-02341066)
1120, 6dkwB, 0.8215, 2.11, 0.381, 269, 252, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 3. 
1121, 4ytfA, 0.8215, 2.16, 0.377, 283, 252, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
1122, 1yi6A, 0.8215, 2.75, 0.479, 274, 259, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
1123, 3rvgA, 0.8214, 2.37, 0.378, 285, 254, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
1124, 3fzoA, 0.8214, 2.34, 0.378, 262, 254, CRYSTAL STRUCTURE OF PYK2-APO PROLINE-RICH TYROSINE KINASE
1125, 2qo9A, 0.8214, 2.60, 0.393, 277, 257, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
1126, 2ivvA, 0.8214, 2.42, 0.427, 282, 253, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
1127, 3dkoA, 0.8213, 2.51, 0.383, 275, 253, COMPLEX BETWEEN THE KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7) AND INHIBITOR ALW-II-49-7
1128, 3bu3A, 0.8213, 2.34, 0.420, 294, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
1129, 1k9aF, 0.8213, 2.48, 0.435, 436, 255, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
1130, 4otfA, 0.8212, 2.59, 0.453, 262, 258, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
1131, 4cmtA, 0.8211, 2.36, 0.411, 284, 253, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(3-(METHYLSULFONYL)PHENYL)PYRIDIN-2-AMINE
1132, 3zewB, 0.8211, 2.11, 0.387, 252, 248, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
1133, 4xg7A, 0.8210, 2.03, 0.396, 266, 250, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1134, 5t68B, 0.8208, 2.01, 0.406, 264, 249, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
1135, 5t18A, 0.8208, 2.66, 0.453, 261, 258, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
1136, 4p5zA, 0.8208, 2.55, 0.386, 267, 254, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
1137, 3t9tA, 0.8208, 2.82, 0.396, 263, 260, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
1138, 3d7tB, 0.8207, 2.55, 0.453, 265, 256, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
1139, 2yn8B, 0.8207, 2.30, 0.386, 260, 251, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1140, 4lrmC, 0.8206, 2.71, 0.381, 293, 260, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
1141, 4bbfD, 0.8206, 2.25, 0.372, 288, 253, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1142, 4py1A, 0.8205, 2.35, 0.341, 289, 255, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
1143, 3vf9A, 0.8205, 1.97, 0.402, 265, 249, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
1144, 3d7uA, 0.8205, 2.30, 0.466, 257, 251, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
1145, 5zwjA, 0.8204, 2.70, 0.389, 267, 257, CRYSTAL STRUCTURE OF EGFR 675-1022 T790M/C797S/V948R IN COMPLEX WITH EAI045 
1146, 5d11A, 0.8204, 2.33, 0.460, 254, 250, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
1147, 3d7uC, 0.8204, 2.30, 0.466, 257, 251, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
1148, 4ytcA, 0.8203, 2.18, 0.377, 284, 252, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
1149, 4bbfA, 0.8203, 2.28, 0.372, 288, 253, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1150, 4trlA, 0.8202, 2.18, 0.414, 268, 251, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
1151, 3jy9A, 0.8202, 2.10, 0.378, 282, 251, JANUS KINASE 2 INHIBITORS
1152, 5flfE, 0.8201, 1.97, 0.403, 258, 248, DISEASE LINKED MUTATION IN FGFR
1153, 3iokA, 0.8201, 2.19, 0.377, 285, 252, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
1154, 4fl3A, 0.8200, 2.41, 0.388, 538, 255, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
1155, 1rqqB, 0.8200, 2.46, 0.418, 294, 256, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
1156, 5y5uA, 0.8199, 1.98, 0.402, 266, 249, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
1157, 5h0gA, 0.8199, 2.67, 0.453, 446, 258, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-N4-DIMETHYLPENTANAMIDE
1158, 3d7uD, 0.8198, 2.01, 0.480, 248, 248, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
1159, 3g5dA, 0.8197, 2.20, 0.476, 256, 248, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
1160, 4mcvA, 0.8196, 2.68, 0.451, 267, 257, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
1161, 4lrmA, 0.8196, 2.80, 0.382, 307, 262, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
1162, 2w1iA, 0.8196, 2.31, 0.379, 284, 253, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
1163, 4wkqA, 0.8195, 2.52, 0.383, 296, 253, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
1164, 5j5sB, 0.8194, 2.47, 0.470, 258, 253, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
1165, 4yjoA, 0.8194, 2.07, 0.402, 267, 249, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
1166, 2w1iB, 0.8194, 2.33, 0.379, 284, 253, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
1167, 3f3tB, 0.8191, 2.39, 0.474, 259, 251, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
1168, 4z16D, 0.8190, 2.34, 0.371, 271, 251, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
1169, 4z16C, 0.8190, 2.24, 0.372, 271, 250, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
1170, 4xg2A, 0.8190, 1.77, 0.408, 259, 245, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
1171, 4z16A, 0.8189, 2.24, 0.372, 271, 250, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
1172, 4ytiA, 0.8189, 2.20, 0.377, 284, 252, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
1173, 4aqcA, 0.8189, 2.33, 0.373, 289, 255, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
1174, 3lpbB, 0.8189, 2.47, 0.380, 284, 255, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
1175, 1k3aA, 0.8189, 2.48, 0.441, 288, 256, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
1176, 4id7A, 0.8188, 2.13, 0.406, 268, 251, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
1177, 5lmbA, 0.8187, 1.93, 0.403, 264, 248, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
1178, 4q9sA, 0.8187, 1.87, 0.402, 252, 249, CRYSTAL STRUCTURE OF HUMAN FOCAL ADHESION KINASE (FAK) BOUND TO COMPOUND1 (35-DIHYDRO[124]TRIAZINO[34-C][14]BENZOXAZIN-2(1H)- ONE)
1179, 2qokA, 0.8187, 2.72, 0.389, 281, 257, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:S768A TRIPLE MUTANT
1180, 2qocA, 0.8187, 2.44, 0.396, 283, 255, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
1181, 5j87D, 0.8186, 2.67, 0.452, 263, 259, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1182, 5walA, 0.8185, 2.20, 0.333, 286, 252, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
1183, 5u6cA, 0.8185, 2.53, 0.459, 272, 257, CRYSTAL STRUCTURE OF THE MER KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
1184, 5h0eA, 0.8185, 2.68, 0.453, 446, 258, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANAMIDE
1185, 3lxnA, 0.8185, 2.38, 0.335, 287, 254, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
1186, 2b7aB, 0.8185, 2.45, 0.379, 287, 256, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
1187, 4zimA, 0.8184, 2.30, 0.378, 285, 254, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
1188, 3el7A, 0.8184, 2.34, 0.468, 254, 250, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 3
1189, 2yjsA, 0.8184, 2.40, 0.411, 286, 253, STRUCTURE OF C1156Y MUTANT ANAPLASTIC LYMPHOMA KINASE
1190, 2qoqA, 0.8184, 2.51, 0.388, 284, 255, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BASE AMP-PNP BOUND STRUCTURE
1191, 5tq3B, 0.8183, 2.39, 0.376, 285, 255, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1192, 5j87C, 0.8183, 2.72, 0.453, 261, 258, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1193, 5cf8A, 0.8183, 2.26, 0.375, 285, 253, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1194, 4xg3A, 0.8183, 1.77, 0.402, 262, 246, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1195, 3svvB, 0.8182, 2.50, 0.468, 257, 252, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
1196, 3d7tA, 0.8181, 1.96, 0.460, 249, 248, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
1197, 4hcuA, 0.8180, 2.84, 0.415, 263, 260, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
1198, 4xg9B, 0.8179, 2.03, 0.406, 265, 249, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1199, 4hgeB, 0.8179, 2.53, 0.377, 288, 257, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
1200, 4dggB, 0.8179, 2.50, 0.458, 259, 253, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
1201, 3mj2A, 0.8179, 2.71, 0.418, 259, 256, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
1202, 3el8B, 0.8179, 2.54, 0.468, 259, 252, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
1203, 5h09A, 0.8178, 2.68, 0.453, 446, 258, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-ETHYL2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOATE
1204, 3sxrB, 0.8177, 2.03, 0.425, 258, 247, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
1205, 4p7eB, 0.8176, 2.45, 0.379, 285, 256, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
1206, 3bu5A, 0.8176, 2.34, 0.419, 291, 253, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
1207, 3io7A, 0.8175, 2.16, 0.378, 282, 251, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
1208, 1pkgA, 0.8175, 2.39, 0.391, 290, 253, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
1209, 5xy1A, 0.8174, 2.12, 0.480, 253, 250, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
1210, 5k9iA, 0.8174, 2.44, 0.474, 258, 253, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
1211, 4lrmE, 0.8172, 2.74, 0.381, 290, 260, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
1212, 4hcvA, 0.8172, 2.80, 0.417, 263, 259, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
1213, 1pkgB, 0.8172, 2.59, 0.388, 277, 255, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
1214, 5fbnC, 0.8171, 2.40, 0.455, 256, 253, BTK KINASE DOMAIN WITH INHIBITOR 1
1215, 3pp0B, 0.8171, 2.78, 0.386, 296, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
1216, 3nz0A, 0.8171, 2.45, 0.337, 285, 255, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
1217, 2zv8A, 0.8171, 2.25, 0.482, 257, 251, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
1218, 5h0hA, 0.8170, 2.69, 0.453, 446, 258, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-NN4-TRIMETHYLPENTANAMIDE
1219, 5h0bA, 0.8170, 2.70, 0.453, 446, 258, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOIC ACID
1220, 4m0zA, 0.8170, 2.89, 0.418, 264, 261, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
1221, 4ji9A, 0.8170, 2.19, 0.377, 284, 252, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
1222, 4giiA, 0.8170, 2.28, 0.336, 289, 253, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
1223, 5tq3A, 0.8168, 2.35, 0.378, 282, 254, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1224, 4m12A, 0.8168, 2.89, 0.418, 264, 261, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
1225, 4m13A, 0.8167, 2.85, 0.419, 264, 260, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
1226, 4e6dA, 0.8167, 2.30, 0.378, 286, 254, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
1227, 5tq5A, 0.8166, 2.47, 0.375, 291, 256, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1228, 4cnhA, 0.8165, 2.43, 0.405, 285, 252, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
1229, 5tobA, 0.8164, 1.51, 0.405, 245, 242, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
1230, 3tjdB, 0.8164, 2.46, 0.379, 287, 256, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
1231, 2qobA, 0.8164, 2.63, 0.375, 279, 256, HUMAN EPHA3 KINASE DOMAIN BASE STRUCTURE
1232, 5tq8A, 0.8163, 2.36, 0.376, 291, 255, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1233, 3en5B, 0.8163, 2.67, 0.473, 261, 256, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
1234, 4kaoA, 0.8162, 2.03, 0.412, 252, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
1235, 4zauA, 0.8160, 2.53, 0.385, 283, 252, AZD9291 COMPLEX WITH WILD TYPE EGFR
1236, 4twoA, 0.8160, 2.60, 0.392, 278, 255, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 164
1237, 4hvhA, 0.8160, 2.16, 0.368, 278, 250, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
1238, 3w2sA, 0.8159, 3.00, 0.382, 307, 262, EGFR KINASE DOMAIN WITH COMPOUND4
1239, 4gihA, 0.8158, 2.25, 0.333, 288, 252, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
1240, 3eyhA, 0.8158, 2.58, 0.362, 285, 254, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
1241, 5d12B, 0.8157, 2.37, 0.466, 253, 249, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
1242, 2qonA, 0.8157, 2.62, 0.392, 281, 255, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742A TRIPLE MUTANT
1243, 2gsfA, 0.8157, 2.71, 0.391, 281, 256, THE HUMAN EPHA3 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
1244, 3tubA, 0.8156, 1.98, 0.405, 253, 247, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-3-((1R2S)-2- PHENYLCYCLOPROPYL)UREA
1245, 4h1mA, 0.8155, 1.92, 0.357, 256, 249, CRYSTAL STRUCTURE OF PYK2 WITH THE INDOLE 10C
1246, 3fupB, 0.8155, 2.50, 0.379, 287, 256, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
1247, 3dkgA, 0.8155, 2.38, 0.377, 281, 252, STRUCTURE OF MUTANT(Y1248L) MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
1248, 3nyxA, 0.8154, 2.40, 0.337, 287, 255, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
1249, 2rfeA, 0.8154, 3.12, 0.382, 286, 262, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
1250, 1gagA, 0.8154, 2.49, 0.415, 300, 258, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
1251, 1rqqA, 0.8153, 2.65, 0.412, 294, 257, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
1252, 1ir3A, 0.8152, 2.50, 0.415, 300, 258, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
1253, 3qgyA, 0.8150, 2.00, 0.423, 246, 246, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
1254, 4m15A, 0.8149, 2.87, 0.419, 263, 260, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
1255, 4m0yA, 0.8148, 2.85, 0.417, 263, 259, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
1256, 3zfyB, 0.8148, 2.47, 0.378, 255, 251, CRYSTAL STRUCTURE OF EPHB3
1257, 3pp0A, 0.8148, 2.84, 0.386, 286, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
1258, 4pdoB, 0.8147, 1.81, 0.400, 261, 245, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
1259, 4f08A, 0.8147, 2.43, 0.376, 288, 255, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
1260, 4qt1A, 0.8146, 2.19, 0.368, 277, 250, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
1261, 4pdoA, 0.8145, 1.82, 0.396, 261, 245, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
1262, 4gk2A, 0.8145, 2.47, 0.389, 265, 252, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 66
1263, 4gj2A, 0.8145, 2.26, 0.337, 288, 252, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
1264, 4lrmD, 0.8144, 2.65, 0.384, 289, 258, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
1265, 4gj3A, 0.8144, 2.26, 0.333, 288, 252, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
1266, 4e20A, 0.8144, 2.36, 0.352, 282, 253, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
1267, 3vs3B, 0.8144, 2.58, 0.461, 431, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
1268, 4puzB, 0.8143, 2.21, 0.404, 265, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
1269, 2qo2A, 0.8143, 2.68, 0.388, 282, 255, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED APO STRUCTURE
1270, 2b7aA, 0.8143, 2.37, 0.379, 284, 253, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
1271, 1uwhA, 0.8143, 2.19, 0.313, 264, 252, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
1272, 5cf4A, 0.8141, 2.20, 0.378, 283, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1273, 4m14A, 0.8141, 2.83, 0.421, 263, 259, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
1274, 1jpaB, 0.8141, 2.55, 0.394, 269, 251, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
1275, 4i6qA, 0.8140, 2.15, 0.369, 277, 249, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
1276, 3fqhA, 0.8140, 1.87, 0.398, 262, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
1277, 2zm3A, 0.8140, 2.50, 0.441, 300, 256, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1278, 2xbaA, 0.8139, 2.36, 0.406, 283, 251, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PHA-E429
1279, 2rfeB, 0.8139, 2.92, 0.382, 273, 259, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
1280, 5ar7B, 0.8138, 2.48, 0.231, 278, 255, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
1281, 4gl9C, 0.8138, 2.29, 0.390, 282, 251, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
1282, 3srvB, 0.8138, 2.02, 0.401, 263, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
1283, 2qo7A, 0.8138, 2.62, 0.390, 278, 254, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED AMP-PNP BOUND
1284, 3u4wA, 0.8137, 3.24, 0.449, 275, 265, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC4B
1285, 3lxpA, 0.8137, 2.51, 0.339, 285, 254, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
1286, 4f08B, 0.8136, 2.51, 0.376, 288, 255, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
1287, 3rcdD, 0.8136, 2.33, 0.382, 271, 251, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
1288, 3lvpA, 0.8136, 2.70, 0.438, 289, 258, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1289, 5fbnD, 0.8135, 2.54, 0.449, 255, 254, BTK KINASE DOMAIN WITH INHIBITOR 1
1290, 6es0A, 0.8134, 2.61, 0.246, 288, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
1291, 5tozA, 0.8134, 2.16, 0.365, 278, 249, JAK3 WITH COVALENT INHIBITOR PF-06651600
1292, 3zfxB, 0.8133, 2.10, 0.411, 254, 246, CRYSTAL STRUCTURE OF EPHB1
1293, 3rcdB, 0.8133, 2.33, 0.382, 271, 251, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
1294, 3pizA, 0.8133, 1.84, 0.461, 245, 245, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH (5-AMINO-1-O- TOLYL-1H-PYRAZOL-4-YL)-[3-(1-METHANESULFONYL-PIPERIDIN-4-YL)-PHENYL]- METHANONE
1295, 2zv9A, 0.8133, 2.30, 0.486, 256, 251, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
1296, 4puzA, 0.8132, 2.13, 0.403, 263, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
1297, 4gl9B, 0.8132, 2.20, 0.388, 280, 250, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
1298, 3lxlA, 0.8131, 2.24, 0.364, 281, 250, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
1299, 5jrsA, 0.8129, 2.69, 0.459, 258, 255, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
1300, 4f4pA, 0.8129, 1.98, 0.409, 262, 247, SYK IN COMPLEX WITH LIGAND LASW836
1301, 3lpbA, 0.8129, 2.22, 0.378, 278, 251, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
1302, 4p4cA, 0.8127, 2.34, 0.386, 266, 251, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
1303, 4gl9A, 0.8127, 2.30, 0.390, 282, 251, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
1304, 3zfxF, 0.8126, 2.03, 0.412, 254, 245, CRYSTAL STRUCTURE OF EPHB1
1305, 1r1wA, 0.8126, 2.33, 0.377, 287, 252, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET
1306, 5e1sA, 0.8125, 2.14, 0.420, 284, 250, THE CRYSTAL STRUCTURE OF INSR TYROSINE KINASE IN COMPLEX WITH THE INHIBITOR BI 885578
1307, 4hgeA, 0.8125, 2.39, 0.379, 284, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
1308, 4h58C, 0.8125, 2.59, 0.298, 272, 258, BRAF IN COMPLEX WITH COMPOUND 3
1309, 2zm3B, 0.8125, 2.75, 0.440, 296, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1310, 6fu5A, 0.8124, 2.64, 0.239, 282, 255, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
1311, 5to8A, 0.8124, 1.80, 0.406, 250, 244, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
1312, 4gl9D, 0.8124, 2.20, 0.388, 282, 250, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
1313, 2rfnB, 0.8124, 2.25, 0.372, 269, 250, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
1314, 3srvA, 0.8123, 2.01, 0.405, 262, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
1315, 2henB, 0.8123, 2.33, 0.390, 259, 251, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
1316, 2yn8A, 0.8122, 2.19, 0.397, 253, 247, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1317, 2zm3D, 0.8121, 2.59, 0.443, 293, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1318, 3uqgB, 0.8120, 2.37, 0.472, 257, 248, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
1319, 3fzsA, 0.8120, 1.84, 0.352, 254, 247, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH BIRB796
1320, 5imxA, 0.8119, 2.21, 0.415, 266, 248, ANAPLASTIC LYMPHOMA KINASE (ALK) CATALYTIC DOMAIN COMPLEXED WITH NOVEL INHIBITOR 3-SULFONYLPYRAZOL-4-AMINO PYRIMIDINE
1321, 2henD, 0.8119, 2.34, 0.390, 259, 251, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
1322, 1sm2A, 0.8118, 1.99, 0.416, 245, 245, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1323, 4hvdA, 0.8117, 2.11, 0.367, 276, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
1324, 4neuA, 0.8116, 2.76, 0.278, 286, 259, X-RAY STRUCTURE OF RECEPTOR INTERACTING PROTEIN 1 (RIP1)KINASE DOMAIN WITH A 1-AMINOISOQUINOLINE INHIBITOR
1325, 2qodA, 0.8116, 2.57, 0.383, 274, 253, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y602F MUTANT
1326, 1uwhB, 0.8116, 2.22, 0.317, 264, 252, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
1327, 4e6dB, 0.8115, 2.53, 0.380, 286, 255, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
1328, 3tjcA, 0.8114, 2.30, 0.377, 284, 252, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
1329, 5bmmA, 0.8113, 3.31, 0.451, 275, 266, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC25B
1330, 2rfnA, 0.8113, 2.26, 0.372, 268, 250, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
1331, 2qoiA, 0.8113, 2.57, 0.383, 274, 253, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F DOUBLE MUTANT
1332, 6fu5B, 0.8112, 2.60, 0.230, 286, 256, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
1333, 4c8bB, 0.8112, 2.40, 0.233, 281, 253, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
1334, 3fupA, 0.8112, 2.42, 0.379, 284, 253, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
1335, 1snuA, 0.8112, 1.98, 0.416, 245, 245, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1336, 5gjdA, 0.8111, 2.43, 0.270, 292, 252, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 2
1337, 2qofA, 0.8111, 2.55, 0.383, 280, 253, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F MUTANT
1338, 4p7eA, 0.8110, 2.39, 0.379, 281, 253, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
1339, 4kioC, 0.8109, 2.42, 0.408, 251, 250, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
1340, 2zv7A, 0.8108, 2.32, 0.482, 257, 251, LYN TYROSINE KINASE DOMAIN APO FORM
1341, 2qooA, 0.8108, 2.57, 0.387, 273, 253, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742F TRIPLE MUTANT
1342, 3fqhB, 0.8107, 1.87, 0.410, 258, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
1343, 3w2rA, 0.8106, 2.63, 0.376, 297, 255, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
1344, 3ekkA, 0.8106, 2.11, 0.408, 285, 250, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
1345, 3zepC, 0.8105, 2.08, 0.368, 276, 247, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
1346, 3vs3A, 0.8105, 2.63, 0.458, 434, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
1347, 3u51A, 0.8103, 2.48, 0.470, 256, 251, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
1348, 1qcfA, 0.8103, 3.07, 0.450, 449, 262, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY- SELECTIVE TYROSINE KINASE INHIBITOR
1349, 4g5jA, 0.8102, 2.52, 0.392, 307, 250, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
1350, 3zfxG, 0.8101, 2.10, 0.412, 253, 245, CRYSTAL STRUCTURE OF EPHB1
1351, 3eygA, 0.8101, 2.47, 0.371, 280, 251, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
1352, 4rioA, 0.8100, 2.29, 0.364, 285, 250, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
1353, 3dkcA, 0.8100, 3.17, 0.363, 312, 267, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
1354, 1k9aD, 0.8099, 2.68, 0.443, 433, 255, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
1355, 5u6bA, 0.8097, 2.57, 0.440, 270, 257, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
1356, 4hzrA, 0.8097, 1.90, 0.406, 261, 244, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
1357, 5ar4B, 0.8096, 2.74, 0.242, 279, 256, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
1358, 2zm3C, 0.8096, 2.69, 0.440, 296, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1359, 6f3fA, 0.8095, 3.17, 0.455, 448, 264, AUTOINHIBITED SRC KINASE BOUND TO ADP
1360, 2vwwA, 0.8095, 2.26, 0.383, 253, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1361, 3vs4A, 0.8093, 2.70, 0.461, 429, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
1362, 2henA, 0.8092, 2.46, 0.389, 259, 252, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
1363, 5p9lA, 0.8091, 2.43, 0.454, 252, 251, BTK1 IN COMPLEX WITH CC 292
1364, 5ng0B, 0.8090, 2.59, 0.250, 282, 256, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
1365, 3tucA, 0.8090, 2.09, 0.401, 257, 247, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-BENZYL-N-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
1366, 2vwuA, 0.8090, 2.25, 0.383, 253, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1367, 2r4bA, 0.8089, 3.14, 0.378, 292, 262, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
1368, 5ttvA, 0.8087, 2.30, 0.364, 280, 250, JAK3 WITH COVALENT INHIBITOR 6
1369, 5ar5A, 0.8086, 2.75, 0.241, 284, 257, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
1370, 5ar2B, 0.8086, 2.77, 0.245, 285, 257, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
1371, 4g9cB, 0.8086, 2.24, 0.310, 264, 252, HUMAN B-RAF KINASE DOMAIN BOUND TO A TYPE II PYRAZOLOPYRIDINE INHIBITOR
1372, 3vs2A, 0.8086, 2.61, 0.460, 430, 252, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
1373, 6es0B, 0.8085, 2.65, 0.242, 287, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
1374, 5j7bB, 0.8085, 2.68, 0.239, 281, 255, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
1375, 3vs1A, 0.8085, 2.58, 0.458, 424, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
1376, 3qgwA, 0.8085, 1.87, 0.424, 244, 243, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
1377, 3plsA, 0.8085, 2.98, 0.357, 298, 263, RON IN COMPLEX WITH LIGAND AMP-PNP
1378, 1i44A, 0.8085, 2.41, 0.421, 282, 252, CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
1379, 4hviA, 0.8084, 2.13, 0.368, 274, 247, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
1380, 5x2aB, 0.8083, 3.56, 0.370, 322, 270, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
1381, 5tq7A, 0.8083, 2.46, 0.375, 275, 253, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1382, 5gjfA, 0.8083, 2.70, 0.267, 298, 255, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 3
1383, 3pj3A, 0.8083, 1.52, 0.458, 240, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-METHYL-5-[(E)- (3-PHENYL-ACRYLOYL)AMINO]-N-(2-PHENYL-3H-IMIDAZO[45-B]PYRIDIN-6-YL)- BENZAMIDE
1384, 2henC, 0.8083, 2.46, 0.389, 259, 252, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
1385, 1k9aC, 0.8082, 2.62, 0.445, 438, 254, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
1386, 3tjdA, 0.8081, 2.42, 0.379, 284, 253, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
1387, 1snxB, 0.8081, 2.00, 0.416, 245, 245, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1388, 1snxA, 0.8080, 2.00, 0.416, 245, 245, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1389, 2qi8B, 0.8079, 2.32, 0.453, 249, 245, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
1390, 5u6bC, 0.8078, 2.59, 0.440, 270, 257, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
1391, 2r4bB, 0.8077, 3.09, 0.375, 291, 261, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
1392, 3vs0B, 0.8076, 2.55, 0.462, 433, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
1393, 1u4dB, 0.8075, 2.12, 0.408, 262, 245, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
1394, 3vryA, 0.8074, 2.75, 0.457, 428, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
1395, 3vrzB, 0.8073, 2.70, 0.470, 430, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
1396, 3u51B, 0.8073, 2.48, 0.472, 255, 250, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
1397, 3bprA, 0.8073, 2.52, 0.451, 261, 253, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
1398, 1p14A, 0.8073, 2.14, 0.418, 287, 249, CRYSTAL STRUCTURE OF A CATALYTIC-LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
1399, 5hidB, 0.8072, 2.41, 0.317, 269, 252, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH AZ628
1400, 3vs6A, 0.8072, 2.67, 0.458, 434, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
1401, 5tq6A, 0.8071, 2.47, 0.381, 274, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1402, 2c0tB, 0.8070, 2.69, 0.448, 429, 252, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
1403, 4xg9A, 0.8068, 1.97, 0.414, 259, 244, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1404, 4l7sA, 0.8068, 2.44, 0.410, 250, 249, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
1405, 3vs7A, 0.8068, 2.52, 0.460, 432, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
1406, 3vs4B, 0.8068, 2.76, 0.457, 434, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
1407, 5ar7A, 0.8067, 2.74, 0.246, 278, 256, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
1408, 3lxkA, 0.8066, 2.40, 0.368, 279, 250, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
1409, 5ng2B, 0.8065, 2.38, 0.238, 278, 252, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
1410, 5d11B, 0.8065, 2.48, 0.464, 255, 248, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
1411, 3vs7B, 0.8065, 2.68, 0.468, 426, 252, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
1412, 4l7sB, 0.8064, 2.44, 0.410, 250, 249, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
1413, 5e1eA, 0.8063, 2.27, 0.373, 279, 249, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
1414, 2hckA, 0.8063, 2.78, 0.457, 437, 256, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
1415, 3lvpC, 0.8062, 2.82, 0.438, 293, 258, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1416, 5j7bA, 0.8061, 2.70, 0.239, 277, 255, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
1417, 5hx8A, 0.8061, 2.54, 0.370, 291, 254, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
1418, 5bmmB, 0.8061, 3.31, 0.453, 275, 265, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC25B
1419, 4mf1B, 0.8061, 1.88, 0.412, 246, 243, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
1420, 4d4rA, 0.8061, 2.10, 0.387, 251, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1421, 5wo4A, 0.8060, 2.56, 0.366, 292, 254, JAK1 COMPLEXED WITH COMPOUND 28
1422, 4g9cA, 0.8060, 2.36, 0.310, 265, 252, HUMAN B-RAF KINASE DOMAIN BOUND TO A TYPE II PYRAZOLOPYRIDINE INHIBITOR
1423, 3rcdC, 0.8060, 2.70, 0.378, 281, 254, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
1424, 3rcdA, 0.8060, 2.69, 0.378, 281, 254, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
1425, 3lvpB, 0.8060, 2.63, 0.441, 295, 256, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1426, 2b4sD, 0.8060, 2.75, 0.418, 294, 256, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
1427, 3vs6B, 0.8059, 2.66, 0.458, 434, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
1428, 2xa4A, 0.8059, 2.20, 0.385, 276, 247, INHIBITORS OF JAK2 KINASE DOMAIN
1429, 5ar3A, 0.8058, 2.65, 0.244, 279, 254, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP
1430, 1kswA, 0.8058, 3.28, 0.453, 449, 265, STRUCTURE OF HUMAN C-SRC TYROSINE KINASE (THR338GLY MUTANT) IN COMPLEX WITH N6-BENZYL ADP
1431, 3zzwB, 0.8057, 2.68, 0.333, 265, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
1432, 3l8pA, 0.8057, 2.39, 0.407, 292, 248, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
1433, 3ii5A, 0.8057, 2.24, 0.316, 262, 250, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
1434, 2c0tA, 0.8057, 2.70, 0.468, 427, 252, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
1435, 4yjpA, 0.8056, 2.24, 0.411, 263, 248, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
1436, 2c0iA, 0.8056, 2.68, 0.468, 433, 252, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
1437, 1ad5A, 0.8055, 2.92, 0.479, 437, 257, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
1438, 5x2fD, 0.8054, 3.29, 0.372, 309, 266, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
1439, 4pp9B, 0.8054, 2.23, 0.415, 247, 246, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
1440, 5k0xA, 0.8053, 2.30, 0.456, 258, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC2541
1441, 4rfmA, 0.8053, 2.28, 0.415, 249, 248, ITK KINASE DOMAIN IN COMPLEX WITH COMPOUND 1 N-{1-[(11-DIOXO-1-THIAN- 2-YL)(PHENYL)METHYL]-1H- PYRAZOL-4-YL}-55-DIFLUORO-5A-METHYL-1H4H 4AH5H5AH6H-CYCLOPROPA[F]INDAZOLE-3-CARBOXAMIDE
1442, 4qpsC, 0.8053, 2.27, 0.376, 276, 250, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
1443, 5ttsA, 0.8052, 2.19, 0.368, 274, 247, JAK3 WITH COVALENT INHIBITOR 4
1444, 3qlfA, 0.8052, 2.20, 0.475, 249, 244, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
1445, 3f5pM, 0.8052, 2.73, 0.440, 295, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1446, 3octA, 0.8051, 1.66, 0.465, 244, 241, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE MUTANT V555R IN COMPLEX WITH DASATINIB
1447, 3vs2B, 0.8050, 2.64, 0.452, 433, 252, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
1448, 2qi8A, 0.8050, 2.36, 0.457, 255, 247, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
1449, 1uwjA, 0.8050, 2.22, 0.316, 264, 250, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
1450, 1u54B, 0.8050, 2.00, 0.406, 261, 244, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
1451, 5wnoA, 0.8049, 2.85, 0.320, 302, 256, CRYSTAL STRUCTURE OF C. ELEGANS LET-23 KINASE DOMAIN COMPLEXED WITH AMP-PNP
1452, 5tq4A, 0.8049, 2.53, 0.375, 290, 256, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1453, 3f5pT, 0.8048, 2.62, 0.443, 295, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1454, 4pp9A, 0.8047, 2.23, 0.415, 246, 246, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
1455, 3f5pS, 0.8046, 2.70, 0.441, 295, 256, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1456, 5lmbB, 0.8045, 2.01, 0.414, 261, 244, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
1457, 3zepD, 0.8045, 2.33, 0.371, 272, 248, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
1458, 3vs1B, 0.8045, 2.64, 0.458, 433, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
1459, 4xg8A, 0.8044, 2.03, 0.404, 258, 245, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1460, 3vs0A, 0.8044, 2.66, 0.468, 428, 252, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
1461, 3vrzA, 0.8042, 2.65, 0.458, 429, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
1462, 3f5pI, 0.8042, 2.70, 0.441, 294, 256, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1463, 2c0oA, 0.8042, 2.71, 0.468, 433, 252, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
1464, 2c0iB, 0.8042, 2.71, 0.468, 433, 252, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
1465, 3f5pD, 0.8041, 2.82, 0.440, 297, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1466, 2b4sB, 0.8041, 2.78, 0.418, 294, 256, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
1467, 3k54A, 0.8040, 1.81, 0.449, 243, 243, STRUCTURES OF HUMAN BRUTON S TYROSINE KINASE IN ACTIVE AND INACTIVE CONFORMATIONS SUGGESTS A MECHANISM OF ACTIVATION FOR TEC FAMILY KINASES.
1468, 3f5pB, 0.8040, 2.83, 0.440, 298, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1469, 3zepA, 0.8039, 2.39, 0.371, 274, 248, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
1470, 3vryB, 0.8039, 2.66, 0.458, 434, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
1471, 1bygA, 0.8039, 2.09, 0.465, 246, 245, KINASE DOMAIN OF HUMAN C-TERMINAL SRC KINASE (CSK) IN COMPLEX WITH INHIBITOR STAUROSPORINE
1472, 1ad5B, 0.8039, 2.95, 0.479, 437, 257, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
1473, 3vs5A, 0.8038, 2.66, 0.468, 429, 252, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
1474, 1uwjB, 0.8038, 2.23, 0.316, 263, 250, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
1475, 5f1zA, 0.8037, 2.36, 0.340, 281, 250, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
1476, 4wrgA, 0.8037, 2.34, 0.386, 289, 246, 1.9 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN
1477, 3f5pH, 0.8037, 2.83, 0.440, 299, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1478, 3f5pG, 0.8037, 2.82, 0.440, 299, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1479, 3f5pC, 0.8037, 2.82, 0.440, 301, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1480, 4yjuA, 0.8036, 2.13, 0.407, 262, 246, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
1481, 3zepB, 0.8036, 2.18, 0.371, 268, 245, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
1482, 3f5pA, 0.8036, 2.83, 0.440, 299, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1483, 3f5pK, 0.8034, 2.68, 0.443, 293, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1484, 5ttuA, 0.8033, 2.02, 0.373, 271, 244, JAK3 WITH COVALENT INHIBITOR 7
1485, 3zmmA, 0.8033, 2.07, 0.389, 273, 244, INHIBITORS OF JAK2 KINASE DOMAIN
1486, 4p2kA, 0.8032, 2.23, 0.386, 259, 249, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
1487, 4h58B, 0.8032, 2.10, 0.316, 262, 247, BRAF IN COMPLEX WITH COMPOUND 3
1488, 4k77A, 0.8031, 2.57, 0.375, 282, 253, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
1489, 4d4rB, 0.8030, 2.98, 0.383, 270, 261, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1490, 3bprD, 0.8030, 2.50, 0.454, 259, 251, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
1491, 2rfeD, 0.8030, 2.93, 0.381, 278, 257, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
1492, 3f5pL, 0.8029, 2.68, 0.443, 293, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1493, 4ludB, 0.8028, 2.53, 0.468, 409, 250, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
1494, 4o91A, 0.8027, 2.32, 0.270, 293, 248, CRYSTAL STRUCTURE OF TYPE II INHIBITOR NG25 BOUND TO TAK1-TAB1
1495, 2c0oB, 0.8026, 2.72, 0.468, 433, 252, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
1496, 5yu9D, 0.8025, 3.11, 0.374, 300, 262, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
1497, 3zfxC, 0.8025, 2.03, 0.413, 248, 242, CRYSTAL STRUCTURE OF EPHB1
1498, 3pj1A, 0.8025, 1.79, 0.465, 241, 241, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 3-(26-DICHLORO- PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-1-METHYL-34- DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
1499, 3miyB, 0.8025, 1.74, 0.408, 240, 240, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
1500, 4i21A, 0.8024, 3.19, 0.384, 290, 263, CRYSTAL STRUCTURE OF L858R + T790M EGFR KINASE DOMAIN IN COMPLEX WITH MIG6 PEPTIDE
1501, 3f5pE, 0.8024, 2.83, 0.440, 299, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1502, 5y5uB, 0.8023, 1.94, 0.413, 257, 242, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
1503, 3f5pF, 0.8023, 2.84, 0.440, 299, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1504, 3bprB, 0.8023, 2.35, 0.450, 256, 249, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
1505, 3vs5B, 0.8022, 2.75, 0.451, 427, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
1506, 4xv9A, 0.8021, 2.12, 0.319, 261, 248, B-RAF KINASE DOMAIN IN COMPLEX WITH PLX5568
1507, 4c62A, 0.8021, 2.11, 0.389, 273, 244, INHIBITORS OF JAK2 KINASE DOMAIN
1508, 3bprC, 0.8021, 2.42, 0.456, 259, 250, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
1509, 4e5wA, 0.8020, 2.76, 0.350, 292, 254, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
1510, 6bbvA, 0.8019, 2.52, 0.364, 289, 253, CRYSTAL STRUCTURE OF JAK2 IN COMPLEX WITH COMPOUND 25
1511, 5e1eB, 0.8019, 2.41, 0.372, 280, 250, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
1512, 4yjtA, 0.8019, 2.17, 0.405, 268, 247, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
1513, 4e1zA, 0.8019, 2.66, 0.349, 288, 255, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
1514, 3f5pR, 0.8019, 2.73, 0.441, 294, 256, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1515, 2qolA, 0.8019, 2.63, 0.363, 271, 251, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596:Y602:S768G TRIPLE MUTANT
1516, 5w86C, 0.8018, 2.25, 0.376, 273, 245, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
1517, 4i5cA, 0.8018, 2.50, 0.375, 279, 251, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
1518, 4i21B, 0.8018, 3.12, 0.385, 302, 262, CRYSTAL STRUCTURE OF L858R + T790M EGFR KINASE DOMAIN IN COMPLEX WITH MIG6 PEPTIDE
1519, 1k2pA, 0.8018, 2.33, 0.466, 258, 247, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
1520, 5ng0A, 0.8017, 2.30, 0.240, 274, 250, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
1521, 1u54A, 0.8017, 2.11, 0.400, 262, 245, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
1522, 5ar5B, 0.8016, 2.66, 0.245, 279, 253, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
1523, 4ivdB, 0.8016, 2.49, 0.375, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
1524, 3of0B, 0.8016, 2.39, 0.472, 251, 246, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
1525, 2hckB, 0.8016, 2.85, 0.457, 437, 256, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
1526, 4ll0B, 0.8015, 2.78, 0.348, 281, 256, EGFR L858R/T790M IN COMPLEX WITH PD168393
1527, 4e4nB, 0.8015, 2.46, 0.375, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
1528, 4e4nA, 0.8015, 2.60, 0.372, 291, 253, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
1529, 5d10A, 0.8014, 2.20, 0.461, 248, 243, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
1530, 3f5pJ, 0.8014, 2.70, 0.443, 293, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1531, 5bpyB, 0.8013, 2.29, 0.451, 247, 246, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
1532, 3zc6B, 0.8013, 2.52, 0.376, 276, 250, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
1533, 3p08B, 0.8013, 2.55, 0.438, 258, 251, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
1534, 2jitB, 0.8013, 2.88, 0.341, 312, 258, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
1535, 3qgyB, 0.8012, 2.12, 0.410, 245, 244, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
1536, 2srcA, 0.8012, 3.18, 0.460, 449, 263, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC IN COMPLEX WITH AMP-PNP
1537, 4ll0A, 0.8011, 2.87, 0.346, 291, 257, EGFR L858R/T790M IN COMPLEX WITH PD168393
1538, 4fk6A, 0.8010, 2.73, 0.354, 285, 254, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
1539, 2rfeC, 0.8010, 2.95, 0.379, 262, 256, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
1540, 5x2fC, 0.8009, 3.18, 0.376, 302, 263, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
1541, 5gnkA, 0.8009, 3.12, 0.378, 277, 259, CRYSTAL STRUCTURE OF EGFR 696-988 T790M IN COMPLEX WITH LXX-6-34
1542, 5hx8B, 0.8008, 2.41, 0.372, 279, 250, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
1543, 4fk6B, 0.8008, 2.68, 0.354, 284, 254, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
1544, 3uqfB, 0.8008, 2.52, 0.464, 253, 248, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
1545, 5w86D, 0.8007, 2.21, 0.380, 272, 245, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
1546, 4c8bA, 0.8007, 2.39, 0.236, 279, 250, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
1547, 4c61B, 0.8007, 1.99, 0.387, 274, 243, INHIBITORS OF JAK2 KINASE DOMAIN
1548, 5ar2A, 0.8006, 2.50, 0.240, 277, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
1549, 4pqnA, 0.8006, 1.95, 0.421, 240, 240, ITK KINASE DOMAIN WITH COMPOUND GNE-9822
1550, 3v5lD, 0.8006, 2.33, 0.402, 246, 246, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
1551, 5x2aC, 0.8005, 3.07, 0.378, 303, 262, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
1552, 5vamA, 0.8005, 2.48, 0.307, 269, 251, BRAF IN COMPLEX WITH RAF709
1553, 5k0kA, 0.8005, 2.41, 0.464, 260, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC2434
1554, 4ehzA, 0.8005, 2.79, 0.353, 290, 255, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
1555, 1k2pB, 0.8005, 2.30, 0.462, 258, 247, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
1556, 2rfdA, 0.8004, 3.16, 0.383, 288, 261, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
1557, 5ng2A, 0.8002, 2.32, 0.233, 274, 249, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
1558, 5gtyH, 0.8002, 3.12, 0.383, 300, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1559, 4hzsD, 0.8002, 3.10, 0.378, 319, 262, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
1560, 4hzsC, 0.8001, 3.11, 0.378, 319, 262, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
1561, 4hzsB, 0.8001, 3.11, 0.378, 319, 262, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
1562, 4hzsA, 0.8001, 3.11, 0.378, 319, 262, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
1563, 4ybkA, 0.8000, 3.06, 0.463, 266, 259, C-HELIX-OUT DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
1564, 2yiyA, 0.8000, 2.34, 0.270, 293, 248, CRYSTAL STRUCTURE OF COMPOUND 8 BOUND TO TAK1-TAB
1565, 4zseA, 0.7999, 3.16, 0.380, 297, 263, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
1566, 4zjvA, 0.7999, 3.14, 0.387, 282, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH MITOGEN- INDUCIBLE GENE 6 PROTEIN
1567, 4zseC, 0.7998, 3.10, 0.378, 301, 262, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
1568, 4ficA, 0.7998, 2.36, 0.457, 251, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
1569, 5tq7B, 0.7997, 2.39, 0.382, 269, 249, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1570, 4zseB, 0.7996, 3.23, 0.385, 313, 262, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
1571, 4k77B, 0.7996, 2.52, 0.375, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
1572, 4c61A, 0.7995, 2.06, 0.391, 272, 243, INHIBITORS OF JAK2 KINASE DOMAIN
1573, 3ppzA, 0.7994, 2.29, 0.363, 264, 248, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1574, 2xa4B, 0.7994, 2.24, 0.386, 275, 246, INHIBITORS OF JAK2 KINASE DOMAIN
1575, 5wo4B, 0.7993, 2.44, 0.372, 280, 250, JAK1 COMPLEXED WITH COMPOUND 28
1576, 4ivbA, 0.7993, 2.59, 0.373, 291, 252, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
1577, 1xkkA, 0.7993, 3.27, 0.373, 289, 263, EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016
1578, 4ivcA, 0.7992, 2.69, 0.375, 291, 253, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
1579, 4i24B, 0.7992, 3.39, 0.374, 304, 265, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
1580, 3zc6A, 0.7992, 2.51, 0.369, 277, 249, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
1581, 4ivdA, 0.7991, 2.63, 0.373, 290, 252, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
1582, 4i5cB, 0.7991, 2.57, 0.373, 291, 252, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
1583, 4e5wB, 0.7991, 2.46, 0.372, 278, 250, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
1584, 3zmmB, 0.7990, 2.01, 0.387, 274, 243, INHIBITORS OF JAK2 KINASE DOMAIN
1585, 1u4dA, 0.7990, 2.18, 0.402, 258, 244, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
1586, 4k11A, 0.7989, 3.07, 0.460, 447, 261, THE STRUCTURE OF 1NA IN COMPLEX WITH SRC T338G
1587, 3d4qA, 0.7989, 2.22, 0.310, 264, 248, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
1588, 2h8hA, 0.7989, 3.11, 0.462, 444, 262, SRC KINASE IN COMPLEX WITH A QUINAZOLINE INHIBITOR
1589, 5x2aD, 0.7988, 3.40, 0.385, 297, 265, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
1590, 4g9rA, 0.7988, 2.24, 0.319, 262, 248, B-RAF V600E KINASE DOMAIN BOUND TO A TYPE II DIHYDROQUINAZOLINE INHIBITOR
1591, 2rgpA, 0.7988, 3.24, 0.370, 284, 262, STRUCTURE OF EGFR IN COMPLEX WITH HYDRAZONE A POTENT DUAL INHIBITOR
1592, 5d7vB, 0.7987, 2.75, 0.401, 264, 257, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1593, 4ivbB, 0.7987, 2.56, 0.375, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
1594, 5h2uB, 0.7986, 2.72, 0.402, 263, 256, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1595, 4jvgB, 0.7986, 2.19, 0.328, 259, 247, B-RAF KINASE IN COMPLEX WITH BIRB796
1596, 3pozA, 0.7985, 3.09, 0.381, 293, 260, EGFR KINASE DOMAIN COMPLEXED WITH TAK-285
1597, 4qpsA, 0.7984, 1.82, 0.375, 270, 240, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
1598, 3w33A, 0.7984, 3.06, 0.386, 297, 259, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 19B
1599, 4hzrB, 0.7983, 1.89, 0.402, 258, 241, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
1600, 4ivcB, 0.7982, 2.57, 0.375, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
1601, 3psdB, 0.7982, 2.23, 0.310, 264, 248, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
1602, 4ksqA, 0.7981, 2.11, 0.317, 258, 246, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR 5B
1603, 3priA, 0.7981, 2.24, 0.306, 264, 248, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1604, 4fc0B, 0.7979, 2.48, 0.316, 263, 250, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
1605, 3faaB, 0.7979, 2.50, 0.247, 324, 251, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
1606, 3priB, 0.7978, 2.25, 0.306, 264, 248, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1607, 3p08A, 0.7978, 2.61, 0.466, 252, 249, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
1608, 5hidA, 0.7977, 2.32, 0.323, 257, 248, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH AZ628
1609, 4lghB, 0.7976, 2.36, 0.461, 247, 243, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
1610, 4hjoA, 0.7976, 3.37, 0.379, 278, 264, CRYSTAL STRUCTURE OF THE INACTIVE EGFR TYROSINE KINASE DOMAIN WITH ERLOTINIB
1611, 2wqbA, 0.7975, 2.40, 0.397, 289, 247, STRUCTURE OF THE TIE2 KINASE DOMAIN IN COMPLEX WITH A THIAZOLOPYRIMIDINE INHIBITOR
1612, 5tq6B, 0.7974, 2.48, 0.386, 271, 249, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1613, 4dbnB, 0.7974, 2.36, 0.305, 263, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
1614, 2jiuB, 0.7974, 3.07, 0.335, 309, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
1615, 5khwA, 0.7973, 2.19, 0.378, 276, 246, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
1616, 3belA, 0.7973, 3.13, 0.373, 280, 260, X-RAY STRUCTURE OF EGFR IN COMPLEX WITH OXIME INHIBITOR
1617, 4mf1A, 0.7972, 1.98, 0.409, 243, 242, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
1618, 4c62B, 0.7972, 1.90, 0.390, 271, 241, INHIBITORS OF JAK2 KINASE DOMAIN
1619, 3c4cB, 0.7972, 1.94, 0.324, 257, 244, B-RAF KINASE IN COMPLEX WITH PLX4720
1620, 2qq7A, 0.7972, 2.32, 0.469, 251, 243, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
1621, 5yu9B, 0.7971, 3.07, 0.382, 295, 259, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
1622, 5vamB, 0.7971, 2.06, 0.318, 260, 245, BRAF IN COMPLEX WITH RAF709
1623, 4zjvB, 0.7971, 2.80, 0.387, 273, 256, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH MITOGEN- INDUCIBLE GENE 6 PROTEIN
1624, 4jvgC, 0.7970, 2.16, 0.333, 258, 246, B-RAF KINASE IN COMPLEX WITH BIRB796
1625, 4g9rB, 0.7970, 2.27, 0.323, 261, 248, B-RAF V600E KINASE DOMAIN BOUND TO A TYPE II DIHYDROQUINAZOLINE INHIBITOR
1626, 3v5lC, 0.7970, 2.23, 0.412, 244, 243, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
1627, 3gopA, 0.7970, 2.52, 0.340, 300, 250, CRYSTAL STRUCTURE OF THE EGF RECEPTOR JUXTAMEMBRANE AND KINASE DOMAINS
1628, 5x2cA, 0.7969, 3.29, 0.371, 304, 264, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(5)
1629, 5wnlA, 0.7969, 2.27, 0.251, 262, 247, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO STAUROSPORINE 
1630, 4ei4B, 0.7969, 2.56, 0.375, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
1631, 3ppjB, 0.7969, 2.26, 0.310, 264, 248, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
1632, 5x2fB, 0.7967, 3.48, 0.373, 312, 268, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
1633, 5u6cB, 0.7966, 2.24, 0.445, 257, 245, CRYSTAL STRUCTURE OF THE MER KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
1634, 3faaE, 0.7964, 2.58, 0.243, 330, 251, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
1635, 3brbB, 0.7964, 2.81, 0.439, 271, 255, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH ADP
1636, 5ar4A, 0.7963, 2.76, 0.242, 274, 252, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
1637, 4kioD, 0.7963, 2.01, 0.423, 242, 241, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
1638, 3v8wB, 0.7963, 2.00, 0.409, 242, 242, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
1639, 5e8xA, 0.7962, 2.52, 0.266, 304, 248, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
1640, 3omvA, 0.7962, 2.23, 0.298, 264, 248, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
1641, 5k0xB, 0.7961, 2.02, 0.446, 254, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC2541
1642, 4fc0A, 0.7961, 2.09, 0.318, 254, 245, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
1643, 1sm2B, 0.7961, 1.97, 0.423, 241, 241, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1644, 5h2uD, 0.7960, 2.65, 0.400, 263, 255, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1645, 4v0gB, 0.7960, 2.44, 0.380, 272, 245, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
1646, 4jvgD, 0.7960, 2.26, 0.328, 262, 247, B-RAF KINASE IN COMPLEX WITH BIRB796
1647, 3ppzB, 0.7960, 2.22, 0.364, 264, 247, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1648, 3d4qB, 0.7960, 2.28, 0.306, 264, 248, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
1649, 2x7oA, 0.7960, 2.53, 0.243, 330, 251, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
1650, 3psbB, 0.7959, 2.15, 0.317, 264, 246, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
1651, 5gtyG, 0.7957, 3.12, 0.381, 299, 260, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1652, 3v8tB, 0.7956, 2.19, 0.407, 244, 243, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
1653, 3ppkB, 0.7956, 2.28, 0.310, 264, 248, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1654, 5d7vC, 0.7955, 2.79, 0.401, 264, 257, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1655, 6cz4A, 0.7954, 2.83, 0.425, 257, 252, STRUCTURE OF THE PTK6 KINASE DOMAIN BOUND TO A TYPE II INHIBITOR 2- {[(3R;4S)-3-FLUORO-1-{[4-(TRIFLUOROMETHOXY)PHENYL]ACETYL}PIPERIDIN-4- YL]OXY}-5-(1-METHYL-1H-IMIDAZOL-4-YL)PYRIDINE-3-CARBOXAMIDE 
1656, 5h2uC, 0.7954, 2.74, 0.398, 264, 256, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1657, 5cnnB, 0.7954, 3.27, 0.375, 304, 264, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
1658, 5yu9A, 0.7953, 3.30, 0.369, 302, 263, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
1659, 4neuB, 0.7953, 2.39, 0.297, 268, 249, X-RAY STRUCTURE OF RECEPTOR INTERACTING PROTEIN 1 (RIP1)KINASE DOMAIN WITH A 1-AMINOISOQUINOLINE INHIBITOR
1660, 4jvgA, 0.7953, 2.27, 0.328, 262, 247, B-RAF KINASE IN COMPLEX WITH BIRB796
1661, 3h10A, 0.7953, 2.92, 0.234, 268, 261, AURORA A INHIBITOR COMPLEX
1662, 2x7oD, 0.7953, 2.54, 0.243, 330, 251, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
1663, 1iasB, 0.7953, 2.56, 0.247, 324, 251, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1664, 4k6zA, 0.7952, 2.54, 0.376, 279, 250, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
1665, 3emgA, 0.7952, 2.02, 0.419, 255, 241, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
1666, 2x7oC, 0.7952, 2.55, 0.243, 330, 251, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
1667, 6bbuA, 0.7951, 2.54, 0.376, 279, 250, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH COMPOUND 25
1668, 5ct7A, 0.7951, 2.08, 0.314, 257, 245, BRAF IN COMPLEX WITH RAF265
1669, 5x2aA, 0.7950, 3.17, 0.378, 297, 262, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
1670, 5ar3B, 0.7950, 2.66, 0.247, 276, 251, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP
1671, 4dbnA, 0.7950, 2.12, 0.318, 257, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
1672, 3skcB, 0.7949, 2.77, 0.297, 276, 256, HUMAN B-RAF KINASE IN COMPLEX WITH AN AMIDE LINKED PYRAZOLOPYRIDINE INHIBITOR
1673, 5wnjA, 0.7948, 2.17, 0.249, 264, 245, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN KINASE 4 (RIPK4) D143N IN COMPLEX WITH LESTAURTINIB 
1674, 5h2uA, 0.7948, 2.92, 0.399, 265, 258, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1675, 4wa9A, 0.7948, 1.57, 0.987, 246, 234, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
1676, 4l53A, 0.7948, 2.72, 0.271, 296, 251, CRYSTAL STRUCTURE OF (1R4R)-4-{4-[7-AMINO-2-(123-BENZOTHIADIAZOL-7- YL)-3-CHLOROFURO[23-C]PYRIDIN-4-YL]-1H-PYRAZOL-1-YL}CYCLOHEXAN-1-OL BOUND TO TAK1-TAB1
1677, 4e4lD, 0.7948, 2.60, 0.367, 281, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
1678, 4e26A, 0.7948, 2.44, 0.304, 270, 250, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
1679, 3q4cB, 0.7948, 2.35, 0.319, 264, 248, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
1680, 3miyA, 0.7948, 1.74, 0.406, 239, 239, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
1681, 3ii5B, 0.7948, 2.11, 0.322, 257, 245, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
1682, 1u46B, 0.7948, 1.96, 0.408, 257, 240, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
1683, 2x7oE, 0.7947, 2.55, 0.243, 330, 251, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
1684, 5yu9C, 0.7946, 3.19, 0.383, 306, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
1685, 4kspA, 0.7946, 2.13, 0.314, 257, 245, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
1686, 1snuB, 0.7946, 2.00, 0.423, 241, 241, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1687, 5f20A, 0.7945, 2.12, 0.348, 274, 244, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
1688, 5d7vD, 0.7945, 2.79, 0.397, 264, 257, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1689, 3kcfB, 0.7945, 2.46, 0.244, 324, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
1690, 5wnmA, 0.7944, 2.18, 0.249, 263, 245, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO TOZASERTIB (VX-680) 
1691, 5x2fA, 0.7943, 3.32, 0.380, 301, 263, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
1692, 5gtyA, 0.7943, 3.31, 0.373, 300, 263, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1693, 5d7vA, 0.7942, 2.96, 0.394, 268, 259, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1694, 2x7oB, 0.7942, 2.56, 0.243, 330, 251, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
1695, 5e8uA, 0.7941, 2.77, 0.263, 306, 251, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
1696, 1u46A, 0.7941, 1.92, 0.404, 255, 240, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
1697, 4v0gA, 0.7940, 2.21, 0.383, 267, 243, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
1698, 3q96B, 0.7940, 2.45, 0.317, 262, 249, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
1699, 4ehzB, 0.7939, 2.56, 0.360, 280, 250, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
1700, 4e26B, 0.7939, 2.20, 0.317, 264, 246, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
1701, 3v8wA, 0.7939, 2.17, 0.407, 243, 243, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
1702, 2auhA, 0.7939, 2.79, 0.410, 297, 256, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
1703, 5gtyD, 0.7938, 3.25, 0.379, 297, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1704, 4fk3B, 0.7938, 2.16, 0.339, 257, 245, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
1705, 3psbA, 0.7938, 2.20, 0.321, 262, 246, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
1706, 3prfA, 0.7938, 2.11, 0.314, 262, 245, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
1707, 4g5pB, 0.7937, 2.81, 0.337, 303, 255, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
1708, 4gs6A, 0.7936, 2.56, 0.273, 294, 249, IRREVERSIBLE INHIBITION OF TAK1 KINASE BY 5Z-7-OXOZEAENOL
1709, 2qq7B, 0.7936, 2.27, 0.467, 244, 240, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
1710, 3psdA, 0.7935, 2.22, 0.313, 262, 246, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
1711, 2hwoA, 0.7935, 2.46, 0.457, 251, 245, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
1712, 5x2cB, 0.7933, 3.25, 0.375, 303, 264, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(5)
1713, 5j79A, 0.7933, 2.83, 0.245, 283, 253, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
1714, 3omvB, 0.7933, 2.30, 0.290, 264, 248, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
1715, 5d41B, 0.7932, 3.32, 0.371, 302, 264, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
1716, 3ppkA, 0.7932, 2.22, 0.317, 262, 246, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1717, 2j4zA, 0.7932, 2.91, 0.239, 263, 259, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
1718, 5vo6A, 0.7931, 2.06, 0.376, 271, 242, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
1719, 5gtyE, 0.7931, 3.25, 0.379, 297, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1720, 4zseD, 0.7931, 3.26, 0.370, 297, 262, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
1721, 3faaC, 0.7931, 2.59, 0.243, 330, 251, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
1722, 3faaA, 0.7931, 2.61, 0.243, 328, 251, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
1723, 3brbA, 0.7931, 2.66, 0.446, 260, 251, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH ADP
1724, 5jgbA, 0.7930, 2.66, 0.272, 295, 250, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 10
1725, 5da3A, 0.7930, 2.76, 0.398, 263, 256, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN WITH INHIBITOR
1726, 4ei4A, 0.7930, 2.68, 0.359, 289, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
1727, 5csxA, 0.7929, 2.32, 0.323, 261, 248, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
1728, 3v5jB, 0.7929, 2.03, 0.407, 241, 241, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
1729, 3lzbB, 0.7929, 3.02, 0.387, 265, 256, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
1730, 5e8wA, 0.7928, 2.45, 0.251, 303, 247, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
1731, 4xg8C, 0.7928, 2.02, 0.412, 254, 240, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1732, 4r5yB, 0.7928, 2.17, 0.322, 254, 245, THE COMPLEX STRUCTURE OF BRAF V600E KINASE DOMAIN WITH A NOVEL BRAF INHIBITOR
1733, 4mhaA, 0.7928, 2.22, 0.467, 256, 246, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC1817
1734, 5v5nA, 0.7927, 2.64, 0.272, 294, 250, CRYSTAL STRUCTURE OF TAKINIB BOUND TO TAK1
1735, 5hvjA, 0.7927, 2.80, 0.276, 283, 254, CRYSTAL STRUCTURE OF LIMK1 D460N MUTANT IN COMPLEX WITH AMP-PNP
1736, 4mbjB, 0.7926, 2.85, 0.301, 276, 256, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINE-BASED INHIBITOR
1737, 2evaA, 0.7925, 2.70, 0.272, 295, 250, STRUCTURAL BASIS FOR THE INTERACTION OF TAK1 KINASE WITH ITS ACTIVATING PROTEIN TAB1
1738, 4e4lE, 0.7924, 2.61, 0.360, 280, 250, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
1739, 3lzbA, 0.7924, 2.94, 0.392, 265, 255, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
1740, 4yjqA, 0.7923, 2.15, 0.410, 264, 244, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000224
1741, 5w86A, 0.7922, 2.12, 0.382, 269, 241, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
1742, 5gtyF, 0.7922, 3.15, 0.377, 297, 260, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1743, 4ehzD, 0.7922, 2.60, 0.360, 280, 250, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
1744, 5j79B, 0.7921, 2.74, 0.243, 277, 251, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
1745, 3tcpA, 0.7921, 2.27, 0.459, 256, 246, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC569
1746, 3tv6B, 0.7920, 2.82, 0.297, 276, 256, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A METHOXYPYRAZOLOPYRIDINYL BENZAMIDE INHIBITOR
1747, 1jqhA, 0.7920, 2.80, 0.443, 291, 255, IGF-1 RECEPTOR KINASE DOMAIN
1748, 3qgwB, 0.7919, 1.87, 0.414, 240, 239, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
1749, 2qlqB, 0.7919, 2.41, 0.467, 248, 242, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
1750, 4eheB, 0.7918, 2.84, 0.297, 276, 256, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOTHIENOPYRIMIDINE-BASED INHIBITOR
1751, 3ppjA, 0.7917, 2.25, 0.313, 262, 246, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
1752, 3kcfE, 0.7917, 2.55, 0.240, 330, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
1753, 3kexA, 0.7915, 3.32, 0.326, 292, 261, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
1754, 2j4zB, 0.7915, 2.93, 0.239, 269, 259, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
1755, 5khxA, 0.7914, 2.35, 0.354, 276, 246, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
1756, 3faaD, 0.7914, 2.63, 0.247, 330, 251, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
1757, 3bbwA, 0.7914, 2.91, 0.395, 268, 253, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN ITS INACTIVE CONFORMATION
1758, 5xgnB, 0.7912, 3.13, 0.340, 308, 259, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
1759, 5w86B, 0.7911, 2.04, 0.381, 267, 239, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
1760, 3zfmA, 0.7911, 2.28, 0.391, 248, 243, CRYSTAL STRUCTURE OF EPHB2
1761, 2wotA, 0.7911, 2.54, 0.243, 303, 247, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
1762, 4lueA, 0.7910, 2.55, 0.463, 422, 246, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
1763, 3lzbD, 0.7910, 2.94, 0.386, 261, 254, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
1764, 6cadA, 0.7909, 2.13, 0.329, 249, 243, CRYSTAL STRUCTURE OF RAF KINASE DOMAIN BOUND TO THE INHIBITOR 2A
1765, 5khwB, 0.7908, 2.40, 0.377, 276, 247, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
1766, 3tv4B, 0.7908, 2.83, 0.297, 276, 256, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN BROMOPYRIDINE BENZAMIDE INHIBITOR
1767, 1jqhC, 0.7908, 2.72, 0.445, 291, 254, IGF-1 RECEPTOR KINASE DOMAIN
1768, 3kexB, 0.7907, 3.21, 0.328, 283, 259, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
1769, 3bbwB, 0.7907, 2.92, 0.395, 275, 253, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN ITS INACTIVE CONFORMATION
1770, 5cnnA, 0.7906, 3.22, 0.387, 300, 261, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
1771, 5gtyC, 0.7905, 3.20, 0.382, 295, 259, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1772, 4ficB, 0.7905, 2.23, 0.471, 245, 240, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
1773, 2ptkA, 0.7904, 2.49, 0.478, 425, 247, CHICKEN SRC TYROSINE KINASE
1774, 2gs7A, 0.7904, 3.38, 0.380, 281, 263, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1775, 3q4cA, 0.7903, 2.30, 0.316, 264, 247, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
1776, 6b8yA, 0.7902, 2.63, 0.253, 304, 249, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-(3- FLUOROPYRIDIN-4-YL)-2-[6-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-7H-PYRROLO[2 3-D]PYRIMIDIN-4-AMINE
1777, 4yjvA, 0.7901, 2.14, 0.407, 263, 243, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
1778, 4x2nA, 0.7901, 2.49, 0.247, 303, 247, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1779, 4x2gA, 0.7901, 2.51, 0.247, 303, 247, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1780, 4ludA, 0.7901, 2.51, 0.473, 421, 245, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
1781, 4l3pA, 0.7901, 2.65, 0.273, 295, 249, CRYSTAL STRUCTURE OF 2-(1-BENZOTHIOPHEN-7-YL)-4-[1-(PIPERIDIN-4-YL)- 1H-PYRAZOL-4-YL]FURO[23-C]PYRIDIN-7-AMINE BOUND TO TAK1-TAB1
1782, 4h58A, 0.7901, 2.24, 0.313, 263, 246, BRAF IN COMPLEX WITH COMPOUND 3
1783, 5gtyB, 0.7900, 3.23, 0.372, 299, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1784, 3kcfC, 0.7900, 2.58, 0.244, 330, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
1785, 4x2fA, 0.7899, 2.59, 0.250, 303, 248, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1786, 4f1tA, 0.7899, 2.63, 0.285, 269, 249, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
1787, 3h10B, 0.7899, 2.92, 0.235, 267, 260, AURORA A INHIBITOR COMPLEX
1788, 3en7A, 0.7899, 2.38, 0.471, 247, 242, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH S1 A MULTITARGETED KINASE INHIBITOR
1789, 1iasE, 0.7898, 2.71, 0.243, 330, 251, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1790, 1iasC, 0.7898, 2.69, 0.243, 330, 251, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1791, 5wfjA, 0.7897, 2.02, 0.379, 265, 240, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
1792, 4x2kA, 0.7897, 2.60, 0.250, 303, 248, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1793, 4x2jA, 0.7897, 2.60, 0.250, 303, 248, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1794, 4rzwB, 0.7896, 2.20, 0.329, 252, 243, CRYSTAL STRUCTURE OF BRAF (R509H) KINASE DOMAIN BOUND TO AZ628
1795, 3v5jA, 0.7896, 2.12, 0.419, 241, 241, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
1796, 2wtvB, 0.7896, 2.75, 0.238, 261, 256, AURORA-A INHIBITOR STRUCTURE
1797, 2gs7B, 0.7896, 3.38, 0.384, 288, 263, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1798, 3ikaB, 0.7895, 3.15, 0.340, 310, 259, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
1799, 2wtvC, 0.7895, 2.75, 0.238, 261, 256, AURORA-A INHIBITOR STRUCTURE
1800, 5w5oE, 0.7894, 2.56, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1801, 3tcpB, 0.7893, 1.96, 0.437, 250, 238, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC569
1802, 4x0mA, 0.7891, 2.50, 0.247, 303, 247, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1803, 3bbtB, 0.7891, 2.98, 0.398, 274, 254, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
1804, 5wnkA, 0.7890, 2.21, 0.250, 263, 244, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO TG100-115 
1805, 5jgaA, 0.7890, 2.70, 0.272, 296, 250, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 11C
1806, 3prfB, 0.7890, 2.07, 0.317, 262, 243, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
1807, 1iasD, 0.7890, 2.69, 0.243, 330, 251, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1808, 6cz3A, 0.7888, 2.70, 0.406, 262, 254, STRUCTURE OF THE PTK6 KINASE DOMAIN BOUND TO A TYPE I INHIBITOR (3- FLUORO-4-{[6-METHYL-3-(1H-PYRAZOL-4-YL)IMIDAZO[1;2-A]PYRAZIN-8- YL]AMINO}PHENYL)(MORPHOLIN-4-YL)METHANONE 
1809, 3q96A, 0.7888, 2.14, 0.316, 253, 244, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
1810, 3kcfA, 0.7887, 2.62, 0.244, 328, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
1811, 5w5oA, 0.7886, 2.57, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1812, 5cnoA, 0.7885, 3.33, 0.374, 300, 262, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
1813, 5d41A, 0.7883, 3.17, 0.377, 300, 260, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
1814, 4yjrA, 0.7883, 2.17, 0.407, 263, 243, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000225
1815, 4i24A, 0.7882, 3.06, 0.381, 295, 257, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
1816, 1b6cD, 0.7882, 2.57, 0.244, 326, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
1817, 6c7yA, 0.7881, 2.36, 0.371, 273, 245, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS1 IN COMPLEX WITH JAK1 KINASE DOMAIN 
1818, 1b6cF, 0.7881, 2.57, 0.244, 326, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
1819, 5c9cA, 0.7880, 2.16, 0.311, 254, 244, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
1820, 4ehzC, 0.7880, 2.52, 0.363, 278, 248, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
1821, 4e4lB, 0.7880, 2.60, 0.361, 279, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
1822, 4yjsA, 0.7879, 1.99, 0.408, 257, 240, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
1823, 4l52A, 0.7879, 2.79, 0.276, 295, 250, CRYSTAL STRUCTURE OF 1-(4-{4-[7-AMINO-2-(123-BENZOTHIADIAZOL-7-YL) FURO[23-C]PYRIDIN-4-YL]-1H-PYRAZOL-1-YL}PIPERIDIN-1-YL)ETHAN-1-ONE BOUND TO TAK1-TAB1
1824, 5e90A, 0.7878, 2.67, 0.262, 303, 248, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
1825, 4yzmB, 0.7878, 2.65, 0.277, 262, 249, HUMANIZED ROCO4 BOUND TO LRRK2-IN1
1826, 2qlqA, 0.7878, 2.32, 0.462, 245, 240, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
1827, 2hwpA, 0.7878, 2.29, 0.450, 245, 240, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
1828, 5j8iA, 0.7877, 2.31, 0.270, 288, 244, CRYSTAL STRUCTURE OF TL11-113 BOUND TO TAK1-TAB1
1829, 4e4xB, 0.7877, 2.82, 0.299, 274, 254, CRYSTAL STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH A DIHYDROPYRIDO[23-D]PYRIMIDINONE-BASED INHIBITOR
1830, 5d10B, 0.7876, 2.34, 0.465, 247, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
1831, 3idpA, 0.7876, 2.22, 0.322, 255, 245, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
1832, 5jgdA, 0.7875, 2.72, 0.272, 295, 250, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 12
1833, 3w32A, 0.7875, 3.56, 0.353, 317, 266, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 20A
1834, 4lghA, 0.7874, 2.29, 0.452, 243, 239, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
1835, 4i22A, 0.7874, 3.17, 0.378, 297, 259, STRUCTURE OF THE MONOMERIC (V948R)GEFITINIB/ERLOTINIB RESISTANT DOUBLE MUTANT (L858R+T790M) EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH GEFITINIB
1836, 3zc6D, 0.7874, 2.60, 0.381, 267, 247, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
1837, 2v7oA, 0.7874, 3.14, 0.215, 305, 260, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
1838, 3bbtD, 0.7873, 2.86, 0.394, 259, 251, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
1839, 5w5oM, 0.7872, 2.63, 0.233, 276, 249, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1840, 5hvkA, 0.7872, 2.82, 0.274, 297, 252, CRYSTAL STRUCTURE OF LIMK1 MUTANT D460N IN COMPLEX WITH FULL-LENGTH COFILIN-1
1841, 4ksqB, 0.7871, 2.01, 0.310, 255, 242, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR 5B
1842, 3og7B, 0.7871, 1.99, 0.336, 254, 241, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
1843, 1iasA, 0.7870, 2.74, 0.243, 330, 251, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1844, 4kspB, 0.7869, 2.22, 0.316, 256, 244, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
1845, 3lzbC, 0.7869, 2.87, 0.389, 259, 252, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
1846, 1rw8A, 0.7869, 2.35, 0.249, 301, 245, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
1847, 4pp7B, 0.7868, 2.85, 0.299, 274, 254, HIGHLY POTENT AND SELECTIVE 3-N-METHYLQUINAZOLINE-4(3H)-ONE BASED INHIBITORS OF B-RAFV600E KINASE
1848, 3lvpD, 0.7868, 2.50, 0.449, 282, 247, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1849, 5w5oJ, 0.7866, 2.58, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1850, 5w5oH, 0.7866, 2.58, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1851, 4u42A, 0.7866, 3.10, 0.230, 282, 257, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
1852, 3kcfD, 0.7866, 2.68, 0.243, 330, 251, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
1853, 5k0kB, 0.7865, 1.81, 0.441, 248, 236, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC2434
1854, 5ar8B, 0.7865, 2.69, 0.239, 274, 251, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
1855, 2hwoB, 0.7865, 2.20, 0.462, 242, 238, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
1856, 5valB, 0.7864, 2.16, 0.316, 254, 244, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
1857, 4kioA, 0.7864, 2.01, 0.416, 240, 238, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
1858, 3zc6C, 0.7864, 2.61, 0.377, 275, 247, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
1859, 3v5lB, 0.7864, 2.15, 0.404, 241, 240, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
1860, 5l6wL, 0.7863, 3.02, 0.280, 290, 254, STRUCTURE OF THE LIMK1-ATPGAMMAS-CFL1 COMPLEX
1861, 5w5oD, 0.7862, 2.60, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1862, 3s95B, 0.7862, 3.08, 0.278, 290, 255, CRYSTAL STRUCTURE OF THE HUMAN LIMK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1863, 5e8zA, 0.7861, 2.68, 0.250, 303, 248, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
1864, 5cnoB, 0.7861, 3.23, 0.385, 302, 260, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
1865, 4obpA, 0.7861, 3.24, 0.228, 285, 259, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
1866, 5w5oG, 0.7860, 2.60, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1867, 4wd5B, 0.7860, 3.20, 0.340, 304, 259, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH QL-X138
1868, 4bchA, 0.7860, 2.90, 0.184, 308, 255, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1869, 3s95A, 0.7859, 3.08, 0.278, 290, 255, CRYSTAL STRUCTURE OF THE HUMAN LIMK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1870, 6bwkA, 0.7858, 2.34, 0.251, 263, 247, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN T357E/S358E MUTANT 
1871, 5w5oK, 0.7858, 2.60, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1872, 5w5oI, 0.7858, 2.60, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1873, 3gt8B, 0.7858, 3.17, 0.385, 292, 260, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1874, 5w5oO, 0.7857, 2.65, 0.237, 276, 249, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1875, 4yzmA, 0.7855, 2.49, 0.267, 260, 247, HUMANIZED ROCO4 BOUND TO LRRK2-IN1
1876, 1jqhB, 0.7855, 2.81, 0.447, 287, 253, IGF-1 RECEPTOR KINASE DOMAIN
1877, 3skcA, 0.7854, 2.31, 0.308, 260, 247, HUMAN B-RAF KINASE IN COMPLEX WITH AN AMIDE LINKED PYRAZOLOPYRIDINE INHIBITOR
1878, 3lokA, 0.7853, 2.45, 0.461, 248, 241, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
1879, 4zk5A, 0.7852, 3.10, 0.226, 286, 257, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
1880, 3v5lA, 0.7852, 2.09, 0.414, 240, 239, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
1881, 3lokB, 0.7852, 2.29, 0.471, 242, 238, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
1882, 5hezB, 0.7851, 2.85, 0.361, 289, 249, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
1883, 2rf9B, 0.7851, 3.17, 0.380, 269, 258, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
1884, 5w5oC, 0.7850, 2.62, 0.230, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1885, 4mh7B, 0.7850, 2.31, 0.453, 255, 245, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC1896
1886, 5w5oL, 0.7849, 2.61, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1887, 2fb8A, 0.7849, 2.20, 0.313, 259, 243, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
1888, 5e8tA, 0.7848, 2.64, 0.251, 302, 247, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
1889, 5d7aA, 0.7848, 3.38, 0.231, 289, 260, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1890, 1b6cB, 0.7848, 2.63, 0.244, 326, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
1891, 5w5oP, 0.7847, 2.62, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1892, 4e4lA, 0.7847, 2.57, 0.364, 277, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
1893, 3mdyA, 0.7846, 2.97, 0.277, 320, 253, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
1894, 5w5oF, 0.7845, 2.62, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1895, 5jh6A, 0.7845, 2.35, 0.258, 288, 244, CRYSTAL STRUCTURE OF TL10-92 BOUND TO TAK1-TAB1
1896, 2ofvA, 0.7845, 2.28, 0.444, 244, 243, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
1897, 6cz2A, 0.7844, 2.76, 0.406, 261, 254, STRUCTURE OF THE PTK6 KINASE DOMAIN 
1898, 4f1mA, 0.7844, 2.75, 0.272, 278, 250, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
1899, 5hvkC, 0.7843, 2.87, 0.274, 291, 252, CRYSTAL STRUCTURE OF LIMK1 MUTANT D460N IN COMPLEX WITH FULL-LENGTH COFILIN-1
1900, 4pniA, 0.7843, 3.30, 0.189, 492, 259, BOVINE G PROTEIN-COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH GSK2163632A
1901, 5w5oB, 0.7842, 2.62, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1902, 4bciA, 0.7841, 2.86, 0.185, 308, 254, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1903, 1py5A, 0.7841, 2.38, 0.249, 301, 245, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
1904, 4f1oA, 0.7840, 2.67, 0.269, 276, 249, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
1905, 6b8uA, 0.7839, 2.22, 0.320, 253, 244, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
1906, 4kioB, 0.7839, 1.90, 0.409, 239, 237, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
1907, 4bcfA, 0.7839, 3.02, 0.187, 307, 256, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1908, 5jrsB, 0.7838, 2.19, 0.460, 240, 239, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
1909, 5hvjB, 0.7838, 2.82, 0.278, 284, 252, CRYSTAL STRUCTURE OF LIMK1 D460N MUTANT IN COMPLEX WITH AMP-PNP
1910, 4mneG, 0.7838, 2.16, 0.314, 259, 242, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1911, 5j95A, 0.7837, 3.18, 0.233, 284, 258, MAP4K4 IN COMPLEX WITH INHIBITOR
1912, 5d7aC, 0.7837, 3.29, 0.224, 286, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1913, 3idpB, 0.7837, 2.26, 0.320, 256, 244, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
1914, 3gt8D, 0.7837, 3.25, 0.386, 295, 259, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1915, 5itaB, 0.7835, 1.98, 0.332, 252, 241, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
1916, 5e8sA, 0.7835, 2.54, 0.245, 301, 245, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
1917, 4lggB, 0.7835, 2.47, 0.465, 245, 241, STRUCTURE OF 3MB-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
1918, 4bcjA, 0.7835, 3.01, 0.187, 309, 256, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1919, 4mbjA, 0.7834, 2.67, 0.312, 269, 250, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINE-BASED INHIBITOR
1920, 3lmgA, 0.7834, 3.05, 0.329, 268, 255, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1921, 2jivA, 0.7834, 3.24, 0.388, 270, 258, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPEX WITH HKI-272
1922, 5cenA, 0.7833, 3.08, 0.314, 281, 255, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
1923, 4bcgA, 0.7833, 3.03, 0.187, 312, 256, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1924, 3gt8A, 0.7833, 3.22, 0.385, 300, 260, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1925, 2ofvB, 0.7833, 2.25, 0.475, 244, 240, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
1926, 5valA, 0.7832, 2.16, 0.314, 254, 242, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
1927, 2fb8B, 0.7832, 2.21, 0.317, 259, 243, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
1928, 1vjyA, 0.7832, 2.52, 0.253, 299, 245, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
1929, 3mdyC, 0.7831, 2.93, 0.278, 320, 252, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
1930, 5j9lA, 0.7830, 2.28, 0.269, 286, 242, CRYSTAL STRUCTURE OF CPT1691 BOUND TO TAK1-TAB1
1931, 4rzwA, 0.7828, 2.06, 0.332, 251, 241, CRYSTAL STRUCTURE OF BRAF (R509H) KINASE DOMAIN BOUND TO AZ628
1932, 4knbD, 0.7828, 2.16, 0.369, 247, 241, C-MET IN COMPLEX WITH OSI LIGAND
1933, 3lmgB, 0.7828, 3.12, 0.336, 268, 256, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1934, 5hi2A, 0.7827, 2.11, 0.332, 247, 241, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH SORAFENIB
1935, 5friA, 0.7827, 2.54, 0.245, 301, 245, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
1936, 3tnhA, 0.7826, 2.95, 0.189, 288, 254, CDK9/CYCLIN T IN COMPLEX WITH CAN508
1937, 5gjgA, 0.7825, 2.60, 0.270, 289, 248, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 4
1938, 4f0fA, 0.7825, 2.69, 0.273, 276, 249, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
1939, 5ko1A, 0.7824, 2.59, 0.250, 265, 248, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 4.
1940, 4r5yA, 0.7824, 2.12, 0.324, 253, 241, THE COMPLEX STRUCTURE OF BRAF V600E KINASE DOMAIN WITH A NOVEL BRAF INHIBITOR
1941, 4otwA, 0.7824, 3.09, 0.336, 272, 256, HER3 PSEUDOKINASE DOMAIN BOUND TO BOSUTINIB
1942, 4yznA, 0.7823, 2.50, 0.276, 269, 246, HUMANIZED ROCO4 BOUND TO COMPOUND 19
1943, 4imyA, 0.7823, 3.06, 0.196, 314, 255, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
1944, 5usqA, 0.7822, 2.40, 0.247, 299, 243, ALK-5 KINASE INHIBITOR COMPLEX
1945, 6gttA, 0.7821, 2.88, 0.250, 282, 252, HUMAN STK10 BOUND TO BIRB-796 
1946, 4mh7A, 0.7821, 1.85, 0.443, 248, 235, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC1896
1947, 6cadB, 0.7820, 2.01, 0.333, 248, 240, CRYSTAL STRUCTURE OF RAF KINASE DOMAIN BOUND TO THE INHIBITOR 2A
1948, 3p86A, 0.7820, 2.21, 0.358, 250, 243, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
1949, 3c4cA, 0.7820, 2.40, 0.325, 258, 246, B-RAF KINASE IN COMPLEX WITH PLX4720
1950, 1b6cH, 0.7820, 2.68, 0.244, 326, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
1951, 6eixA, 0.7819, 2.74, 0.264, 312, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
1952, 4mwiA, 0.7819, 2.54, 0.251, 266, 247, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN
1953, 2jivB, 0.7819, 3.16, 0.391, 272, 258, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPEX WITH HKI-272
1954, 5d7aB, 0.7817, 3.46, 0.230, 286, 261, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1955, 3my1A, 0.7817, 3.04, 0.187, 314, 256, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
1956, 5wniA, 0.7816, 2.28, 0.247, 263, 243, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN KINASE 4 (RIPK4) D143N IN COMPLEX WITH ATP 
1957, 5hezD, 0.7816, 3.06, 0.363, 289, 251, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
1958, 4mneC, 0.7816, 2.18, 0.310, 260, 242, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1959, 5hezA, 0.7814, 2.53, 0.371, 287, 245, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
1960, 5c9cB, 0.7814, 2.19, 0.322, 251, 242, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
1961, 4yhtB, 0.7814, 2.19, 0.322, 258, 242, BRAF COMPLEXED WITH AN INHIBITOR
1962, 4j8mA, 0.7814, 2.88, 0.235, 265, 255, AURORA A IN COMPLEX WITH CD532
1963, 4ehgA, 0.7814, 2.47, 0.312, 262, 247, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOPYRIDIMINE-BASED INHIBITOR
1964, 3tv6A, 0.7814, 2.68, 0.312, 268, 250, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A METHOXYPYRAZOLOPYRIDINYL BENZAMIDE INHIBITOR
1965, 3gt8C, 0.7814, 3.34, 0.387, 296, 261, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1966, 4mneB, 0.7813, 2.36, 0.306, 270, 245, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1967, 4m67A, 0.7813, 2.55, 0.251, 264, 247, CRYSTAL STRUCTURE OF THE HUMAN MLKL KINASE-LIKE DOMAIN
1968, 5ct7B, 0.7812, 2.05, 0.307, 254, 241, BRAF IN COMPLEX WITH RAF265
1969, 4eheA, 0.7812, 2.74, 0.312, 266, 250, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOTHIENOPYRIMIDINE-BASED INHIBITOR
1970, 3tn8A, 0.7812, 2.98, 0.188, 304, 255, CDK9/CYCLIN T IN COMPLEX WITH CAN508
1971, 6aywB, 0.7809, 3.08, 0.208, 293, 255, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1972, 4gfoA, 0.7809, 2.22, 0.349, 272, 241, TYK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
1973, 4zy4B, 0.7808, 3.21, 0.219, 292, 260, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
1974, 2rf9A, 0.7808, 3.19, 0.390, 280, 259, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
1975, 4mnfA, 0.7807, 2.15, 0.324, 257, 241, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
1976, 6gt1B, 0.7806, 2.96, 0.231, 269, 255, NEK7 BOUND TO PURINE INHIBITOR 
1977, 5ng3A, 0.7806, 2.88, 0.224, 283, 254, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1978, 4ehgB, 0.7804, 2.45, 0.321, 260, 246, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOPYRIDIMINE-BASED INHIBITOR
1979, 2wxvA, 0.7803, 3.02, 0.241, 302, 253, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
1980, 2wihA, 0.7803, 3.02, 0.241, 302, 253, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
1981, 4mneF, 0.7802, 2.12, 0.311, 258, 241, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1982, 4riwC, 0.7800, 3.11, 0.337, 275, 258, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
1983, 3mi9A, 0.7800, 3.13, 0.192, 328, 255, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
1984, 3mfsA, 0.7800, 3.18, 0.226, 303, 257, CASK-4M CAM KINASE DOMAIN AMPPNP
1985, 3tacA, 0.7799, 3.04, 0.214, 324, 257, CRYSTAL STRUCTURE OF THE LIPRIN-ALPHA/CASK COMPLEX
1986, 3miaA, 0.7798, 3.13, 0.192, 324, 255, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
1987, 2bkzA, 0.7798, 3.03, 0.241, 302, 253, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
1988, 6gt1A, 0.7797, 2.97, 0.236, 267, 254, NEK7 BOUND TO PURINE INHIBITOR 
1989, 5di1A, 0.7797, 3.19, 0.233, 285, 258, MAP4K4 IN COMPLEX WITH AN INHIBITOR
1990, 4uy9B, 0.7797, 3.20, 0.342, 315, 257, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
1991, 4riyC, 0.7797, 3.08, 0.335, 275, 257, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
1992, 4uy9A, 0.7795, 3.05, 0.345, 313, 255, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
1993, 4eokC, 0.7795, 2.76, 0.244, 299, 250, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
1994, 2p0cA, 0.7795, 2.33, 0.455, 249, 242, CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER
1995, 2hwpB, 0.7795, 2.14, 0.464, 239, 235, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
1996, 1vywA, 0.7795, 3.05, 0.241, 302, 253, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
1997, 4or5F, 0.7794, 3.21, 0.195, 324, 256, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
1998, 4itjB, 0.7794, 2.72, 0.285, 276, 249, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
1999, 2rfdB, 0.7794, 3.48, 0.360, 286, 261, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
2000, 2bpmA, 0.7794, 3.04, 0.237, 302, 253, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
2001, 4u45A, 0.7793, 3.38, 0.228, 289, 259, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
2002, 4rixC, 0.7793, 3.13, 0.337, 275, 258, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
2003, 3c0hB, 0.7792, 3.13, 0.215, 300, 256, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
2004, 5ig1A, 0.7790, 3.13, 0.242, 300, 256, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
2005, 4cfuA, 0.7789, 2.78, 0.244, 299, 250, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2006, 3mfuA, 0.7789, 3.05, 0.224, 302, 255, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
2007, 6aywA, 0.7788, 2.99, 0.209, 293, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2008, 3utoB, 0.7788, 3.13, 0.198, 566, 258, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
2009, 3lq5A, 0.7788, 2.93, 0.186, 307, 253, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
2010, 6c4dB, 0.7787, 2.60, 0.290, 266, 245, STRUCTURE BASED DESIGN OF RIP1 KINASE INHIBITORS
2011, 4c2vB, 0.7787, 2.72, 0.210, 280, 252, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
2012, 2lgcA, 0.7787, 3.01, 0.208, 359, 255, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
2013, 5xyzB, 0.7786, 1.56, 0.455, 234, 231, THE STRUCTURE OF HUMAN BTK KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR 
2014, 4zy5B, 0.7786, 3.21, 0.219, 287, 260, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
2015, 4u44A, 0.7786, 3.27, 0.226, 286, 257, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
2016, 4e4xA, 0.7785, 2.65, 0.315, 267, 248, CRYSTAL STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH A DIHYDROPYRIDO[23-D]PYRIMIDINONE-BASED INHIBITOR
2017, 5cwzB, 0.7783, 3.40, 0.224, 284, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2018, 4b8mB, 0.7783, 2.73, 0.210, 279, 252, AURORA B KINASE IN COMPLEX WITH VX-680
2019, 6c3eB, 0.7782, 2.35, 0.298, 259, 242, CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
2020, 6b16B, 0.7782, 3.18, 0.221, 281, 258, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
2021, 4joaA, 0.7782, 2.31, 0.423, 250, 239, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 7-AZAINDOLE BASED INHIBITOR
2022, 4eoqC, 0.7782, 2.85, 0.232, 275, 250, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
2023, 4eopA, 0.7782, 2.87, 0.247, 297, 251, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2024, 5hezC, 0.7781, 2.77, 0.368, 289, 247, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
2025, 4eosA, 0.7781, 2.87, 0.231, 296, 251, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2026, 4c2wB, 0.7781, 2.73, 0.210, 277, 252, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
2027, 3tv4A, 0.7781, 2.65, 0.310, 264, 248, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN BROMOPYRIDINE BENZAMIDE INHIBITOR
2028, 6c4dC, 0.7780, 2.31, 0.293, 258, 242, STRUCTURE BASED DESIGN OF RIP1 KINASE INHIBITORS
2029, 2c4gA, 0.7780, 3.08, 0.241, 301, 253, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
2030, 4yhtA, 0.7779, 2.20, 0.315, 256, 241, BRAF COMPLEXED WITH AN INHIBITOR
2031, 3utoA, 0.7779, 3.15, 0.198, 559, 258, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
2032, 2c4gC, 0.7779, 2.94, 0.246, 300, 252, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
2033, 4xv1B, 0.7778, 1.90, 0.333, 249, 237, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7904
2034, 4pp7A, 0.7778, 2.69, 0.313, 267, 249, HIGHLY POTENT AND SELECTIVE 3-N-METHYLQUINAZOLINE-4(3H)-ONE BASED INHIBITORS OF B-RAFV600E KINASE
2035, 5vloB, 0.7777, 3.11, 0.208, 293, 255, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2036, 4wboA, 0.7777, 3.29, 0.195, 497, 257, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
2037, 4cqeB, 0.7777, 1.96, 0.335, 248, 239, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
2038, 4imyE, 0.7776, 2.99, 0.194, 313, 253, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
2039, 2wtvD, 0.7776, 2.95, 0.238, 262, 256, AURORA-A INHIBITOR STRUCTURE
2040, 4wboD, 0.7775, 3.28, 0.195, 491, 257, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
2041, 2wtvA, 0.7775, 2.95, 0.238, 262, 256, AURORA-A INHIBITOR STRUCTURE
2042, 4mnfB, 0.7774, 2.22, 0.311, 257, 241, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
2043, 2wpaA, 0.7774, 3.05, 0.241, 302, 253, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
2044, 2c5vA, 0.7774, 2.74, 0.238, 296, 248, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2045, 4zp5A, 0.7773, 3.38, 0.231, 284, 260, MAP4K4 IN COMPLEX WITH INHIBITOR
2046, 4cfnA, 0.7773, 2.89, 0.219, 296, 251, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2047, 3c0hA, 0.7773, 3.05, 0.216, 300, 255, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
2048, 3bhuA, 0.7771, 2.82, 0.245, 297, 249, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
2049, 2wevC, 0.7771, 2.84, 0.241, 296, 249, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2050, 1oguA, 0.7771, 2.93, 0.223, 296, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
2051, 4or5A, 0.7770, 3.23, 0.195, 319, 256, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
2052, 4eojC, 0.7770, 2.91, 0.235, 282, 251, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
2053, 4cfvA, 0.7769, 2.77, 0.233, 300, 249, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2054, 2c5oC, 0.7769, 2.76, 0.238, 296, 248, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2055, 4ysmA, 0.7768, 3.08, 0.259, 475, 255, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
2056, 2wouA, 0.7768, 2.54, 0.243, 299, 243, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
2057, 2gcdA, 0.7768, 3.22, 0.238, 308, 256, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
2058, 5tc0B, 0.7767, 2.18, 0.454, 250, 240, STRUCTURE-BASED OPTIMIZATION OF 1H-IMIDAZOLE-2-CARBOXAMIDES AS AXL KINASE INHIBITORS UTILIZING A MER MUTANT SURROGATE
2059, 5cwzA, 0.7767, 3.30, 0.229, 284, 258, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2060, 4eomC, 0.7767, 2.93, 0.231, 275, 251, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2061, 2c5oA, 0.7767, 2.85, 0.241, 296, 249, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2062, 4lueB, 0.7766, 2.51, 0.473, 417, 241, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
2063, 3c0iA, 0.7765, 3.02, 0.217, 298, 254, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
2064, 2bkzC, 0.7765, 2.85, 0.244, 298, 250, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
2065, 4bcmA, 0.7764, 2.99, 0.230, 295, 252, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2066, 3c0gB, 0.7764, 3.16, 0.215, 320, 256, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
2067, 3blqA, 0.7764, 3.03, 0.190, 295, 253, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
2068, 1u5qA, 0.7764, 3.17, 0.235, 308, 255, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2069, 2vn9B, 0.7763, 3.02, 0.209, 301, 254, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
2070, 2vgpB, 0.7763, 2.76, 0.210, 277, 252, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
2071, 2c5xC, 0.7763, 2.78, 0.234, 296, 248, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2072, 2c5xA, 0.7763, 2.76, 0.234, 296, 248, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2073, 1koaA, 0.7763, 3.11, 0.195, 447, 256, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
2074, 4j53A, 0.7761, 3.25, 0.209, 293, 258, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
2075, 4f0gA, 0.7761, 2.27, 0.274, 263, 241, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM
2076, 4eolC, 0.7761, 2.83, 0.240, 299, 250, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2077, 2c5vC, 0.7761, 2.78, 0.234, 296, 248, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2078, 1oiuA, 0.7761, 2.93, 0.231, 296, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2079, 1fvvC, 0.7761, 2.83, 0.237, 298, 249, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
2080, 4ysmB, 0.7760, 3.08, 0.259, 475, 255, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
2081, 3eocA, 0.7760, 2.80, 0.225, 295, 249, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
2082, 2x7fB, 0.7760, 2.98, 0.238, 288, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2083, 2vn9A, 0.7760, 3.02, 0.209, 301, 254, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
2084, 2owbA, 0.7760, 3.24, 0.213, 294, 258, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
2085, 4wboC, 0.7759, 3.31, 0.195, 481, 257, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
2086, 4ec8A, 0.7759, 3.04, 0.189, 325, 254, STRUCTURE OF FULL LENGTH CDK9 IN COMPLEX WITH CYCLINT AND DRB
2087, 3v8tA, 0.7759, 2.24, 0.418, 238, 237, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
2088, 3en7B, 0.7759, 2.12, 0.464, 237, 233, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH S1 A MULTITARGETED KINASE INHIBITOR
2089, 3bhtA, 0.7759, 2.82, 0.241, 297, 249, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
2090, 2whbA, 0.7759, 2.83, 0.233, 296, 249, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2091, 1urcC, 0.7759, 2.85, 0.241, 296, 249, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
2092, 1urcA, 0.7759, 2.84, 0.245, 296, 249, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
2093, 5deyB, 0.7758, 3.16, 0.221, 281, 258, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2094, 2x7fC, 0.7758, 3.02, 0.238, 285, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2095, 2c5nA, 0.7758, 2.87, 0.244, 296, 250, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2096, 1fvvA, 0.7758, 2.88, 0.240, 298, 250, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
2097, 4j52A, 0.7757, 3.26, 0.209, 293, 258, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
2098, 2whbC, 0.7757, 2.85, 0.241, 296, 249, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2099, 4c02A, 0.7756, 2.65, 0.268, 313, 246, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
2100, 3ej1A, 0.7756, 2.80, 0.233, 295, 249, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
2101, 3blrA, 0.7756, 2.97, 0.186, 300, 253, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
2102, 2gcdB, 0.7756, 3.08, 0.244, 308, 254, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
2103, 1ol2A, 0.7756, 2.85, 0.241, 296, 249, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
2104, 3mfrA, 0.7755, 3.10, 0.224, 302, 255, CASK-4M CAM KINASE DOMAIN NATIVE
2105, 2wfyA, 0.7755, 2.83, 0.245, 295, 249, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2106, 2c5nC, 0.7755, 2.79, 0.234, 296, 248, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2107, 2bpmC, 0.7755, 2.87, 0.240, 299, 250, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
2108, 5ng3D, 0.7754, 2.84, 0.226, 278, 252, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
2109, 4i20A, 0.7754, 3.53, 0.392, 287, 263, CRYSTAL STRUCTURE OF MONOMERIC (V948R) PRIMARY ONCOGENIC MUTANT L858R EGFR KINASE DOMAIN
2110, 4cfuC, 0.7754, 2.93, 0.244, 272, 250, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2111, 4zy6B, 0.7753, 3.14, 0.222, 280, 257, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2112, 3bhvA, 0.7753, 2.85, 0.241, 297, 249, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
2113, 5ta6A, 0.7752, 3.26, 0.209, 294, 258, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
2114, 5fd2A, 0.7752, 2.88, 0.313, 264, 249, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
2115, 4cfwA, 0.7751, 2.81, 0.241, 299, 249, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2116, 3en6A, 0.7751, 2.07, 0.461, 236, 232, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP102 A MULTITARGETED KINASE INHIBITOR
2117, 2x1nC, 0.7751, 2.88, 0.245, 296, 249, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2118, 1u5rA, 0.7751, 3.25, 0.238, 308, 256, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2119, 4lggA, 0.7750, 2.34, 0.447, 241, 237, STRUCTURE OF 3MB-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
2120, 3eocC, 0.7750, 2.77, 0.226, 293, 248, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
2121, 2x1nA, 0.7750, 2.87, 0.245, 296, 249, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2122, 2v22C, 0.7750, 2.79, 0.230, 296, 248, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2123, 1okwC, 0.7750, 2.86, 0.245, 296, 249, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
2124, 3qupA, 0.7749, 2.11, 0.431, 241, 239, INHIBITOR BOUND STRUCTURE OF THE KINASE DOMAIN OF THE MURINE RECEPTOR TYROSINE KINASE TYRO3 (SKY)
2125, 2wxvC, 0.7749, 2.86, 0.240, 299, 250, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
2126, 2i40C, 0.7749, 2.85, 0.241, 296, 249, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
2127, 1vywC, 0.7749, 2.88, 0.236, 299, 250, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
2128, 2wihC, 0.7748, 2.89, 0.248, 299, 250, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
2129, 2v22A, 0.7748, 2.86, 0.241, 296, 249, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2130, 2uueA, 0.7748, 2.86, 0.241, 296, 249, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2131, 1ol2C, 0.7748, 2.88, 0.245, 296, 249, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
2132, 4wboB, 0.7747, 3.34, 0.190, 495, 258, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
2133, 4mhaB, 0.7747, 1.97, 0.440, 246, 234, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC1817
2134, 3uohB, 0.7747, 3.16, 0.234, 264, 256, AURORA A IN COMPLEX WITH RPM1722
2135, 3uohA, 0.7747, 3.16, 0.234, 264, 256, AURORA A IN COMPLEX WITH RPM1722
2136, 2uueC, 0.7747, 2.89, 0.241, 296, 249, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2137, 1kobB, 0.7747, 3.04, 0.191, 352, 256, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2138, 2wfyC, 0.7745, 2.85, 0.245, 296, 249, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2139, 3en5A, 0.7744, 2.21, 0.457, 238, 234, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
2140, 4fx3C, 0.7743, 2.94, 0.244, 298, 250, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
2141, 3itzA, 0.7743, 3.29, 0.214, 357, 257, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
2142, 3c0gA, 0.7743, 3.05, 0.217, 309, 254, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
2143, 2wevA, 0.7743, 2.89, 0.241, 296, 249, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2144, 5if1A, 0.7742, 2.78, 0.234, 298, 248, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
2145, 4ec9A, 0.7742, 3.09, 0.186, 306, 253, CRYSTAL STRUCTURE OF FULL-LENGTH CDK9 IN COMPLEX WITH CYCLIN T
2146, 1ol1C, 0.7742, 2.90, 0.245, 296, 249, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
2147, 1oguC, 0.7742, 2.91, 0.236, 272, 250, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
2148, 6c4dD, 0.7741, 2.66, 0.293, 266, 246, STRUCTURE BASED DESIGN OF RIP1 KINASE INHIBITORS
2149, 5w5oN, 0.7741, 2.64, 0.233, 272, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2150, 3f5xC, 0.7741, 2.87, 0.237, 298, 249, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
2151, 4cfnC, 0.7740, 2.93, 0.239, 296, 251, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2152, 1kobA, 0.7740, 3.02, 0.191, 352, 256, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2153, 5if1C, 0.7739, 2.78, 0.242, 296, 248, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
2154, 3ej1C, 0.7739, 2.82, 0.237, 294, 249, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
2155, 1ol1A, 0.7739, 2.86, 0.233, 296, 249, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
2156, 1okwA, 0.7739, 2.87, 0.245, 296, 249, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
2157, 6babD, 0.7738, 2.94, 0.210, 291, 252, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2158, 3qhrC, 0.7738, 2.91, 0.248, 297, 250, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
2159, 3mftA, 0.7738, 3.03, 0.220, 302, 254, CASK-4M CAM KINASE DOMAIN MN2+
2160, 2rkuA, 0.7738, 3.26, 0.209, 294, 258, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
2161, 1h1rA, 0.7738, 2.90, 0.237, 296, 249, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
2162, 3qhrA, 0.7736, 2.91, 0.248, 297, 250, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
2163, 3e5aA, 0.7736, 2.74, 0.240, 264, 250, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
2164, 6b3eA, 0.7735, 3.13, 0.228, 309, 254, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
2165, 3unzB, 0.7735, 3.13, 0.239, 263, 255, AURORA A IN COMPLEX WITH RPM1679
2166, 1h1sA, 0.7735, 2.78, 0.234, 296, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
2167, 3unzA, 0.7734, 3.13, 0.239, 263, 255, AURORA A IN COMPLEX WITH RPM1679
2168, 3qhwC, 0.7734, 2.91, 0.248, 297, 250, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
2169, 3fc2A, 0.7734, 3.33, 0.209, 293, 258, PLK1 IN COMPLEX WITH BI6727
2170, 1okvA, 0.7734, 2.85, 0.241, 295, 249, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
2171, 1finA, 0.7733, 2.88, 0.241, 298, 249, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
2172, 5i4nA, 0.7732, 2.90, 0.257, 275, 253, CRYSTAL STRUCTURE OF THE E596A V617F MUTANT JAK2 PSEUDOKINASE DOMAIN BOUND TO MG-ATP
2173, 5horA, 0.7732, 1.99, 0.393, 247, 234, CRYSTAL STRUCTURE OF C-MET-M1250T IN COMPLEX WITH SAR125844.
2174, 5cyiA, 0.7732, 2.90, 0.229, 298, 249, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
2175, 3uo6B, 0.7732, 3.07, 0.242, 264, 256, AURORA A IN COMPLEX WITH YL5-083
2176, 3uo6A, 0.7732, 3.07, 0.242, 264, 256, AURORA A IN COMPLEX WITH YL5-083
2177, 3c51A, 0.7732, 3.31, 0.195, 487, 257, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 3.55A
2178, 5nevA, 0.7731, 2.81, 0.234, 295, 248, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
2179, 4l9iB, 0.7731, 3.36, 0.194, 493, 258, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
2180, 4eooC, 0.7731, 2.93, 0.236, 297, 250, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2181, 3qhwA, 0.7731, 2.91, 0.248, 297, 250, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
2182, 2vgoB, 0.7731, 2.76, 0.195, 277, 251, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
2183, 2iw8A, 0.7731, 2.80, 0.234, 297, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2184, 1tkiB, 0.7731, 2.87, 0.174, 321, 253, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2185, 4yc3A, 0.7730, 3.05, 0.243, 295, 251, CDK1/CYCLINB1/CKS2 APO
2186, 3uokB, 0.7730, 3.22, 0.237, 265, 257, AURORA A IN COMPLEX WITH YL5-81-1
2187, 3dogA, 0.7730, 3.00, 0.240, 297, 250, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
2188, 1tkiA, 0.7730, 2.87, 0.174, 321, 253, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2189, 1oi9A, 0.7730, 2.79, 0.234, 295, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2190, 4eomA, 0.7729, 2.81, 0.230, 296, 248, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2191, 3uokA, 0.7729, 3.22, 0.237, 265, 257, AURORA A IN COMPLEX WITH YL5-81-1
2192, 1u5qB, 0.7729, 3.13, 0.244, 308, 254, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2193, 1okvC, 0.7729, 2.95, 0.248, 296, 250, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
2194, 5vioC, 0.7728, 2.78, 0.220, 271, 246, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
2195, 5lqeA, 0.7728, 2.80, 0.238, 295, 248, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
2196, 3bhvC, 0.7728, 2.90, 0.241, 271, 249, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
2197, 2ou7A, 0.7728, 3.30, 0.214, 292, 257, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
2198, 1h28C, 0.7728, 2.93, 0.237, 296, 249, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
2199, 1h1qA, 0.7728, 2.73, 0.239, 296, 247, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
2200, 4idtB, 0.7727, 3.06, 0.207, 335, 256, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
2201, 4fx3A, 0.7727, 2.95, 0.244, 298, 250, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
2202, 3tzmA, 0.7727, 2.40, 0.250, 295, 240, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
2203, 3ddpC, 0.7727, 2.84, 0.242, 298, 248, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
2204, 1h26A, 0.7727, 2.85, 0.246, 296, 248, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
2205, 5hesB, 0.7726, 2.70, 0.320, 278, 247, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
2206, 5cyiC, 0.7726, 2.73, 0.239, 296, 247, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
2207, 4imyC, 0.7726, 3.01, 0.191, 310, 251, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
2208, 4c57A, 0.7726, 2.99, 0.235, 310, 251, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
2209, 3ddpA, 0.7726, 2.82, 0.234, 297, 248, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
2210, 2wmaA, 0.7726, 2.75, 0.239, 296, 247, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2211, 3lm0A, 0.7725, 2.93, 0.226, 278, 252, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
2212, 2wpaC, 0.7725, 2.92, 0.240, 299, 250, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
2213, 5vilC, 0.7724, 2.79, 0.220, 271, 246, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
2214, 5hq0A, 0.7724, 2.87, 0.249, 292, 249, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
2215, 4y72A, 0.7724, 2.87, 0.249, 292, 249, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
2216, 5ceoA, 0.7723, 2.69, 0.320, 269, 247, DLK IN COMPLEX WITH INHIBITOR 2-((6-(33-DIFLUOROPYRROLIDIN-1-YL)-4- (1-(OXETAN-3-YL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)ISONICOTINONITRILE
2217, 2acxB, 0.7723, 3.25, 0.199, 492, 256, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
2218, 2acxA, 0.7723, 3.38, 0.190, 495, 258, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
2219, 5ax9A, 0.7722, 3.21, 0.236, 282, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2220, 4c57B, 0.7722, 3.03, 0.235, 308, 251, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
2221, 5cepA, 0.7721, 2.68, 0.316, 269, 247, DLK IN COMPLEX WITH INHIBITOR N-(1-ISOPROPYL-5-(PIPERIDIN-4-YL)-1H- PYRAZOL-3-YL)-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE
2222, 4eoqA, 0.7721, 2.82, 0.226, 295, 248, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
2223, 2g9xA, 0.7721, 2.92, 0.229, 298, 249, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
2224, 2cciA, 0.7721, 2.84, 0.246, 296, 248, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
2225, 5eakA, 0.7720, 2.62, 0.256, 305, 246, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
2226, 4bcnA, 0.7720, 2.89, 0.241, 296, 249, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2227, 3lm5A, 0.7720, 2.96, 0.222, 274, 252, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
2228, 2cchA, 0.7720, 2.90, 0.245, 296, 249, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
2229, 1h28A, 0.7720, 2.84, 0.238, 296, 248, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
2230, 5oneA, 0.7719, 2.74, 0.240, 257, 250, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
2231, 5izjB, 0.7719, 3.22, 0.240, 325, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
2232, 4xv2B, 0.7719, 2.16, 0.329, 249, 240, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH DABRAFENIB
2233, 4fk3A, 0.7719, 2.25, 0.328, 251, 241, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
2234, 3ddqA, 0.7719, 2.79, 0.239, 296, 247, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
2235, 2wipA, 0.7719, 2.92, 0.234, 297, 248, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
2236, 1pkdC, 0.7719, 2.88, 0.242, 296, 248, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
2237, 4m3qA, 0.7718, 1.82, 0.437, 243, 231, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC1917
2238, 2y7jA, 0.7718, 2.86, 0.210, 284, 248, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2239, 5vloA, 0.7717, 2.96, 0.207, 290, 251, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2240, 4o2zA, 0.7717, 2.84, 0.217, 363, 249, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
2241, 4eojA, 0.7717, 2.78, 0.231, 295, 247, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
2242, 4bcoA, 0.7717, 2.93, 0.241, 298, 249, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2243, 3my5A, 0.7717, 2.82, 0.234, 296, 248, CDK2/CYCLINA IN COMPLEX WITH DRB
2244, 2wmbA, 0.7717, 2.90, 0.245, 296, 249, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2245, 5ajqA, 0.7716, 3.28, 0.236, 280, 258, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
2246, 4idtA, 0.7716, 3.17, 0.206, 334, 257, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
2247, 4cfmA, 0.7716, 2.84, 0.246, 296, 248, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2248, 3uojB, 0.7716, 3.12, 0.235, 263, 255, AURORA A IN COMPLEX WITH RPM1715
2249, 3f5xA, 0.7716, 2.87, 0.246, 297, 248, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
2250, 5cswA, 0.7715, 2.25, 0.320, 254, 241, B-RAF IN COMPLEX WITH DABRAFENIB
2251, 4nstA, 0.7715, 3.12, 0.249, 322, 253, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2252, 4jnwA, 0.7715, 2.88, 0.170, 320, 253, BACTERIALLY EXPRESSED TITIN KINASE
2253, 4cxaA, 0.7715, 3.07, 0.237, 329, 253, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
2254, 4bcpA, 0.7715, 2.87, 0.242, 298, 248, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2255, 3uojA, 0.7715, 3.12, 0.235, 263, 255, AURORA A IN COMPLEX WITH RPM1715
2256, 3blhA, 0.7715, 3.03, 0.190, 291, 252, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
2257, 5td2A, 0.7714, 1.97, 0.448, 240, 232, STRUCTURE-BASED OPTIMIZATION OF 1H-IMIDAZOLE-2-CARBOXAMIDES AS AXL KINASE INHIBITORS UTILIZING A MER MUTANT SURROGATE
2258, 4l3lA, 0.7714, 3.35, 0.227, 291, 260, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
2259, 4eonA, 0.7714, 2.89, 0.245, 299, 249, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2260, 3en6B, 0.7714, 2.36, 0.455, 239, 235, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP102 A MULTITARGETED KINASE INHIBITOR
2261, 1u5rB, 0.7714, 3.21, 0.243, 308, 255, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2262, 1oi9C, 0.7714, 2.81, 0.234, 296, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2263, 3mj1A, 0.7712, 1.48, 0.412, 228, 228, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR RO5191614
2264, 3c50B, 0.7712, 3.45, 0.193, 496, 259, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
2265, 3c4zA, 0.7712, 3.31, 0.195, 493, 257, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 1.84A
2266, 1h1qC, 0.7712, 2.75, 0.243, 296, 247, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
2267, 5izjA, 0.7711, 3.22, 0.240, 328, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
2268, 4nusA, 0.7711, 3.21, 0.234, 301, 256, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
2269, 3h9rA, 0.7711, 2.65, 0.269, 312, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
2270, 1pkdA, 0.7711, 2.87, 0.242, 296, 248, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
2271, 5ceqA, 0.7710, 2.69, 0.316, 269, 247, DLK IN COMPLEX WITH INHIBITOR 2-((1-CYCLOPENTYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)AMINO)ISONICOTINONITRILE
2272, 3t8oA, 0.7710, 3.50, 0.193, 493, 259, RHODOPSIN KINASE (GRK1) L166K MUTANT AT 2.5A RESOLUTION
2273, 2bfxB, 0.7710, 2.69, 0.209, 275, 249, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
2274, 4ogrA, 0.7709, 3.25, 0.192, 314, 255, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
2275, 3tniA, 0.7709, 2.83, 0.185, 297, 249, STRUCTURE OF CDK9/CYCLIN T F241L
2276, 2y7jC, 0.7709, 2.89, 0.218, 284, 248, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2277, 1oiyA, 0.7709, 3.00, 0.232, 293, 250, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2278, 1h25A, 0.7709, 2.94, 0.245, 293, 249, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
2279, 5lmkA, 0.7708, 2.85, 0.238, 296, 248, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
2280, 4o0rB, 0.7708, 3.06, 0.224, 282, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2281, 3q53A, 0.7708, 3.05, 0.229, 291, 253, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
2282, 3c50A, 0.7708, 3.38, 0.194, 499, 258, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
2283, 1qmzA, 0.7708, 2.94, 0.245, 296, 249, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
2284, 1h27A, 0.7708, 2.86, 0.246, 296, 248, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
2285, 5nevC, 0.7707, 2.76, 0.235, 296, 247, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
2286, 1e9hC, 0.7707, 2.84, 0.238, 296, 248, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
2287, 6g4yA, 0.7706, 3.11, 0.191, 322, 257, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 1A 
2288, 6c4dA, 0.7706, 2.55, 0.295, 267, 244, STRUCTURE BASED DESIGN OF RIP1 KINASE INHIBITORS
2289, 4rvtA, 0.7706, 3.26, 0.228, 281, 254, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
2290, 4eooA, 0.7706, 2.93, 0.233, 294, 249, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2291, 3tnwA, 0.7706, 2.95, 0.233, 295, 249, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
2292, 2hy81, 0.7706, 3.24, 0.224, 293, 255, PAK1 COMPLEX WITH ST2001
2293, 1qmzC, 0.7706, 2.92, 0.249, 296, 249, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
2294, 1h1sC, 0.7706, 2.82, 0.238, 296, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
2295, 1h1rC, 0.7706, 2.83, 0.234, 296, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
2296, 5wijA, 0.7705, 3.12, 0.259, 274, 255, JAK2 PSEUDOKINASE IN COMPLEX WITH NU6140 
2297, 5vo1A, 0.7705, 2.70, 0.316, 269, 247, DLK IN COMPLEX WITH COMPOUND 10 (5-(1-ISOPROPYL-5-(3-(OXETAN-3-YL)-3- AZABICYCLO[3.1.0]HEXAN-6-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL) PYRIDIN-2-AMINE)
2298, 3uolB, 0.7705, 3.20, 0.234, 263, 256, AURORA A IN COMPLEX WITH SO2-162
2299, 3uolA, 0.7705, 3.20, 0.234, 263, 256, AURORA A IN COMPLEX WITH SO2-162
2300, 3bhuC, 0.7705, 3.01, 0.244, 271, 250, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
2301, 2p0cB, 0.7705, 2.38, 0.452, 248, 241, CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER
2302, 5imeB, 0.7704, 3.05, 0.217, 280, 253, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
2303, 5cswB, 0.7704, 2.42, 0.326, 252, 242, B-RAF IN COMPLEX WITH DABRAFENIB
2304, 4uzdB, 0.7704, 2.77, 0.223, 258, 251, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
2305, 4jnwB, 0.7704, 2.90, 0.174, 321, 253, BACTERIALLY EXPRESSED TITIN KINASE
2306, 3wf9A, 0.7704, 3.18, 0.230, 287, 257, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
2307, 3wf8A, 0.7704, 3.32, 0.224, 287, 259, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
2308, 2iw6A, 0.7704, 2.91, 0.233, 292, 249, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2309, 1finC, 0.7704, 2.93, 0.241, 298, 249, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
2310, 4bcnC, 0.7703, 2.96, 0.240, 295, 250, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2311, 3qc9D, 0.7703, 3.46, 0.193, 486, 259, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
2312, 3qc9C, 0.7703, 3.46, 0.193, 482, 259, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
2313, 4nstC, 0.7702, 3.07, 0.234, 317, 252, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2314, 4itjA, 0.7702, 2.55, 0.300, 261, 243, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
2315, 3qc9A, 0.7702, 3.46, 0.193, 486, 259, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
2316, 2wzjC, 0.7702, 2.65, 0.236, 310, 246, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2317, 2biyA, 0.7702, 3.29, 0.227, 287, 256, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
2318, 5uoxA, 0.7701, 2.75, 0.220, 263, 245, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2319, 5lvpD, 0.7701, 3.03, 0.231, 276, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2320, 4cfxA, 0.7701, 2.92, 0.237, 298, 249, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2321, 3qc9B, 0.7701, 3.46, 0.193, 481, 259, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
2322, 5ta8A, 0.7700, 3.23, 0.210, 294, 257, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
2323, 1h24C, 0.7700, 2.91, 0.246, 293, 248, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
2324, 5vo2A, 0.7699, 2.70, 0.316, 269, 247, DLK IN COMPLEX WITH INHIBITOR 5-(1-ISOPROPYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE (COMPOUND 7)
2325, 5t8oA, 0.7699, 3.06, 0.187, 324, 256, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO IMIDAZOBENZOXEPIN COMPOUND 3
2326, 5v24B, 0.7698, 2.73, 0.216, 263, 245, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2327, 5lvpB, 0.7698, 2.97, 0.232, 276, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2328, 4lg4B, 0.7698, 3.13, 0.236, 284, 254, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2329, 2yacA, 0.7698, 3.26, 0.211, 290, 256, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
2330, 4yzbA, 0.7697, 3.07, 0.257, 466, 253, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
2331, 4eoiA, 0.7697, 2.94, 0.241, 294, 249, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2332, 5k3yB, 0.7696, 2.77, 0.192, 277, 250, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
2333, 4l42A, 0.7696, 3.39, 0.227, 299, 260, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
2334, 3hmmA, 0.7696, 2.38, 0.255, 293, 239, STRUCTURE OF ALK5 + GW855857
2335, 2wzjA, 0.7696, 2.67, 0.236, 310, 246, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2336, 2iw9A, 0.7696, 2.91, 0.226, 293, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2337, 2cchC, 0.7696, 2.94, 0.245, 296, 249, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
2338, 5vioD, 0.7695, 2.85, 0.215, 271, 246, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
2339, 5vilA, 0.7695, 2.84, 0.215, 271, 246, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
2340, 5hieB, 0.7695, 2.89, 0.309, 259, 249, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
2341, 4i1zA, 0.7695, 3.59, 0.384, 287, 263, CRYSTAL STRUCTURE OF THE MONOMERIC (V948R) FORM OF THE GEFITINIB/ERLOTINIB RESISTANT EGFR KINASE DOMAIN L858R+T790M
2342, 4a4lA, 0.7695, 3.35, 0.210, 290, 257, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
2343, 3kk8A, 0.7695, 3.06, 0.206, 283, 253, CAMKII SUBSTRATE COMPLEX A
2344, 3c4xA, 0.7695, 3.37, 0.195, 496, 257, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
2345, 2uzlC, 0.7695, 2.89, 0.250, 295, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2346, 1oiyC, 0.7695, 2.92, 0.245, 296, 249, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2347, 5vioA, 0.7694, 2.83, 0.215, 271, 246, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
2348, 4m69A, 0.7694, 3.16, 0.249, 284, 253, CRYSTAL STRUCTURE OF THE MOUSE RIP3-MLKL COMPLEX
2349, 4cfxC, 0.7694, 2.84, 0.246, 298, 248, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2350, 3c4yA, 0.7694, 3.44, 0.193, 478, 259, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
2351, 1h27C, 0.7694, 2.88, 0.242, 291, 248, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
2352, 4l46A, 0.7693, 3.47, 0.235, 317, 260, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
2353, 5wilA, 0.7692, 3.13, 0.259, 274, 255, JAK2 PSEUDOKINASE IN COMPLEX WITH AZD7762 
2354, 5ng3B, 0.7692, 2.71, 0.230, 275, 248, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
2355, 3bhtC, 0.7692, 2.92, 0.246, 270, 248, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
2356, 4bcoC, 0.7691, 2.85, 0.235, 269, 247, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2357, 3zrkB, 0.7691, 3.53, 0.177, 348, 260, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2358, 2bfyB, 0.7691, 2.78, 0.192, 278, 250, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2359, 6gt1D, 0.7690, 2.81, 0.222, 260, 248, NEK7 BOUND TO PURINE INHIBITOR 
2360, 5eykB, 0.7690, 2.78, 0.192, 275, 250, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
2361, 4bcmC, 0.7690, 2.88, 0.246, 294, 248, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2362, 2uzlA, 0.7690, 2.83, 0.243, 295, 247, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2363, 5vioB, 0.7689, 2.74, 0.216, 271, 245, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
2364, 5lqeC, 0.7689, 2.87, 0.242, 296, 248, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
2365, 4yhjB, 0.7689, 3.23, 0.200, 490, 255, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
2366, 4cfwC, 0.7689, 2.97, 0.245, 297, 249, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2367, 4asxA, 0.7689, 2.71, 0.253, 310, 245, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
2368, 3eidA, 0.7689, 2.98, 0.233, 292, 249, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
2369, 1unlB, 0.7689, 2.89, 0.235, 292, 247, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
2370, 1unlA, 0.7689, 2.74, 0.233, 292, 245, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
2371, 4kikA, 0.7688, 3.25, 0.222, 618, 257, HUMAN IKB KINASE BETA
2372, 6g4zA, 0.7687, 3.12, 0.187, 322, 256, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
2373, 5hesA, 0.7687, 2.95, 0.320, 287, 250, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
2374, 4eopC, 0.7687, 2.96, 0.245, 296, 249, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2375, 3fe3B, 0.7687, 3.14, 0.240, 317, 254, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
2376, 1okyA, 0.7687, 3.14, 0.229, 281, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2377, 4l3jA, 0.7686, 3.39, 0.231, 291, 260, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
2378, 4i5hA, 0.7686, 3.06, 0.200, 335, 250, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
2379, 4ogrE, 0.7685, 3.13, 0.190, 310, 252, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
2380, 4fvrA, 0.7685, 2.95, 0.257, 274, 253, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN MUTANT V617F (MG- ATP-BOUND FORM)
2381, 5winA, 0.7684, 3.13, 0.259, 274, 255, JAK2 PSEUDOKINASE IN COMPLEX WITH JNJ7706621 
2382, 2wzjB, 0.7684, 2.69, 0.236, 310, 246, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2383, 1p5eC, 0.7684, 2.98, 0.241, 296, 249, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
2384, 3nyoB, 0.7683, 3.50, 0.193, 553, 259, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
2385, 2wzjF, 0.7683, 2.70, 0.236, 310, 246, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2386, 5xyzA, 0.7682, 1.48, 0.467, 230, 227, THE STRUCTURE OF HUMAN BTK KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR 
2387, 5m4fA, 0.7682, 2.91, 0.169, 330, 249, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
2388, 5hlnB, 0.7682, 3.57, 0.177, 346, 260, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
2389, 5acbC, 0.7682, 3.18, 0.228, 324, 254, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
2390, 3nynB, 0.7682, 3.50, 0.193, 553, 259, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
2391, 3iw4C, 0.7682, 3.05, 0.241, 332, 253, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
2392, 3c4wB, 0.7682, 3.44, 0.190, 518, 258, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
2393, 3c4wA, 0.7682, 3.39, 0.195, 494, 257, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
2394, 1h24A, 0.7682, 2.80, 0.247, 293, 247, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
2395, 6b3eC, 0.7681, 3.16, 0.221, 307, 253, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
2396, 5vilB, 0.7681, 2.76, 0.216, 271, 245, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
2397, 5ho7A, 0.7681, 3.22, 0.228, 280, 254, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2398, 4w8eA, 0.7681, 2.93, 0.248, 290, 250, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
2399, 4ogrI, 0.7681, 3.36, 0.195, 318, 256, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
2400, 2iw6C, 0.7681, 2.95, 0.249, 295, 249, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2401, 2cciC, 0.7681, 2.99, 0.249, 296, 249, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
2402, 5itaA, 0.7680, 2.32, 0.333, 250, 240, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
2403, 3thbA, 0.7680, 3.20, 0.216, 287, 255, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
2404, 2hakF, 0.7680, 2.98, 0.249, 318, 253, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
2405, 2g9xC, 0.7680, 2.92, 0.234, 274, 248, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
2406, 5lvpC, 0.7679, 3.01, 0.232, 275, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2407, 5lcpA, 0.7679, 3.15, 0.241, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH FASUDIL (M77)
2408, 5knjB, 0.7679, 2.49, 0.259, 259, 243, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
2409, 5ax9C, 0.7679, 3.42, 0.234, 282, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2410, 4yhjA, 0.7679, 3.23, 0.200, 501, 255, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
2411, 3socB, 0.7679, 2.68, 0.249, 309, 245, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
2412, 2wipC, 0.7679, 2.74, 0.229, 292, 245, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
2413, 2uzeA, 0.7679, 2.91, 0.246, 295, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2414, 5lvpA, 0.7678, 3.02, 0.232, 275, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2415, 4cqeA, 0.7678, 2.23, 0.321, 250, 240, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
2416, 1uvrA, 0.7678, 3.23, 0.228, 284, 254, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
2417, 6b8uB, 0.7677, 2.30, 0.317, 248, 240, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
2418, 5hx6A, 0.7677, 2.49, 0.306, 259, 242, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
2419, 4eonC, 0.7677, 3.03, 0.244, 298, 250, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2420, 3pwyA, 0.7677, 3.28, 0.231, 281, 255, CRYSTAL STRUCTURE OF AN EXTENDER (SPD28345)-MODIFIED HUMAN PDK1 COMPLEX 2
2421, 2y7jB, 0.7677, 2.81, 0.220, 281, 246, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2422, 2wmbC, 0.7677, 2.77, 0.236, 266, 246, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2423, 2uzeC, 0.7677, 2.91, 0.246, 295, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2424, 5ho8A, 0.7676, 3.24, 0.228, 278, 254, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2425, 4ithB, 0.7676, 2.67, 0.302, 270, 245, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
2426, 3h10D, 0.7676, 2.83, 0.243, 255, 251, AURORA A INHIBITOR COMPLEX
2427, 5vilD, 0.7675, 2.87, 0.215, 271, 246, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
2428, 5e8yA, 0.7675, 2.49, 0.266, 298, 241, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
2429, 4xx9A, 0.7675, 3.21, 0.228, 288, 254, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
2430, 4fvqA, 0.7675, 3.07, 0.256, 274, 254, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (MG-ATP-BOUND FORM)
2431, 4eoiC, 0.7675, 2.89, 0.246, 296, 248, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2432, 2i40A, 0.7675, 3.03, 0.233, 291, 249, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
2433, 1wbwA, 0.7675, 3.19, 0.241, 351, 253, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
2434, 1uu8A, 0.7675, 3.23, 0.228, 277, 254, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
2435, 1howA, 0.7675, 3.15, 0.160, 346, 250, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
2436, 1gy3C, 0.7675, 2.94, 0.246, 295, 248, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
2437, 1fmkA, 0.7675, 3.15, 0.480, 437, 254, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC
2438, 4itiB, 0.7674, 2.67, 0.287, 270, 244, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
2439, 2cjmC, 0.7674, 2.77, 0.236, 294, 246, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
2440, 1uu9A, 0.7674, 3.24, 0.228, 276, 254, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
2441, 5lcuA, 0.7673, 3.16, 0.241, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A S-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 01)
2442, 2vrxB, 0.7673, 2.71, 0.210, 274, 248, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
2443, 1gy3A, 0.7673, 2.88, 0.239, 295, 247, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
2444, 5veeA, 0.7672, 3.16, 0.189, 289, 254, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
2445, 4wnkA, 0.7672, 3.31, 0.187, 499, 256, CRYSTAL STRUCTURE OF BOVINE G PROTEIN COUPLED-RECEPTOR KINASE 5 IN COMPLEX WITH CCG215022
2446, 4fzdB, 0.7672, 2.75, 0.254, 275, 248, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH WSF MOTIF
2447, 4a4oA, 0.7672, 3.29, 0.211, 290, 256, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
2448, 3nyoA, 0.7672, 3.43, 0.194, 553, 258, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
2449, 1h1wA, 0.7672, 3.31, 0.227, 284, 255, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
2450, 5hieA, 0.7671, 2.88, 0.310, 258, 248, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
2451, 4eqcA, 0.7671, 3.19, 0.228, 296, 254, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
2452, 3o0gA, 0.7671, 2.77, 0.241, 289, 245, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
2453, 2xchA, 0.7671, 3.20, 0.229, 278, 253, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2454, 1okzA, 0.7671, 3.21, 0.229, 276, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
2455, 5kpkB, 0.7670, 3.64, 0.177, 344, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
2456, 3nunA, 0.7670, 3.23, 0.228, 278, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
2457, 1yhwA, 0.7670, 3.26, 0.224, 293, 255, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
2458, 5t8qA, 0.7669, 3.08, 0.196, 323, 255, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO ARYL PYRROLE FRAGMENT 17
2459, 4eorA, 0.7669, 2.96, 0.226, 293, 248, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
2460, 3bhhB, 0.7669, 2.86, 0.209, 289, 249, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2461, 5nttA, 0.7668, 2.98, 0.163, 276, 251, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
2462, 4rqvA, 0.7668, 3.24, 0.228, 288, 254, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
2463, 4ii5A, 0.7668, 2.94, 0.242, 295, 248, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
2464, 4iebA, 0.7668, 3.08, 0.246, 472, 252, CRYSTAL STRUCTURE OF A GLY128MET MUTANT OF THE TOXOPLASMA CDPK TGME49_101440
2465, 3zrmB, 0.7668, 3.52, 0.178, 347, 259, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
2466, 3rwqA, 0.7668, 3.25, 0.228, 283, 254, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
2467, 1uv5A, 0.7668, 3.60, 0.173, 348, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
2468, 1p5eA, 0.7668, 3.02, 0.237, 296, 249, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
2469, 5wimA, 0.7667, 3.10, 0.260, 274, 254, JAK2 PSEUDOKINASE IN COMPLEX WITH AT9283 
2470, 5wikB, 0.7667, 3.18, 0.259, 274, 255, JAK2 PSEUDOKINASE IN COMPLEX WITH BI-D1870 
2471, 5o0eA, 0.7667, 3.12, 0.238, 349, 252, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND FASUDIL 
2472, 4ii5C, 0.7667, 2.93, 0.246, 295, 248, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
2473, 4eosC, 0.7667, 2.90, 0.238, 296, 248, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2474, 3zrlB, 0.7667, 3.55, 0.177, 347, 260, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2475, 3we4A, 0.7667, 3.30, 0.230, 286, 257, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
2476, 3nynA, 0.7667, 3.44, 0.194, 553, 258, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
2477, 5odtA, 0.7666, 3.10, 0.237, 258, 253, AURORA-A IN COMPLEX WITH TACC3
2478, 4riyA, 0.7666, 3.18, 0.332, 269, 253, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
2479, 4qmwA, 0.7666, 2.93, 0.259, 286, 251, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
2480, 4eolA, 0.7666, 2.94, 0.250, 294, 248, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2481, 3c4xB, 0.7666, 3.47, 0.189, 475, 259, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
2482, 2x7fA, 0.7666, 3.06, 0.240, 276, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2483, 2bujA, 0.7666, 3.09, 0.203, 291, 251, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2484, 4qmxA, 0.7665, 2.89, 0.248, 287, 250, MST3 IN COMPLEX WITH SARACATINIB
2485, 2uzdC, 0.7665, 2.83, 0.240, 295, 246, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2486, 2bdwB, 0.7665, 3.01, 0.222, 309, 252, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
2487, 6fyrA, 0.7664, 3.12, 0.225, 355, 249, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CPD-2 AT 1.42A 
2488, 5ok3A, 0.7664, 3.12, 0.238, 349, 252, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP241 AND FASUDIL 
2489, 5kpkA, 0.7664, 3.68, 0.176, 346, 261, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
2490, 5hlnA, 0.7664, 3.55, 0.178, 346, 259, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
2491, 4qmsA, 0.7664, 2.81, 0.249, 283, 249, MST3 IN COMPLEX WITH DASATINIB
2492, 1yhvA, 0.7664, 3.26, 0.224, 293, 255, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
2493, 1jstC, 0.7664, 2.86, 0.243, 297, 247, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
2494, 5t8oB, 0.7663, 3.15, 0.191, 328, 257, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO IMIDAZOBENZOXEPIN COMPOUND 3
2495, 5m71A, 0.7663, 3.16, 0.241, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH AN (R)-METHYL SUBSTITUED FASUDIL-DERIVATIVE. 
2496, 4bcpC, 0.7663, 2.78, 0.237, 267, 245, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2497, 2qnjB, 0.7663, 3.00, 0.243, 322, 251, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
2498, 5ng3C, 0.7662, 2.92, 0.233, 272, 249, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
2499, 5kz8A, 0.7662, 2.70, 0.258, 302, 244, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
2500, 4i3zA, 0.7662, 2.96, 0.242, 295, 248, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
2501, 4cxaC, 0.7662, 3.13, 0.242, 330, 252, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
2502, 3nnwA, 0.7662, 3.36, 0.240, 349, 254, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
2503, 3m1sA, 0.7662, 3.60, 0.173, 348, 260, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
2504, 2eu9A, 0.7662, 3.21, 0.224, 345, 250, CRYSTAL STRUCTURE OF CLK3
2505, 1w82A, 0.7662, 3.27, 0.241, 351, 253, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2506, 5l1zA, 0.7661, 3.15, 0.190, 310, 252, TAR COMPLEX WITH HIV-1 TAT-AFF4-P-TEFB
2507, 5jsmA, 0.7661, 2.84, 0.316, 265, 247, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2508, 4i3zC, 0.7661, 2.96, 0.242, 295, 248, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
2509, 4dawA, 0.7661, 3.13, 0.225, 293, 253, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
2510, 4b4lA, 0.7661, 3.18, 0.213, 299, 254, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
2511, 3my5C, 0.7661, 2.79, 0.237, 266, 245, CDK2/CYCLINA IN COMPLEX WITH DRB
2512, 1fq1B, 0.7661, 3.05, 0.240, 295, 250, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
2513, 5hngA, 0.7660, 3.25, 0.228, 280, 254, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2514, 4o0tB, 0.7660, 3.24, 0.214, 280, 257, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2515, 3lijA, 0.7660, 2.92, 0.256, 465, 250, CRYSTAL STRUCTURE OF FULL LENGTH CPCDPK3 (CGD5_820) IN COMPLEX WITH CA2+ AND AMPPNP
2516, 3kb7A, 0.7660, 3.28, 0.211, 289, 256, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2517, 3g2fA, 0.7660, 2.85, 0.224, 302, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE II (BMPR2) AT 2.35 A RESOLUTION
2518, 2c6tC, 0.7660, 2.91, 0.243, 295, 247, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2519, 1h26C, 0.7660, 2.84, 0.240, 267, 246, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
2520, 4aotA, 0.7659, 3.22, 0.249, 278, 253, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
2521, 3dt1A, 0.7659, 3.43, 0.211, 356, 256, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
2522, 5hx6B, 0.7658, 2.43, 0.298, 264, 238, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
2523, 4riwA, 0.7658, 3.25, 0.331, 269, 254, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
2524, 3up2A, 0.7658, 2.95, 0.241, 266, 253, AURORA A IN COMPLEX WITH RPM1686
2525, 3gfeA, 0.7658, 3.37, 0.224, 352, 255, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
2526, 2wzjD, 0.7658, 2.64, 0.241, 313, 245, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2527, 6g4yB, 0.7657, 3.20, 0.187, 328, 257, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 1A 
2528, 4un0C, 0.7657, 3.12, 0.230, 308, 252, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
2529, 4rixA, 0.7657, 3.19, 0.332, 269, 253, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
2530, 4l44A, 0.7657, 3.51, 0.231, 321, 260, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
2531, 4fzaB, 0.7657, 2.79, 0.250, 281, 248, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
2532, 4eorC, 0.7657, 2.94, 0.230, 270, 248, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
2533, 3zrmA, 0.7657, 3.65, 0.176, 344, 261, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
2534, 3zrkA, 0.7657, 3.59, 0.177, 345, 260, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2535, 3sayA, 0.7657, 3.70, 0.177, 347, 260, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
2536, 3qd3A, 0.7657, 3.26, 0.228, 278, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
2537, 5l2wA, 0.7656, 2.81, 0.240, 297, 246, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
2538, 5g6vA, 0.7656, 3.14, 0.216, 308, 250, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INHIBITOR
2539, 5dfpA, 0.7656, 3.15, 0.233, 292, 253, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
2540, 5dewB, 0.7656, 3.18, 0.219, 281, 256, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
2541, 4nu1A, 0.7656, 3.53, 0.178, 356, 259, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N-TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
2542, 4dn5B, 0.7656, 3.05, 0.208, 330, 255, CRYSTAL STRUCTURE OF NF-KB-INDUCING KINASE (NIK)
2543, 4dn5A, 0.7656, 3.05, 0.208, 331, 255, CRYSTAL STRUCTURE OF NF-KB-INDUCING KINASE (NIK)
2544, 1q5kA, 0.7656, 3.55, 0.174, 345, 259, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
2545, 1muoA, 0.7656, 2.67, 0.243, 251, 247, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
2546, 3e92A, 0.7655, 3.22, 0.234, 348, 252, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
2547, 1q41B, 0.7655, 3.54, 0.174, 343, 259, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
2548, 4qmzA, 0.7654, 2.98, 0.259, 286, 251, MST3 IN COMPLEX WITH SUNITINIB
2549, 3q52A, 0.7654, 3.14, 0.225, 292, 253, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
2550, 3bhhA, 0.7654, 2.88, 0.213, 289, 249, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2551, 6gn1B, 0.7653, 3.53, 0.178, 339, 259, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
2552, 5ebzJ, 0.7653, 3.59, 0.194, 655, 263, CRYSTAL STRUCTURE OF HUMAN IKK1
2553, 4u41A, 0.7653, 3.30, 0.231, 275, 255, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
2554, 3zrlA, 0.7653, 3.66, 0.176, 345, 261, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2555, 3d7zA, 0.7653, 3.20, 0.234, 348, 252, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
2556, 2uzbA, 0.7653, 2.98, 0.238, 295, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2557, 2c6tA, 0.7653, 2.99, 0.250, 295, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2558, 1q99B, 0.7653, 3.22, 0.155, 364, 251, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
2559, 6gn1A, 0.7652, 3.53, 0.178, 339, 259, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
2560, 5ut2A, 0.7652, 3.04, 0.257, 273, 253, JAK2 JH2 IN COMPLEX WITH PRT062607
2561, 5uorB, 0.7652, 2.76, 0.217, 262, 244, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2562, 5m57A, 0.7652, 2.76, 0.233, 261, 245, NEK2 BOUND TO ARYLAMINOPURINE 6
2563, 5efqA, 0.7652, 3.31, 0.220, 321, 255, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2564, 4g3eA, 0.7652, 3.10, 0.188, 314, 255, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 6-ALKYNYLINDOLINE (CMP1)
2565, 4eokA, 0.7652, 2.88, 0.235, 293, 247, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
2566, 3m1sB, 0.7652, 3.52, 0.174, 349, 259, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
2567, 3f88A, 0.7652, 3.69, 0.180, 340, 261, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
2568, 2yabB, 0.7652, 3.41, 0.214, 299, 257, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
2569, 2oo8X, 0.7652, 1.87, 0.432, 259, 229, SYNTHESIS STRUCTURAL ANALYSIS AND SAR STUDIES OF TRIAZINE DERIVATIVES AS POTENT SELECTIVE TIE-2 INHIBITORS
2570, 1h25C, 0.7652, 2.88, 0.244, 278, 246, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
2571, 5hvyA, 0.7651, 3.16, 0.210, 335, 252, CDK8/CYCC IN COMPLEX WITH COMPOUND 20
2572, 4xv2A, 0.7651, 2.26, 0.326, 247, 239, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH DABRAFENIB
2573, 4idvC, 0.7651, 3.20, 0.205, 335, 258, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
2574, 3q4tB, 0.7651, 2.69, 0.254, 308, 244, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
2575, 2uzdA, 0.7651, 2.97, 0.246, 295, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2576, 1q97B, 0.7651, 3.22, 0.155, 361, 251, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
2577, 4qmyA, 0.7650, 2.92, 0.248, 287, 250, MST3 IN COMPLEX WITH STAUROSPORINE
2578, 2uzbC, 0.7650, 2.98, 0.230, 292, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2579, 1q8zB, 0.7650, 3.08, 0.153, 364, 249, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
2580, 1jstA, 0.7650, 2.98, 0.246, 297, 248, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
2581, 1j1bA, 0.7650, 3.54, 0.174, 354, 259, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
2582, 5ut4A, 0.7649, 3.10, 0.260, 273, 254, JAK2 JH2 IN COMPLEX WITH NVP-BSK805
2583, 5f94A, 0.7649, 3.65, 0.177, 346, 260, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2584, 3w10A, 0.7649, 3.10, 0.223, 263, 256, AURORA KINASE A COMPLEXED TO PYRAZOLE AMINOQUINOLINE I
2585, 2x4fB, 0.7649, 3.10, 0.208, 288, 255, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2586, 2qnjA, 0.7649, 3.05, 0.247, 318, 251, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
2587, 6b8jA, 0.7648, 3.61, 0.178, 344, 259, CO-STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE BETA WITH A SELECTIVE (5-IMIDAZOL-2-YL-4-PHENYLPYRIMIDIN-2-YL)[2-(2-PYRIDYLAMINO) ETHYL]AMINE INHIBITOR
2588, 5m4cA, 0.7648, 2.98, 0.169, 329, 249, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
2589, 5f94B, 0.7648, 3.64, 0.177, 349, 260, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2590, 4fvpA, 0.7648, 3.15, 0.259, 274, 255, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (APO FORM)
2591, 3juhB, 0.7648, 3.21, 0.167, 334, 252, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
2592, 3du8A, 0.7648, 3.54, 0.174, 336, 259, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
2593, 3a7iA, 0.7648, 2.98, 0.259, 286, 251, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
2594, 2w5bA, 0.7648, 3.17, 0.217, 271, 254, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
2595, 1stcE, 0.7648, 3.19, 0.237, 334, 253, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
2596, 1pyxB, 0.7648, 3.55, 0.174, 338, 259, GSK-3 BETA COMPLEXED WITH AMP-PNP
2597, 5kbqB, 0.7647, 3.00, 0.215, 273, 251, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
2598, 5jsmC, 0.7647, 2.74, 0.320, 262, 244, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2599, 4otdA, 0.7647, 3.04, 0.251, 334, 251, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
2600, 4nttB, 0.7647, 3.19, 0.241, 339, 253, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
2601, 4nm3A, 0.7647, 3.66, 0.177, 357, 260, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N- TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
2602, 3ztxB, 0.7647, 2.71, 0.206, 272, 247, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
2603, 3sayB, 0.7647, 3.69, 0.177, 347, 260, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
2604, 4deaA, 0.7646, 2.97, 0.241, 266, 253, AURORA A IN COMPLEX WITH YL1-038-18
2605, 3tnwC, 0.7646, 2.82, 0.240, 291, 246, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
2606, 3sc1A, 0.7646, 3.24, 0.229, 278, 253, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
2607, 3nusA, 0.7646, 3.17, 0.230, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
2608, 2wzjE, 0.7646, 2.72, 0.236, 310, 246, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2609, 5lqfA, 0.7645, 2.80, 0.253, 287, 245, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
2610, 3eidC, 0.7645, 2.94, 0.239, 290, 247, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
2611, 2xuuA, 0.7645, 3.44, 0.206, 301, 257, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
2612, 1pyxA, 0.7645, 3.65, 0.173, 343, 260, GSK-3 BETA COMPLEXED WITH AMP-PNP
2613, 1j1cA, 0.7645, 3.55, 0.174, 354, 259, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
2614, 4oboA, 0.7644, 3.30, 0.231, 275, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
2615, 4nm0A, 0.7644, 3.59, 0.181, 356, 259, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
2616, 4idvB, 0.7644, 3.21, 0.202, 335, 258, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
2617, 3rwpA, 0.7644, 3.16, 0.230, 277, 252, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
2618, 3gc8A, 0.7644, 2.81, 0.218, 347, 248, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
2619, 4yfiB, 0.7643, 2.54, 0.262, 262, 240, TNNI3K COMPLEXED WITH INHIBITOR 1
2620, 4nm5A, 0.7643, 3.67, 0.177, 361, 260, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
2621, 3nuyA, 0.7643, 3.18, 0.230, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
2622, 1e9hA, 0.7643, 2.82, 0.244, 295, 246, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
2623, 5lcrA, 0.7642, 3.21, 0.241, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH OPEN-CHAIN FASUDIL-DERIVATIVE (LIGAND 04)
2624, 4l9iA, 0.7642, 3.41, 0.195, 504, 257, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
2625, 3nuuA, 0.7642, 3.11, 0.227, 276, 251, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
2626, 1yqjA, 0.7642, 3.35, 0.224, 356, 255, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
2627, 1uu3A, 0.7642, 3.17, 0.230, 276, 252, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
2628, 6gt1C, 0.7641, 2.81, 0.234, 257, 248, NEK7 BOUND TO PURINE INHIBITOR 
2629, 4nm7A, 0.7641, 3.57, 0.178, 355, 259, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
2630, 4fr4F, 0.7641, 3.31, 0.217, 346, 254, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2631, 2yaaB, 0.7641, 3.42, 0.214, 299, 257, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
2632, 5e91A, 0.7640, 2.59, 0.266, 297, 241, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
2633, 2ckeB, 0.7640, 3.32, 0.207, 300, 256, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2634, 1j1cB, 0.7640, 3.64, 0.173, 364, 260, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
2635, 1h1pA, 0.7640, 2.92, 0.246, 296, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
2636, 6g4zB, 0.7639, 3.14, 0.200, 325, 255, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
2637, 3l1sB, 0.7639, 3.58, 0.178, 330, 259, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
2638, 2y7jD, 0.7639, 2.88, 0.220, 281, 246, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2639, 2clqA, 0.7639, 2.77, 0.217, 263, 244, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2640, 1r0eB, 0.7639, 3.70, 0.176, 344, 261, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
2641, 3gc8B, 0.7638, 2.74, 0.211, 346, 247, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
2642, 3fxzA, 0.7638, 3.16, 0.225, 292, 253, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
2643, 2jd5B, 0.7638, 3.25, 0.155, 360, 251, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
2644, 2ckeC, 0.7638, 3.39, 0.210, 300, 257, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2645, 1w98A, 0.7638, 2.93, 0.239, 297, 247, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
2646, 1j1bB, 0.7638, 3.64, 0.173, 364, 260, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
2647, 5oxgC, 0.7637, 2.77, 0.273, 301, 245, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
2648, 5eakB, 0.7637, 2.54, 0.260, 300, 242, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
2649, 4f7nA, 0.7637, 3.21, 0.202, 334, 252, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 11 (1- [3-TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(5- HYDROXYPENTYL)UREA)
2650, 3f7zA, 0.7637, 3.63, 0.174, 339, 259, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
2651, 1uu7A, 0.7637, 3.18, 0.230, 280, 252, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
2652, 5tx5A, 0.7636, 2.55, 0.302, 259, 242, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
2653, 5ig1B, 0.7636, 3.25, 0.243, 304, 255, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
2654, 4qnaA, 0.7636, 2.86, 0.249, 284, 249, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
2655, 4b7tA, 0.7636, 3.62, 0.173, 350, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND LEUCETTINE L4
2656, 3nnuA, 0.7636, 3.33, 0.237, 348, 253, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
2657, 3i4bB, 0.7636, 3.51, 0.171, 347, 258, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
2658, 3hgkA, 0.7636, 3.21, 0.259, 286, 251, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
2659, 2iw9C, 0.7636, 2.86, 0.236, 268, 246, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2660, 4c2vA, 0.7635, 2.76, 0.215, 270, 247, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
2661, 4asxB, 0.7635, 2.79, 0.257, 307, 245, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
2662, 4acgB, 0.7635, 3.56, 0.174, 350, 259, GSK3B IN COMPLEX WITH INHIBITOR
2663, 3iecB, 0.7635, 2.80, 0.253, 313, 245, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2664, 3gxlA, 0.7635, 2.46, 0.261, 285, 238, ALK-5 KINASE COMPLEX WITH GW857175
2665, 3f88B, 0.7635, 3.68, 0.172, 340, 261, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
2666, 2eufB, 0.7635, 2.82, 0.232, 282, 246, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
2667, 1q41A, 0.7635, 3.65, 0.173, 339, 260, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
2668, 5ut1A, 0.7634, 3.08, 0.261, 272, 253, JAK2 JH2 IN COMPLEX WITH BI-D1870
2669, 5acbD, 0.7634, 3.17, 0.233, 319, 253, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
2670, 4lgdB, 0.7634, 3.28, 0.222, 350, 257, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2671, 3hx4A, 0.7634, 3.00, 0.249, 467, 249, CRYSTAL STRUCTURE OF CDPK1 OF TOXOPLASMA GONDII TGME49_101440 IN PRESENCE OF CALCIUM
2672, 2jldB, 0.7634, 3.55, 0.174, 349, 259, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
2673, 2jd5A, 0.7634, 3.06, 0.161, 353, 248, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
2674, 2bfxA, 0.7634, 2.82, 0.214, 269, 248, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
2675, 1r0eA, 0.7634, 3.60, 0.173, 344, 260, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
2676, 1q4lA, 0.7634, 3.62, 0.170, 342, 259, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
2677, 1q5kB, 0.7633, 3.67, 0.173, 344, 260, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
2678, 1q3wB, 0.7633, 3.67, 0.173, 341, 260, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
2679, 6c0tA, 0.7632, 3.25, 0.240, 334, 254, CRYSTAL STRUCTURE OF CGMP-DEPENDENT PROTEIN KINASE IALPHA (PKG IALPHA) CATALYTIC DOMAIN BOUND WITH N46 
2680, 5oy4A, 0.7632, 3.71, 0.176, 349, 261, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
2681, 5nqcA, 0.7632, 3.11, 0.159, 331, 251, CK2ALPHA IN COMPLEX WITH NMR154
2682, 4qmuA, 0.7632, 2.95, 0.248, 286, 250, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
2683, 4qmnA, 0.7632, 2.91, 0.260, 283, 250, MST3 IN COMPLEX WITH BOSUTINIB
2684, 4achB, 0.7632, 3.55, 0.174, 350, 259, GSK3B IN COMPLEX WITH INHIBITOR
2685, 3zdiA, 0.7632, 3.76, 0.176, 348, 261, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND INHIBITOR 7D
2686, 3du8B, 0.7632, 3.65, 0.173, 339, 260, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
2687, 2o5kA, 0.7632, 3.64, 0.173, 350, 260, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
2688, 5m6yA, 0.7631, 3.20, 0.241, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A METHYLISOQUINOLINE FASUDIL-DERIVATIVE 
2689, 5m51A, 0.7631, 2.68, 0.234, 260, 244, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
2690, 5hieC, 0.7631, 2.49, 0.320, 253, 241, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
2691, 5ebzK, 0.7631, 3.43, 0.200, 655, 260, CRYSTAL STRUCTURE OF HUMAN IKK1
2692, 5ebzB, 0.7631, 3.63, 0.194, 655, 263, CRYSTAL STRUCTURE OF HUMAN IKK1
2693, 5b0xA, 0.7631, 2.92, 0.173, 329, 248, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
2694, 4idvA, 0.7631, 3.23, 0.205, 335, 258, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
2695, 3q3bB, 0.7631, 3.57, 0.174, 341, 259, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
2696, 3orzB, 0.7631, 3.20, 0.225, 278, 253, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2697, 3f7zB, 0.7631, 3.67, 0.177, 339, 260, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
2698, 2jgzA, 0.7631, 2.68, 0.238, 288, 244, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
2699, 5oy4B, 0.7630, 3.71, 0.176, 353, 261, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
2700, 5ebzD, 0.7630, 3.55, 0.195, 655, 262, CRYSTAL STRUCTURE OF HUMAN IKK1
2701, 3qcqA, 0.7630, 3.19, 0.230, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
2702, 3orzD, 0.7630, 3.20, 0.225, 278, 253, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2703, 3o7lD, 0.7630, 3.34, 0.240, 333, 254, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
2704, 1q99A, 0.7630, 3.07, 0.157, 354, 248, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
2705, 4fzfB, 0.7629, 2.86, 0.247, 279, 247, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH DKI
2706, 4fr4D, 0.7629, 3.24, 0.213, 346, 253, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2707, 4acgA, 0.7629, 3.57, 0.174, 350, 259, GSK3B IN COMPLEX WITH INHIBITOR
2708, 5tx5B, 0.7628, 2.52, 0.307, 263, 238, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
2709, 4ptgA, 0.7628, 3.58, 0.181, 333, 259, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
2710, 4pteB, 0.7628, 3.66, 0.177, 347, 260, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
2711, 4nw5A, 0.7628, 3.47, 0.241, 302, 257, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
2712, 3soaA, 0.7628, 3.18, 0.221, 436, 253, FULL-LENGTH HUMAN CAMKII
2713, 3my0M, 0.7628, 2.78, 0.249, 298, 245, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2714, 2v5qA, 0.7628, 3.25, 0.218, 285, 252, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
2715, 1q4lB, 0.7628, 3.56, 0.178, 337, 258, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
2716, 1f5qA, 0.7628, 3.02, 0.238, 296, 248, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
2717, 1bx6A, 0.7628, 3.21, 0.241, 337, 253, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
2718, 5td2B, 0.7627, 2.27, 0.453, 242, 236, STRUCTURE-BASED OPTIMIZATION OF 1H-IMIDAZOLE-2-CARBOXAMIDES AS AXL KINASE INHIBITORS UTILIZING A MER MUTANT SURROGATE
2719, 5ebzG, 0.7627, 3.61, 0.190, 655, 263, CRYSTAL STRUCTURE OF HUMAN IKK1
2720, 5ebzE, 0.7627, 3.56, 0.195, 655, 262, CRYSTAL STRUCTURE OF HUMAN IKK1
2721, 4ptgB, 0.7627, 3.68, 0.177, 332, 260, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
2722, 4ic7A, 0.7627, 2.81, 0.211, 355, 246, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
2723, 4gcjA, 0.7627, 3.37, 0.245, 304, 257, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
2724, 4g3dB, 0.7627, 3.33, 0.202, 318, 258, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
2725, 3qcxA, 0.7627, 3.19, 0.230, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
2726, 3nnvA, 0.7627, 3.27, 0.242, 348, 252, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
2727, 5ut3A, 0.7626, 3.09, 0.261, 272, 253, JAK2 JH2 IN COMPLEX WITH IKK-2 INHIBITOR VI
2728, 5airA, 0.7626, 3.56, 0.174, 353, 259, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
2729, 4qmmA, 0.7626, 3.05, 0.259, 288, 251, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
2730, 4krcA, 0.7626, 3.11, 0.245, 297, 249, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
2731, 4fr4A, 0.7626, 3.32, 0.213, 350, 253, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2732, 3q3bA, 0.7626, 3.68, 0.173, 344, 260, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
2733, 3juhA, 0.7626, 3.21, 0.163, 334, 252, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
2734, 3g2fB, 0.7626, 2.75, 0.225, 300, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE II (BMPR2) AT 2.35 A RESOLUTION
2735, 2oxyA, 0.7626, 3.01, 0.169, 327, 249, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
2736, 5m6vA, 0.7625, 3.21, 0.241, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A DOUBLE METHYLATED FASUDIL-DERIVATIVE 
2737, 5jsmD, 0.7625, 2.96, 0.320, 259, 247, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2738, 3wowA, 0.7625, 3.01, 0.173, 334, 249, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
2739, 3wikA, 0.7625, 3.08, 0.180, 334, 250, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
2740, 3pupB, 0.7625, 3.56, 0.174, 347, 259, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
2741, 3iw4B, 0.7625, 3.09, 0.243, 325, 251, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
2742, 3iw4A, 0.7625, 3.01, 0.243, 330, 251, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
2743, 2welA, 0.7625, 2.78, 0.207, 304, 246, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
2744, 2jldA, 0.7625, 3.66, 0.173, 349, 260, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
2745, 1q8zA, 0.7625, 3.25, 0.156, 354, 250, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
2746, 1h1pC, 0.7625, 2.98, 0.242, 296, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
2747, 5t8pA, 0.7624, 3.33, 0.186, 327, 258, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO BENZOXEPIN COMPOUND 2
2748, 5m56B, 0.7624, 3.08, 0.160, 328, 250, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
2749, 5jsmB, 0.7624, 2.86, 0.321, 263, 246, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2750, 4lgdA, 0.7624, 3.41, 0.221, 350, 258, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2751, 3dogC, 0.7624, 2.83, 0.241, 267, 245, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
2752, 1oiuC, 0.7624, 2.84, 0.237, 265, 245, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2753, 5ntjA, 0.7623, 3.23, 0.234, 346, 252, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUND RKP032 
2754, 5efqC, 0.7623, 3.19, 0.214, 325, 252, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2755, 4rzvA, 0.7623, 2.51, 0.317, 261, 243, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
2756, 4fr4C, 0.7623, 3.42, 0.209, 344, 254, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2757, 4afjA, 0.7623, 3.58, 0.179, 342, 257, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
2758, 3pupA, 0.7623, 3.57, 0.174, 346, 259, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
2759, 3og7A, 0.7623, 2.28, 0.328, 247, 238, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
2760, 3i4bA, 0.7623, 3.63, 0.170, 359, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
2761, 1ds5C, 0.7623, 3.11, 0.164, 328, 250, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
2762, 5m75A, 0.7622, 3.22, 0.241, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A (S)-METHYL SUBSTITUED FASUDIL-DERIVATIVE 
2763, 5es1A, 0.7622, 2.63, 0.256, 304, 242, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2764, 5ei6A, 0.7622, 2.97, 0.165, 264, 249, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
2765, 3sd0A, 0.7622, 3.68, 0.172, 350, 261, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
2766, 3qcsA, 0.7622, 3.21, 0.230, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
2767, 1i09B, 0.7622, 3.62, 0.178, 341, 259, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
2768, 1ds5B, 0.7622, 3.12, 0.164, 328, 250, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
2769, 6ft7B, 0.7621, 3.27, 0.228, 356, 250, CRYSTAL STRUCTURE OF CLK3 IN COMPLEX WITH COMPOUND 8A 
2770, 5ut6A, 0.7621, 3.10, 0.261, 272, 253, JAK2 JH2 IN COMPLEX WITH A DIAMINOPYRIMIDINE
2771, 4uzdA, 0.7621, 2.79, 0.233, 254, 249, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
2772, 4ez7A, 0.7621, 3.37, 0.242, 302, 256, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
2773, 4aotB, 0.7621, 3.26, 0.253, 279, 253, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
2774, 3ddqC, 0.7621, 2.83, 0.241, 266, 245, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
2775, 5ut0A, 0.7620, 3.10, 0.261, 272, 253, JAK2 JH2 IN COMPLEX WITH AT9283
2776, 4krdA, 0.7620, 2.97, 0.251, 294, 247, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
2777, 4kikB, 0.7620, 3.44, 0.232, 648, 259, HUMAN IKB KINASE BETA
2778, 4acdA, 0.7620, 3.68, 0.173, 350, 260, GSK3B IN COMPLEX WITH INHIBITOR
2779, 3uo5A, 0.7620, 3.01, 0.241, 267, 253, AURORA A IN COMPLEX WITH YL1-038-31
2780, 3qd4A, 0.7620, 3.23, 0.230, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
2781, 2p4iB, 0.7620, 1.82, 0.430, 258, 228, EVOLUTION OF A HIGHLY SELECTIVE AND POTENT 2-(PYRIDIN-2-YL)- 135-TRIAZINE TIE-2 KINASE INHIBITOR
2782, 2ckeD, 0.7620, 3.33, 0.207, 300, 256, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2783, 2ckeA, 0.7620, 3.48, 0.205, 301, 258, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2784, 1yojA, 0.7620, 2.11, 0.454, 233, 229, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN
2785, 1ql6A, 0.7620, 2.97, 0.214, 281, 248, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
2786, 5lqfD, 0.7619, 2.65, 0.248, 285, 242, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
2787, 5lctA, 0.7619, 3.21, 0.241, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A R-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 02)
2788, 5hbjA, 0.7619, 3.31, 0.206, 342, 253, CDK8-CYCC IN COMPLEX WITH 8-[2-AMINO-3-CHLORO-5-(1-METHYL-1H-INDAZOL- 5-YL)-PYRIDIN-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
2789, 5ebzH, 0.7619, 3.54, 0.195, 655, 262, CRYSTAL STRUCTURE OF HUMAN IKK1
2790, 4nzwB, 0.7619, 2.78, 0.249, 266, 245, CRYSTAL STRUCTURE OF STK25-MO25 COMPLEX
2791, 4iw0A, 0.7619, 3.45, 0.173, 647, 260, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
2792, 4achA, 0.7619, 3.58, 0.174, 350, 259, GSK3B IN COMPLEX WITH INHIBITOR
2793, 3ztxA, 0.7619, 2.78, 0.215, 269, 247, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
2794, 3l1sA, 0.7619, 3.65, 0.178, 336, 259, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
2795, 2x0gA, 0.7619, 3.40, 0.214, 318, 257, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
2796, 2hakE, 0.7619, 3.01, 0.254, 318, 252, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
2797, 1ykrA, 0.7619, 3.07, 0.234, 298, 252, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
2798, 1h8fB, 0.7619, 3.68, 0.173, 350, 260, GLYCOGEN SYNTHASE KINASE 3 BETA.
2799, 5de2A, 0.7618, 3.05, 0.223, 267, 251, STRUCTURAL MECHANISM OF NEK7 ACTIVATION BY NEK9-INDUCED DIMERISATION
2800, 4yzbB, 0.7618, 2.95, 0.261, 464, 249, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
2801, 4fr4B, 0.7618, 3.26, 0.209, 350, 253, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2802, 3uo4A, 0.7618, 3.02, 0.241, 266, 253, AURORA A IN COMPLEX WITH RPM1680
2803, 2r7bA, 0.7618, 3.11, 0.232, 274, 250, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
2804, 5hlpA, 0.7617, 3.75, 0.177, 337, 260, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
2805, 4f6uA, 0.7617, 3.21, 0.202, 334, 252, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 5 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-[3-(MORPHOLIN-4-YL) PROPYL]UREA)
2806, 3l9mA, 0.7617, 3.14, 0.242, 338, 252, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
2807, 1zmwA, 0.7617, 2.70, 0.246, 302, 244, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
2808, 5lvlA, 0.7616, 3.18, 0.231, 285, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
2809, 5kplA, 0.7616, 3.73, 0.173, 339, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
2810, 4nw6A, 0.7616, 3.41, 0.238, 302, 256, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
2811, 4l00B, 0.7616, 3.05, 0.258, 278, 252, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
2812, 4iq6B, 0.7616, 3.58, 0.174, 332, 259, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
2813, 4f6sA, 0.7616, 3.21, 0.208, 328, 250, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 7 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]UREA)
2814, 2pmnX, 0.7616, 3.35, 0.175, 340, 257, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP-SITE INHIBITOR
2815, 2ow3A, 0.7616, 3.77, 0.179, 346, 262, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
2816, 1o9uA, 0.7616, 3.54, 0.174, 349, 258, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
2817, 5ackA, 0.7615, 3.19, 0.230, 286, 252, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
2818, 4md7H, 0.7615, 3.15, 0.163, 330, 251, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
2819, 4fr4E, 0.7615, 3.26, 0.213, 342, 253, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2820, 4acdB, 0.7615, 3.69, 0.173, 350, 260, GSK3B IN COMPLEX WITH INHIBITOR
2821, 4accA, 0.7615, 3.68, 0.173, 350, 260, GSK3B IN COMPLEX WITH INHIBITOR
2822, 3qcyA, 0.7615, 3.17, 0.231, 275, 251, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
2823, 3axwA, 0.7615, 2.93, 0.173, 329, 248, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
2824, 1wbsA, 0.7615, 3.53, 0.238, 351, 256, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
2825, 1w83A, 0.7615, 3.46, 0.239, 351, 255, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2826, 1h8fA, 0.7615, 3.67, 0.173, 352, 260, GLYCOGEN SYNTHASE KINASE 3 BETA.
2827, 5uszA, 0.7614, 3.10, 0.261, 272, 253, JAK2 JH2 IN COMPLEX WITH JNJ-7706621
2828, 5ebzA, 0.7614, 3.56, 0.195, 655, 262, CRYSTAL STRUCTURE OF HUMAN IKK1
2829, 5e92A, 0.7614, 2.65, 0.269, 298, 242, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
2830, 4rqkA, 0.7614, 3.17, 0.231, 285, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
2831, 3uodA, 0.7614, 3.02, 0.241, 266, 253, AURORA A IN COMPLEX WITH RPM1693
2832, 3q4zB, 0.7614, 3.13, 0.217, 279, 253, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
2833, 3bhyA, 0.7614, 2.85, 0.226, 268, 248, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
2834, 5o91A, 0.7613, 3.00, 0.169, 266, 249, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604W MUTANT IN COMPLEX WITH CPD-5
2835, 5h9bA, 0.7613, 2.87, 0.227, 269, 247, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
2836, 4cfvC, 0.7613, 2.76, 0.243, 264, 243, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2837, 3pxfA, 0.7613, 3.31, 0.235, 302, 255, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
2838, 3l9lA, 0.7613, 3.14, 0.242, 338, 252, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
2839, 3iopA, 0.7613, 3.12, 0.232, 275, 250, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
2840, 3gb2A, 0.7613, 3.75, 0.177, 340, 260, GSK3BETA INHIBITOR COMPLEX
2841, 2yaaA, 0.7613, 3.53, 0.213, 300, 258, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
2842, 2ow3B, 0.7613, 3.70, 0.176, 351, 261, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
2843, 2iw8C, 0.7613, 2.86, 0.237, 265, 245, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2844, 1ds5D, 0.7613, 3.12, 0.164, 328, 250, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
2845, 5lmkC, 0.7612, 2.85, 0.233, 265, 245, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
2846, 5byyA, 0.7612, 2.84, 0.207, 338, 246, ERK5 IN COMPLEX WITH SMALL MOLECULE
2847, 4w9wA, 0.7612, 2.78, 0.196, 306, 245, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
2848, 4md7G, 0.7612, 3.10, 0.164, 332, 250, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
2849, 4aw1A, 0.7612, 3.32, 0.233, 283, 253, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
2850, 2xckA, 0.7612, 3.17, 0.228, 275, 250, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2851, 2qluA, 0.7612, 2.62, 0.241, 297, 241, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
2852, 2clqB, 0.7612, 2.63, 0.224, 259, 241, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2853, 5ut5A, 0.7611, 3.04, 0.258, 272, 252, JAK2 JH2 IN COMPLEX WITH GLPG0634
2854, 5te0A, 0.7611, 2.83, 0.176, 316, 245, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
2855, 4otgA, 0.7611, 3.09, 0.251, 322, 251, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
2856, 4g3dA, 0.7611, 3.20, 0.203, 324, 256, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
2857, 3q9xB, 0.7611, 3.01, 0.165, 330, 249, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
2858, 3ha6A, 0.7611, 2.91, 0.240, 263, 250, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
2859, 2w5aA, 0.7611, 3.10, 0.222, 267, 252, HUMAN NEK2 KINASE ADP-BOUND
2860, 5ebzC, 0.7610, 3.61, 0.195, 655, 262, CRYSTAL STRUCTURE OF HUMAN IKK1
2861, 4qmtA, 0.7610, 2.98, 0.260, 284, 250, MST3 IN COMPLEX WITH HESPERADIN
2862, 4f6wA, 0.7610, 3.13, 0.212, 330, 250, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 1 (N-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-4-[2-({[3-TERT-BUTYL- 1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]CARBAMOYL}AMINO)ETHYL]PIPERAZINE- 1-CARBOXAMIDE)
2863, 4b8mA, 0.7610, 2.80, 0.215, 270, 247, AURORA B KINASE IN COMPLEX WITH VX-680
2864, 3pxzA, 0.7610, 3.37, 0.234, 302, 256, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
2865, 3hrfA, 0.7610, 3.11, 0.232, 284, 250, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
2866, 3h9oA, 0.7610, 3.12, 0.232, 275, 250, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
2867, 1wbvA, 0.7610, 3.32, 0.245, 351, 253, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
2868, 1rejA, 0.7610, 3.25, 0.241, 333, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
2869, 1q3wA, 0.7610, 3.68, 0.173, 344, 260, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
2870, 5xyyA, 0.7609, 3.33, 0.233, 350, 253, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
2871, 4qmvA, 0.7609, 3.13, 0.243, 288, 251, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
2872, 4l01B, 0.7609, 2.98, 0.256, 274, 250, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
2873, 4g3cA, 0.7609, 3.07, 0.189, 315, 254, CRYSTAL STRUCTURE OF APO MURINE NF-KAPPAB INDUCING KINASE (NIK)
2874, 3iecA, 0.7609, 2.77, 0.255, 311, 243, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2875, 2bfyA, 0.7609, 2.77, 0.198, 270, 247, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2876, 1z5mA, 0.7609, 3.18, 0.231, 275, 251, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
2877, 1wbtA, 0.7609, 3.47, 0.239, 351, 255, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
2878, 1ds5A, 0.7609, 3.05, 0.165, 328, 249, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
2879, 5hlpB, 0.7608, 3.79, 0.176, 335, 261, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
2880, 4yfiD, 0.7608, 2.55, 0.264, 261, 239, TNNI3K COMPLEXED WITH INHIBITOR 1
2881, 4pteA, 0.7608, 3.52, 0.179, 341, 257, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
2882, 3p86B, 0.7608, 1.87, 0.355, 239, 231, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
2883, 3hgkB, 0.7608, 3.18, 0.263, 286, 251, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
2884, 2wmaC, 0.7608, 2.87, 0.253, 265, 245, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2885, 2pe0A, 0.7608, 3.18, 0.231, 275, 251, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
2886, 5t8qB, 0.7607, 3.27, 0.187, 328, 257, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO ARYL PYRROLE FRAGMENT 17
2887, 4lgdD, 0.7607, 3.39, 0.217, 338, 258, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2888, 3q5iA, 0.7607, 3.12, 0.254, 470, 248, CRYSTAL STRUCTURE OF PBANKA_031420
2889, 3my0N, 0.7607, 2.78, 0.250, 300, 244, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2890, 3dbqA, 0.7607, 2.99, 0.174, 259, 247, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
2891, 3ag9B, 0.7607, 3.14, 0.238, 317, 252, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
2892, 2wqnA, 0.7607, 2.85, 0.226, 259, 248, STRUCTURE OF ADP-BOUND HUMAN NEK7
2893, 2v5qB, 0.7607, 3.29, 0.210, 285, 252, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
2894, 5f95A, 0.7606, 3.51, 0.174, 345, 258, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2895, 4j7bA, 0.7606, 3.35, 0.217, 284, 253, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
2896, 4afjB, 0.7606, 3.46, 0.180, 346, 255, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
2897, 3my0V, 0.7606, 2.70, 0.251, 282, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2898, 2a27D, 0.7606, 3.46, 0.210, 304, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2899, 1jwhA, 0.7606, 3.04, 0.165, 336, 249, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
2900, 5lvoA, 0.7605, 3.17, 0.231, 285, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
2901, 4w8dA, 0.7605, 3.15, 0.243, 289, 251, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
2902, 4bidB, 0.7605, 2.71, 0.232, 258, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2903, 3iecC, 0.7605, 2.77, 0.255, 311, 243, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2904, 2cjmA, 0.7605, 2.78, 0.230, 285, 244, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
2905, 5hieD, 0.7604, 2.65, 0.313, 253, 243, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
2906, 5etiA, 0.7604, 3.40, 0.211, 355, 256, STRUCTURE OF DEAD KINASE MAPK14
2907, 4md9P, 0.7604, 2.96, 0.173, 328, 248, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2908, 4j1rB, 0.7604, 3.71, 0.177, 346, 260, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2909, 4accB, 0.7604, 3.58, 0.174, 350, 259, GSK3B IN COMPLEX WITH INHIBITOR
2910, 3sd0B, 0.7604, 3.68, 0.177, 349, 260, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
2911, 3my0B, 0.7604, 2.69, 0.251, 295, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2912, 3fe3A, 0.7604, 3.19, 0.241, 317, 253, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
2913, 2zjwA, 0.7604, 3.01, 0.169, 332, 248, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
2914, 1oukA, 0.7604, 3.32, 0.229, 348, 253, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
2915, 6ft7A, 0.7603, 3.22, 0.229, 356, 249, CRYSTAL STRUCTURE OF CLK3 IN COMPLEX WITH COMPOUND 8A 
2916, 5xs2A, 0.7603, 3.38, 0.212, 366, 255, CDK8-CYCC IN COMPLEX WITH COMPOUND 17:3-CHLORO-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
2917, 5nhvA, 0.7603, 2.79, 0.216, 345, 245, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2918, 5larA, 0.7603, 3.05, 0.236, 350, 250, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
2919, 3my0U, 0.7603, 2.70, 0.251, 285, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2920, 3my0L, 0.7603, 2.81, 0.250, 296, 244, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2921, 3h30A, 0.7603, 3.17, 0.159, 333, 251, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
2922, 2oxyB, 0.7603, 3.07, 0.169, 327, 249, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
2923, 1szmA, 0.7603, 3.08, 0.235, 317, 251, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2924, 1q3dB, 0.7603, 3.77, 0.172, 339, 261, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
2925, 5o2cA, 0.7602, 3.58, 0.252, 368, 262, CRYSTAL STRUCTURE OF WNK3 KINASE AND CCT1 DIDOMAIN IN A UNPHOSPHORYLATED STATE
2926, 5hd7A, 0.7602, 2.68, 0.209, 347, 244, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
2927, 4u43A, 0.7602, 3.63, 0.227, 287, 260, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
2928, 4j1rD, 0.7602, 3.70, 0.177, 345, 260, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2929, 4j1rC, 0.7602, 3.71, 0.177, 344, 260, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2930, 4fbxA, 0.7602, 3.16, 0.163, 333, 251, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
2931, 3hgkD, 0.7602, 3.17, 0.264, 286, 250, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
2932, 3a7fA, 0.7602, 3.15, 0.247, 283, 251, HUMAN MST3 KINASE
2933, 2vgoA, 0.7602, 2.82, 0.215, 268, 247, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
2934, 1dawA, 0.7602, 3.20, 0.171, 327, 251, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
2935, 5nhhA, 0.7601, 2.91, 0.215, 348, 246, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2936, 5jrqA, 0.7601, 2.59, 0.322, 258, 242, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
2937, 5ceiA, 0.7601, 3.26, 0.202, 345, 252, CRYSTAL STRUCTURE OF CDK8:CYCLIN C COMPLEX WITH COMPOUND 22
2938, 4usfB, 0.7601, 3.53, 0.233, 285, 258, HUMAN SLK WITH SB-440719
2939, 4u8zA, 0.7601, 3.06, 0.248, 289, 250, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
2940, 4ptcB, 0.7601, 3.51, 0.178, 347, 258, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
2941, 4ptcA, 0.7601, 3.52, 0.178, 342, 258, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
2942, 4f7jA, 0.7601, 3.11, 0.205, 326, 249, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 3 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(2-HYDROXYETHYL) UREA)
2943, 3nayB, 0.7601, 3.18, 0.228, 278, 250, PDK1 IN COMPLEX WITH INHIBITOR MP6
2944, 3ionA, 0.7601, 3.09, 0.233, 274, 249, PDK1 IN COMPLEX WITH COMPOUND 8H
2945, 3ds6D, 0.7601, 3.23, 0.226, 349, 252, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
2946, 2yabA, 0.7601, 3.42, 0.215, 299, 256, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
2947, 2x4fA, 0.7601, 3.18, 0.200, 289, 255, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2948, 2b54A, 0.7601, 3.15, 0.233, 298, 253, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
2949, 5tvtA, 0.7600, 2.67, 0.226, 321, 243, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
2950, 5hniY, 0.7600, 2.04, 0.381, 245, 231, CRYSTAL STRUCTURE OF CMET WT WITH COMPOUND 3
2951, 4j71A, 0.7600, 3.66, 0.178, 347, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
2952, 4ib5C, 0.7600, 3.11, 0.168, 332, 250, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
2953, 4cfmC, 0.7600, 2.84, 0.254, 266, 244, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2954, 3qa0B, 0.7600, 3.05, 0.165, 330, 249, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
2955, 3kxhA, 0.7600, 3.05, 0.165, 326, 249, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
2956, 2vrxA, 0.7600, 2.83, 0.215, 268, 247, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
2957, 1q97A, 0.7600, 3.00, 0.163, 351, 246, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
2958, 1phkA, 0.7600, 2.91, 0.215, 277, 247, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
2959, 5kplB, 0.7599, 3.79, 0.177, 339, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
2960, 5etcA, 0.7599, 3.40, 0.216, 355, 255, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
2961, 4md7E, 0.7599, 3.02, 0.165, 332, 249, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
2962, 4j1rA, 0.7599, 3.74, 0.176, 343, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2963, 3wilA, 0.7599, 3.02, 0.169, 331, 248, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
2964, 3q9wA, 0.7599, 3.03, 0.169, 328, 248, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
2965, 3iecD, 0.7599, 2.78, 0.255, 311, 243, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2966, 2uw7A, 0.7599, 3.27, 0.233, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
2967, 2a2aD, 0.7599, 3.37, 0.199, 303, 256, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2968, 4md7F, 0.7598, 3.08, 0.164, 332, 250, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
2969, 4m69B, 0.7598, 2.84, 0.244, 264, 250, CRYSTAL STRUCTURE OF THE MOUSE RIP3-MLKL COMPLEX
2970, 4ib5B, 0.7598, 3.08, 0.176, 329, 250, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
2971, 4bicB, 0.7598, 2.66, 0.228, 259, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2972, 3orzC, 0.7598, 3.15, 0.227, 276, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2973, 3orzA, 0.7598, 3.15, 0.227, 276, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2974, 3hmpA, 0.7597, 2.84, 0.171, 258, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
2975, 2a2aC, 0.7597, 3.36, 0.207, 303, 256, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2976, 1q8yB, 0.7597, 3.07, 0.154, 357, 247, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
2977, 1lp4A, 0.7597, 3.23, 0.171, 327, 251, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
2978, 5motA, 0.7596, 2.98, 0.170, 328, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
2979, 5knjA, 0.7596, 2.51, 0.253, 252, 241, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
2980, 5hbeA, 0.7596, 3.41, 0.201, 344, 254, CDK8-CYCC IN COMPLEX WITH 8-[3-CHLORO-5-(1-METHYL-22-DIOXO-2 3- DIHYDRO-1H-2L6-BENZO[C]ISOTHIAZOL-5-YL)-PYRIDIN- 4-YL]-1-OXA-38- DIAZA-SPIRO[4.5]DECAN-2-ONE
2981, 4c35A, 0.7596, 3.23, 0.242, 337, 252, PKA-S6K1 CHIMERA WITH COMPOUND 1 (NU1085) BOUND
2982, 2jdvA, 0.7596, 3.25, 0.233, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
2983, 5v19B, 0.7595, 2.80, 0.215, 260, 242, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2984, 5airB, 0.7595, 3.69, 0.173, 361, 260, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
2985, 4j71B, 0.7595, 3.67, 0.177, 347, 260, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
2986, 4dedA, 0.7595, 3.06, 0.241, 265, 253, AURORA A IN COMPLEX WITH YL1-038-21
2987, 4crlA, 0.7595, 3.41, 0.205, 339, 254, CRYSTAL STRUCTURE OF HUMAN CDK8-CYCLIN C IN COMPLEX WITH CORTISTATIN A
2988, 4a06A, 0.7595, 3.10, 0.233, 282, 249, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
2989, 3ofmA, 0.7595, 3.02, 0.165, 325, 249, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
2990, 3l9mB, 0.7595, 3.24, 0.241, 336, 253, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
2991, 3hgkC, 0.7595, 3.11, 0.261, 284, 249, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
2992, 2jedB, 0.7595, 3.01, 0.245, 320, 249, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
2993, 1ungA, 0.7595, 2.75, 0.236, 288, 242, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
2994, 1dayA, 0.7595, 3.20, 0.171, 327, 251, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
2995, 6c3eA, 0.7594, 2.77, 0.299, 258, 244, CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
2996, 5kpmA, 0.7594, 3.77, 0.177, 344, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
2997, 5csvA, 0.7594, 2.96, 0.170, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
2998, 3rinA, 0.7594, 3.20, 0.219, 349, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2999, 3fy0A, 0.7594, 3.16, 0.218, 292, 252, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
3000, 2zb1A, 0.7594, 3.16, 0.240, 345, 250, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
3001, 2pe2A, 0.7594, 3.19, 0.231, 275, 251, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
3002, 2a27H, 0.7594, 3.48, 0.210, 304, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3003, 5owlB, 0.7593, 3.13, 0.164, 332, 250, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
3004, 5hkmA, 0.7593, 3.11, 0.233, 272, 249, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
3005, 4tnbA, 0.7593, 3.37, 0.180, 529, 256, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH SANGIVAMYCIN
3006, 4j7bD, 0.7593, 3.31, 0.218, 281, 252, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
3007, 3up7A, 0.7593, 3.02, 0.242, 264, 252, AURORA A IN COMPLEX WITH YL1-038-09
3008, 3socA, 0.7593, 2.86, 0.253, 307, 245, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
3009, 2pmlX, 0.7593, 3.31, 0.176, 340, 256, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP ANALOGUE
3010, 2c6eA, 0.7593, 2.83, 0.243, 251, 247, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
3011, 2a27F, 0.7593, 3.47, 0.210, 303, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3012, 2a27B, 0.7593, 3.48, 0.210, 303, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3013, 5t1hA, 0.7592, 3.05, 0.169, 331, 249, CRYSTAL STRUCTURE OF CK2
3014, 5oy6D, 0.7592, 2.58, 0.279, 292, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3015, 5ljjA, 0.7592, 2.95, 0.169, 264, 248, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
3016, 5kpmB, 0.7592, 3.76, 0.177, 345, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
3017, 5uq2A, 0.7591, 3.09, 0.245, 296, 249, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
3018, 5nhpA, 0.7591, 2.83, 0.212, 338, 245, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3019, 4j8nC, 0.7591, 3.01, 0.242, 266, 252, AURORA A KINASE APO
3020, 4bckA, 0.7591, 3.00, 0.230, 298, 248, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3021, 3rcjA, 0.7591, 3.07, 0.234, 281, 248, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
3022, 3fwqA, 0.7591, 3.23, 0.155, 334, 252, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
3023, 2qkwB, 0.7591, 3.35, 0.262, 290, 252, STRUCTURAL BASIS FOR ACTIVATION OF PLANT IMMUNITY BY BACTERIAL EFFECTOR PROTEIN AVRPTO
3024, 2pvnA, 0.7591, 3.17, 0.171, 327, 251, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
3025, 1zmwB, 0.7591, 2.75, 0.246, 302, 244, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
3026, 1xhaA, 0.7591, 3.27, 0.241, 348, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
3027, 5up3A, 0.7590, 2.71, 0.216, 258, 241, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3028, 5owhA, 0.7590, 3.16, 0.155, 334, 251, HIGH SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3-AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
3029, 5kz8B, 0.7590, 2.64, 0.261, 300, 241, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
3030, 5ebzF, 0.7590, 3.65, 0.194, 655, 263, CRYSTAL STRUCTURE OF HUMAN IKK1
3031, 4qteA, 0.7590, 2.74, 0.213, 348, 244, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
3032, 4qtbB, 0.7590, 2.71, 0.217, 348, 244, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
3033, 4qmqA, 0.7590, 3.19, 0.254, 289, 252, MST3 IN COMPLEX WITH CP-673451
3034, 3my0A, 0.7590, 2.83, 0.250, 296, 244, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3035, 2gphA, 0.7590, 2.82, 0.208, 345, 245, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
3036, 5ke0A, 0.7589, 2.83, 0.216, 340, 245, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
3037, 5k00A, 0.7589, 2.44, 0.225, 311, 240, MELK IN COMPLEX WITH NVS-MELK5
3038, 5icpA, 0.7589, 3.44, 0.201, 343, 254, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (5-METHYL-IMIDAZO[51-B][134]THIADIAZOL-2-YL)-METHANONE
3039, 4qtbA, 0.7589, 2.80, 0.216, 351, 245, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
3040, 4qmpA, 0.7589, 3.15, 0.243, 289, 251, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
3041, 4lopC, 0.7589, 3.18, 0.235, 341, 251, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
3042, 3fwqB, 0.7589, 3.26, 0.159, 334, 252, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
3043, 3a7gB, 0.7589, 2.96, 0.256, 290, 250, HUMAN MST3 KINASE
3044, 2b53A, 0.7589, 3.06, 0.231, 294, 251, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
3045, 2a27G, 0.7589, 3.48, 0.210, 303, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3046, 2a27C, 0.7589, 3.48, 0.210, 303, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3047, 5u6iA, 0.7588, 2.75, 0.209, 339, 244, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
3048, 5mz3A, 0.7588, 3.49, 0.239, 350, 255, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
3049, 5h8bA, 0.7588, 3.06, 0.169, 331, 249, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
3050, 5d9kB, 0.7588, 3.02, 0.238, 280, 248, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
3051, 4xv3A, 0.7588, 2.28, 0.325, 244, 237, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7922
3052, 4m3qB, 0.7588, 1.99, 0.453, 236, 232, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC1917
3053, 4j8nB, 0.7588, 3.02, 0.242, 266, 252, AURORA A KINASE APO
3054, 4idvD, 0.7588, 3.30, 0.202, 335, 258, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
3055, 4ic7D, 0.7588, 2.85, 0.211, 353, 246, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
3056, 4g3eB, 0.7588, 3.24, 0.196, 325, 255, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 6-ALKYNYLINDOLINE (CMP1)
3057, 3my0W, 0.7588, 2.67, 0.252, 281, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3058, 5xvfA, 0.7587, 3.26, 0.190, 289, 253, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH062
3059, 5uq1C, 0.7587, 2.93, 0.248, 289, 246, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
3060, 5t5tA, 0.7587, 2.86, 0.233, 368, 245, AMPK BOUND TO ALLOSTERIC ACTIVATOR
3061, 5nw8A, 0.7587, 3.23, 0.238, 337, 252, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP032 AND FASUDIL 
3062, 5hniX, 0.7587, 2.18, 0.375, 245, 232, CRYSTAL STRUCTURE OF CMET WT WITH COMPOUND 3
3063, 5ap6A, 0.7587, 3.00, 0.165, 262, 249, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3064, 4qmoA, 0.7587, 3.17, 0.243, 288, 251, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
3065, 4md8G, 0.7587, 3.15, 0.168, 332, 250, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
3066, 4debA, 0.7587, 3.02, 0.242, 264, 252, AURORA A IN COMPLEX WITH RK2-17-01
3067, 3my0R, 0.7587, 2.66, 0.252, 294, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3068, 2zmdA, 0.7587, 2.88, 0.166, 259, 247, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
3069, 1ouyA, 0.7587, 3.31, 0.234, 350, 252, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
3070, 1m7qA, 0.7587, 3.16, 0.220, 348, 250, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
3071, 5n1vA, 0.7586, 3.09, 0.169, 331, 249, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
3072, 5h8eA, 0.7586, 3.06, 0.169, 331, 249, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
3073, 5f95B, 0.7586, 3.65, 0.178, 338, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
3074, 4oliA, 0.7586, 3.11, 0.284, 539, 250, THE PSEUDOKINASE/KINASE PROTEIN FROM JAK-FAMILY MEMBER TYK2
3075, 4iz5D, 0.7586, 2.84, 0.204, 347, 245, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
3076, 4iz5C, 0.7586, 2.83, 0.204, 347, 245, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
3077, 4iz5B, 0.7586, 2.83, 0.204, 347, 245, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
3078, 3orxG, 0.7586, 3.05, 0.233, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3079, 3my0G, 0.7586, 2.67, 0.252, 294, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3080, 3h30B, 0.7586, 3.19, 0.155, 333, 251, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
3081, 2oscA, 0.7586, 1.77, 0.429, 255, 226, SYNTHESIS STRUCTURAL ANALYSIS AND SAR STUDIES OF TRIAZINE DERIVATIVES AS POTENT SELECTIVE TIE-2 INHIBITORS
3082, 1zogA, 0.7586, 3.12, 0.172, 325, 250, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
3083, 1q8yA, 0.7586, 3.03, 0.163, 351, 246, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
3084, 4iz5A, 0.7585, 2.84, 0.204, 347, 245, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
3085, 4dgoA, 0.7585, 3.14, 0.172, 325, 250, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
3086, 4bibB, 0.7585, 2.72, 0.224, 258, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3087, 4b99A, 0.7585, 3.00, 0.211, 335, 247, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
3088, 3zyaA, 0.7585, 2.90, 0.224, 346, 246, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
3089, 3fknA, 0.7585, 3.24, 0.239, 346, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
3090, 3a7hB, 0.7585, 2.95, 0.256, 290, 250, HUMAN MST3 KINASE IN COMPLEX WITH ATP
3091, 2uw6A, 0.7585, 3.16, 0.231, 334, 251, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
3092, 2uvyA, 0.7585, 3.23, 0.230, 333, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
3093, 2uvxA, 0.7585, 3.26, 0.233, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
3094, 2a2aA, 0.7585, 3.44, 0.206, 304, 257, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3095, 5d9kA, 0.7584, 3.03, 0.238, 280, 248, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
3096, 5cspA, 0.7584, 2.97, 0.170, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
3097, 4wsqA, 0.7584, 2.88, 0.183, 317, 246, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3098, 4md8E, 0.7584, 3.19, 0.167, 332, 251, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
3099, 4anmA, 0.7584, 3.13, 0.172, 328, 250, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
3100, 3kq7A, 0.7584, 3.38, 0.245, 348, 253, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
3101, 2uw4A, 0.7584, 3.22, 0.230, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
3102, 6gipA, 0.7583, 2.61, 0.279, 296, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH A QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 2; 5-DIMETHYL CORE. 
3103, 5n1vB, 0.7583, 3.08, 0.169, 331, 249, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
3104, 4rrvA, 0.7583, 3.11, 0.233, 283, 249, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND PIFTIDE
3105, 4j8nA, 0.7583, 3.03, 0.242, 266, 252, AURORA A KINASE APO
3106, 3qd0A, 0.7583, 3.17, 0.232, 274, 250, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
3107, 3pxqA, 0.7583, 3.52, 0.241, 298, 257, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
3108, 3orxF, 0.7583, 3.05, 0.233, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3109, 3c13A, 0.7583, 3.07, 0.169, 328, 248, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
3110, 2a27E, 0.7583, 3.49, 0.210, 303, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3111, 1xh8A, 0.7583, 3.28, 0.237, 337, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
3112, 5x5oA, 0.7582, 3.31, 0.303, 291, 254, CRYSTAL STRUCTURE OF ZAK IN COMPLEX WITH COMPOUND D2829
3113, 4uyaA, 0.7582, 2.28, 0.360, 274, 236, STRUCTURE OF MLK4 KINASE DOMAIN WITH ATPGAMMAS
3114, 4qfrA, 0.7582, 2.86, 0.233, 361, 245, STRUCTURE OF AMPK IN COMPLEX WITH CL-A769662 ACTIVATOR AND STAUROSPORINE INHIBITOR
3115, 4o0sA, 0.7582, 2.93, 0.240, 265, 250, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3116, 3agmA, 0.7582, 3.26, 0.241, 337, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
3117, 2pe1A, 0.7582, 3.21, 0.231, 275, 251, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
3118, 2a27A, 0.7582, 3.50, 0.210, 304, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3119, 1bkxA, 0.7582, 3.27, 0.245, 337, 253, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
3120, 5twlA, 0.7581, 2.81, 0.225, 319, 244, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
3121, 5ei8A, 0.7581, 2.93, 0.173, 261, 248, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3122, 3bqcA, 0.7581, 3.07, 0.169, 328, 248, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
3123, 2pmoX, 0.7581, 3.40, 0.175, 340, 257, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH HYMENIALDISINE
3124, 1zzlA, 0.7581, 3.20, 0.215, 351, 251, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
3125, 1zohA, 0.7581, 3.15, 0.172, 326, 250, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
3126, 1rekA, 0.7581, 3.27, 0.241, 336, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
3127, 1gngA, 0.7581, 3.81, 0.176, 348, 262, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
3128, 4nh1B, 0.7580, 3.04, 0.173, 332, 249, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
3129, 4md8F, 0.7580, 3.12, 0.168, 332, 250, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
3130, 4l45A, 0.7580, 3.21, 0.238, 317, 252, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
3131, 3l9lB, 0.7580, 3.27, 0.241, 337, 253, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
3132, 3at2A, 0.7580, 3.10, 0.165, 334, 249, CRYSTAL STRUCTURE OF CK2ALPHA
3133, 2jdtA, 0.7580, 3.29, 0.233, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
3134, 2a2aB, 0.7580, 3.40, 0.207, 303, 256, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3135, 1wzyA, 0.7580, 2.89, 0.212, 350, 245, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
3136, 1q3dA, 0.7580, 3.80, 0.172, 339, 261, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
3137, 6babB, 0.7579, 2.86, 0.212, 285, 245, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
3138, 5t31B, 0.7579, 3.80, 0.180, 333, 261, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
3139, 5t31A, 0.7579, 3.78, 0.180, 334, 261, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
3140, 4lopB, 0.7579, 3.14, 0.236, 350, 250, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
3141, 4l00A, 0.7579, 3.25, 0.265, 277, 253, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
3142, 3orxH, 0.7579, 3.06, 0.233, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3143, 2uw3A, 0.7579, 3.26, 0.230, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
3144, 5n1dA, 0.7578, 3.22, 0.242, 348, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-METHYL-1-(5-PYRIDIN-3-YLOXYFURAN-2-YL) METHANAMINE
3145, 4qyyA, 0.7578, 2.70, 0.205, 337, 244, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
3146, 4md8H, 0.7578, 3.13, 0.164, 331, 250, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
3147, 4iq6A, 0.7578, 3.66, 0.178, 324, 258, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
3148, 4dgnA, 0.7578, 3.15, 0.172, 325, 250, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
3149, 2vo0A, 0.7578, 3.29, 0.233, 340, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
3150, 1wmkF, 0.7578, 3.47, 0.210, 303, 257, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3151, 1j91A, 0.7578, 3.09, 0.169, 327, 249, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
3152, 5vjaB, 0.7577, 2.82, 0.215, 266, 246, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
3153, 4tl0A, 0.7577, 3.46, 0.211, 300, 256, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
3154, 4nttA, 0.7577, 3.26, 0.241, 339, 253, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
3155, 4nh1A, 0.7577, 3.04, 0.173, 330, 249, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
3156, 4loqD, 0.7577, 3.17, 0.236, 351, 250, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
3157, 4f7sA, 0.7577, 3.32, 0.202, 339, 252, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
3158, 4ct1A, 0.7577, 3.12, 0.225, 283, 249, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
3159, 3dneA, 0.7577, 3.29, 0.237, 336, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
3160, 1wmkC, 0.7577, 3.46, 0.214, 303, 257, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3161, 6g97A, 0.7576, 2.93, 0.216, 344, 245, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3162, 5ooiB, 0.7576, 3.01, 0.161, 325, 248, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
3163, 5nhoA, 0.7576, 2.85, 0.216, 343, 245, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3164, 5nhlA, 0.7576, 2.75, 0.213, 345, 244, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3165, 5hd4A, 0.7576, 2.72, 0.213, 347, 244, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
3166, 4uv0A, 0.7576, 3.43, 0.215, 300, 256, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
3167, 4anbA, 0.7576, 3.34, 0.215, 282, 256, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
3168, 3erkA, 0.7576, 2.81, 0.205, 350, 244, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
3169, 3be9A, 0.7576, 3.14, 0.172, 327, 250, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
3170, 2xikA, 0.7576, 3.13, 0.248, 288, 250, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
3171, 2uw0A, 0.7576, 3.26, 0.230, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
3172, 2oxdA, 0.7576, 3.14, 0.172, 325, 250, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
3173, 2f7xE, 0.7576, 3.42, 0.235, 336, 255, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
3174, 6e4uA, 0.7575, 2.87, 0.233, 365, 245, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
3175, 5uuuA, 0.7575, 3.56, 0.189, 414, 259, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
3176, 5t8pB, 0.7575, 3.34, 0.190, 328, 258, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO BENZOXEPIN COMPOUND 2
3177, 4ib5A, 0.7575, 3.13, 0.164, 331, 250, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
3178, 4c34A, 0.7575, 3.27, 0.238, 336, 252, PKA-S6K1 CHIMERA WITH STAUROSPORINE BOUND
3179, 3py3A, 0.7575, 3.11, 0.228, 355, 250, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
3180, 3hrcA, 0.7575, 3.03, 0.234, 279, 248, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
3181, 2r0iA, 0.7575, 2.72, 0.256, 300, 242, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
3182, 2oh0E, 0.7575, 3.42, 0.235, 336, 255, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
3183, 2f57B, 0.7575, 3.20, 0.194, 299, 252, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
3184, 2c6dA, 0.7575, 2.88, 0.241, 254, 249, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
3185, 1z9xB, 0.7575, 3.39, 0.207, 303, 256, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
3186, 1wmkE, 0.7575, 3.46, 0.210, 313, 257, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3187, 1wmkD, 0.7575, 3.46, 0.210, 314, 257, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3188, 1wmkB, 0.7575, 3.46, 0.210, 314, 257, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3189, 1wmkA, 0.7575, 3.47, 0.210, 303, 257, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3190, 1smhA, 0.7575, 3.20, 0.242, 348, 252, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
3191, 6c9dB, 0.7574, 3.09, 0.242, 422, 248, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
3192, 5vibA, 0.7574, 3.29, 0.237, 308, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
3193, 5i5zA, 0.7574, 3.35, 0.202, 345, 252, CDK8-CYCC IN COMPLEX WITH 8-(1-METHYL-22-DIOXO-23-DIHYDRO-1H-2L6- BENZO[C]ISOTHIAZOL-5-YL)-[16]NAPHTHYRIDINE-2-CARBOXYLIC ACID METHYLAMIDE
3194, 5fg8A, 0.7574, 2.92, 0.227, 269, 247, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
3195, 4ubaB, 0.7574, 3.10, 0.169, 333, 249, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
3196, 4qfsA, 0.7574, 2.87, 0.233, 361, 245, STRUCTURE OF AMPK IN COMPLEX WITH BR2-A769662CORE ACTIVATOR AND STAUROSPORINE INHIBITOR
3197, 4kd1A, 0.7574, 3.20, 0.233, 298, 253, CDK2 IN COMPLEX WITH DINACICLIB
3198, 4bggA, 0.7574, 2.59, 0.279, 296, 240, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3199, 4an2A, 0.7574, 3.37, 0.222, 282, 257, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
3200, 3orxC, 0.7574, 3.25, 0.235, 283, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3201, 3orxA, 0.7574, 3.25, 0.235, 283, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3202, 1xh5A, 0.7574, 3.30, 0.237, 335, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
3203, 1wmkH, 0.7574, 3.46, 0.210, 304, 257, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3204, 1lr4A, 0.7574, 3.13, 0.172, 327, 250, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
3205, 4lg4F, 0.7573, 3.11, 0.222, 276, 248, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3206, 4g3cB, 0.7573, 3.30, 0.191, 327, 257, CRYSTAL STRUCTURE OF APO MURINE NF-KAPPAB INDUCING KINASE (NIK)
3207, 4bggB, 0.7573, 2.58, 0.279, 293, 240, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3208, 2r0iB, 0.7573, 2.62, 0.257, 300, 241, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
3209, 2qc6A, 0.7573, 3.09, 0.165, 326, 249, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
3210, 2ojfE, 0.7573, 3.43, 0.235, 336, 255, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
3211, 1z9xA, 0.7573, 3.39, 0.207, 303, 256, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
3212, 1wmkG, 0.7573, 3.46, 0.210, 313, 257, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3213, 6fypA, 0.7572, 3.25, 0.229, 348, 249, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CX-4945 AT 2.29A 
3214, 6e4tA, 0.7572, 2.88, 0.233, 361, 245, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
3215, 5mohA, 0.7572, 2.94, 0.171, 326, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
3216, 5ebzL, 0.7572, 3.64, 0.179, 655, 262, CRYSTAL STRUCTURE OF HUMAN IKK1
3217, 4md9E, 0.7572, 3.00, 0.169, 329, 248, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
3218, 4loqB, 0.7572, 3.23, 0.235, 351, 251, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
3219, 3rpsA, 0.7572, 3.19, 0.155, 334, 251, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
3220, 3j4rE, 0.7572, 3.27, 0.240, 325, 254, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
3221, 3j4rD, 0.7572, 3.27, 0.240, 325, 254, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
3222, 3j4qE, 0.7572, 3.27, 0.240, 325, 254, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
3223, 3j4qD, 0.7572, 3.27, 0.240, 325, 254, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
3224, 6g9aA, 0.7571, 2.76, 0.214, 341, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3225, 5w5qA, 0.7571, 3.46, 0.230, 291, 256, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
3226, 5deyA, 0.7571, 3.29, 0.237, 295, 253, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
3227, 4l01A, 0.7571, 3.12, 0.266, 274, 252, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
3228, 3my0Q, 0.7571, 2.71, 0.252, 294, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3229, 5nhjA, 0.7570, 2.85, 0.216, 345, 245, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3230, 4w9xA, 0.7570, 2.77, 0.197, 300, 244, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
3231, 4tndA, 0.7570, 3.35, 0.180, 529, 255, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH AMP-PNP
3232, 4md9L, 0.7570, 3.00, 0.165, 328, 248, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
3233, 4md9G, 0.7570, 3.03, 0.169, 329, 248, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
3234, 4dgmA, 0.7570, 3.16, 0.172, 326, 250, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
3235, 2w5hA, 0.7570, 3.15, 0.219, 265, 251, HUMAN NEK2 KINASE APO
3236, 2pvmA, 0.7570, 3.14, 0.172, 327, 250, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
3237, 5hbhA, 0.7569, 3.52, 0.205, 336, 254, CDK8-CYCC IN COMPLEX WITH 5-{5-CHLORO-4-[1-(2-METHOXY-ETHYL)-18- DIAZA-SPIRO[4.5]DEC-8-YL]-PYRIDIN-3-YL}-1-METHYL-13-DIHYDRO- BENZO[C]ISOTHIAZOLE 22-DIOXIDE
3238, 5d9lA, 0.7569, 3.13, 0.226, 299, 248, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
3239, 4ub7A, 0.7569, 3.19, 0.159, 334, 251, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
3240, 4rerA, 0.7569, 2.77, 0.238, 458, 244, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX BOUND TO AMP AND CYCLODEXTRIN
3241, 4o0vA, 0.7569, 3.35, 0.189, 290, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3242, 4e7wA, 0.7569, 3.77, 0.192, 359, 261, STRUCTURE OF GSK3 FROM USTILAGO MAYDIS
3243, 3a7jA, 0.7569, 3.17, 0.254, 286, 252, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
3244, 1wbnA, 0.7569, 3.44, 0.244, 351, 254, FRAGMENT BASED P38 INHIBITORS
3245, 1i09A, 0.7569, 3.67, 0.178, 338, 259, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
3246, 6babA, 0.7568, 3.09, 0.212, 290, 250, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
3247, 5ufuA, 0.7568, 2.88, 0.233, 368, 245, STRUCTURE OF AMPK BOUND TO ACTIVATOR
3248, 5lvnA, 0.7568, 3.13, 0.233, 283, 249, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
3249, 5i3oB, 0.7568, 2.91, 0.192, 302, 245, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3250, 4wo5B, 0.7568, 2.43, 0.317, 257, 240, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
3251, 4md9K, 0.7568, 3.02, 0.173, 328, 248, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
3252, 4lopD, 0.7568, 3.14, 0.221, 351, 249, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
3253, 3orxE, 0.7568, 3.12, 0.233, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3254, 3my0S, 0.7568, 2.71, 0.252, 294, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3255, 3mb6A, 0.7568, 3.09, 0.169, 329, 248, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
3256, 6g93A, 0.7567, 2.76, 0.214, 343, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3257, 6e4wA, 0.7567, 2.89, 0.233, 361, 245, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
3258, 5k3yA, 0.7567, 2.78, 0.196, 267, 245, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
3259, 5idpA, 0.7567, 3.28, 0.206, 342, 252, CDK8-CYCC IN COMPLEX WITH (3-AMINO-1H-INDAZOL-5-YL)-[(S)-2-(4-FLUORO- PHENYL)-PIPERIDIN-1-YL]-METHANONE
3260, 4zsjA, 0.7567, 2.81, 0.208, 344, 245, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
3261, 2vo3A, 0.7567, 3.27, 0.230, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
3262, 2uztA, 0.7567, 3.34, 0.236, 336, 254, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
3263, 2oxxA, 0.7567, 3.17, 0.172, 325, 250, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
3264, 1zoeA, 0.7567, 3.16, 0.176, 325, 250, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
3265, 1g3nE, 0.7567, 3.05, 0.227, 293, 247, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
3266, 4u6rA, 0.7566, 3.32, 0.213, 403, 249, CRYSTAL STRUCTURE OF HUMAN IRE1 CYTOPLASMIC DOMAINS IN COMPLEX WITH A SULFONAMIDE INHIBITOR.
3267, 4u40A, 0.7566, 3.36, 0.231, 295, 255, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
3268, 4loqC, 0.7566, 3.15, 0.236, 337, 250, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
3269, 1svhA, 0.7566, 3.31, 0.237, 335, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
3270, 1ol5A, 0.7566, 2.95, 0.240, 263, 250, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
3271, 5vedA, 0.7565, 3.30, 0.190, 289, 253, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3272, 5vd1A, 0.7565, 3.01, 0.187, 295, 246, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
3273, 5kq5A, 0.7565, 2.88, 0.233, 362, 245, AMPK BOUND TO ALLOSTERIC ACTIVATOR
3274, 5ebzI, 0.7565, 3.53, 0.196, 655, 260, CRYSTAL STRUCTURE OF HUMAN IKK1
3275, 4yuqA, 0.7565, 3.19, 0.260, 462, 250, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
3276, 4uj2A, 0.7565, 3.30, 0.241, 335, 253, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
3277, 3q4tA, 0.7565, 2.78, 0.255, 305, 243, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
3278, 3kxmA, 0.7565, 3.16, 0.172, 326, 250, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
3279, 3kxgA, 0.7565, 3.15, 0.172, 326, 250, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
3280, 2vz6A, 0.7565, 3.05, 0.228, 291, 250, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
3281, 2vnwA, 0.7565, 3.28, 0.230, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
3282, 2uzuE, 0.7565, 3.44, 0.235, 336, 255, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
3283, 6fykB, 0.7564, 3.30, 0.213, 349, 249, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
3284, 5lvmA, 0.7564, 3.05, 0.234, 283, 248, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
3285, 4lg4C, 0.7564, 3.16, 0.224, 288, 250, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3286, 4lg4A, 0.7564, 3.28, 0.230, 289, 252, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3287, 2yixA, 0.7564, 3.19, 0.223, 351, 251, TRIAZOLOPYRIDINE INHIBITORS OF P38
3288, 2gnfA, 0.7564, 3.27, 0.245, 339, 253, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
3289, 5u94A, 0.7563, 2.65, 0.218, 263, 243, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
3290, 5ts8A, 0.7563, 3.11, 0.169, 332, 249, Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 56-DIBROMOBENZOTRIAZOLE
3291, 5owlA, 0.7563, 3.09, 0.165, 331, 249, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
3292, 5lcqA, 0.7563, 3.35, 0.241, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH LONG-CHAIN FASUDIL-DERIVATIVE (LIGAND 05)
3293, 5kwhA, 0.7563, 3.12, 0.169, 331, 249, CRYSTAL STRUCTURE OF CK2
3294, 5ku8A, 0.7563, 3.05, 0.169, 328, 248, CRYSTAL STRUCTURE OF CK2
3295, 5g6vB, 0.7563, 3.25, 0.227, 302, 247, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INHIBITOR
3296, 4rllA, 0.7563, 3.09, 0.173, 329, 248, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
3297, 4looA, 0.7563, 3.03, 0.223, 349, 247, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
3298, 3rpsB, 0.7563, 3.23, 0.155, 334, 251, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
3299, 3my0H, 0.7563, 2.71, 0.252, 294, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3300, 2uvzA, 0.7563, 3.25, 0.230, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
3301, 1zwsF, 0.7563, 3.06, 0.204, 278, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3302, 1zwsB, 0.7563, 3.14, 0.211, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3303, 1j91B, 0.7563, 3.11, 0.165, 327, 249, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
3304, 1ctpE, 0.7563, 3.32, 0.241, 332, 253, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
3305, 4obqA, 0.7562, 3.15, 0.222, 275, 248, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
3306, 4md9F, 0.7562, 3.04, 0.169, 327, 248, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
3307, 4l43A, 0.7562, 3.32, 0.237, 316, 253, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
3308, 4c2wA, 0.7562, 2.83, 0.215, 268, 246, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
3309, 3oomA, 0.7562, 2.70, 0.278, 297, 241, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00507
3310, 3my0C, 0.7562, 2.80, 0.251, 299, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3311, 3mtfB, 0.7562, 2.78, 0.277, 298, 242, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
3312, 3ctqA, 0.7562, 2.75, 0.226, 336, 243, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
3313, 2pvkA, 0.7562, 3.15, 0.172, 327, 250, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
3314, 2c1aA, 0.7562, 3.31, 0.237, 335, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
3315, 1buhA, 0.7562, 2.98, 0.230, 287, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
3316, 6ccyA, 0.7561, 3.01, 0.249, 325, 249, CRYSTAL STRUCTURE OF AKT1 IN COMPLEX WITH A SELECTIVE INHIBITOR 
3317, 4qnyA, 0.7561, 2.87, 0.211, 333, 246, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
3318, 4h3qA, 0.7561, 2.96, 0.211, 352, 246, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3319, 3u9cA, 0.7561, 3.08, 0.165, 331, 249, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
3320, 3q4uD, 0.7561, 2.75, 0.277, 299, 242, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3321, 3pe2A, 0.7561, 3.06, 0.173, 327, 248, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
3322, 3kxnA, 0.7561, 3.10, 0.165, 327, 249, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
3323, 3dlsD, 0.7561, 2.92, 0.224, 284, 245, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3324, 2zoqA, 0.7561, 2.81, 0.221, 351, 244, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
3325, 1pw2A, 0.7561, 3.17, 0.226, 294, 252, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
3326, 5e8vA, 0.7560, 2.72, 0.270, 296, 241, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
3327, 4rzvB, 0.7560, 2.99, 0.301, 271, 249, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
3328, 4o27B, 0.7560, 3.21, 0.255, 281, 251, CRYSTAL STRUCTURE OF MST3-MO25 COMPLEX WITH WIF MOTIF
3329, 4c0tA, 0.7560, 3.27, 0.221, 290, 253, CANDIDA ALBICANS PKH KINASE DOMAIN
3330, 3r0tA, 0.7560, 3.01, 0.174, 327, 247, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
3331, 3pvgA, 0.7560, 3.16, 0.172, 326, 250, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
3332, 3my0F, 0.7560, 2.72, 0.252, 294, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3333, 3my0E, 0.7560, 2.71, 0.252, 294, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3334, 2zmcA, 0.7560, 2.85, 0.174, 260, 247, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
3335, 2fysA, 0.7560, 2.99, 0.211, 348, 246, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
3336, 1g3nA, 0.7560, 3.06, 0.227, 293, 247, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
3337, 1cmkE, 0.7560, 3.23, 0.242, 348, 252, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
3338, 5oniB, 0.7559, 3.21, 0.167, 334, 251, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
3339, 5l8kA, 0.7559, 2.91, 0.241, 266, 249, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
3340, 4o0wA, 0.7559, 2.89, 0.241, 259, 249, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3341, 4ntsB, 0.7559, 3.22, 0.242, 341, 252, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
3342, 4loqA, 0.7559, 3.26, 0.231, 352, 251, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
3343, 4bbmA, 0.7559, 3.65, 0.254, 314, 260, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
3344, 3u87A, 0.7559, 3.02, 0.169, 329, 248, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
3345, 3orxD, 0.7559, 3.23, 0.236, 282, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3346, 2ya9B, 0.7559, 3.45, 0.215, 299, 256, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
3347, 2w4kA, 0.7559, 3.51, 0.215, 301, 256, X-RAY STRUCTURE OF A DAP-KINASE 2-302
3348, 2pvlA, 0.7559, 3.17, 0.172, 327, 250, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
3349, 1lpuA, 0.7559, 3.25, 0.171, 327, 251, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
3350, 1gngB, 0.7559, 3.78, 0.176, 355, 261, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
3351, 1di9A, 0.7559, 3.41, 0.245, 348, 253, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
3352, 5n9sA, 0.7558, 2.85, 0.167, 259, 246, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
3353, 4umqA, 0.7558, 2.75, 0.221, 314, 244, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3354, 4izaA, 0.7558, 2.90, 0.209, 346, 244, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
3355, 4deeA, 0.7558, 3.05, 0.242, 271, 252, AURORA A IN COMPLEX WITH ADP
3356, 3u9cB, 0.7558, 3.07, 0.165, 331, 249, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
3357, 3lauA, 0.7558, 2.67, 0.242, 251, 244, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
3358, 2uw8A, 0.7558, 3.27, 0.230, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
3359, 4qfgA, 0.7557, 2.72, 0.230, 365, 243, STRUCTURE OF AMPK IN COMPLEX WITH STAUROSPORINE INHIBITOR AND IN THE ABSENCE OF A SYNTHETIC ACTIVATOR
3360, 4md9M, 0.7557, 3.07, 0.169, 331, 249, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
3361, 4j8nD, 0.7557, 3.02, 0.239, 265, 251, AURORA A KINASE APO
3362, 4b6lA, 0.7557, 3.12, 0.239, 281, 251, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
3363, 3warA, 0.7557, 3.18, 0.172, 334, 250, CRYSTAL STRUCTURE OF HUMAN CK2A
3364, 3nayA, 0.7557, 3.11, 0.225, 278, 249, PDK1 IN COMPLEX WITH INHIBITOR MP6
3365, 3ambA, 0.7557, 3.30, 0.249, 340, 253, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
3366, 1zwsD, 0.7557, 3.16, 0.211, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3367, 1m2rA, 0.7557, 3.13, 0.165, 327, 249, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
3368, 5ooiA, 0.7556, 3.11, 0.161, 329, 249, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
3369, 5oniA, 0.7556, 3.24, 0.167, 334, 251, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
3370, 5ehoA, 0.7556, 2.82, 0.163, 258, 245, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3371, 4ujbA, 0.7556, 3.31, 0.241, 344, 253, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
3372, 4axaA, 0.7556, 3.32, 0.233, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1S)-2-AMINO-1-( 4-CHLOROPHENYL)-1-(4-(1H-PYRAZOL-4-YL)PHENYL)ETHAN-1-OL
3373, 3otuA, 0.7556, 3.06, 0.231, 276, 247, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
3374, 3dlsA, 0.7556, 2.92, 0.229, 285, 245, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3375, 2ya9A, 0.7556, 3.47, 0.215, 299, 256, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
3376, 2f7eE, 0.7556, 3.45, 0.235, 336, 255, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
3377, 2exmA, 0.7556, 3.24, 0.237, 298, 253, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
3378, 1na7A, 0.7556, 3.01, 0.170, 326, 247, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
3379, 1f3mC, 0.7556, 3.36, 0.219, 287, 256, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
3380, 6c9dA, 0.7555, 3.10, 0.242, 425, 248, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
3381, 5m56A, 0.7555, 3.14, 0.164, 331, 250, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
3382, 5k5nB, 0.7555, 3.49, 0.181, 334, 254, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
3383, 5ap1A, 0.7555, 2.95, 0.162, 268, 247, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3384, 4itiA, 0.7555, 3.06, 0.283, 272, 247, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
3385, 4bhnB, 0.7555, 2.64, 0.226, 257, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3386, 4aw0A, 0.7555, 3.14, 0.233, 283, 249, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
3387, 3qa0A, 0.7555, 3.12, 0.169, 330, 249, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
3388, 3q9yA, 0.7555, 3.05, 0.169, 327, 248, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
3389, 3pe1A, 0.7555, 3.01, 0.174, 327, 247, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
3390, 2yakA, 0.7555, 3.16, 0.216, 277, 250, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
3391, 2wqmA, 0.7555, 2.82, 0.220, 258, 246, STRUCTURE OF APO HUMAN NEK7
3392, 2gngA, 0.7555, 3.28, 0.245, 338, 253, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
3393, 1zwsG, 0.7555, 3.16, 0.211, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3394, 1re8A, 0.7555, 3.29, 0.241, 337, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
3395, 5n9nA, 0.7554, 3.17, 0.177, 329, 249, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
3396, 5eykA, 0.7554, 2.85, 0.199, 263, 246, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
3397, 4uzhA, 0.7554, 2.67, 0.242, 251, 244, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
3398, 4rewA, 0.7554, 2.93, 0.236, 411, 246, CRYSTAL STRUCTURE OF THE NON-PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX
3399, 4qp8B, 0.7554, 2.88, 0.212, 337, 245, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
3400, 4bicA, 0.7554, 2.75, 0.220, 260, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3401, 3ngaA, 0.7554, 3.11, 0.169, 331, 249, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
3402, 3fmmA, 0.7554, 3.25, 0.228, 346, 250, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
3403, 2vnyA, 0.7554, 3.29, 0.230, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
3404, 2pvhA, 0.7554, 3.17, 0.172, 327, 250, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
3405, 1jamA, 0.7554, 3.26, 0.171, 327, 251, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
3406, 6fylA, 0.7553, 3.13, 0.215, 340, 247, X-RAY STRUCTURE OF CLK2-KD(136-496)/CX-4945 AT 1.95A 
3407, 5t1hB, 0.7553, 3.14, 0.169, 331, 249, CRYSTAL STRUCTURE OF CK2
3408, 5mrdA, 0.7553, 2.98, 0.223, 283, 247, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
3409, 5m0bA, 0.7553, 3.35, 0.241, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A SHORT-CHAINED N-(2-AMINOETHYL)ISOQUINOLINE-5-SULFONAMIDE) FASUDIL-DERIVATIVE (LIGAND 03) 
3410, 5i3rB, 0.7553, 2.93, 0.192, 302, 245, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3411, 4z83E, 0.7553, 3.22, 0.238, 335, 252, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 47A
3412, 4xbrA, 0.7553, 3.30, 0.190, 315, 253, IN CELLULO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA
3413, 4uj1A, 0.7553, 3.31, 0.241, 335, 253, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
3414, 4lopA, 0.7553, 3.15, 0.221, 351, 249, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
3415, 3zo3A, 0.7553, 3.25, 0.234, 337, 252, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
3416, 2qvsE, 0.7553, 3.16, 0.242, 323, 252, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
3417, 5oy6B, 0.7552, 2.61, 0.279, 292, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3418, 5h8eB, 0.7552, 3.14, 0.169, 331, 249, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
3419, 5h8bB, 0.7552, 3.14, 0.169, 331, 249, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
3420, 3mptA, 0.7552, 3.20, 0.232, 347, 250, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
3421, 2q0nA, 0.7552, 3.15, 0.187, 293, 251, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
3422, 5nguA, 0.7551, 2.82, 0.205, 339, 244, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3423, 5mmrA, 0.7551, 2.95, 0.175, 326, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
3424, 5cquA, 0.7551, 3.01, 0.170, 328, 247, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
3425, 4qp7A, 0.7551, 2.73, 0.206, 337, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
3426, 4ij9A, 0.7551, 3.25, 0.238, 335, 252, BOVINE PKA C-ALPHA IN COMPLEX WITH 2-[[5-(4-PYRIDYL)-1H-124-TRIAZOL- 3-YL]SULFANYL]-1-(2-THIOPHENYL)ETHANONE
3427, 4bcqA, 0.7551, 2.86, 0.229, 292, 245, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3428, 3wyyA, 0.7551, 2.97, 0.167, 258, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
3429, 3wf7A, 0.7551, 3.50, 0.228, 288, 259, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
3430, 3r8pA, 0.7551, 3.19, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
3431, 3pzhA, 0.7551, 3.18, 0.172, 327, 250, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
3432, 3l9nA, 0.7551, 3.31, 0.241, 332, 253, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
3433, 3d5uA, 0.7551, 3.33, 0.226, 288, 252, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
3434, 3c4yB, 0.7551, 3.36, 0.179, 466, 251, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
3435, 2uw5A, 0.7551, 3.21, 0.231, 333, 251, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
3436, 2f7zE, 0.7551, 3.46, 0.235, 336, 255, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
3437, 5vjaA, 0.7550, 2.80, 0.216, 266, 245, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
3438, 4qnyB, 0.7550, 2.89, 0.211, 339, 246, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
3439, 4fmqA, 0.7550, 2.87, 0.208, 350, 245, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3440, 4figB, 0.7550, 3.36, 0.189, 292, 254, CATALYTIC DOMAIN OF HUMAN PAK4
3441, 4dglC, 0.7550, 3.19, 0.165, 334, 249, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
3442, 3wyxA, 0.7550, 2.98, 0.167, 258, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
3443, 3rm6A, 0.7550, 3.08, 0.228, 293, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
3444, 3raiA, 0.7550, 3.06, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
3445, 3q9zB, 0.7550, 3.19, 0.164, 332, 250, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
3446, 3ds6C, 0.7550, 3.25, 0.224, 349, 250, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
3447, 2zb0A, 0.7550, 3.48, 0.244, 349, 254, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
3448, 2a0cX, 0.7550, 3.16, 0.231, 294, 251, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
3449, 1q61A, 0.7550, 3.32, 0.237, 335, 253, PKA TRIPLE MUTANT MODEL OF PKB
3450, 1m2pA, 0.7550, 3.12, 0.165, 325, 249, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
3451, 6gmdB, 0.7549, 2.97, 0.167, 326, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
3452, 5n9kA, 0.7549, 3.03, 0.170, 329, 247, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
3453, 4umtA, 0.7549, 2.77, 0.216, 316, 245, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3454, 4f7lA, 0.7549, 3.29, 0.213, 328, 249, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 2 (TERT- BUTYL [3-({[3-TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5- YL]CARBAMOYL}AMINO)PROPYL]CARBAMATE)
3455, 3w8lA, 0.7549, 2.99, 0.170, 326, 247, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
3456, 3q4uB, 0.7549, 2.74, 0.279, 300, 240, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3457, 3e93A, 0.7549, 3.40, 0.238, 346, 252, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
3458, 3e8cD, 0.7549, 3.30, 0.237, 344, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3459, 2gnhA, 0.7549, 3.29, 0.245, 338, 253, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
3460, 5tc0A, 0.7548, 1.85, 0.442, 238, 226, STRUCTURE-BASED OPTIMIZATION OF 1H-IMIDAZOLE-2-CARBOXAMIDES AS AXL KINASE INHIBITORS UTILIZING A MER MUTANT SURROGATE
3461, 5oxgD, 0.7548, 2.63, 0.279, 293, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3462, 5oslA, 0.7548, 3.02, 0.170, 328, 247, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 7
3463, 5ax9B, 0.7548, 3.31, 0.236, 274, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
3464, 3my0D, 0.7548, 2.77, 0.252, 298, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3465, 3e8cF, 0.7548, 3.30, 0.237, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3466, 3e8cB, 0.7548, 3.30, 0.237, 344, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3467, 3e8cA, 0.7548, 3.30, 0.237, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3468, 2clxA, 0.7548, 3.16, 0.227, 293, 251, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
3469, 1pjkA, 0.7548, 3.09, 0.177, 331, 248, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
3470, 1om1A, 0.7548, 3.18, 0.172, 325, 250, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
3471, 1j3hB, 0.7548, 3.17, 0.243, 327, 251, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
3472, 5oxgB, 0.7547, 2.63, 0.279, 296, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3473, 5os7A, 0.7547, 3.04, 0.166, 326, 247, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
3474, 5kwhB, 0.7547, 3.21, 0.172, 331, 250, CRYSTAL STRUCTURE OF CK2
3475, 5j7sA, 0.7547, 2.36, 0.255, 279, 235, CRYSTAL STRUCTURE OF SM1-71 BOUND TO TAK1-TAB1
3476, 5fgkA, 0.7547, 3.18, 0.209, 331, 249, CDK8-CYCC IN COMPLEX WITH 8-[3-(3-AMINO-1H-INDAZOL-6-YL)-5-CHLORO- PYRIDINE-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
3477, 5cu2A, 0.7547, 3.05, 0.166, 328, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
3478, 5cqwA, 0.7547, 3.11, 0.169, 331, 249, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
3479, 4uynA, 0.7547, 2.70, 0.246, 249, 244, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
3480, 4o22A, 0.7547, 3.29, 0.238, 336, 252, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
3481, 4ie9A, 0.7547, 3.32, 0.237, 335, 253, BOVINE PKA C-ALPHA IN COMPLEX WITH 3-PYRIDYLMETHYL-5-METHYL-1H- PYRAZOLE-3-CARBOXYLATE
3482, 3owjA, 0.7547, 3.13, 0.173, 328, 248, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
3483, 3my0I, 0.7547, 2.69, 0.253, 293, 241, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3484, 3gc9B, 0.7547, 2.82, 0.230, 339, 244, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
3485, 3e8cE, 0.7547, 3.30, 0.237, 336, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3486, 3e8cC, 0.7547, 3.30, 0.237, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3487, 3d5wA, 0.7547, 3.28, 0.223, 284, 251, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
3488, 2zoqB, 0.7547, 2.91, 0.220, 351, 245, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
3489, 2pvrA, 0.7547, 3.02, 0.166, 328, 247, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
3490, 2bdwA, 0.7547, 3.31, 0.204, 309, 255, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
3491, 6g9hA, 0.7546, 2.73, 0.214, 343, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3492, 6bfnA, 0.7546, 3.45, 0.224, 301, 254, CRYSTAL STRUCTURE OF HUMAN IRAK1
3493, 5clpB, 0.7546, 3.05, 0.170, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
3494, 4ix4B, 0.7546, 3.84, 0.141, 350, 263, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH ADP
3495, 3zo2A, 0.7546, 3.27, 0.234, 340, 252, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
3496, 3wf5A, 0.7546, 3.33, 0.229, 277, 253, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
3497, 3u8wA, 0.7546, 3.28, 0.211, 349, 251, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
3498, 3qqlA, 0.7546, 3.19, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR L3
3499, 3ngaB, 0.7546, 3.11, 0.169, 331, 249, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
3500, 2pvjA, 0.7546, 3.17, 0.172, 326, 250, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
3501, 2ojgA, 0.7546, 2.74, 0.209, 337, 244, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
3502, 5dn3A, 0.7545, 3.12, 0.238, 264, 252, AURORA A IN COMPLEX WITH ATP AND AA35.
3503, 5bmsA, 0.7545, 3.32, 0.190, 290, 253, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
3504, 4ujaA, 0.7545, 3.32, 0.241, 336, 253, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
3505, 4kwpA, 0.7545, 3.16, 0.177, 329, 249, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
3506, 4fv7A, 0.7545, 2.86, 0.217, 342, 244, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
3507, 4erkA, 0.7545, 2.79, 0.205, 350, 244, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
3508, 3q04A, 0.7545, 3.11, 0.165, 328, 248, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
3509, 3krwA, 0.7545, 3.58, 0.189, 618, 259, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
3510, 2xnbA, 0.7545, 3.29, 0.245, 296, 253, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
3511, 2w1cA, 0.7545, 3.06, 0.240, 261, 250, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3512, 2gnjA, 0.7545, 3.32, 0.241, 335, 253, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
3513, 1xo2B, 0.7545, 3.05, 0.235, 289, 247, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
3514, 5mrbA, 0.7544, 2.78, 0.164, 264, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
3515, 4zsgA, 0.7544, 2.98, 0.207, 347, 246, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
3516, 4md9H, 0.7544, 3.05, 0.169, 328, 248, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
3517, 4figA, 0.7544, 3.33, 0.190, 292, 253, CATALYTIC DOMAIN OF HUMAN PAK4
3518, 3owlA, 0.7544, 3.12, 0.173, 330, 248, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
3519, 3kmwA, 0.7544, 3.18, 0.262, 268, 252, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MGATP)
3520, 2xmyA, 0.7544, 3.19, 0.230, 295, 252, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
3521, 6gdqA, 0.7543, 2.79, 0.214, 339, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3522, 6fyvA, 0.7543, 3.26, 0.238, 329, 248, X-RAY STRUCTURE OF CLK4-KD(146-480)/CX-4945 AT 2.46A 
3523, 5xvuB, 0.7543, 3.07, 0.182, 321, 247, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
3524, 5vhbA, 0.7543, 3.29, 0.234, 325, 252, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITOR
3525, 5oxgA, 0.7543, 2.65, 0.279, 293, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3526, 5aneA, 0.7543, 3.19, 0.226, 294, 252, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
3527, 4usdA, 0.7543, 3.08, 0.249, 268, 249, HUMAN STK10 (LOK) WITH SB-633825
3528, 4ixpA, 0.7543, 3.10, 0.212, 334, 250, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
3529, 3aglB, 0.7543, 3.31, 0.241, 335, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
3530, 2xzsA, 0.7543, 3.44, 0.212, 301, 255, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
3531, 2vo6A, 0.7543, 3.30, 0.230, 335, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
3532, 2uzvA, 0.7543, 3.47, 0.235, 336, 255, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
3533, 1xh9A, 0.7543, 3.25, 0.246, 336, 252, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
3534, 1golA, 0.7543, 2.81, 0.201, 357, 244, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
3535, 6fykA, 0.7542, 3.31, 0.213, 349, 249, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
3536, 5xvuC, 0.7542, 3.09, 0.174, 321, 247, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
3537, 5n3gA, 0.7542, 3.27, 0.238, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (R)-14-OXAZEPAN-6-OL
3538, 5ku8B, 0.7542, 3.21, 0.180, 331, 250, CRYSTAL STRUCTURE OF CK2
3539, 5hnbA, 0.7542, 3.33, 0.203, 342, 251, CDK8-CYCC IN COMPLEX WITH [6-HYDROXY-3-(3-METHYL-BENZYL)-1H-INDAZOL-5- YL]-((S)-3-HYDROXY-PYRROLIDIN-1-YL)-METHANONE
3540, 5dewA, 0.7542, 3.40, 0.232, 295, 254, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
3541, 4zegA, 0.7542, 2.94, 0.176, 260, 245, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3542, 4wo5A, 0.7542, 2.88, 0.318, 266, 245, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
3543, 4ubaA, 0.7542, 3.33, 0.175, 333, 252, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
3544, 4ix5B, 0.7542, 3.87, 0.137, 350, 263, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH AMP-PNP
3545, 3repA, 0.7542, 3.18, 0.262, 268, 252, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MNATP)
3546, 3qziA, 0.7542, 3.20, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
3547, 3q9xA, 0.7542, 3.13, 0.169, 330, 249, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
3548, 3py1A, 0.7542, 3.54, 0.240, 302, 258, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
3549, 3e8eI, 0.7542, 3.32, 0.237, 345, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3550, 3a8xA, 0.7542, 3.23, 0.215, 334, 251, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
3551, 2ojiA, 0.7542, 2.79, 0.205, 344, 244, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
3552, 5xvuA, 0.7541, 3.08, 0.178, 321, 247, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
3553, 5n84A, 0.7541, 2.88, 0.172, 256, 244, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
3554, 5n3rA, 0.7541, 3.28, 0.238, 336, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(CARBAMOYLAMINO)-4- METHYLSULFANYLBUTANOIC ACID
3555, 5mo7B, 0.7541, 3.01, 0.175, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3556, 5m4uA, 0.7541, 3.10, 0.153, 332, 248, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
3557, 5idnA, 0.7541, 3.30, 0.208, 336, 250, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (3-METHYL-1H-PYRAZOLO[34-B]PYRIDIN-5-YL)-METHANONE
3558, 4z84A, 0.7541, 3.24, 0.238, 335, 252, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 34A
3559, 4qp4A, 0.7541, 2.81, 0.217, 337, 244, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3560, 4bckC, 0.7541, 3.03, 0.235, 293, 247, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3561, 3u87B, 0.7541, 3.04, 0.169, 329, 248, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
3562, 3qzhA, 0.7541, 3.20, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
3563, 3orxB, 0.7541, 3.21, 0.237, 280, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3564, 2vgpA, 0.7541, 2.69, 0.214, 265, 243, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
3565, 2gnlA, 0.7541, 3.32, 0.241, 338, 253, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
3566, 1tvoA, 0.7541, 2.78, 0.213, 350, 244, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3567, 6c0uA, 0.7540, 3.25, 0.242, 338, 252, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CALPHA SUBUNIT BOUND WITH N46 
3568, 5oulA, 0.7540, 3.11, 0.173, 327, 248, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
3569, 4xw4A, 0.7540, 3.31, 0.238, 334, 252, X-RAY STRUCTURE OF PKAC WITH AMPPNP SP20 CALCIUM IONS
3570, 4ianA, 0.7540, 3.12, 0.199, 321, 246, CRYSTAL STRUCTURE OF APO HUMAN PRPF4B KINASE DOMAIN
3571, 3wf6A, 0.7540, 3.33, 0.229, 277, 253, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
3572, 1zwsH, 0.7540, 3.17, 0.211, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3573, 5y90A, 0.7539, 3.37, 0.231, 304, 255, MAP2K7 MUTANT -C218S
3574, 5vczA, 0.7539, 3.04, 0.191, 294, 246, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB ISOMER
3575, 5n1gA, 0.7539, 3.28, 0.238, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-(2-AMINO-13-THIAZOL-4-YL)-1- OXASPIRO[4.5]DECAN-2-ONE
3576, 5mo7A, 0.7539, 3.07, 0.174, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3577, 5j5xA, 0.7539, 3.31, 0.241, 340, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1416
3578, 5ct0A, 0.7539, 3.05, 0.170, 326, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
3579, 3qx4A, 0.7539, 3.15, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
3580, 2ojjA, 0.7539, 2.77, 0.205, 344, 244, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
3581, 1oveA, 0.7539, 3.33, 0.222, 349, 252, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
3582, 5n7vA, 0.7538, 2.92, 0.170, 260, 247, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
3583, 5n1fA, 0.7538, 3.28, 0.238, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-QUINOLIN-5-YLPYRIDINE-3-CARBOXAMIDE
3584, 4ra4A, 0.7538, 3.07, 0.245, 317, 249, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
3585, 4ks8A, 0.7538, 3.28, 0.198, 286, 252, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
3586, 4fieB, 0.7538, 3.35, 0.190, 300, 253, FULL-LENGTH HUMAN PAK4
3587, 4fieA, 0.7538, 3.35, 0.190, 300, 253, FULL-LENGTH HUMAN PAK4
3588, 3x2uA, 0.7538, 3.31, 0.238, 336, 252, MICHAELIS-LIKE INITIAL COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT.
3589, 2f57A, 0.7538, 3.21, 0.179, 297, 251, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
3590, 1w84A, 0.7538, 3.44, 0.233, 351, 253, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3591, 1pxjA, 0.7538, 3.20, 0.226, 294, 252, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
3592, 1erkA, 0.7538, 2.83, 0.205, 357, 244, STRUCTURE OF SIGNAL-REGULATED KINASE
3593, 6fyiA, 0.7537, 3.17, 0.215, 336, 247, X-RAY STRUCTURE OF CLK2-KD(130-496)/TG003 AT 2.6A 
3594, 5vcyA, 0.7537, 3.09, 0.186, 296, 247, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
3595, 5n23A, 0.7537, 3.31, 0.250, 333, 252, PROTEIN KINASE A MUTANTS AS SURROGATE MODEL FOR AURORA B WITH AT9283 INHIBITOR
3596, 3rpoA, 0.7537, 3.21, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
3597, 3royA, 0.7537, 3.16, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
3598, 3r7yA, 0.7537, 3.21, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
3599, 3r6xA, 0.7537, 3.20, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
3600, 3oxtA, 0.7537, 3.28, 0.246, 335, 252, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
3601, 3owkA, 0.7537, 3.14, 0.169, 330, 248, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
3602, 3mvjE, 0.7537, 3.30, 0.241, 334, 253, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
3603, 2z7lA, 0.7537, 2.61, 0.199, 329, 241, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
3604, 2c1bA, 0.7537, 3.34, 0.237, 335, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
3605, 2b9iA, 0.7537, 2.82, 0.262, 338, 244, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
3606, 1q62A, 0.7537, 3.26, 0.234, 336, 252, PKA DOUBLE MUTANT MODEL OF PKB
3607, 1hckA, 0.7537, 3.19, 0.226, 294, 252, HUMAN CYCLIN-DEPENDENT KINASE 2
3608, 5xqxA, 0.7536, 3.26, 0.209, 340, 249, HUMAN CDK8-CYCC IN COMPLEX WITH COMPOUND 4: N-METHYL-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
3609, 5cu6A, 0.7536, 3.11, 0.173, 327, 248, CRYSTAL STRUCTURE OF CK2ALPHA
3610, 5bnjA, 0.7536, 3.25, 0.204, 343, 250, CDK8/CYCC IN COMPLEX WITH 8-{3-CHLORO-5-[4-(1-METHYL-1H-PYRAZOL-4-YL)- PHENYL]-PYRIDIN- 4-YL}-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
3611, 4ix6B, 0.7536, 3.87, 0.137, 350, 263, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE SOAKED WITH ATP
3612, 4c38A, 0.7536, 3.28, 0.238, 334, 252, PKA-S6K1 CHIMERA WITH COMPOUND 21E (CCT239066) BOUND
3613, 4c37A, 0.7536, 3.28, 0.238, 335, 252, PKA-S6K1 CHIMERA WITH COMPOUND 21A (CCT196539) BOUND
3614, 3tv7B, 0.7536, 3.51, 0.205, 397, 258, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
3615, 3rgfA, 0.7536, 3.23, 0.193, 321, 249, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC
3616, 3q4uC, 0.7536, 2.64, 0.279, 296, 240, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3617, 3pwdA, 0.7536, 3.20, 0.172, 327, 250, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
3618, 2b9jA, 0.7536, 2.76, 0.251, 337, 243, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
3619, 1zwsC, 0.7536, 3.17, 0.211, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3620, 1mruB, 0.7536, 2.84, 0.221, 271, 244, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3621, 6fykC, 0.7535, 3.23, 0.218, 349, 248, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
3622, 5x8iB, 0.7535, 3.24, 0.222, 327, 248, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
3623, 5uplA, 0.7535, 3.30, 0.194, 290, 253, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTEFACE - 2 PEPTIDE: PAK4FL CDC42 - UNREFINED
3624, 5osdA, 0.7535, 3.13, 0.238, 266, 252, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3625, 5n9lA, 0.7535, 3.20, 0.181, 329, 249, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
3626, 5n3jA, 0.7535, 3.29, 0.238, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-NITROBENZOIC ACID
3627, 5k5nA, 0.7535, 3.55, 0.177, 331, 254, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
3628, 5cu0A, 0.7535, 3.05, 0.166, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
3629, 4ifcA, 0.7535, 3.11, 0.199, 327, 246, CRYSTAL STRUCTURE OF ADP-BOUND HUMAN PRPF4B KINASE DOMAIN
3630, 2vz6B, 0.7535, 3.20, 0.230, 294, 252, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
3631, 1wvxA, 0.7535, 3.08, 0.222, 275, 248, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3632, 1j3hA, 0.7535, 3.18, 0.240, 329, 250, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
3633, 1hclA, 0.7535, 3.18, 0.226, 294, 252, HUMAN CYCLIN-DEPENDENT KINASE 2
3634, 5vcvA, 0.7534, 3.25, 0.190, 287, 248, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH DASATINIB
3635, 5v61A, 0.7534, 2.68, 0.212, 348, 241, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
3636, 5os7B, 0.7534, 3.02, 0.171, 325, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
3637, 5omyA, 0.7534, 3.23, 0.155, 332, 251, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
3638, 5n3qA, 0.7534, 3.28, 0.238, 336, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINOBENZAMIDE
3639, 5cx9A, 0.7534, 3.07, 0.170, 328, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
3640, 5bx6A, 0.7534, 3.33, 0.241, 343, 253, PKA IN COMPLEX WITH A HALOGENATED PHTHALAZINONE FRAGMENT COMPOUND.
3641, 4yxsA, 0.7534, 3.34, 0.237, 335, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
3642, 4yxrA, 0.7534, 3.34, 0.237, 334, 253, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
3643, 4uj9A, 0.7534, 3.34, 0.241, 339, 253, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
3644, 4qmlA, 0.7534, 2.95, 0.262, 280, 248, MST3 IN COMPLEX WITH AMP-PNP
3645, 3r71A, 0.7534, 3.21, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
3646, 3ocbA, 0.7534, 2.98, 0.251, 315, 247, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
3647, 3anqB, 0.7534, 3.18, 0.215, 343, 246, HUMAN DYRK1A/INHIBITOR COMPLEX
3648, 3anqA, 0.7534, 3.16, 0.211, 342, 246, HUMAN DYRK1A/INHIBITOR COMPLEX
3649, 2gniA, 0.7534, 3.33, 0.245, 338, 253, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
3650, 2gfcA, 0.7534, 3.34, 0.237, 335, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
3651, 2f2uB, 0.7534, 3.38, 0.207, 383, 256, CRYSTAL STRUCTURE OF THE RHO-KINASE KINASE DOMAIN
3652, 1vebA, 0.7534, 3.33, 0.237, 338, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
3653, 1m2qA, 0.7534, 3.17, 0.169, 327, 249, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
3654, 6gmdA, 0.7533, 3.02, 0.171, 325, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
3655, 5v62A, 0.7533, 2.76, 0.212, 349, 241, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
3656, 5mmrB, 0.7533, 3.00, 0.167, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
3657, 5eh0A, 0.7533, 2.94, 0.175, 258, 246, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3658, 5cqwB, 0.7533, 3.12, 0.169, 331, 249, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
3659, 4jqeA, 0.7533, 3.22, 0.169, 369, 249, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
3660, 4bcqC, 0.7533, 2.93, 0.236, 292, 246, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3661, 3r1sA, 0.7533, 3.21, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
3662, 3qrtA, 0.7533, 3.17, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
3663, 1pxiA, 0.7533, 3.19, 0.226, 294, 252, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
3664, 6b2eA, 0.7532, 2.82, 0.242, 442, 244, STRUCTURE OF FULL LENGTH HUMAN AMPK (A2B2G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4. 
3665, 5oueA, 0.7532, 3.10, 0.170, 328, 247, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
3666, 5cu4A, 0.7532, 3.04, 0.174, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
3667, 5ctpB, 0.7532, 3.09, 0.166, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
3668, 5ar8A, 0.7532, 2.43, 0.242, 255, 236, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
3669, 4xrlA, 0.7532, 2.68, 0.202, 337, 242, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3670, 4qp9A, 0.7532, 2.84, 0.213, 335, 244, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
3671, 3q4uA, 0.7532, 2.83, 0.277, 298, 242, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3672, 3p1aA, 0.7532, 3.14, 0.190, 281, 248, STRUCTURE OF HUMAN MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE- SPECIFIC CDC2-INHIBITORY KINASE MYT1 (PKMYT1)
3673, 3oogA, 0.7532, 3.26, 0.242, 333, 252, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
3674, 3gp0A, 0.7532, 2.72, 0.216, 333, 241, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
3675, 3amaA, 0.7532, 3.26, 0.250, 342, 252, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
3676, 2vo7A, 0.7532, 3.34, 0.237, 335, 253, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
3677, 5x8iA, 0.7531, 3.24, 0.222, 328, 248, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
3678, 5otyA, 0.7531, 3.13, 0.173, 327, 248, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
3679, 5os8A, 0.7531, 3.11, 0.173, 327, 248, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
3680, 5n1hA, 0.7531, 3.28, 0.238, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL 4-(AMINOMETHYL)BENZOATE
3681, 5mmfA, 0.7531, 3.01, 0.171, 326, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
3682, 5m0uA, 0.7531, 3.17, 0.241, 346, 249, APOSTRUCTURE STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) FROM CHO CELLS WITH A PEPTIDIC INHIBITOR FRAGMENT 
3683, 5kz7B, 0.7531, 2.57, 0.265, 296, 238, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
3684, 4yuqB, 0.7531, 3.11, 0.258, 462, 248, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
3685, 3vqhA, 0.7531, 3.34, 0.241, 344, 253, BROMINE SAD PARTIALLY RESOLVES MULTIPLE BINDING MODES FOR PKA INHIBITOR H-89
3686, 3qx2A, 0.7531, 3.21, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
3687, 3nrmA, 0.7531, 3.11, 0.243, 263, 251, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
3688, 3f3zA, 0.7531, 3.35, 0.209, 271, 253, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
3689, 3dndA, 0.7531, 3.33, 0.237, 334, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
3690, 2f49A, 0.7531, 2.78, 0.254, 335, 244, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
3691, 2b9hA, 0.7531, 2.85, 0.262, 337, 244, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
3692, 6g9mA, 0.7530, 2.79, 0.210, 341, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3693, 5modA, 0.7530, 3.01, 0.167, 327, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3694, 5m0cA, 0.7530, 3.33, 0.241, 336, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE FASUDIL-FRAGMENT ISOQUINOLINE-5-SULFONAMIDE 
3695, 4rlkA, 0.7530, 3.20, 0.172, 327, 250, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
3696, 4jajA, 0.7530, 3.07, 0.239, 265, 251, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
3697, 3pvuA, 0.7530, 3.50, 0.187, 609, 257, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
3698, 3krxA, 0.7530, 3.60, 0.189, 618, 259, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
3699, 3hv4A, 0.7530, 3.13, 0.231, 339, 247, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
3700, 5vcxA, 0.7529, 3.12, 0.190, 287, 247, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (UNTREATED) IN COMPLEX WITH SARACATINIB
3701, 5dt3A, 0.7529, 3.12, 0.235, 263, 251, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
3702, 4cfhA, 0.7529, 2.82, 0.230, 401, 244, STRUCTURE OF AN ACTIVE FORM OF MAMMALIAN AMPK
3703, 3qwjA, 0.7529, 3.21, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
3704, 3nr9A, 0.7529, 3.21, 0.222, 341, 248, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
3705, 3hkoA, 0.7529, 3.23, 0.234, 319, 252, CRYSTAL STRUCTURE OF A CDPK KINASE DOMAIN FROM CRYPTOSPORIDIUM PARVUM CGD7_40
3706, 3dlsF, 0.7529, 2.86, 0.235, 281, 243, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3707, 2f2cB, 0.7529, 2.81, 0.236, 280, 242, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
3708, 5orhB, 0.7528, 3.01, 0.167, 325, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
3709, 5m4iA, 0.7528, 3.24, 0.159, 331, 251, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
3710, 5a3xC, 0.7528, 3.19, 0.215, 333, 246, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
3711, 5a3xB, 0.7528, 3.18, 0.211, 340, 246, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
3712, 4wbbB, 0.7528, 3.29, 0.238, 334, 252, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
3713, 3zo4A, 0.7528, 3.34, 0.237, 335, 253, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
3714, 3x2wA, 0.7528, 3.32, 0.238, 336, 252, MICHAELIS COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
3715, 3kk9A, 0.7528, 2.90, 0.212, 275, 245, CAMKII SUBSTRATE COMPLEX B
3716, 3flyA, 0.7528, 3.39, 0.231, 347, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
3717, 3at4A, 0.7528, 3.20, 0.177, 331, 249, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
3718, 3anrA, 0.7528, 3.16, 0.215, 342, 246, HUMAN DYRK1A/HARMINE COMPLEX
3719, 1xh7A, 0.7528, 3.32, 0.234, 337, 252, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
3720, 6gi6A, 0.7527, 2.79, 0.277, 298, 242, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH A QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 5-METHYL CORE. 
3721, 5umoA, 0.7527, 2.73, 0.189, 347, 243, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
3722, 5o5mA, 0.7527, 3.32, 0.238, 336, 252, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND RKP117 
3723, 5n3tA, 0.7527, 3.30, 0.238, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 5-CHLOROTHIOPHENE-2-SULFONAMIDE
3724, 5mo8A, 0.7527, 3.09, 0.170, 325, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3725, 5izfA, 0.7527, 3.30, 0.241, 336, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1408
3726, 4qo9B, 0.7527, 3.07, 0.256, 285, 250, MST3 IN COMPLEX WITH DANUSERTIB
3727, 3r73A, 0.7527, 3.22, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
3728, 3e3bX, 0.7527, 3.23, 0.168, 334, 250, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
3729, 3ckxA, 0.7527, 2.91, 0.264, 276, 246, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
3730, 2y0aA, 0.7527, 3.51, 0.207, 300, 256, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
3731, 1sveA, 0.7527, 3.34, 0.237, 341, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
3732, 5uzkA, 0.7526, 3.35, 0.241, 335, 253, CRYSTAL STRUCTURE OF PKA BOUND TO AN PYRROLO PYRIDINE INHIBITOR
3733, 5cvhA, 0.7526, 3.08, 0.174, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA
3734, 4umrA, 0.7526, 2.80, 0.221, 313, 244, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3735, 4qp3B, 0.7526, 2.79, 0.210, 331, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
3736, 4jdiA, 0.7526, 3.20, 0.191, 289, 251, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
3737, 4ijpB, 0.7526, 3.11, 0.199, 333, 246, CRYSTAL STRUCTURE OF HUMAN PRPF4B KINASE DOMAIN IN COMPLEX WITH 4-{5- [(2-CHLORO-PYRIDIN-4-YLMETHYL)-CARBAMOYL]-THIOPHEN-2-YL}- BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMINE
3738, 4c33A, 0.7526, 3.30, 0.238, 335, 252, PKA-S6K1 CHIMERA APO
3739, 4bn1A, 0.7526, 3.04, 0.240, 261, 250, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
3740, 4an9A, 0.7526, 3.30, 0.224, 281, 255, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
3741, 3qxoA, 0.7526, 3.22, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
3742, 2jedA, 0.7526, 3.10, 0.245, 324, 249, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
3743, 5uvcA, 0.7525, 3.64, 0.197, 457, 259, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
3744, 5otzA, 0.7525, 3.12, 0.173, 327, 248, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
3745, 5byzA, 0.7525, 2.81, 0.205, 348, 244, ERK5 IN COMPLEX WITH SMALL MOLECULE
3746, 4xv1A, 0.7525, 2.21, 0.342, 239, 234, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7904
3747, 4o0xA, 0.7525, 3.36, 0.190, 290, 253, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3748, 4ijpA, 0.7525, 3.12, 0.199, 330, 246, CRYSTAL STRUCTURE OF HUMAN PRPF4B KINASE DOMAIN IN COMPLEX WITH 4-{5- [(2-CHLORO-PYRIDIN-4-YLMETHYL)-CARBAMOYL]-THIOPHEN-2-YL}- BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMINE
3749, 4fifB, 0.7525, 3.40, 0.189, 292, 254, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
3750, 4fifA, 0.7525, 3.40, 0.189, 293, 254, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
3751, 3vquA, 0.7525, 2.84, 0.164, 258, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
3752, 3tv7D, 0.7525, 3.50, 0.210, 397, 257, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
3753, 3r1qA, 0.7525, 3.18, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
3754, 3nx8A, 0.7525, 3.36, 0.237, 333, 253, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
3755, 3mb7A, 0.7525, 3.22, 0.177, 330, 249, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
3756, 3cohB, 0.7525, 2.66, 0.239, 247, 243, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3757, 1svgA, 0.7525, 3.35, 0.237, 338, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
3758, 5os5A, 0.7524, 3.14, 0.234, 267, 252, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3759, 5mpjA, 0.7524, 3.08, 0.170, 326, 247, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
3760, 5cu0B, 0.7524, 3.08, 0.166, 325, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
3761, 3pvwA, 0.7524, 3.62, 0.201, 613, 259, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
3762, 3kkvA, 0.7524, 3.30, 0.234, 335, 252, STRUCTURE OF PKA WITH A PROTEIN KINASE B-SELECTIVE INHIBITOR.
3763, 3at3A, 0.7524, 3.19, 0.181, 332, 249, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
3764, 5n93A, 0.7523, 2.84, 0.160, 259, 244, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
3765, 4ix3B, 0.7523, 3.80, 0.145, 350, 262, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE
3766, 4ditA, 0.7523, 3.73, 0.180, 328, 256, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
3767, 4bggD, 0.7523, 2.54, 0.283, 286, 237, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3768, 3v8sD, 0.7523, 3.44, 0.202, 397, 257, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
3769, 1ydsE, 0.7523, 3.34, 0.237, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
3770, 6b1uA, 0.7522, 2.97, 0.245, 441, 245, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
3771, 5n3nA, 0.7522, 3.21, 0.239, 337, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE [(2R)-24-DIHYDROXY-4-OXOBUTYL]- TRIMETHYLAZANIUM
3772, 5n3iA, 0.7522, 3.22, 0.239, 337, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL (2S)-2-AMINO-3-PHENYLPROPANOATE
3773, 5isoC, 0.7522, 2.98, 0.244, 429, 246, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
3774, 4usdB, 0.7522, 3.10, 0.242, 267, 248, HUMAN STK10 (LOK) WITH SB-633825
3775, 4s33A, 0.7522, 2.79, 0.201, 347, 244, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
3776, 4o0rA, 0.7522, 3.43, 0.232, 293, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3777, 4iz7A, 0.7522, 2.76, 0.206, 344, 243, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
3778, 4f70A, 0.7522, 3.09, 0.203, 327, 246, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 4 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-[2-(MORPHOLIN-4-YL) ETHYL]UREA)
3779, 4c4eA, 0.7522, 2.81, 0.160, 256, 243, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3780, 3r28A, 0.7522, 3.19, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
3781, 3pooA, 0.7522, 3.36, 0.241, 331, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
3782, 3nizA, 0.7522, 3.06, 0.238, 288, 244, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
3783, 3my0T, 0.7522, 2.68, 0.254, 292, 240, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3784, 3anrB, 0.7522, 3.10, 0.212, 342, 245, HUMAN DYRK1A/HARMINE COMPLEX
3785, 2gfsA, 0.7522, 3.21, 0.229, 344, 249, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3201195
3786, 2erzE, 0.7522, 3.26, 0.242, 334, 252, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
3787, 1xh4A, 0.7522, 3.32, 0.234, 334, 252, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
3788, 6eqiC, 0.7521, 3.27, 0.189, 392, 249, STRUCTURE OF PINK1 BOUND TO UBIQUITIN
3789, 5n3pA, 0.7521, 3.30, 0.238, 336, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 1H-INDOL-5-OL
3790, 5l2qB, 0.7521, 3.11, 0.165, 282, 249, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
3791, 5h8gA, 0.7521, 3.05, 0.183, 324, 246, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
3792, 5dnrA, 0.7521, 3.11, 0.239, 264, 251, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
3793, 5bx7A, 0.7521, 3.35, 0.241, 343, 253, PKA IN COMPLEX WITH A BENZOTHIOPHENE FRAGMENT COMPOUND.
3794, 5a3xD, 0.7521, 3.19, 0.212, 331, 245, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
3795, 4nifE, 0.7521, 2.91, 0.208, 348, 245, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
3796, 4ks7A, 0.7521, 3.24, 0.202, 286, 252, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
3797, 3nr9C, 0.7521, 3.26, 0.218, 347, 248, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
3798, 3bv2A, 0.7521, 2.83, 0.227, 337, 242, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
3799, 2zazA, 0.7521, 3.17, 0.218, 345, 248, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
3800, 6ehkA, 0.7520, 3.14, 0.173, 327, 248, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712 AND COMPOUND 37
3801, 4xw5A, 0.7520, 3.23, 0.239, 334, 251, X-RAY STRUCTURE OF PKAC WITH ATP CP20 CALCIUM IONS
3802, 4utdA, 0.7520, 2.99, 0.241, 266, 249, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
3803, 4txcA, 0.7520, 3.11, 0.217, 276, 249, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3804, 3my0O, 0.7520, 2.76, 0.253, 297, 241, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3805, 3ds6B, 0.7520, 3.14, 0.234, 343, 248, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
3806, 3dlsE, 0.7520, 3.00, 0.224, 282, 245, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3807, 1ydrE, 0.7520, 3.33, 0.237, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
3808, 1jwhB, 0.7520, 3.28, 0.179, 335, 251, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
3809, 5otlB, 0.7519, 3.10, 0.170, 326, 247, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 29
3810, 5mo6B, 0.7519, 3.04, 0.167, 324, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3811, 5kz7A, 0.7519, 2.57, 0.265, 296, 238, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
3812, 4s2zA, 0.7519, 2.75, 0.193, 346, 243, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
3813, 4a07A, 0.7519, 3.08, 0.239, 282, 247, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
3814, 3qruA, 0.7519, 3.14, 0.231, 295, 251, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
3815, 3cohA, 0.7519, 2.67, 0.239, 247, 243, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3816, 2i6lA, 0.7519, 2.71, 0.200, 292, 240, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
3817, 5he0A, 0.7518, 3.61, 0.193, 621, 259, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
3818, 5ct0B, 0.7518, 3.04, 0.167, 326, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
3819, 5b2lA, 0.7518, 3.32, 0.237, 288, 253, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
3820, 4yffB, 0.7518, 2.59, 0.274, 264, 237, TNNI3K COMPLEXED WITH INHIBITOR 2
3821, 4y85A, 0.7518, 2.91, 0.188, 307, 245, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
3822, 4s34A, 0.7518, 2.81, 0.205, 343, 244, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
3823, 4ifcB, 0.7518, 3.12, 0.196, 329, 245, CRYSTAL STRUCTURE OF ADP-BOUND HUMAN PRPF4B KINASE DOMAIN
3824, 3r7eA, 0.7518, 3.18, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
3825, 3fmhA, 0.7518, 3.29, 0.236, 347, 250, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
3826, 3anrC, 0.7518, 3.06, 0.209, 337, 244, HUMAN DYRK1A/HARMINE COMPLEX
3827, 5n3lA, 0.7517, 3.31, 0.238, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-[(1R)-2-AMINO-1-HYDROXYETHYL]BENZENE-1 2-DIOL
3828, 5n3kA, 0.7517, 3.30, 0.238, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE O-GUANIDINO-L-HOMOSERINE
3829, 5movA, 0.7517, 3.01, 0.175, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
3830, 5ho6A, 0.7517, 2.23, 0.393, 240, 229, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH CMPD.
3831, 5ei2A, 0.7517, 2.94, 0.179, 256, 246, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3832, 4qp8A, 0.7517, 2.72, 0.202, 335, 242, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
3833, 4nifB, 0.7517, 2.92, 0.208, 349, 245, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
3834, 4nctD, 0.7517, 3.18, 0.212, 331, 245, HUMAN DYRK1A IN COMPLEX WITH PKC412
3835, 4fuxA, 0.7517, 2.82, 0.210, 342, 243, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
3836, 4arkA, 0.7517, 3.40, 0.219, 291, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
3837, 3zuvC, 0.7517, 2.75, 0.207, 357, 241, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
3838, 1q8wA, 0.7517, 3.31, 0.234, 334, 252, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
3839, 6g9dA, 0.7516, 2.79, 0.210, 345, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3840, 5unpB, 0.7516, 3.30, 0.214, 347, 248, STRUCTURE OF CDC2-LIKE KINASE 2 (CLK2) IN COMPLEX WITH COMPOUND T-025 [N2-METHYL-N4-(PYRIMIDIN-2-YLMETHYL)-5-(QUINOLIN-6-YL)-7H-PYRROLO[2; 3-D]PYRIMIDINE-2;4-DIAMINE] 
3841, 5unpA, 0.7516, 3.30, 0.214, 347, 248, STRUCTURE OF CDC2-LIKE KINASE 2 (CLK2) IN COMPLEX WITH COMPOUND T-025 [N2-METHYL-N4-(PYRIMIDIN-2-YLMETHYL)-5-(QUINOLIN-6-YL)-7H-PYRROLO[2; 3-D]PYRIMIDINE-2;4-DIAMINE] 
3842, 5oumA, 0.7516, 3.02, 0.171, 326, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
3843, 5ehlA, 0.7516, 2.79, 0.172, 258, 244, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3844, 5a3xA, 0.7516, 3.12, 0.216, 342, 245, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
3845, 4ysjB, 0.7516, 3.21, 0.257, 462, 249, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
3846, 4lmnA, 0.7516, 3.38, 0.219, 292, 256, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
3847, 4bieB, 0.7516, 2.59, 0.231, 257, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3848, 3r83A, 0.7516, 3.23, 0.230, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
3849, 3db6A, 0.7516, 3.37, 0.226, 287, 252, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
3850, 2x4zA, 0.7516, 3.24, 0.183, 290, 251, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
3851, 6b2pA, 0.7515, 2.62, 0.221, 255, 240, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
3852, 5vd0A, 0.7515, 3.13, 0.190, 293, 247, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH MK1775
3853, 5oueB, 0.7515, 3.04, 0.167, 326, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
3854, 5orhA, 0.7515, 3.04, 0.171, 324, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
3855, 5moeA, 0.7515, 3.03, 0.167, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3856, 5mo5A, 0.7515, 3.03, 0.175, 326, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3857, 4umuA, 0.7515, 2.82, 0.216, 316, 245, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3858, 4ix4A, 0.7515, 3.77, 0.142, 346, 260, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH ADP
3859, 4ez3A, 0.7515, 3.14, 0.232, 294, 250, CDK2 IN COMPLEX WITH NSC 134199
3860, 4ct2A, 0.7515, 3.14, 0.227, 277, 247, HUMAN PDK1-PKCZETA KINASE CHIMERA
3861, 3zu7A, 0.7515, 2.90, 0.201, 344, 244, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
3862, 3zo1A, 0.7515, 3.33, 0.234, 339, 252, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
3863, 3r7vA, 0.7515, 3.19, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
3864, 2x6dA, 0.7515, 2.96, 0.246, 255, 248, AURORA-A BOUND TO AN INHIBITOR
3865, 6g91A, 0.7514, 2.82, 0.214, 344, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3866, 5oumB, 0.7514, 3.04, 0.167, 326, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
3867, 5mmfB, 0.7514, 3.03, 0.167, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
3868, 4zzoA, 0.7514, 2.82, 0.206, 339, 243, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
3869, 4y85B, 0.7514, 2.90, 0.184, 306, 245, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
3870, 4s32A, 0.7514, 2.83, 0.205, 346, 244, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
3871, 4lfiB, 0.7514, 3.24, 0.180, 371, 250, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
3872, 4i6hA, 0.7514, 3.54, 0.220, 285, 255, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3873, 4hptE, 0.7514, 3.36, 0.241, 335, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING COMPLETE PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
3874, 4c36A, 0.7514, 3.29, 0.238, 335, 252, PKA-S6K1 CHIMERA WITH COMPOUND 15E (CCT147581) BOUND
3875, 3qwkA, 0.7514, 3.20, 0.235, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
3876, 3iphA, 0.7514, 3.29, 0.237, 345, 249, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
3877, 3e8nA, 0.7514, 3.18, 0.227, 291, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
3878, 1o6yA, 0.7514, 2.59, 0.221, 260, 240, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
3879, 1f0qA, 0.7514, 3.26, 0.164, 329, 250, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
3880, 4i6bA, 0.7513, 3.56, 0.224, 285, 255, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3881, 4i5pA, 0.7513, 3.60, 0.220, 284, 255, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3882, 4fv3A, 0.7513, 2.77, 0.206, 346, 243, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
3883, 4fv2A, 0.7513, 2.80, 0.206, 344, 243, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
3884, 3gc9A, 0.7513, 2.77, 0.231, 335, 242, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
3885, 3fl5A, 0.7513, 3.23, 0.172, 324, 250, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
3886, 3fkoA, 0.7513, 3.15, 0.231, 343, 247, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
3887, 3e8eE, 0.7513, 3.35, 0.237, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3888, 3dlsC, 0.7513, 2.97, 0.234, 281, 244, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3889, 2y9qA, 0.7513, 2.89, 0.213, 349, 244, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3890, 2uzwE, 0.7513, 3.40, 0.236, 336, 254, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
3891, 1wboA, 0.7513, 3.52, 0.240, 351, 254, FRAGMENT BASED P38 INHIBITORS
3892, 5cx9B, 0.7512, 3.04, 0.167, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
3893, 4xp2A, 0.7512, 2.76, 0.210, 337, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3894, 4m66A, 0.7512, 2.76, 0.256, 268, 238, CRYSTAL STRUCTURE OF THE MOUSE RIP3 KINASE DOMAIN
3895, 4lfiA, 0.7512, 3.24, 0.180, 370, 250, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
3896, 4fv1A, 0.7512, 2.75, 0.206, 342, 243, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
3897, 3ovvA, 0.7512, 3.37, 0.241, 335, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
3898, 3nszA, 0.7512, 3.13, 0.170, 327, 247, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
3899, 3ds6A, 0.7512, 3.15, 0.234, 343, 248, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
3900, 2xruA, 0.7512, 2.89, 0.243, 253, 247, AURORA-A T288E COMPLEXED WITH PHA-828300
3901, 2qurA, 0.7512, 3.35, 0.241, 338, 253, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
3902, 2qg5A, 0.7512, 3.35, 0.187, 284, 252, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3903, 1xh6A, 0.7512, 3.28, 0.238, 331, 252, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
3904, 1mruA, 0.7512, 2.74, 0.218, 269, 243, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3905, 5v60A, 0.7511, 2.76, 0.212, 347, 241, PHOSPHO-ERK2 BOUND TO AMP-PCP
3906, 5osjA, 0.7511, 3.25, 0.230, 292, 252, CDK2(WT) WITH COVALENT ADDUCT AT C177
3907, 5orjA, 0.7511, 3.04, 0.171, 325, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
3908, 5mo8B, 0.7511, 3.05, 0.171, 324, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3909, 5cu2B, 0.7511, 3.05, 0.167, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
3910, 5a4lB, 0.7511, 3.16, 0.216, 339, 245, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
3911, 4qp1B, 0.7511, 2.79, 0.210, 343, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3912, 4ix5A, 0.7511, 3.79, 0.138, 346, 260, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH AMP-PNP
3913, 4ianB, 0.7511, 3.07, 0.196, 319, 245, CRYSTAL STRUCTURE OF APO HUMAN PRPF4B KINASE DOMAIN
3914, 2xzsB, 0.7511, 3.39, 0.213, 293, 254, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
3915, 2erkA, 0.7511, 2.75, 0.207, 351, 241, PHOSPHORYLATED MAP KINASE ERK2
3916, 1zwsE, 0.7511, 3.20, 0.211, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3917, 1r39A, 0.7511, 3.32, 0.224, 345, 250, THE STRUCTURE OF P38ALPHA
3918, 1pxpA, 0.7511, 3.09, 0.216, 294, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
3919, 5upkB, 0.7510, 3.27, 0.194, 288, 252, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTERFACE - 3 PEPTIDE: PAK4CAT PAK4-N45 CDC42
3920, 5otrA, 0.7510, 3.14, 0.173, 327, 248, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 14
3921, 5o7iA, 0.7510, 2.70, 0.211, 340, 242, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
3922, 5lcjA, 0.7510, 2.77, 0.210, 345, 243, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
3923, 5ezvA, 0.7510, 2.90, 0.242, 441, 244, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
3924, 4zloA, 0.7510, 3.20, 0.222, 277, 252, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
3925, 4qp6B, 0.7510, 2.80, 0.206, 334, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
3926, 4o0tA, 0.7510, 3.41, 0.236, 292, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3927, 4ekkA, 0.7510, 3.00, 0.251, 318, 247, AKT1 WITH AMP-PNP
3928, 4c4jA, 0.7510, 2.77, 0.169, 261, 243, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3929, 3my0P, 0.7510, 2.71, 0.254, 290, 240, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3930, 1zwsA, 0.7510, 3.22, 0.211, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3931, 1jbpE, 0.7510, 3.35, 0.241, 339, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
3932, 4s30A, 0.7509, 2.73, 0.193, 342, 243, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
3933, 4pnkA, 0.7509, 3.59, 0.186, 625, 258, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
3934, 4i6fA, 0.7509, 3.55, 0.220, 285, 255, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3935, 4gubA, 0.7509, 3.08, 0.174, 329, 247, CASEIN KINASE II BOUND TO INHIBITOR
3936, 4g3fA, 0.7509, 3.31, 0.188, 312, 255, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 2-(AMINOTHIAZOLY)PHENOL (CMP2)
3937, 3v8sB, 0.7509, 3.48, 0.202, 397, 257, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
3938, 3r21A, 0.7509, 2.90, 0.247, 254, 247, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3939, 3cqwA, 0.7509, 2.91, 0.252, 318, 246, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
3940, 2fysB, 0.7509, 2.65, 0.195, 338, 241, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
3941, 6ge0A, 0.7508, 2.74, 0.211, 343, 242, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3942, 6b5jB, 0.7508, 2.66, 0.269, 264, 238, TNNI3K COMPLEXED WITH A 46-DIAMINOPYRIMIDINE
3943, 5mowA, 0.7508, 3.07, 0.175, 328, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
3944, 5he2A, 0.7508, 3.50, 0.187, 628, 257, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
3945, 4zznA, 0.7508, 2.79, 0.206, 338, 243, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
3946, 4iakA, 0.7508, 3.34, 0.238, 334, 252, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
3947, 3flwA, 0.7508, 3.39, 0.227, 345, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
3948, 3fbvK, 0.7508, 3.13, 0.215, 422, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3949, 5n87A, 0.7507, 2.84, 0.173, 255, 243, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
3950, 5mo5B, 0.7507, 3.05, 0.167, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3951, 5cvhB, 0.7507, 3.05, 0.171, 324, 246, CRYSTAL STRUCTURE OF CK2ALPHA
3952, 5a54B, 0.7507, 3.16, 0.216, 339, 245, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
3953, 4xneA, 0.7507, 2.78, 0.202, 344, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3954, 4uakA, 0.7507, 3.51, 0.199, 404, 256, MRCK BETA IN COMPLEX WITH ADP
3955, 4qp7B, 0.7507, 2.74, 0.202, 335, 242, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
3956, 3sdjK, 0.7507, 3.02, 0.221, 422, 244, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3957, 3qtwA, 0.7507, 3.22, 0.235, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
3958, 3anqC, 0.7507, 3.14, 0.208, 340, 245, HUMAN DYRK1A/INHIBITOR COMPLEX
3959, 1zmuB, 0.7507, 2.45, 0.249, 296, 237, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
3960, 1r3cA, 0.7507, 3.63, 0.243, 349, 255, THE STRUCTURE OF P38ALPHA C162S MUTANT
3961, 1jluE, 0.7507, 3.36, 0.241, 337, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
3962, 6b5jD, 0.7506, 2.35, 0.270, 257, 233, TNNI3K COMPLEXED WITH A 46-DIAMINOPYRIMIDINE
3963, 5orkA, 0.7506, 3.06, 0.175, 324, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
3964, 5n3sA, 0.7506, 3.23, 0.239, 337, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-HYDROXYBENZAMIDE
3965, 5jznA, 0.7506, 2.95, 0.234, 268, 244, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
3966, 5dh3B, 0.7506, 3.26, 0.241, 283, 249, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
3967, 5cshA, 0.7506, 3.06, 0.167, 324, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
3968, 5aikA, 0.7506, 3.16, 0.208, 344, 245, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
3969, 4zslA, 0.7506, 2.81, 0.210, 341, 243, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
3970, 4q9zB, 0.7506, 3.25, 0.244, 308, 250, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
3971, 3u4uA, 0.7506, 3.06, 0.163, 327, 246, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
3972, 3e8eP, 0.7506, 3.35, 0.237, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3973, 3a8xB, 0.7506, 3.04, 0.218, 329, 248, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
3974, 1h4lB, 0.7506, 2.61, 0.232, 278, 237, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
3975, 6fyoA, 0.7505, 3.31, 0.226, 331, 248, X-RAY STRUCTURE OF CLK1-KD(148-484)/CPD-2 AT 2.32A 
3976, 6cnhA, 0.7505, 2.81, 0.196, 321, 240, HUMAN PRPF4B IN COMPLEX WITH REBASTINIB
3977, 5n3mA, 0.7505, 3.32, 0.238, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE D-ARGININE
3978, 5isoA, 0.7505, 2.98, 0.244, 453, 246, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
3979, 5g1xA, 0.7505, 2.93, 0.243, 262, 247, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH N-MYC
3980, 4zzmA, 0.7505, 2.86, 0.206, 344, 243, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
3981, 4o0yA, 0.7505, 3.38, 0.190, 290, 253, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3982, 4jbqA, 0.7505, 2.81, 0.248, 257, 246, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3983, 4ix6A, 0.7505, 3.78, 0.142, 346, 260, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE SOAKED WITH ATP
3984, 4grbA, 0.7505, 3.07, 0.171, 327, 246, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
3985, 4dh5A, 0.7505, 3.31, 0.238, 333, 252, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ADP PHOSPHATE AND IP20
3986, 3owpA, 0.7505, 3.29, 0.242, 334, 252, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
3987, 3gcuA, 0.7505, 3.00, 0.241, 339, 245, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
3988, 3fbvD, 0.7505, 3.13, 0.215, 422, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3989, 2wo6A, 0.7505, 3.17, 0.211, 344, 246, HUMAN DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A IN COMPLEX WITH A CONSENSUS SUBSTRATE PEPTIDE
3990, 5vd3A, 0.7504, 3.12, 0.191, 293, 246, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (DE-PHOSPHORYLATED) IN COMPLEX WITH SARACATINIB
3991, 5ouuB, 0.7504, 3.07, 0.167, 325, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
3992, 5ot5A, 0.7504, 3.13, 0.170, 326, 247, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
3993, 5n3hA, 0.7504, 3.23, 0.239, 337, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE PYRIDINE-3-CARBOXAMIDE
3994, 5modB, 0.7504, 3.07, 0.167, 324, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3995, 5ajqB, 0.7504, 3.29, 0.251, 267, 247, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
3996, 4u44B, 0.7504, 3.71, 0.203, 296, 261, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
3997, 4o6lA, 0.7504, 2.89, 0.177, 257, 243, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
3998, 3sdjD, 0.7504, 3.03, 0.221, 422, 244, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3999, 3rk9A, 0.7504, 3.15, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
4000, 3rawA, 0.7504, 3.51, 0.231, 351, 251, CRYSTAL STRUCTURE OF HUMAN CDC-LIKE KINASE 3 ISOFORM IN COMPLEX WITH LEUCETTINE L41
4001, 3r63A, 0.7504, 2.77, 0.189, 347, 243, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
4002, 3qxpA, 0.7504, 3.16, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
4003, 3hmnA, 0.7504, 2.87, 0.169, 255, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
4004, 5vcwA, 0.7503, 3.18, 0.194, 285, 247, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PELITINIB
4005, 5l8lA, 0.7503, 2.98, 0.241, 263, 249, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
4006, 4yc6E, 0.7503, 3.09, 0.239, 285, 247, CDK1/CKS1
4007, 4xj0B, 0.7503, 2.84, 0.214, 338, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
4008, 4qp4B, 0.7503, 2.74, 0.202, 335, 242, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
4009, 4h3pA, 0.7503, 2.81, 0.215, 342, 242, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
4010, 3tnqB, 0.7503, 3.33, 0.238, 331, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
4011, 3qbnA, 0.7503, 2.79, 0.236, 250, 246, STRUCTURE OF HUMAN AURORA A IN COMPLEX WITH A DIAMINOPYRIMIDINE
4012, 3idbA, 0.7503, 3.36, 0.241, 341, 253, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
4013, 3flzA, 0.7503, 3.39, 0.231, 347, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
4014, 3fbvC, 0.7503, 3.06, 0.216, 415, 245, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4015, 3e8eA, 0.7503, 3.36, 0.237, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
4016, 5ot6A, 0.7502, 3.12, 0.170, 327, 247, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
4017, 5oquA, 0.7502, 3.06, 0.171, 324, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
4018, 5lxmA, 0.7502, 2.98, 0.246, 266, 248, CRYSTAL STRUCTURE OF AURORA-A BOUND TO A HYDROCARBON-STAPLED PROTEOMIMETIC OF TPX2
4019, 5l2qA, 0.7502, 3.05, 0.173, 293, 248, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
4020, 4wsqB, 0.7502, 2.98, 0.180, 310, 245, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4021, 4wnpA, 0.7502, 2.81, 0.267, 273, 243, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
4022, 4lgdC, 0.7502, 3.33, 0.206, 349, 252, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4023, 4ix3A, 0.7502, 3.71, 0.147, 346, 259, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE
4024, 4iafA, 0.7502, 3.33, 0.238, 333, 252, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
4025, 4gt3A, 0.7502, 2.83, 0.206, 347, 243, ATP-BOUND FORM OF THE ERK2 KINASE
4026, 4g3gA, 0.7502, 3.22, 0.189, 312, 254, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) V408L BOUND TO A 2-(AMINOTHIAZOLYL)PHENOL (CMP3)
4027, 3sdjC, 0.7502, 2.93, 0.222, 415, 243, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4028, 3mtfA, 0.7502, 2.74, 0.279, 296, 240, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
4029, 6g8xA, 0.7501, 2.90, 0.213, 338, 244, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4030, 5m0lA, 0.7501, 3.27, 0.242, 338, 252, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE METHYLATED FASUDIL-DERIVED FRAGMENT N-METHYLISOQUINOLINE-5- SULFONAMIDE (LIGAND 02) 
4031, 4x6rA, 0.7501, 3.31, 0.238, 347, 252, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
4032, 4qpaA, 0.7501, 2.76, 0.198, 331, 242, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
4033, 4qp2B, 0.7501, 2.66, 0.199, 329, 241, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
4034, 4ewqA, 0.7501, 3.06, 0.224, 346, 246, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
4035, 3x2vA, 0.7501, 3.35, 0.238, 331, 252, MICHAELIS-LIKE COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
4036, 3rk7A, 0.7501, 3.14, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
4037, 3fbvN, 0.7501, 3.06, 0.216, 415, 245, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4038, 3fbvF, 0.7501, 3.06, 0.216, 415, 245, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4039, 2qg5B, 0.7501, 3.32, 0.187, 280, 252, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
4040, 5mp8A, 0.7500, 3.06, 0.175, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
4041, 5jrqB, 0.7500, 2.38, 0.322, 246, 236, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
4042, 5ap7A, 0.7500, 2.88, 0.169, 263, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4043, 5aikB, 0.7500, 3.21, 0.215, 342, 246, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
4044, 4zhxA, 0.7500, 2.90, 0.242, 408, 244, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
4045, 4yffA, 0.7500, 2.58, 0.275, 264, 236, TNNI3K COMPLEXED WITH INHIBITOR 2
4046, 4jrnA, 0.7500, 3.48, 0.173, 349, 254, ROP18 KINASE DOMAIN IN COMPLEX WITH AMP-PNP AND SUCROSE
4047, 4dg2E, 0.7500, 3.34, 0.238, 347, 252, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
4048, 4bhnA, 0.7500, 2.75, 0.218, 256, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4049, 3rkbA, 0.7500, 3.16, 0.228, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
4050, 3pp1A, 0.7500, 3.27, 0.225, 291, 253, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
4051, 3ow4A, 0.7500, 2.93, 0.252, 317, 246, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
4052, 3hv5A, 0.7500, 3.00, 0.241, 339, 245, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
4053, 2gu8A, 0.7500, 3.38, 0.245, 335, 253, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
4054, 2fumB, 0.7500, 2.74, 0.219, 262, 242, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4055, 2fa2A, 0.7500, 2.72, 0.259, 333, 243, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
4056, 2f49B, 0.7500, 2.84, 0.258, 337, 244, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
4057, 1q8uA, 0.7500, 3.35, 0.237, 341, 253, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
4058, 6b5jC, 0.7499, 2.28, 0.267, 260, 232, TNNI3K COMPLEXED WITH A 46-DIAMINOPYRIMIDINE
4059, 5othA, 0.7499, 3.13, 0.170, 326, 247, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
4060, 5cu3A, 0.7499, 3.08, 0.175, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
4061, 5a4qB, 0.7499, 3.19, 0.220, 335, 245, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
4062, 5a4eB, 0.7499, 3.22, 0.216, 322, 245, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
4063, 4erwA, 0.7499, 3.13, 0.237, 292, 249, CDK2 IN COMPLEX WITH STAUROSPORINE
4064, 3sdjM, 0.7499, 2.98, 0.226, 415, 243, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4065, 3sdjF, 0.7499, 2.98, 0.226, 415, 243, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4066, 3ow3A, 0.7499, 3.38, 0.241, 334, 253, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
4067, 3gu5A, 0.7499, 3.20, 0.217, 280, 249, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
4068, 3fbvG, 0.7499, 3.06, 0.216, 415, 245, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4069, 3fbvA, 0.7499, 3.06, 0.216, 415, 245, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4070, 2x39A, 0.7499, 3.03, 0.227, 316, 247, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
4071, 2c5yA, 0.7499, 3.13, 0.229, 290, 249, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
4072, 1w7hA, 0.7499, 3.46, 0.237, 351, 253, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4073, 1q24A, 0.7499, 3.37, 0.233, 335, 253, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
4074, 5otiA, 0.7498, 3.13, 0.170, 327, 247, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 27
4075, 5nxcL, 0.7498, 3.21, 0.280, 274, 250, LIM DOMAIN KINASE 1 (LIMK1) IN COMPLEX WITH PF-00477736
4076, 5n3oA, 0.7498, 3.24, 0.239, 335, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-(13-OXAZOL-5-YL)ANILINE
4077, 5mo6A, 0.7498, 3.06, 0.167, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
4078, 4xw6A, 0.7498, 3.32, 0.238, 334, 252, X-RAY STRUCTURE OF PKAC WITH ADP FREE PHOSPHATE ION CP20 MAGNESIUM IONS
4079, 4nctA, 0.7498, 3.18, 0.212, 341, 245, HUMAN DYRK1A IN COMPLEX WITH PKC412
4080, 4mwhA, 0.7498, 3.21, 0.173, 371, 249, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
4081, 4jdhA, 0.7498, 3.24, 0.191, 289, 251, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
4082, 4fi1A, 0.7498, 3.20, 0.173, 371, 249, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
4083, 3sdmG, 0.7498, 3.07, 0.216, 415, 245, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4084, 3sdmF, 0.7498, 3.07, 0.216, 415, 245, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4085, 3sdmE, 0.7498, 3.07, 0.216, 415, 245, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4086, 3sdmD, 0.7498, 3.07, 0.216, 415, 245, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4087, 3sdmC, 0.7498, 3.07, 0.216, 415, 245, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4088, 3sdmB, 0.7498, 3.07, 0.216, 415, 245, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4089, 3sdmA, 0.7498, 3.07, 0.216, 415, 245, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4090, 3sdjE, 0.7498, 2.98, 0.226, 415, 243, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4091, 3sdjB, 0.7498, 2.95, 0.222, 415, 243, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4092, 3fbvL, 0.7498, 3.07, 0.216, 415, 245, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4093, 3fbvH, 0.7498, 3.06, 0.216, 415, 245, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4094, 3fbvB, 0.7498, 3.07, 0.216, 415, 245, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4095, 3e8eB, 0.7498, 3.36, 0.237, 337, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
4096, 3bx5A, 0.7498, 2.96, 0.226, 338, 243, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
4097, 3bhhD, 0.7498, 2.99, 0.207, 286, 246, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
4098, 6ginA, 0.7497, 2.74, 0.279, 296, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH AN QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 4-MORPHOLINOPHENYL SOLVENT ACCESSIBLE GROUP. 
4099, 5ehyA, 0.7497, 2.84, 0.169, 255, 242, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4100, 5ctpA, 0.7497, 3.08, 0.167, 324, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
4101, 4xrjA, 0.7497, 2.80, 0.202, 344, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4102, 4xj0A, 0.7497, 2.88, 0.206, 345, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
4103, 4js8A, 0.7497, 2.88, 0.168, 259, 244, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
4104, 4ib3A, 0.7497, 3.33, 0.238, 336, 252, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH ADP PHOSPHORYLATED PEPTIDE PSP20 AND NO METAL
4105, 4g6oA, 0.7497, 2.70, 0.203, 339, 241, CRYSTAL STRUCTURE OF THE ERK2
4106, 4an3A, 0.7497, 3.29, 0.217, 280, 254, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
4107, 3qtqA, 0.7497, 3.16, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
4108, 3ocbB, 0.7497, 3.04, 0.251, 319, 247, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
4109, 3nnxA, 0.7497, 2.93, 0.236, 336, 242, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
4110, 3fbvM, 0.7497, 3.06, 0.216, 415, 245, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4111, 2jdsA, 0.7497, 3.35, 0.234, 334, 252, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
4112, 1bl6A, 0.7497, 3.63, 0.243, 351, 255, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
4113, 6g9nA, 0.7496, 2.83, 0.210, 344, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4114, 5orjB, 0.7496, 3.06, 0.171, 324, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
4115, 5mowB, 0.7496, 3.08, 0.171, 324, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
4116, 4yfiC, 0.7496, 2.78, 0.269, 269, 238, TNNI3K COMPLEXED WITH INHIBITOR 1
4117, 4yfiA, 0.7496, 2.75, 0.261, 268, 238, TNNI3K COMPLEXED WITH INHIBITOR 1
4118, 4yffD, 0.7496, 2.47, 0.269, 257, 234, TNNI3K COMPLEXED WITH INHIBITOR 2
4119, 4o21A, 0.7496, 3.34, 0.238, 333, 252, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
4120, 4g6lA, 0.7496, 3.33, 0.205, 336, 249, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
4121, 3zuvA, 0.7496, 2.75, 0.207, 357, 241, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
4122, 3sdjL, 0.7496, 2.96, 0.222, 415, 243, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4123, 3sdjH, 0.7496, 2.96, 0.222, 415, 243, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4124, 3p0mA, 0.7496, 3.38, 0.241, 335, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
4125, 3mv5A, 0.7496, 3.12, 0.250, 315, 248, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
4126, 3fbvE, 0.7496, 3.07, 0.216, 415, 245, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4127, 3e8eL, 0.7496, 3.36, 0.237, 336, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
4128, 3dbeA, 0.7496, 3.36, 0.224, 284, 250, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 557
4129, 3bv3A, 0.7496, 2.80, 0.231, 338, 242, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
4130, 2gmxA, 0.7496, 2.84, 0.226, 357, 243, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
4131, 6ft8A, 0.7495, 3.38, 0.229, 338, 249, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 8G 
4132, 5oy6A, 0.7495, 2.66, 0.280, 291, 239, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4133, 5cwzC, 0.7495, 3.20, 0.224, 271, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
4134, 5aikC, 0.7495, 3.20, 0.211, 342, 246, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
4135, 4usfA, 0.7495, 3.48, 0.244, 277, 254, HUMAN SLK WITH SB-440719
4136, 4iacA, 0.7495, 3.35, 0.238, 333, 252, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION AMP-PCP AND PSEUDO-SUBSTRATE PEPTIDE SP20
4137, 3sdjN, 0.7495, 2.97, 0.222, 415, 243, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4138, 3sdjG, 0.7495, 2.96, 0.222, 415, 243, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4139, 3mvhA, 0.7495, 3.19, 0.250, 311, 248, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
4140, 5oy6C, 0.7494, 2.68, 0.280, 291, 239, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4141, 5objA, 0.7494, 3.01, 0.242, 260, 248, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
4142, 5nhfA, 0.7494, 2.82, 0.202, 339, 243, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
4143, 4zs0A, 0.7494, 2.98, 0.243, 257, 247, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
4144, 4iazA, 0.7494, 3.35, 0.238, 334, 252, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH BA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
4145, 3qzfA, 0.7494, 3.23, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
4146, 3flsA, 0.7494, 3.26, 0.226, 343, 248, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
4147, 2wu6A, 0.7494, 3.44, 0.228, 350, 250, CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH DKI
4148, 1ydtE, 0.7494, 3.29, 0.238, 334, 252, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
4149, 6g33B, 0.7493, 3.35, 0.230, 337, 248, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
4150, 5oryA, 0.7493, 3.10, 0.240, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4151, 5mpjB, 0.7493, 3.06, 0.171, 324, 246, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
4152, 4zthA, 0.7493, 2.85, 0.235, 339, 243, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
4153, 4yc6C, 0.7493, 3.06, 0.243, 285, 247, CDK1/CKS1
4154, 4xozA, 0.7493, 2.80, 0.202, 341, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4155, 4wnpB, 0.7493, 2.84, 0.270, 272, 244, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
4156, 3hmoA, 0.7493, 2.81, 0.165, 257, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
4157, 3d83A, 0.7493, 3.40, 0.243, 347, 251, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
4158, 6g92A, 0.7492, 2.84, 0.210, 343, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4159, 5ikwA, 0.7492, 2.94, 0.196, 297, 245, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
4160, 5he3A, 0.7492, 3.59, 0.182, 623, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
4161, 5a4tB, 0.7492, 3.20, 0.220, 339, 245, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
4162, 4wnoA, 0.7492, 2.87, 0.270, 272, 244, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
4163, 4s31A, 0.7492, 2.84, 0.205, 347, 244, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
4164, 3sdjA, 0.7492, 3.07, 0.216, 415, 245, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4165, 3r9dA, 0.7492, 3.18, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
4166, 3nr9B, 0.7492, 3.23, 0.219, 347, 247, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
4167, 3mwuA, 0.7492, 3.27, 0.227, 447, 251, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-95
4168, 2jdoA, 0.7492, 3.04, 0.227, 314, 247, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
4169, 1zmvB, 0.7492, 2.58, 0.248, 296, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
4170, 1q8tA, 0.7492, 3.37, 0.237, 338, 253, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
4171, 6b1uC, 0.7491, 2.99, 0.245, 459, 245, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
4172, 5a4eA, 0.7491, 3.19, 0.212, 341, 245, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
4173, 4ae6A, 0.7491, 3.28, 0.242, 319, 252, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
4174, 3mblA, 0.7491, 3.43, 0.219, 290, 256, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
4175, 3eqfA, 0.7491, 3.29, 0.226, 314, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
4176, 5a4tA, 0.7490, 3.18, 0.212, 341, 245, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
4177, 4y5qA, 0.7490, 3.28, 0.227, 449, 251, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH AMP
4178, 4xp3A, 0.7490, 2.83, 0.210, 339, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4179, 4jboA, 0.7490, 3.19, 0.243, 266, 251, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
4180, 4iirA, 0.7490, 3.08, 0.197, 325, 244, CRYSTAL STRUCTURE OF AMPPNP-BOUND HUMAN PRPF4B KINASE DOMAIN
4181, 3s3iA, 0.7490, 3.44, 0.230, 349, 252, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4182, 3rawB, 0.7490, 3.46, 0.232, 349, 250, CRYSTAL STRUCTURE OF HUMAN CDC-LIKE KINASE 3 ISOFORM IN COMPLEX WITH LEUCETTINE L41
4183, 2wo6B, 0.7490, 3.06, 0.217, 339, 244, HUMAN DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A IN COMPLEX WITH A CONSENSUS SUBSTRATE PEPTIDE
4184, 2bujB, 0.7490, 3.09, 0.206, 286, 248, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
4185, 1jktA, 0.7490, 3.26, 0.220, 276, 250, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
4186, 6eiiA, 0.7489, 3.07, 0.175, 326, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
4187, 5ot5B, 0.7489, 3.09, 0.167, 325, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
4188, 5hgiA, 0.7489, 3.25, 0.216, 395, 245, CRYSTAL STRUCTURE OF APO HUMAN IRE1 ALPHA
4189, 5cvfA, 0.7489, 3.08, 0.175, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
4190, 4iirB, 0.7489, 3.05, 0.198, 327, 243, CRYSTAL STRUCTURE OF AMPPNP-BOUND HUMAN PRPF4B KINASE DOMAIN
4191, 3rniA, 0.7489, 3.24, 0.231, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
4192, 3rm7A, 0.7489, 3.28, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
4193, 3rk5A, 0.7489, 3.18, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
4194, 3qamE, 0.7489, 3.38, 0.237, 348, 253, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
4195, 2bcjA, 0.7489, 3.60, 0.190, 624, 258, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
4196, 2b52A, 0.7489, 3.11, 0.227, 283, 247, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
4197, 1wvwA, 0.7489, 3.17, 0.217, 275, 249, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
4198, 5otdA, 0.7488, 3.15, 0.170, 327, 247, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
4199, 5lpvA, 0.7488, 2.96, 0.272, 282, 243, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH AMPPNP AND MN FROM ARABIDOPSIS THALIANA
4200, 5dr2A, 0.7488, 3.02, 0.245, 264, 249, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
4201, 5a54A, 0.7488, 3.20, 0.216, 341, 245, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
4202, 5a4qA, 0.7488, 3.18, 0.212, 341, 245, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
4203, 4mq1A, 0.7488, 3.15, 0.216, 345, 245, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
4204, 4iayA, 0.7488, 3.36, 0.238, 333, 252, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
4205, 4fa2A, 0.7488, 2.88, 0.235, 339, 243, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
4206, 3qudA, 0.7488, 3.09, 0.232, 345, 246, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO-BENZOPHENONE
4207, 3nieA, 0.7488, 2.96, 0.191, 369, 246, CRYSTAL STRUCTURE OF PF11_0147
4208, 2gtnA, 0.7488, 2.85, 0.236, 337, 242, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
4209, 2ds1A, 0.7488, 3.13, 0.226, 290, 248, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4210, 1mq4A, 0.7488, 3.08, 0.240, 261, 250, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
4211, 6ginB, 0.7487, 2.76, 0.279, 296, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH AN QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 4-MORPHOLINOPHENYL SOLVENT ACCESSIBLE GROUP. 
4212, 5vcwB, 0.7487, 3.05, 0.191, 285, 246, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PELITINIB
4213, 5otoA, 0.7487, 3.16, 0.170, 327, 247, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
4214, 5oquB, 0.7487, 3.08, 0.171, 324, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
4215, 5j1wA, 0.7487, 3.51, 0.224, 338, 250, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
4216, 5he1A, 0.7487, 3.58, 0.190, 618, 258, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
4217, 4g6nA, 0.7487, 2.84, 0.202, 341, 243, CRYSTAL STRUCTURE OF THE ERK2
4218, 4dfzE, 0.7487, 3.35, 0.238, 347, 252, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
4219, 2vx3A, 0.7487, 3.11, 0.216, 346, 245, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
4220, 2vu3A, 0.7487, 3.06, 0.233, 285, 245, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4221, 1rdqE, 0.7487, 3.38, 0.241, 340, 253, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
4222, 6b5jA, 0.7486, 2.49, 0.274, 263, 234, TNNI3K COMPLEXED WITH A 46-DIAMINOPYRIMIDINE
4223, 5moeB, 0.7486, 3.01, 0.171, 323, 245, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
4224, 5ezvC, 0.7486, 3.01, 0.245, 440, 245, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
4225, 4yc6G, 0.7486, 3.06, 0.243, 285, 247, CDK1/CKS1
4226, 4byiA, 0.7486, 2.85, 0.244, 254, 246, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
4227, 3queA, 0.7486, 3.04, 0.233, 343, 245, HUMAN P38 MAP KINASE IN COMPLEX WITH SKEPINONE-L
4228, 3qqfA, 0.7486, 3.28, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR L1
4229, 3fklA, 0.7486, 3.25, 0.245, 344, 249, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
4230, 6g9kA, 0.7485, 2.77, 0.207, 343, 242, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4231, 5oseA, 0.7485, 3.12, 0.240, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4232, 5mxxA, 0.7485, 3.01, 0.193, 361, 244, CRYSTAL STRUCTURE OF HUMAN SR PROTEIN KINASE 1 (SRPK1) IN COMPLEX WITH COMPOUND 1
4233, 5j1wB, 0.7485, 3.45, 0.225, 337, 249, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
4234, 4yljD, 0.7485, 3.14, 0.216, 347, 245, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
4235, 4mq1D, 0.7485, 3.12, 0.217, 336, 244, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
4236, 3r8uA, 0.7485, 3.23, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
4237, 3pxrA, 0.7485, 3.22, 0.227, 294, 251, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
4238, 3h9fA, 0.7485, 2.95, 0.171, 260, 245, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYRIMIDO-DIAZEPIN LIGAND
4239, 3c9wB, 0.7485, 2.62, 0.210, 336, 238, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
4240, 2v0dA, 0.7485, 3.17, 0.233, 292, 249, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
4241, 2gtmA, 0.7485, 3.02, 0.225, 341, 244, MUTATED MOUSE P38 MAP KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-892579
4242, 2fumD, 0.7485, 2.72, 0.223, 258, 242, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4243, 6gdmA, 0.7484, 2.75, 0.194, 341, 242, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4244, 5ot6B, 0.7484, 3.09, 0.171, 326, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
4245, 5lw1B, 0.7484, 2.86, 0.212, 355, 245, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
4246, 5ih9A, 0.7484, 2.72, 0.229, 308, 240, MELK IN COMPLEX WITH NVS-MELK8A
4247, 5c03B, 0.7484, 2.92, 0.287, 260, 244, CRYSTAL STRUCTURE OF KINASE
4248, 4y83B, 0.7484, 2.90, 0.189, 302, 244, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
4249, 4x6qC, 0.7484, 3.30, 0.238, 334, 252, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
4250, 4ntsA, 0.7484, 3.22, 0.236, 341, 250, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
4251, 4mq2A, 0.7484, 3.12, 0.216, 343, 245, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
4252, 3tnpF, 0.7484, 3.31, 0.238, 334, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
4253, 3tnpC, 0.7484, 3.31, 0.238, 334, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
4254, 3nieB, 0.7484, 2.98, 0.191, 367, 246, CRYSTAL STRUCTURE OF PF11_0147
4255, 3fjqE, 0.7484, 3.39, 0.241, 334, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
4256, 2w4jA, 0.7484, 3.22, 0.221, 276, 249, X-RAY STRUCTURE OF A DAP-KINASE 2-277
4257, 1y8yA, 0.7484, 3.13, 0.225, 292, 249, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
4258, 1h07A, 0.7484, 3.18, 0.229, 285, 249, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4259, 6bfnB, 0.7483, 3.52, 0.217, 294, 254, CRYSTAL STRUCTURE OF HUMAN IRAK1
4260, 5orzA, 0.7483, 3.12, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4261, 5obrA, 0.7483, 2.91, 0.244, 255, 246, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
4262, 5cu3B, 0.7483, 3.09, 0.175, 324, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
4263, 4yu2A, 0.7483, 3.16, 0.215, 348, 246, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
4264, 4d2tA, 0.7483, 2.99, 0.234, 316, 244, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4265, 4cvaA, 0.7483, 2.86, 0.174, 254, 242, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4266, 1yw2A, 0.7483, 3.01, 0.224, 341, 245, MUTATED MUS MUSCULUS P38 KINASE (MP38)
4267, 1h4lA, 0.7483, 2.66, 0.232, 278, 237, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
4268, 5uorA, 0.7482, 2.58, 0.234, 249, 235, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4269, 5cvgA, 0.7482, 2.94, 0.169, 326, 243, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
4270, 5a4lA, 0.7482, 3.20, 0.216, 341, 245, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
4271, 5a4eD, 0.7482, 3.12, 0.213, 331, 244, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
4272, 4yc6A, 0.7482, 3.12, 0.243, 285, 247, CDK1/CKS1
4273, 4pf4A, 0.7482, 3.19, 0.225, 278, 249, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
4274, 3gu6A, 0.7482, 3.22, 0.221, 280, 249, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
4275, 3c9wA, 0.7482, 2.70, 0.209, 336, 239, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
4276, 5orrA, 0.7481, 3.11, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4277, 5aikD, 0.7481, 3.15, 0.209, 342, 244, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
4278, 4wnpD, 0.7481, 2.77, 0.269, 272, 242, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
4279, 4cfeC, 0.7481, 3.00, 0.245, 403, 245, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
4280, 4au8B, 0.7481, 2.81, 0.246, 277, 240, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
4281, 4aguC, 0.7481, 2.75, 0.251, 278, 239, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
4282, 3w8lB, 0.7481, 3.09, 0.174, 326, 247, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
4283, 3d14A, 0.7481, 3.08, 0.245, 262, 249, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
4284, 2r3oA, 0.7481, 3.05, 0.227, 289, 247, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4285, 2no3A, 0.7481, 2.80, 0.219, 357, 242, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
4286, 1apmE, 0.7481, 3.38, 0.237, 338, 253, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
4287, 5o90A, 0.7480, 2.89, 0.223, 330, 242, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
4288, 5j1vB, 0.7480, 3.45, 0.221, 337, 249, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
4289, 3ql8A, 0.7480, 3.25, 0.231, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
4290, 3dgkA, 0.7480, 3.21, 0.221, 278, 249, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
4291, 2ozaB, 0.7480, 2.83, 0.226, 340, 243, STRUCTURE OF P38ALPHA COMPLEX
4292, 2i0hA, 0.7480, 3.39, 0.222, 349, 252, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH AN ARYLPYRIDAZINONE
4293, 2c69A, 0.7480, 3.21, 0.228, 292, 250, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
4294, 5osfA, 0.7479, 3.12, 0.240, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4295, 5os1A, 0.7479, 3.13, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4296, 4u7zA, 0.7479, 3.23, 0.227, 291, 251, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
4297, 4rvtB, 0.7479, 3.77, 0.209, 297, 263, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
4298, 4jaiA, 0.7479, 2.90, 0.241, 249, 245, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH N-{4-[(6-OXO-56- DIHYDROBENZO[C][18]NAPHTHYRIDIN-1-YL)AMINO]PHENYL}BENZAMIDE
4299, 4bi0A, 0.7479, 2.75, 0.170, 254, 241, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4300, 3rpvA, 0.7479, 3.12, 0.221, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
4301, 3r8lA, 0.7479, 3.15, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L3-4
4302, 3r1yA, 0.7479, 3.23, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
4303, 3qu0A, 0.7479, 3.16, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
4304, 2c6iA, 0.7479, 3.11, 0.230, 292, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
4305, 5orvA, 0.7478, 3.12, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4306, 5orpA, 0.7478, 3.13, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4307, 4nctB, 0.7478, 3.22, 0.212, 333, 245, HUMAN DYRK1A IN COMPLEX WITH PKC412
4308, 4jdkA, 0.7478, 3.32, 0.195, 288, 251, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
4309, 4dh8A, 0.7478, 3.36, 0.238, 333, 252, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20
4310, 3s0oA, 0.7478, 3.21, 0.227, 293, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
4311, 3qqkA, 0.7478, 3.11, 0.225, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L4
4312, 3fhiA, 0.7478, 3.38, 0.241, 336, 253, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
4313, 2vx3D, 0.7478, 3.09, 0.217, 342, 244, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
4314, 5orsA, 0.7477, 3.13, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4315, 5nadA, 0.7477, 2.72, 0.170, 256, 241, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
4316, 5ci7A, 0.7477, 2.79, 0.273, 276, 242, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
4317, 4ztrA, 0.7477, 2.85, 0.245, 249, 245, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
4318, 4u40B, 0.7477, 3.77, 0.217, 299, 263, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
4319, 4nctC, 0.7477, 3.18, 0.213, 339, 244, HUMAN DYRK1A IN COMPLEX WITH PKC412
4320, 4eklA, 0.7477, 2.95, 0.252, 329, 246, AKT1 WITH GDC0068
4321, 4dglD, 0.7477, 3.16, 0.181, 328, 249, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
4322, 3fmkA, 0.7477, 3.43, 0.227, 346, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
4323, 5os3A, 0.7476, 3.13, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4324, 5orwA, 0.7476, 3.12, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4325, 5lw1H, 0.7476, 2.89, 0.216, 355, 245, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
4326, 4bggC, 0.7476, 2.70, 0.282, 279, 238, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4327, 3sqqA, 0.7476, 3.12, 0.221, 288, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
4328, 3pvbA, 0.7476, 3.33, 0.242, 341, 252, CRYSTAL STRUCTURE OF (73-244)RIA:C HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
4329, 3o71A, 0.7476, 2.90, 0.201, 340, 244, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
4330, 3lhjA, 0.7476, 3.17, 0.228, 341, 246, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
4331, 2c6oA, 0.7476, 3.14, 0.225, 290, 249, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
4332, 2c6kA, 0.7476, 3.21, 0.228, 292, 250, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
4333, 1jklA, 0.7476, 3.22, 0.225, 280, 249, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
4334, 6eiiB, 0.7475, 3.10, 0.175, 326, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
4335, 5vjaC, 0.7475, 2.93, 0.209, 265, 244, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
4336, 5ornA, 0.7475, 3.11, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4337, 5nxdA, 0.7475, 2.81, 0.292, 271, 240, LIM DOMAIN KINASE 2 (LIMK2) IN COMPLEX WITH TH-300
4338, 5m5aA, 0.7475, 2.73, 0.228, 315, 241, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4339, 5j1wC, 0.7475, 3.48, 0.225, 316, 249, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
4340, 5a4lC, 0.7475, 3.18, 0.217, 332, 244, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
4341, 4wb5A, 0.7475, 3.37, 0.238, 335, 252, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
4342, 4ib1A, 0.7475, 3.37, 0.242, 335, 252, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH K+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
4343, 4bc6A, 0.7475, 3.09, 0.243, 285, 243, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
4344, 3vw6A, 0.7475, 2.75, 0.218, 255, 238, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
4345, 3qywA, 0.7475, 2.87, 0.206, 340, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4346, 3npcA, 0.7475, 3.12, 0.211, 357, 246, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
4347, 3anqD, 0.7475, 3.17, 0.217, 334, 244, HUMAN DYRK1A/INHIBITOR COMPLEX
4348, 2b9fA, 0.7475, 3.00, 0.257, 337, 245, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
4349, 1z57A, 0.7475, 3.41, 0.225, 333, 249, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH 10Z-HYMENIALDISINE
4350, 1fmoE, 0.7475, 3.40, 0.241, 336, 253, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
4351, 1b38A, 0.7475, 3.14, 0.234, 290, 248, HUMAN CYCLIN-DEPENDENT KINASE 2
4352, 6b4wA, 0.7474, 3.04, 0.175, 259, 246, TTK IN COMPLEX WITH INHIBITOR
4353, 5twzA, 0.7474, 2.66, 0.221, 313, 240, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
4354, 5j1vA, 0.7474, 3.52, 0.224, 338, 250, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
4355, 5ihcA, 0.7474, 2.44, 0.224, 305, 237, MELK IN COMPLEX WITH NVS-MELK12B
4356, 5a54D, 0.7474, 3.06, 0.215, 334, 242, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
4357, 4mq1B, 0.7474, 3.10, 0.221, 340, 244, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
4358, 4dfxE, 0.7474, 3.37, 0.238, 347, 252, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
4359, 4bieA, 0.7474, 2.75, 0.223, 257, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4360, 3rjcA, 0.7474, 3.19, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L4-12
4361, 2vx3B, 0.7474, 3.11, 0.217, 340, 244, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
4362, 1gz8A, 0.7474, 3.09, 0.226, 290, 248, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
4363, 5os0A, 0.7473, 3.13, 0.240, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4364, 5jt2B, 0.7473, 2.74, 0.317, 251, 240, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4365, 5a14A, 0.7473, 3.19, 0.252, 284, 246, HUMAN CDK2 WITH TYPE II INHIBITOR
4366, 4l8mA, 0.7473, 3.02, 0.230, 339, 244, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOXEPINONE
4367, 3w1fA, 0.7473, 2.90, 0.164, 259, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
4368, 3vn9A, 0.7473, 3.95, 0.228, 291, 263, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
4369, 3ti1A, 0.7473, 3.17, 0.232, 294, 250, CDK2 IN COMPLEX WITH SUNITINIB
4370, 3qtzA, 0.7473, 3.12, 0.225, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
4371, 2c6mA, 0.7473, 3.13, 0.226, 290, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
4372, 1zz2A, 0.7473, 3.07, 0.234, 337, 244, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
4373, 5x3fB, 0.7472, 3.16, 0.233, 348, 249, CRYSTAL STRUCTURE OF THE YGJG-PROTEIN A-ZPA963-PKA CATALYTIC DOMAIN
4374, 5vefA, 0.7472, 3.28, 0.191, 289, 251, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
4375, 5otfA, 0.7472, 3.61, 0.198, 411, 257, MRCK BETA IN COMPLEX WITH BDP-00009066
4376, 5orxA, 0.7472, 3.13, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4377, 5i3oA, 0.7472, 2.97, 0.196, 302, 245, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
4378, 5a4tD, 0.7472, 3.23, 0.217, 332, 244, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
4379, 5a4lD, 0.7472, 3.16, 0.213, 334, 244, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
4380, 4yo4A, 0.7472, 3.22, 0.225, 280, 249, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
4381, 4y83A, 0.7472, 2.90, 0.189, 299, 244, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
4382, 4o0uA, 0.7472, 3.01, 0.237, 259, 249, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
4383, 4mk0A, 0.7472, 3.57, 0.183, 631, 257, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH A A RATIONALLY DESIGNED PAROXETINE DERIVATIVE
4384, 4fijA, 0.7472, 3.29, 0.195, 291, 251, CATALYTIC DOMAIN OF HUMAN PAK4
4385, 4fihA, 0.7472, 3.29, 0.191, 291, 251, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
4386, 4b8lA, 0.7472, 2.72, 0.215, 249, 242, AURORA B KINASE P353G MUTANT
4387, 3w55A, 0.7472, 2.80, 0.216, 335, 241, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
4388, 3tiyA, 0.7472, 3.19, 0.232, 293, 250, CDK2 IN COMPLEX WITH NSC 35676
4389, 3h0zC, 0.7472, 2.68, 0.236, 246, 242, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4390, 3gu4A, 0.7472, 3.24, 0.217, 280, 249, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
4391, 3cquA, 0.7472, 3.04, 0.251, 318, 247, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
4392, 3a8wB, 0.7472, 3.26, 0.213, 327, 249, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
4393, 2uzoA, 0.7472, 3.10, 0.230, 290, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
4394, 1e1vA, 0.7472, 3.05, 0.227, 290, 247, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
4395, 1blxA, 0.7472, 3.61, 0.195, 305, 256, P19INK4D/CDK6 COMPLEX
4396, 5oroA, 0.7471, 3.13, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4397, 5ci6B, 0.7471, 2.68, 0.217, 350, 240, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
4398, 5anjA, 0.7471, 3.20, 0.233, 291, 249, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4399, 4rj3A, 0.7471, 3.14, 0.226, 287, 248, CDK2 WITH EGFR INHIBITOR COMPOUND 8
4400, 4qp1A, 0.7471, 2.84, 0.206, 342, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
4401, 4n4sA, 0.7471, 2.90, 0.201, 342, 244, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
4402, 4ib0A, 0.7471, 3.37, 0.238, 334, 252, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH NA+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
4403, 4cffC, 0.7471, 3.01, 0.245, 422, 245, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
4404, 4aguB, 0.7471, 2.76, 0.247, 276, 239, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
4405, 3r9hA, 0.7471, 3.19, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
4406, 3pj8A, 0.7471, 3.29, 0.233, 288, 249, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
4407, 3flqA, 0.7471, 3.34, 0.225, 345, 249, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
4408, 2c6eB, 0.7471, 2.73, 0.240, 246, 242, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
4409, 5othB, 0.7470, 3.12, 0.171, 324, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
4410, 5kbqA, 0.7470, 3.46, 0.233, 289, 253, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
4411, 5jzjA, 0.7470, 2.84, 0.232, 271, 241, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
4412, 5dr9A, 0.7470, 2.90, 0.244, 257, 246, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
4413, 5dr6A, 0.7470, 2.91, 0.244, 257, 246, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
4414, 5c03A, 0.7470, 2.88, 0.288, 260, 243, CRYSTAL STRUCTURE OF KINASE
4415, 5ap4A, 0.7470, 2.93, 0.169, 257, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4416, 5a4qD, 0.7470, 3.17, 0.213, 334, 244, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
4417, 4yu2D, 0.7470, 3.14, 0.216, 346, 245, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
4418, 4yljC, 0.7470, 3.16, 0.220, 346, 245, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
4419, 4fiiA, 0.7470, 3.30, 0.195, 291, 251, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
4420, 4cfeA, 0.7470, 3.01, 0.245, 425, 245, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
4421, 3r8zA, 0.7470, 3.21, 0.232, 290, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
4422, 3gu8A, 0.7470, 3.22, 0.225, 278, 249, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
4423, 3gu7A, 0.7470, 3.25, 0.221, 280, 249, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
4424, 3bhhC, 0.7470, 2.99, 0.208, 285, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
4425, 2vtlA, 0.7470, 3.14, 0.230, 290, 248, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4426, 2qcsA, 0.7470, 3.35, 0.238, 335, 252, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
4427, 2nryB, 0.7470, 3.04, 0.273, 286, 242, CRYSTAL STRUCTURE OF IRAK-4
4428, 1pxoA, 0.7470, 3.24, 0.223, 294, 251, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
4429, 3wzkA, 0.7469, 2.86, 0.165, 258, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
4430, 3lfnA, 0.7469, 3.20, 0.230, 285, 248, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
4431, 3h0zA, 0.7469, 2.79, 0.246, 248, 244, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4432, 3gc0A, 0.7469, 2.75, 0.203, 278, 241, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
4433, 2hakD, 0.7469, 2.93, 0.261, 309, 245, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4434, 6g33C, 0.7468, 3.46, 0.229, 336, 249, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
4435, 5w7tA, 0.7468, 3.20, 0.264, 276, 250, STRUCTURE OF PHOSPHORYLATED WNK1 
4436, 5oteA, 0.7468, 3.60, 0.195, 407, 257, MRCK BETA IN COMPLEX WITH BDP-00008900
4437, 5osmA, 0.7468, 3.42, 0.227, 292, 251, CDK2(F80C C177A) WITH COVALENT ADDUCT AT C80
4438, 5orkB, 0.7468, 3.05, 0.176, 323, 245, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
4439, 4ualA, 0.7468, 3.47, 0.204, 403, 255, MRCK BETA IN COMPLEX WITH BDP00005290
4440, 4ekkB, 0.7468, 3.15, 0.250, 318, 248, AKT1 WITH AMP-PNP
4441, 4cffA, 0.7468, 2.92, 0.242, 424, 244, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
4442, 4aw2A, 0.7468, 3.52, 0.184, 398, 256, CRYSTAL STRUCTURE OF CDC42 BINDING PROTEIN KINASE ALPHA (MRCK ALPHA)
4443, 3qtuA, 0.7468, 3.14, 0.225, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
4444, 3qalE, 0.7468, 3.40, 0.237, 339, 253, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
4445, 3dfcB, 0.7468, 3.24, 0.217, 280, 249, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
4446, 1pmeA, 0.7468, 2.71, 0.204, 333, 240, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
4447, 6ft9A, 0.7467, 3.46, 0.225, 336, 249, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
4448, 5otoB, 0.7467, 3.13, 0.167, 324, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
4449, 5ap0A, 0.7467, 2.61, 0.167, 254, 239, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4450, 5a54C, 0.7467, 3.18, 0.217, 332, 244, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
4451, 4yu2B, 0.7467, 3.16, 0.216, 347, 245, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
4452, 4umpD, 0.7467, 2.96, 0.221, 321, 244, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4453, 4ehvA, 0.7467, 2.93, 0.222, 337, 243, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
4454, 4eh3A, 0.7467, 2.82, 0.227, 339, 242, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F2 AND RL87
4455, 4azeB, 0.7467, 3.16, 0.216, 345, 245, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
4456, 4azeA, 0.7467, 3.16, 0.216, 348, 245, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
4457, 4aaaA, 0.7467, 3.32, 0.279, 295, 251, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
4458, 3zhpC, 0.7467, 3.51, 0.239, 272, 255, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
4459, 3q9zA, 0.7467, 3.37, 0.175, 332, 251, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
4460, 2no3B, 0.7467, 2.98, 0.230, 357, 244, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
4461, 1ol7A, 0.7467, 3.07, 0.237, 261, 249, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
4462, 5v19A, 0.7466, 2.65, 0.247, 250, 235, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
4463, 5myvB, 0.7466, 3.04, 0.189, 349, 244, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
4464, 5jznB, 0.7466, 2.90, 0.223, 266, 242, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
4465, 4yljB, 0.7466, 3.08, 0.221, 347, 244, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
4466, 4bi2A, 0.7466, 2.83, 0.174, 253, 242, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4467, 3ow4B, 0.7466, 2.98, 0.252, 317, 246, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
4468, 3o7lB, 0.7466, 3.30, 0.240, 326, 250, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
4469, 3cikA, 0.7466, 3.53, 0.183, 619, 257, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
4470, 2vtrA, 0.7466, 3.16, 0.230, 290, 248, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4471, 2h96B, 0.7466, 2.95, 0.230, 357, 244, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
4472, 1zmuA, 0.7466, 2.37, 0.251, 293, 235, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
4473, 1wfcA, 0.7466, 3.16, 0.220, 340, 246, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
4474, 1ig1A, 0.7466, 3.24, 0.221, 280, 249, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
4475, 5lw1E, 0.7465, 2.90, 0.216, 355, 245, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
4476, 4iadA, 0.7465, 3.29, 0.239, 334, 251, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
4477, 2w1zB, 0.7465, 3.40, 0.122, 358, 254, ROP2 FROM TOXOPLASMA GONDII:  A VIRULENCE FACTOR WITH A PROTEIN-KINASE FOLD AND NO ENZYMATIC ACTIVITY.
4478, 2vtmA, 0.7465, 3.15, 0.230, 290, 248, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4479, 2jdrA, 0.7465, 2.95, 0.228, 316, 246, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
4480, 2fumA, 0.7465, 2.76, 0.220, 263, 241, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4481, 1f3mD, 0.7465, 3.35, 0.221, 285, 253, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
4482, 5dzcA, 0.7464, 3.54, 0.231, 816, 255, CRYSTAL STRUCTURE OF PVX_084705 IN COMPLEX WITH AMP-PNP
4483, 5a4qC, 0.7464, 3.19, 0.213, 332, 244, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
4484, 4ypdA, 0.7464, 3.24, 0.225, 281, 249, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
4485, 4mq2D, 0.7464, 3.12, 0.221, 329, 244, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
4486, 4hpuE, 0.7464, 3.39, 0.238, 336, 252, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING PARTIAL PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
4487, 4azeC, 0.7464, 3.16, 0.216, 348, 245, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
4488, 3o8uA, 0.7464, 2.74, 0.222, 332, 239, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4489, 3flnC, 0.7464, 3.40, 0.225, 343, 249, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
4490, 2wtwA, 0.7464, 2.86, 0.245, 256, 245, AURORA-A INHIBITOR STRUCTURE (2ND CRYSTAL FORM)
4491, 2uw9A, 0.7464, 3.07, 0.227, 316, 247, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
4492, 2qg5D, 0.7464, 3.38, 0.187, 283, 251, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
4493, 1ym7C, 0.7464, 3.59, 0.178, 607, 258, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
4494, 1bmkA, 0.7464, 3.56, 0.237, 351, 253, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
4495, 5u6yL, 0.7463, 3.11, 0.234, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4496, 5u6yK, 0.7463, 3.11, 0.234, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4497, 5u6yJ, 0.7463, 3.11, 0.234, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4498, 5u6yI, 0.7463, 3.11, 0.234, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4499, 5u6yH, 0.7463, 3.11, 0.234, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4500, 5u6yG, 0.7463, 3.11, 0.234, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4501, 5u6yF, 0.7463, 3.11, 0.234, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4502, 5u6yE, 0.7463, 3.11, 0.234, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4503, 5u6yD, 0.7463, 3.11, 0.234, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4504, 5u6yC, 0.7463, 3.11, 0.234, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4505, 5u6yB, 0.7463, 3.11, 0.234, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4506, 5u6yA, 0.7463, 3.11, 0.234, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4507, 5na0A, 0.7463, 2.79, 0.174, 253, 241, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
4508, 5lckA, 0.7463, 2.78, 0.215, 345, 242, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
4509, 5dosA, 0.7463, 3.02, 0.243, 259, 247, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
4510, 5av2A, 0.7463, 3.19, 0.226, 275, 248, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
4511, 4yljA, 0.7463, 3.16, 0.220, 346, 245, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
4512, 4y85C, 0.7463, 2.99, 0.184, 303, 245, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
4513, 4xv3B, 0.7463, 1.87, 0.330, 238, 227, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7922
4514, 4o6lB, 0.7463, 2.59, 0.162, 256, 240, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4515, 4m66B, 0.7463, 2.62, 0.260, 265, 235, CRYSTAL STRUCTURE OF THE MOUSE RIP3 KINASE DOMAIN
4516, 4dh7A, 0.7463, 3.30, 0.239, 333, 251, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20 
4517, 4dh3A, 0.7463, 3.37, 0.238, 333, 252, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ATP AND IP20
4518, 3s00A, 0.7463, 3.30, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR L4-14
4519, 3qklA, 0.7463, 3.08, 0.251, 317, 247, SPIROCHROMANE AKT INHIBITORS
4520, 3iggA, 0.7463, 3.02, 0.220, 290, 246, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
4521, 3eqdA, 0.7463, 3.31, 0.226, 315, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
4522, 2vx3C, 0.7463, 3.12, 0.221, 338, 244, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
4523, 1pxlA, 0.7463, 3.04, 0.224, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
4524, 1bl7A, 0.7463, 3.62, 0.241, 351, 253, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
4525, 1atpE, 0.7463, 3.32, 0.242, 334, 252, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
4526, 5cs6A, 0.7462, 3.17, 0.170, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
4527, 5av3A, 0.7462, 3.20, 0.222, 275, 248, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
4528, 5av1A, 0.7462, 3.19, 0.226, 275, 248, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
4529, 4jdjA, 0.7462, 3.24, 0.196, 288, 250, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
4530, 4gv1A, 0.7462, 3.12, 0.250, 329, 248, PKB ALPHA IN COMPLEX WITH AZD5363
4531, 4dg3E, 0.7462, 3.38, 0.238, 335, 252, CRYSTAL STRUCTURE OF R336A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED TURN MOTIF.
4532, 4d2pC, 0.7462, 2.91, 0.227, 316, 242, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4533, 3qyzA, 0.7462, 2.89, 0.206, 339, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4534, 3ncgA, 0.7462, 3.27, 0.228, 426, 250, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR NM-PP1
4535, 1ym7B, 0.7462, 3.59, 0.178, 608, 258, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
4536, 1jksA, 0.7462, 3.25, 0.221, 280, 249, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
4537, 5otdB, 0.7461, 3.13, 0.167, 324, 246, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
4538, 5g15A, 0.7461, 3.18, 0.221, 265, 249, STRUCTURE AURORA A (122-403) BOUND TO ACTIVATING MONOBODY MB1 AND AMPPCP
4539, 5dpvA, 0.7461, 2.92, 0.244, 257, 246, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
4540, 4prjA, 0.7461, 2.83, 0.245, 251, 245, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
4541, 4mq2B, 0.7461, 3.12, 0.217, 338, 244, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
4542, 4m97A, 0.7461, 3.75, 0.236, 465, 263, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM NEOSPORA CANINUM
4543, 3p7aA, 0.7461, 2.72, 0.222, 332, 239, P38 INHIBITOR-BOUND
4544, 3eqiA, 0.7461, 3.31, 0.226, 315, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
4545, 3dv3A, 0.7461, 3.29, 0.232, 288, 250, MEK1 WITH PF-04622664 BOUND
4546, 3anrD, 0.7461, 3.16, 0.213, 340, 244, HUMAN DYRK1A/HARMINE COMPLEX
4547, 1jkkA, 0.7461, 3.25, 0.221, 277, 249, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
4548, 5lpzA, 0.7460, 3.11, 0.263, 283, 243, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1196) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
4549, 5l2qD, 0.7460, 3.19, 0.165, 294, 249, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
4550, 4umpB, 0.7460, 2.96, 0.230, 324, 243, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4551, 4u43B, 0.7460, 3.79, 0.221, 302, 262, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
4552, 4ae9A, 0.7460, 3.29, 0.239, 321, 251, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
4553, 3mvjA, 0.7460, 3.39, 0.241, 334, 253, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
4554, 1ym7A, 0.7460, 3.60, 0.182, 608, 258, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
4555, 1h0vA, 0.7460, 3.14, 0.226, 288, 248, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
4556, 1b39A, 0.7460, 3.15, 0.234, 290, 248, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
4557, 5kkrB, 0.7459, 3.38, 0.217, 272, 253, KSR2:MEK1 COMPLEX BOUND TO THE SMALL MOLECULE APS-2-79
4558, 5i3rA, 0.7459, 2.99, 0.196, 302, 245, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
4559, 5dt4A, 0.7459, 3.02, 0.243, 259, 247, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
4560, 4oh4A, 0.7459, 3.06, 0.263, 299, 243, CRYSTAL STRUCTURE OF BRI1 IN COMPLEX WITH BKI1
4561, 4ek3A, 0.7459, 3.11, 0.231, 287, 247, CRYSTAL STRUCTURE OF APO CDK2
4562, 4dhfA, 0.7459, 3.05, 0.243, 258, 247, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
4563, 4c4fA, 0.7459, 2.86, 0.174, 254, 242, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4564, 4aguA, 0.7459, 2.78, 0.251, 277, 239, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
4565, 3pscA, 0.7459, 3.55, 0.183, 614, 257, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
4566, 3dlsB, 0.7459, 3.00, 0.227, 280, 242, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
4567, 3a7gA, 0.7459, 3.12, 0.256, 289, 250, HUMAN MST3 KINASE
4568, 2wu7A, 0.7459, 3.47, 0.228, 348, 250, CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH V25
4569, 5os6A, 0.7458, 3.15, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4570, 4l67A, 0.7458, 3.39, 0.190, 289, 252, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
4571, 3npcB, 0.7458, 3.06, 0.212, 356, 245, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
4572, 2r3pA, 0.7458, 3.08, 0.227, 289, 247, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4573, 2cpkE, 0.7458, 3.30, 0.239, 333, 251, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
4574, 2cdzA, 0.7458, 3.28, 0.192, 289, 250, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
4575, 2c6lA, 0.7458, 3.19, 0.229, 291, 249, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
4576, 6ft9C, 0.7457, 3.39, 0.226, 337, 248, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
4577, 5y9mA, 0.7457, 2.99, 0.160, 320, 244, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
4578, 5os4A, 0.7457, 3.15, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4579, 5jr7C, 0.7457, 3.27, 0.239, 335, 251, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
4580, 5c01B, 0.7457, 2.91, 0.296, 260, 243, CRYSTAL STRUCTURE OF KINASE
4581, 5ap3A, 0.7457, 2.83, 0.170, 253, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4582, 5a4tC, 0.7457, 3.14, 0.214, 332, 243, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
4583, 4zp5B, 0.7457, 3.81, 0.218, 300, 262, MAP4K4 IN COMPLEX WITH INHIBITOR
4584, 4zhxC, 0.7457, 2.93, 0.242, 452, 244, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
4585, 4yo6C, 0.7457, 3.10, 0.262, 286, 244, IRAK4-INHIBITOR CO-STRUCTURE
4586, 4fklA, 0.7457, 3.15, 0.234, 290, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4587, 4dh1A, 0.7457, 3.38, 0.242, 333, 252, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH LOW MG2+ ATP AND IP20
4588, 4bi1A, 0.7457, 2.65, 0.172, 252, 239, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4589, 3qtxA, 0.7457, 3.21, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
4590, 5oo0A, 0.7456, 3.15, 0.230, 288, 248, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
4591, 5jr7A, 0.7456, 3.28, 0.239, 335, 251, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
4592, 4yu2C, 0.7456, 3.17, 0.216, 346, 245, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
4593, 4ysjA, 0.7456, 3.11, 0.264, 459, 246, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
4594, 4qpaB, 0.7456, 2.86, 0.206, 345, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
4595, 3igoA, 0.7456, 3.14, 0.238, 446, 248, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CDPK1 CGD3_920
4596, 3fmjA, 0.7456, 3.32, 0.233, 344, 249, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
4597, 2w1eA, 0.7456, 2.96, 0.244, 252, 246, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4598, 2r3fA, 0.7456, 3.16, 0.230, 290, 248, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4599, 1e1xA, 0.7456, 3.04, 0.228, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
4600, 6g9jA, 0.7455, 2.75, 0.195, 347, 241, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4601, 5ukmA, 0.7455, 3.64, 0.179, 621, 257, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
4602, 5magA, 0.7455, 2.84, 0.232, 314, 241, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4603, 4zjjA, 0.7455, 3.11, 0.230, 280, 248, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4604, 4iaiA, 0.7455, 3.31, 0.239, 333, 251, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH CA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
4605, 2r3rA, 0.7455, 3.08, 0.227, 290, 247, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4606, 1ym7D, 0.7455, 3.61, 0.178, 599, 258, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
4607, 1f5qC, 0.7455, 3.04, 0.239, 288, 243, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
4608, 5w5qB, 0.7454, 3.74, 0.214, 297, 262, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
4609, 4yffC, 0.7454, 2.36, 0.272, 258, 232, TNNI3K COMPLEXED WITH INHIBITOR 2
4610, 4xbuA, 0.7454, 3.30, 0.195, 292, 251, IN VITRO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA PEPTIDE
4611, 4ek5A, 0.7454, 3.14, 0.231, 289, 247, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4612, 4dg0E, 0.7454, 3.31, 0.239, 338, 251, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
4613, 2h96A, 0.7454, 2.90, 0.222, 358, 243, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
4614, 1w8cA, 0.7454, 3.20, 0.229, 290, 249, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
4615, 1l3rE, 0.7454, 3.40, 0.238, 338, 252, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
4616, 5uoxB, 0.7453, 2.73, 0.224, 252, 237, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4617, 5t1tC, 0.7453, 3.11, 0.280, 286, 243, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4618, 4mq1C, 0.7453, 3.18, 0.217, 328, 244, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
4619, 3vw6B, 0.7453, 2.67, 0.229, 253, 236, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
4620, 3gfwA, 0.7453, 2.84, 0.178, 253, 241, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYROLO-PYRIDIN LIGAND
4621, 2w1gA, 0.7453, 2.88, 0.245, 254, 245, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4622, 1y91A, 0.7453, 3.15, 0.227, 286, 247, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
4623, 1s9jA, 0.7453, 3.35, 0.231, 289, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4624, 6ft9B, 0.7452, 3.42, 0.226, 337, 248, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
4625, 5j95B, 0.7452, 3.76, 0.218, 300, 261, MAP4K4 IN COMPLEX WITH INHIBITOR
4626, 5f0aA, 0.7452, 3.49, 0.228, 811, 254, CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND 1-TERT-BUTYL-3-(3- CHLOROPHENOXY)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE INHIBITOR
4627, 4fkuA, 0.7452, 3.17, 0.218, 293, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4628, 4ek4A, 0.7452, 3.12, 0.231, 287, 247, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4629, 4cegA, 0.7452, 3.26, 0.243, 264, 251, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
4630, 3fl4A, 0.7452, 3.13, 0.237, 339, 245, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO5634
4631, 3ehaA, 0.7452, 3.22, 0.222, 279, 248, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
4632, 3cekA, 0.7452, 2.98, 0.172, 256, 244, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
4633, 1zmvA, 0.7452, 2.52, 0.250, 293, 236, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
4634, 6c2yA, 0.7451, 3.56, 0.195, 617, 256, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257142 
4635, 5av0A, 0.7451, 3.20, 0.226, 275, 248, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
4636, 4gvaA, 0.7451, 2.87, 0.202, 345, 243, ADP-BOUND FORM OF THE ERK2 KINASE
4637, 4eh7A, 0.7451, 2.76, 0.229, 337, 240, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
4638, 3o8pA, 0.7451, 2.86, 0.231, 336, 242, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4639, 3bwjA, 0.7451, 3.38, 0.234, 338, 252, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
4640, 3a8wA, 0.7451, 3.29, 0.217, 326, 249, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
4641, 2c68A, 0.7451, 3.24, 0.228, 290, 250, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
4642, 1cdkB, 0.7451, 3.41, 0.241, 342, 253, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
4643, 5n7pA, 0.7450, 3.42, 0.245, 350, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINO-5-(PYRROLIDIN-1-YL)-1H-PYRAZOLE- 4-CARBONITRILE
4644, 4fv0A, 0.7450, 2.80, 0.186, 341, 242, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
4645, 3d2iA, 0.7450, 2.93, 0.248, 255, 246, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
4646, 2p55A, 0.7450, 3.54, 0.215, 289, 256, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4647, 5n37A, 0.7449, 3.39, 0.242, 347, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-(13-BENZODIOXOL-5-YLMETHYL) CYCLOPENTANAMINE
4648, 5f9eB, 0.7449, 3.18, 0.246, 293, 248, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
4649, 5auyA, 0.7449, 3.21, 0.222, 275, 248, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
4650, 5aafA, 0.7449, 2.92, 0.244, 254, 246, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
4651, 4wb8A, 0.7449, 3.40, 0.238, 334, 252, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT) EXON 1 DELETION
4652, 4u81A, 0.7449, 3.31, 0.232, 289, 250, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
4653, 4njdA, 0.7449, 3.30, 0.191, 290, 251, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
4654, 4mq2C, 0.7449, 3.15, 0.217, 339, 244, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
4655, 2pk9A, 0.7449, 2.88, 0.246, 287, 240, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
4656, 3f5gA, 0.7448, 3.22, 0.222, 279, 248, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
4657, 3eb0A, 0.7448, 3.24, 0.195, 311, 246, CRYSTAL STRUCTURE OF CGD4_240 FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH INDIRUBIN E804
4658, 2balA, 0.7448, 2.97, 0.224, 337, 241, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
4659, 1pxnA, 0.7448, 3.21, 0.224, 294, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
4660, 5t1sC, 0.7447, 3.09, 0.254, 284, 244, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4661, 5ortA, 0.7447, 3.15, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4662, 5di1B, 0.7447, 3.81, 0.218, 300, 262, MAP4K4 IN COMPLEX WITH AN INHIBITOR
4663, 5dh3A, 0.7447, 3.28, 0.242, 287, 248, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
4664, 5ap2A, 0.7447, 3.00, 0.172, 256, 244, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4665, 4wihA, 0.7447, 3.42, 0.245, 350, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS
4666, 4dhfB, 0.7447, 3.00, 0.244, 258, 246, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
4667, 3eqbA, 0.7447, 3.32, 0.232, 289, 250, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4668, 2w1zA, 0.7447, 3.38, 0.123, 354, 253, ROP2 FROM TOXOPLASMA GONDII:  A VIRULENCE FACTOR WITH A PROTEIN-KINASE FOLD AND NO ENZYMATIC ACTIVITY.
4669, 1pf8A, 0.7447, 3.60, 0.231, 298, 255, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
4670, 5lxdA, 0.7446, 3.22, 0.199, 385, 246, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
4671, 4ztsA, 0.7446, 2.77, 0.247, 249, 243, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
4672, 4wb7A, 0.7446, 3.39, 0.238, 402, 252, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
4673, 4eh8A, 0.7446, 2.72, 0.226, 336, 239, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F7 AND RL87
4674, 4dymA, 0.7446, 2.70, 0.278, 293, 237, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00135
4675, 4cv9A, 0.7446, 2.99, 0.169, 254, 242, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4676, 3gcqA, 0.7446, 2.77, 0.225, 337, 240, HUMAN P38 MAP KINASE IN COMPLEX WITH RL45
4677, 2y4iC, 0.7446, 3.48, 0.220, 313, 255, KSR2-MEK1 HETERODIMER
4678, 2dwbA, 0.7446, 3.01, 0.239, 259, 247, AURORA-A KINASE COMPLEXED WITH AMPPNP
4679, 1v0bA, 0.7446, 3.19, 0.214, 286, 248, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
4680, 5mahA, 0.7445, 2.79, 0.228, 316, 241, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4681, 5dykA, 0.7445, 3.49, 0.221, 809, 253, CRYSTAL STRUCTURE OF PF3D7_1436600
4682, 5ax3A, 0.7445, 2.89, 0.212, 329, 241, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
4683, 5auvA, 0.7445, 3.22, 0.222, 275, 248, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
4684, 4q9zA, 0.7445, 3.23, 0.245, 331, 249, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
4685, 4p90B, 0.7445, 2.87, 0.219, 262, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
4686, 4mygA, 0.7445, 2.77, 0.221, 335, 240, MAPK13 ACTIVE FORM
4687, 4fkiA, 0.7445, 3.25, 0.230, 287, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4688, 3v5wA, 0.7445, 3.59, 0.183, 623, 257, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
4689, 3twjA, 0.7445, 3.55, 0.213, 396, 258, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
4690, 3o8tA, 0.7445, 2.74, 0.226, 332, 239, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG-MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4691, 2onlB, 0.7445, 3.07, 0.246, 339, 244, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4692, 6eimB, 0.7444, 3.20, 0.241, 295, 245, HUMAN STK10 BOUND TO GW683134A
4693, 5lxdB, 0.7444, 3.22, 0.199, 385, 246, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
4694, 4wg5A, 0.7444, 3.56, 0.227, 464, 260, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1647
4695, 4mxaA, 0.7444, 3.65, 0.226, 459, 261, CDPK1 FROM NEOSPORA CANINUM IN COMPLEX WITH INHIBITOR RM-1-132
4696, 4mx9A, 0.7444, 3.57, 0.227, 459, 260, CDPK1 FROM NEOSPORA CANINUM IN COMPLEX WITH INHIBITOR UW1294
4697, 4g3dD, 0.7444, 2.84, 0.213, 290, 244, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
4698, 4eh4A, 0.7444, 2.70, 0.230, 337, 239, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F3 AND RL87
4699, 3vuiA, 0.7444, 2.97, 0.230, 355, 243, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
4700, 3p7bA, 0.7444, 2.75, 0.222, 332, 239, P38 INHIBITOR-BOUND
4701, 3k5uA, 0.7444, 2.89, 0.244, 260, 246, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
4702, 2j50B, 0.7444, 2.77, 0.248, 249, 242, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4703, 2j50A, 0.7444, 2.77, 0.248, 249, 242, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4704, 2fa2B, 0.7444, 2.81, 0.255, 332, 243, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
4705, 5o21B, 0.7443, 3.30, 0.257, 273, 249, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
4706, 5myvC, 0.7443, 3.06, 0.189, 348, 244, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
4707, 5iu2B, 0.7443, 2.96, 0.184, 313, 244, DISCOVERY OF IMIDAZOQUINOLINES AS A NOVEL CLASS OF POTENT SELECTIVE AND IN VIVO EFFICACIOUS COT KINASE INHIBITORS
4708, 5hu3A, 0.7443, 3.01, 0.225, 266, 244, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
4709, 4wb7B, 0.7443, 3.40, 0.238, 402, 252, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
4710, 4d2wC, 0.7443, 2.88, 0.229, 313, 240, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4711, 4cv8A, 0.7443, 2.99, 0.177, 255, 243, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4712, 3vugA, 0.7443, 2.96, 0.235, 356, 243, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
4713, 3teiA, 0.7443, 2.76, 0.212, 339, 240, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
4714, 3sdjJ, 0.7443, 3.01, 0.227, 413, 242, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4715, 3sdjI, 0.7443, 3.02, 0.227, 413, 242, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4716, 3m11A, 0.7443, 2.93, 0.240, 256, 246, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
4717, 2r3hA, 0.7443, 3.15, 0.235, 289, 247, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4718, 5uyjA, 0.7442, 3.15, 0.253, 281, 245, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
4719, 5twyA, 0.7442, 2.89, 0.241, 313, 241, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
4720, 5jt2A, 0.7442, 2.94, 0.315, 257, 241, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4721, 3amyA, 0.7442, 2.77, 0.159, 318, 239, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
4722, 5i0bA, 0.7441, 3.15, 0.198, 288, 248, STRUCTURE OF PAK4
4723, 5auwA, 0.7441, 3.17, 0.227, 274, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
4724, 5aaeA, 0.7441, 2.91, 0.244, 252, 246, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
4725, 4ztnC, 0.7441, 3.07, 0.267, 284, 243, IRAK4-INHIBITOR CO-STRUCTURE
4726, 4d2vC, 0.7441, 2.95, 0.223, 316, 242, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4727, 3p78A, 0.7441, 2.73, 0.226, 332, 239, P38 INHIBITOR-BOUND
4728, 3hv3A, 0.7441, 2.78, 0.225, 335, 240, HUMAN P38 MAP KINASE IN COMPLEX WITH RL49
4729, 3fbvJ, 0.7441, 3.13, 0.221, 413, 244, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4730, 3fbvI, 0.7441, 3.13, 0.221, 413, 244, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4731, 1ol6A, 0.7441, 2.69, 0.242, 245, 240, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
4732, 4zk5B, 0.7440, 3.67, 0.208, 294, 259, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
4733, 4appA, 0.7440, 3.31, 0.191, 291, 251, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
4734, 3lfsA, 0.7440, 3.19, 0.230, 290, 248, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
4735, 3hp2A, 0.7440, 2.88, 0.236, 341, 242, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
4736, 1y8gA, 0.7440, 2.72, 0.244, 292, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
4737, 1p38A, 0.7440, 3.63, 0.237, 351, 253, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
4738, 6babC, 0.7439, 3.11, 0.216, 284, 245, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
4739, 5ouuA, 0.7439, 3.02, 0.173, 324, 243, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
4740, 4zy4A, 0.7439, 3.33, 0.229, 288, 249, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
4741, 4xp0A, 0.7439, 2.77, 0.191, 336, 241, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4742, 4wb6A, 0.7439, 3.38, 0.238, 336, 252, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
4743, 4u80A, 0.7439, 3.32, 0.232, 286, 250, MEK 1 KINASE BOUND TO G799
4744, 4bidA, 0.7439, 2.83, 0.218, 254, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4745, 3r22A, 0.7439, 2.99, 0.244, 255, 246, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
4746, 2r3iA, 0.7439, 3.10, 0.227, 289, 247, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4747, 1unhA, 0.7439, 2.63, 0.234, 276, 235, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
4748, 5u7qB, 0.7438, 3.60, 0.195, 385, 257, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
4749, 5e7rA, 0.7438, 2.22, 0.279, 273, 229, CRYSTAL STRUCTURE OF TL10-81 BOUND TO TAK1-TAB1
4750, 5auxA, 0.7438, 3.23, 0.222, 275, 248, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
4751, 4wb6B, 0.7438, 3.42, 0.241, 340, 253, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
4752, 4d2tD, 0.7438, 3.00, 0.221, 319, 244, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4753, 3v3vA, 0.7438, 2.94, 0.235, 351, 243, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
4754, 3twjB, 0.7438, 3.89, 0.199, 395, 266, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
4755, 3p7cA, 0.7438, 2.70, 0.227, 332, 238, P38 INHIBITOR-BOUND
4756, 3p5kA, 0.7438, 2.78, 0.222, 332, 239, P38 INHIBITOR-BOUND
4757, 3o2mB, 0.7438, 3.02, 0.230, 358, 244, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
4758, 2phkA, 0.7438, 3.19, 0.219, 277, 247, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
4759, 6cpgD, 0.7437, 2.99, 0.242, 252, 248, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) IN COMPLEX WITH INHIBITING MONOBODY AND AT9283 IN AN INACTIVE CONFORMATION 
4760, 5o21A, 0.7437, 3.32, 0.257, 272, 249, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
4761, 5av4A, 0.7437, 3.18, 0.227, 274, 247, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
4762, 3vvhA, 0.7437, 3.50, 0.229, 287, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
4763, 3vuhA, 0.7437, 2.97, 0.230, 355, 243, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
4764, 3o2mA, 0.7437, 2.95, 0.226, 358, 243, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
4765, 3eh9A, 0.7437, 3.25, 0.222, 278, 248, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
4766, 1z9xC, 0.7437, 3.43, 0.208, 303, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
4767, 1unhB, 0.7437, 2.63, 0.234, 276, 235, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
4768, 6f3dB, 0.7436, 3.09, 0.281, 283, 242, IRAK4 IN COMPLEX WITH INHIBITOR 
4769, 5mp8B, 0.7436, 3.07, 0.176, 323, 244, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
4770, 5f9eA, 0.7436, 3.28, 0.249, 334, 249, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
4771, 4lynA, 0.7436, 3.12, 0.237, 287, 245, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
4772, 3ns9A, 0.7436, 3.16, 0.231, 289, 247, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
4773, 3a7hA, 0.7436, 3.17, 0.256, 289, 250, HUMAN MST3 KINASE IN COMPLEX WITH ATP
4774, 1lezA, 0.7436, 3.11, 0.244, 343, 246, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
4775, 6fd3A, 0.7435, 3.22, 0.234, 296, 248, THIOPHOSPHORYLATED PAK3 KINASE DOMAIN
4776, 4ka3A, 0.7435, 3.10, 0.238, 340, 244, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
4777, 4euuB, 0.7435, 3.00, 0.184, 307, 245, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
4778, 2okrA, 0.7435, 3.09, 0.238, 339, 244, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4779, 2nryA, 0.7435, 3.15, 0.272, 286, 243, CRYSTAL STRUCTURE OF IRAK-4
4780, 5ih8A, 0.7434, 2.69, 0.231, 306, 238, MELK IN COMPLEX WITH NVS-MELK1
4781, 3ku2A, 0.7434, 3.70, 0.240, 457, 262, CRYSTAL STRUCTURE OF INACTIVATED FORM OF CDPK1 FROM TOXOPLASMA GONDII TGME49.101440
4782, 3eqhA, 0.7434, 3.45, 0.220, 314, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
4783, 2xh5A, 0.7434, 3.03, 0.228, 316, 246, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
4784, 5n7uA, 0.7433, 3.44, 0.245, 350, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-BROMO-35-DIMETHYL-1H-PYRAZOLE
4785, 4zjiA, 0.7433, 2.92, 0.229, 278, 245, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4786, 4qtaA, 0.7433, 2.78, 0.209, 335, 239, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
4787, 4d2pD, 0.7433, 3.01, 0.221, 317, 244, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4788, 4d2pB, 0.7433, 2.95, 0.223, 323, 242, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4789, 3r8vA, 0.7433, 3.35, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
4790, 3n9xB, 0.7433, 3.10, 0.191, 374, 246, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
4791, 3lfqA, 0.7433, 3.17, 0.231, 289, 247, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
4792, 6ehuA, 0.7432, 3.28, 0.169, 327, 248, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
4793, 4ztlA, 0.7432, 3.14, 0.267, 280, 243, IRAK4-INHIBITOR CO-STRUCTURE
4794, 3wzjA, 0.7432, 2.82, 0.169, 257, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6- (CYCLOHEXYLAMINO)-8-(((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)AMINO) IMIDAZO[12-B]PYRIDAZIN-3-YL)-N-CYCLOPROPYLBENZAMIDE
4795, 3qqjA, 0.7432, 3.23, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L2
4796, 3ag9A, 0.7432, 3.30, 0.224, 323, 250, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
4797, 5y9mX, 0.7431, 3.00, 0.156, 319, 243, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
4798, 4im2A, 0.7431, 3.40, 0.174, 618, 253, STRUCTURE OF TANK-BINDING KINASE 1
4799, 3v04A, 0.7431, 3.50, 0.216, 289, 255, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
4800, 3o50B, 0.7431, 2.94, 0.241, 249, 245, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4801, 3d15A, 0.7431, 2.95, 0.248, 256, 246, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
4802, 3aglA, 0.7431, 3.33, 0.242, 338, 252, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
4803, 2w1fA, 0.7431, 2.90, 0.245, 253, 245, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4804, 2etkA, 0.7431, 3.52, 0.215, 400, 256, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
4805, 1lewA, 0.7431, 2.93, 0.236, 341, 242, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
4806, 4zjiB, 0.7430, 3.15, 0.222, 276, 248, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4807, 4l6qB, 0.7430, 3.64, 0.205, 388, 258, ROCK2 IN COMPLEX WITH BENZOXABOROLE
4808, 4jr7A, 0.7430, 3.15, 0.164, 367, 244, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
4809, 4iz7C, 0.7430, 2.87, 0.202, 340, 242, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
4810, 3vudA, 0.7430, 2.97, 0.230, 355, 243, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
4811, 3tizA, 0.7430, 3.26, 0.220, 293, 250, CDK2 IN COMPLEX WITH NSC 111848
4812, 2etrB, 0.7430, 3.50, 0.210, 398, 257, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
4813, 1oirA, 0.7430, 3.13, 0.224, 286, 246, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
4814, 5mafA, 0.7429, 2.81, 0.232, 315, 241, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4815, 5kx8C, 0.7429, 3.17, 0.270, 287, 244, IRAK4-INHIBITOR CO-STRUCTURE
4816, 5iu2A, 0.7429, 2.99, 0.184, 312, 244, DISCOVERY OF IMIDAZOQUINOLINES AS A NOVEL CLASS OF POTENT SELECTIVE AND IN VIVO EFFICACIOUS COT KINASE INHIBITORS
4817, 4im0A, 0.7429, 3.41, 0.178, 619, 253, STRUCTURE OF TANK-BINDING KINASE 1
4818, 4gsbA, 0.7429, 2.73, 0.200, 343, 240, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
4819, 4d2pA, 0.7429, 2.93, 0.232, 313, 241, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4820, 4b9dB, 0.7429, 3.32, 0.197, 295, 249, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
4821, 3vukA, 0.7429, 2.98, 0.235, 355, 243, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
4822, 3ma6B, 0.7429, 3.32, 0.246, 266, 252, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
4823, 6b2qB, 0.7428, 3.06, 0.237, 266, 245, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
4824, 4fkgA, 0.7428, 3.22, 0.231, 286, 247, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4825, 4eh6A, 0.7428, 2.70, 0.223, 335, 238, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F5 AND RL87
4826, 4c4iA, 0.7428, 2.91, 0.178, 253, 242, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4827, 3sa0A, 0.7428, 2.76, 0.178, 354, 241, COMPLEX OF ERK2 WITH NORATHYRIOL
4828, 3ornA, 0.7428, 3.37, 0.221, 280, 253, MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH CH4987655 AND MGAMP-PNP
4829, 3o17A, 0.7428, 3.00, 0.230, 357, 244, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
4830, 3hllA, 0.7428, 2.89, 0.228, 337, 241, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
4831, 3hegA, 0.7428, 2.65, 0.223, 333, 238, P38 IN COMPLEX WITH SORAFENIB
4832, 2vd5A, 0.7428, 3.52, 0.201, 390, 254, STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII
4833, 6dcgA, 0.7427, 2.79, 0.204, 326, 240, DISCOVERY OF MK-8353: AN ORALLY BIOAVAILABLE DUAL MECHANISM ERK INHIBITOR FOR ONCOLOGY 
4834, 5wngD, 0.7427, 3.56, 0.222, 396, 257, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
4835, 4xs2A, 0.7427, 3.12, 0.267, 283, 243, IRAK4-INHIBITOR CO-STRUCTURE
4836, 4o6eA, 0.7427, 2.73, 0.206, 328, 238, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
4837, 4h3bA, 0.7427, 3.12, 0.207, 351, 246, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
4838, 4apcB, 0.7427, 3.34, 0.201, 296, 249, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
4839, 5ezrA, 0.7426, 3.50, 0.232, 803, 254, CRYSTAL STRUCTURE OF PVX_084705 BOUND TO COMPOUND
4840, 5dylA, 0.7426, 3.48, 0.226, 802, 252, CRYSTAL STRUCTURE OF PVX_084705
4841, 5auuA, 0.7426, 3.20, 0.227, 274, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
4842, 4zjiD, 0.7426, 3.48, 0.221, 280, 253, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4843, 4i5mA, 0.7426, 3.43, 0.225, 273, 249, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
4844, 3vvhC, 0.7426, 3.35, 0.230, 283, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
4845, 3dj7A, 0.7426, 3.02, 0.247, 257, 247, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
4846, 5autA, 0.7425, 3.20, 0.223, 274, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
4847, 4lv8A, 0.7425, 3.57, 0.132, 360, 258, MURINE IRGA6 BOUND TO TOXOPLASMA ROP5C A PSEUDOKINASE GDI
4848, 4kinB, 0.7425, 3.19, 0.233, 341, 245, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4849, 4h3bC, 0.7425, 3.13, 0.207, 351, 246, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
4850, 3mh1A, 0.7425, 2.75, 0.217, 337, 240, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
4851, 3gubA, 0.7425, 3.29, 0.225, 278, 249, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
4852, 3begA, 0.7425, 2.95, 0.186, 348, 242, CRYSTAL STRUCTURE OF SR PROTEIN KINASE 1 COMPLEXED TO ITS SUBSTRATE ASF/SF2
4853, 2etkB, 0.7425, 3.50, 0.210, 398, 257, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
4854, 1pxkA, 0.7425, 3.13, 0.227, 290, 247, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
4855, 4eh2A, 0.7424, 2.83, 0.229, 337, 240, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
4856, 4d2wA, 0.7424, 3.01, 0.236, 314, 242, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4857, 4d2vD, 0.7424, 3.04, 0.221, 318, 244, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4858, 3qzgA, 0.7424, 3.25, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
4859, 3oz6A, 0.7424, 2.65, 0.248, 343, 238, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
4860, 1y8gB, 0.7424, 2.86, 0.243, 292, 239, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
4861, 5oyfA, 0.7423, 3.25, 0.173, 327, 248, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 31
4862, 3f5uA, 0.7423, 3.28, 0.222, 279, 248, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
4863, 5vi9A, 0.7422, 3.30, 0.230, 306, 248, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
4864, 4i94A, 0.7422, 3.50, 0.208, 297, 250, STRUCTURE OF BSK8 IN COMPLEX WITH AMP-PNP
4865, 4bkyA, 0.7422, 2.72, 0.238, 311, 239, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH PYRROLOPYRAZOLE INHIBITOR
4866, 3rocA, 0.7422, 3.06, 0.230, 337, 243, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
4867, 3gc7A, 0.7422, 3.47, 0.219, 349, 251, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH A DIHYDROQUINAZOLINONE
4868, 5n66A, 0.7421, 2.53, 0.225, 332, 236, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9J
4869, 4ztlD, 0.7421, 3.12, 0.272, 285, 243, IRAK4-INHIBITOR CO-STRUCTURE
4870, 4ux9C, 0.7421, 2.70, 0.222, 333, 239, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
4871, 3vvhB, 0.7421, 3.35, 0.230, 290, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
4872, 3fdnA, 0.7421, 2.94, 0.248, 261, 246, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
4873, 2ghmA, 0.7421, 2.99, 0.223, 336, 242, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
4874, 4wnpC, 0.7420, 2.89, 0.269, 271, 242, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
4875, 4au8A, 0.7420, 2.83, 0.248, 276, 238, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
4876, 3zonA, 0.7420, 2.98, 0.292, 261, 243, HUMAN TYK2 PSEUDOKINASE DOMAIN BOUND TO A KINASE INHIBITOR
4877, 3zlyA, 0.7420, 3.31, 0.224, 310, 250, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
4878, 3p79A, 0.7420, 2.76, 0.222, 332, 239, P38 INHIBITOR-BOUND
4879, 3fmlA, 0.7420, 3.38, 0.218, 342, 248, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6224
4880, 6cd6B, 0.7419, 3.04, 0.222, 266, 243, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
4881, 5w5jB, 0.7419, 2.78, 0.229, 257, 240, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
4882, 5n3cA, 0.7419, 3.35, 0.243, 348, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE THIOPHENE-3-CARBOXIMIDAMIDE
4883, 5k4jA, 0.7419, 3.14, 0.237, 282, 245, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
4884, 4ux9B, 0.7419, 2.60, 0.219, 327, 237, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
4885, 4qo9A, 0.7419, 3.17, 0.262, 280, 248, MST3 IN COMPLEX WITH DANUSERTIB
4886, 4i94B, 0.7419, 3.74, 0.209, 297, 253, STRUCTURE OF BSK8 IN COMPLEX WITH AMP-PNP
4887, 3uliA, 0.7419, 3.19, 0.228, 286, 246, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
4888, 3n9xA, 0.7419, 3.06, 0.192, 374, 245, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
4889, 3fz1A, 0.7419, 3.19, 0.228, 284, 246, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
4890, 3c5uA, 0.7419, 2.81, 0.232, 338, 241, P38 ALPHA MAP KINASE COMPLEXED WITH A BENZOTHIAZOLE BASED INHIBITOR
4891, 2r3gA, 0.7419, 3.10, 0.233, 287, 245, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4892, 1omwA, 0.7419, 3.65, 0.175, 614, 257, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
4893, 5uklA, 0.7418, 3.61, 0.183, 630, 257, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
4894, 5oszA, 0.7418, 3.27, 0.173, 327, 248, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 23
4895, 5orlA, 0.7418, 3.21, 0.244, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4896, 5n1kA, 0.7418, 3.38, 0.243, 341, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-AMINO-1-(4-FLUOROPHENYL)ETHANOL
4897, 4yp8C, 0.7418, 3.12, 0.280, 287, 243, IRAK4-INHIBITOR CO-STRUCTURE
4898, 4y73C, 0.7418, 3.18, 0.270, 290, 244, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4899, 4fkvA, 0.7418, 3.12, 0.229, 282, 245, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4900, 4d2tC, 0.7418, 2.86, 0.229, 313, 240, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4901, 3le6A, 0.7418, 3.11, 0.229, 283, 245, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
4902, 2f9gA, 0.7418, 2.76, 0.264, 332, 239, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
4903, 6ehuB, 0.7417, 3.23, 0.170, 327, 247, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
4904, 5mhqA, 0.7417, 3.26, 0.226, 291, 248, CCT068127 IN COMPLEX WITH CDK2
4905, 5lpwA, 0.7417, 2.82, 0.264, 280, 239, CRYSTAL STRUCTURE OF THE APO-BRI1 KINASE DOMAIN (865-1160)
4906, 4ztmA, 0.7417, 3.10, 0.267, 287, 243, IRAK4-INHIBITOR CO-STRUCTURE
4907, 4umpC, 0.7417, 2.75, 0.227, 311, 238, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4908, 4ra5B, 0.7417, 3.19, 0.246, 310, 248, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
4909, 4m84A, 0.7417, 3.65, 0.231, 464, 260, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1455
4910, 3qqgA, 0.7417, 3.26, 0.228, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L2-5
4911, 3qkkA, 0.7417, 3.05, 0.252, 326, 246, SPIROCHROMANE AKT INHIBITORS
4912, 3k2lA, 0.7417, 3.16, 0.201, 402, 244, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2)
4913, 2vagA, 0.7417, 3.39, 0.228, 330, 246, CRYSTAL STRUCTURE OF DI-PHOSPHORYLATED HUMAN CLK1 IN COMPLEX WITH A NOVEL SUBSTITUTED INDOLE INHIBITOR
4914, 2onlA, 0.7417, 3.09, 0.243, 338, 243, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4915, 2i0eA, 0.7417, 2.98, 0.262, 326, 244, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
4916, 1xr1A, 0.7417, 3.20, 0.224, 277, 245, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
4917, 6cd6D, 0.7416, 3.05, 0.222, 267, 243, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
4918, 6cd6C, 0.7416, 3.01, 0.222, 265, 243, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
4919, 4ux9A, 0.7416, 2.77, 0.221, 343, 240, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
4920, 4l6qA, 0.7416, 3.57, 0.207, 388, 256, ROCK2 IN COMPLEX WITH BENZOXABOROLE
4921, 4ithA, 0.7416, 2.45, 0.305, 247, 233, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
4922, 4bhzA, 0.7416, 2.67, 0.168, 251, 238, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4923, 4b0gA, 0.7416, 2.70, 0.242, 247, 240, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
4924, 1h01A, 0.7416, 3.13, 0.224, 286, 246, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4925, 1a9uA, 0.7416, 3.48, 0.225, 351, 249, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
4926, 5hvuA, 0.7415, 3.51, 0.215, 394, 256, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH A PYRIDINE THIAZOLE PIPERIDINE INHIBITOR
4927, 5dt0A, 0.7415, 2.99, 0.244, 259, 246, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
4928, 5drdA, 0.7415, 2.98, 0.244, 259, 246, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
4929, 5buiA, 0.7415, 2.80, 0.222, 338, 239, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
4930, 4useA, 0.7415, 3.15, 0.243, 286, 243, HUMAN STK10 (LOK) WITH SB-633825
4931, 3qqhA, 0.7415, 3.25, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L2-2
4932, 3fmnA, 0.7415, 3.35, 0.238, 341, 248, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO2530
4933, 6bfaA, 0.7414, 3.66, 0.227, 464, 260, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1553
4934, 5n32A, 0.7414, 3.35, 0.235, 345, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-CHLOROBENZYL CARBAMIMIDOTHIOATE
4935, 5k4iA, 0.7414, 2.84, 0.218, 336, 239, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
4936, 5bx0A, 0.7414, 3.40, 0.225, 315, 253, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
4937, 4ylkA, 0.7414, 2.98, 0.215, 341, 242, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-CHLORO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLONE-6-CARBOXYLIC ACID INHIBITOR 5S
4938, 3nwwA, 0.7414, 3.05, 0.227, 339, 242, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
4939, 3ndmD, 0.7414, 3.55, 0.222, 396, 257, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
4940, 3kvwA, 0.7414, 3.30, 0.211, 403, 246, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2) IN COMPLEX WITH AN INDIRUBIN LIGAND
4941, 3fskA, 0.7414, 3.30, 0.242, 342, 248, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6257
4942, 2nruB, 0.7414, 3.09, 0.281, 294, 242, CRYSTAL STRUCTURE OF IRAK-4
4943, 1cdkA, 0.7414, 3.45, 0.241, 342, 253, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
4944, 5uiqC, 0.7413, 2.83, 0.283, 280, 237, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4945, 5cshB, 0.7413, 3.07, 0.169, 323, 243, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
4946, 5c01A, 0.7413, 2.91, 0.302, 258, 242, CRYSTAL STRUCTURE OF KINASE
4947, 5auzA, 0.7413, 3.22, 0.223, 274, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
4948, 5aagA, 0.7413, 2.92, 0.245, 253, 245, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
4949, 4yllA, 0.7413, 2.98, 0.215, 340, 242, CRYSTAL STRUCTURE OF DYRK1AA IN COMPLEX WITH 10-BROMO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLONE-6-CARBOXYLIC ACID INHIBITOR 5T
4950, 4bf2B, 0.7413, 2.62, 0.231, 252, 234, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4951, 3zhpD, 0.7413, 3.30, 0.255, 264, 251, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
4952, 2oibB, 0.7413, 2.94, 0.276, 278, 239, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4953, 6gihA, 0.7412, 3.12, 0.180, 324, 245, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
4954, 5vjaD, 0.7412, 2.94, 0.211, 261, 242, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
4955, 5vc5A, 0.7412, 2.98, 0.181, 261, 243, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
4956, 5os2A, 0.7412, 3.13, 0.246, 261, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
4957, 4ra5A, 0.7412, 3.30, 0.245, 332, 249, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
4958, 4bibA, 0.7412, 2.81, 0.224, 254, 237, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4959, 3v01A, 0.7412, 3.47, 0.217, 289, 254, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
4960, 3t9iA, 0.7412, 3.20, 0.225, 273, 244, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
4961, 3qkmA, 0.7412, 3.04, 0.252, 329, 246, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
4962, 3ha8A, 0.7412, 3.30, 0.230, 342, 248, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/COMPOUND 14B
4963, 6cpfA, 0.7411, 2.88, 0.246, 259, 244, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION 
4964, 5w7tB, 0.7411, 3.09, 0.267, 276, 247, STRUCTURE OF PHOSPHORYLATED WNK1 
4965, 4ztmD, 0.7411, 3.19, 0.267, 282, 243, IRAK4-INHIBITOR CO-STRUCTURE
4966, 4zjiC, 0.7411, 3.44, 0.222, 281, 252, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4967, 4u41B, 0.7411, 3.84, 0.202, 297, 262, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
4968, 3hl7A, 0.7411, 2.94, 0.237, 336, 241, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
4969, 3eqgA, 0.7411, 3.29, 0.215, 314, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
4970, 1o6lA, 0.7411, 3.13, 0.227, 316, 247, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
4971, 1jsvA, 0.7411, 3.11, 0.233, 287, 245, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
4972, 5yf9X, 0.7410, 2.90, 0.158, 319, 241, CRYSTAL STRUCTURE OF CK2A2 FORM-2 
4973, 5jq5A, 0.7410, 3.13, 0.233, 287, 245, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
4974, 4oboB, 0.7410, 3.78, 0.203, 297, 261, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
4975, 4n0sA, 0.7410, 2.88, 0.190, 348, 242, COMPLEX OF ERK2 WITH CAFFEIC ACID
4976, 4iwpA, 0.7410, 3.65, 0.173, 628, 255, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
4977, 3tl8D, 0.7410, 3.29, 0.279, 306, 247, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4978, 3gcvA, 0.7410, 3.05, 0.230, 338, 244, HUMAN P38 MAP KINASE IN COMPLEX WITH RL62
4979, 3c4eB, 0.7410, 3.36, 0.223, 273, 247, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
4980, 5n3eA, 0.7409, 3.36, 0.239, 348, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 6-DIMETHYLAMINOPYRIDINE-3-CARBOXYLIC ACID
4981, 5n3aA, 0.7409, 3.43, 0.238, 349, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-METHYL-5-(1-METHYLIMIDAZOL-2-YL)-13- THIAZOL-2-AMINE
4982, 5mhiA, 0.7409, 3.41, 0.246, 348, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (5-CHLORO-2-METHOXYPHENYL)METHANAMINE
4983, 5clpA, 0.7409, 3.05, 0.169, 322, 242, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
4984, 4zxtA, 0.7409, 2.86, 0.186, 348, 242, COMPLEX OF ERK2 WITH CATECHOL
4985, 4u45B, 0.7409, 3.79, 0.208, 295, 260, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
4986, 4f9aA, 0.7409, 3.13, 0.171, 315, 245, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
4987, 4euuA, 0.7409, 3.04, 0.184, 307, 245, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
4988, 3jy0A, 0.7409, 3.19, 0.225, 275, 244, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
4989, 2etrA, 0.7409, 3.55, 0.215, 400, 256, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
4990, 5ztnA, 0.7408, 3.23, 0.204, 395, 245, THE CRYSTAL STRUCTURE OF HUMAN DYRK2 IN COMPLEX WITH CURCUMIN 
4991, 5wg4A, 0.7408, 3.59, 0.188, 621, 255, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257284
4992, 5uy6A, 0.7408, 3.15, 0.254, 282, 244, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
4993, 4onaA, 0.7408, 3.72, 0.230, 465, 261, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1517
4994, 4cqgA, 0.7408, 2.89, 0.232, 313, 241, THE CRYSTAL STRUCTURE OF MPK38 IN COMPLEX WITH OTSSP167 AN ORALLY-ADMINISTRATIVE MELK SELECTIVE INHIBITOR
4995, 3uc3A, 0.7408, 2.88, 0.219, 272, 242, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.3
4996, 2wtkB, 0.7408, 3.44, 0.205, 311, 249, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
4997, 5jzjB, 0.7407, 2.85, 0.230, 261, 239, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
4998, 4iwqA, 0.7407, 3.54, 0.173, 626, 254, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
4999, 4f9wA, 0.7407, 2.90, 0.237, 336, 241, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
5000, 3objA, 0.7407, 2.67, 0.227, 332, 238, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
